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Abstract 
Human norovirus is a major cause of viral gastroenteritis worldwide, yet there are no licensed 
antivirals or a vaccine. This is mainly due to the lack of an efficient cell culture system for human 
norovirus which has prevented full understanding of norovirus replication. Murine norovirus (MNV), 
which can be grown in permissive cells and manipulated by reverse genetics, now provides a model 
for studying norovirus replication. Here, to firstly identify the essential viral factors required for 
replication, the entire MNV genome was subjected to transposon-mediated insertional mutagenesis 
and insertion profiling. Validation of the technique and genome-wide profiling of over 2000 
insertions revealed the essential regions of each protein and probed the importance of known 
functional motifs. Identification of tolerated insertion sites led to the generation of the first epitope-
tagged noroviruses, carrying the FLAG tag in three proteins of unknown function. This facilitated 
SILAC-based proteomic studies to identify host cell factors involved in norovirus replication, which 
may represent potential antiviral targets. With the availability of a small animal model of infection, 
MNV also provides the opportunity to develop rational approaches to norovirus attenuation. One 
approach that has been successful for attenuating other RNA viruses involves harnessing the 
regulatory capacity of the cellular microRNA machinery to control viral replication and tropism. This 
approach was applied to MNV by inserting a microglial-specific microRNA target sequence into the 
MNV genome which successfully attenuated norovirus replication in permissive cell lines expressing 
the cognate microRNA. A second rational approach to attenuation was based on manipulating the 
rate and fidelity of the viral polymerase, which has been shown to affect RNA virus pathogenesis and 
can lead to attenuation. To this aim a panel of MNV polymerase mutants were engineered and 
characterised for their growth and fidelity and their ability to establish acute and persistent 
infections in vivo.  
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1. Introduction 
 Classification of the Caliciviridae  1.1
The Caliciviridae family is comprised of small, non-enveloped positive strand RNA viruses and 
includes a variety of human and animal pathogens. As a family they exhibit a broad host range and 
are able to cause a wide spectrum of disease in their respective hosts, from gastroenteritis to 
respiratory infection to systemic haemorrhagic disease. Classification into the Caliciviridae family 
was originally based on virus morphology, as by electron microscopy all viruses exhibit cup-like 
depressions on the surface of the viral capsid, giving rise to the family name from the Latin calyx for 
cup (Figure 1.1). With the advent of genome sequencing, a new system for classification and 
nomenclature was established (154).  
 
 
Figure 1.1. Typical morphology of calicivirus capsids. The Caliciviridae family was named after cup-
like depressions evident on the surface of the virion. A. Electron microscopy of Norwalk Virus, the 
prototypical human norovirus strain, isolated from stool samples. The bar represents 50nm. B. X-ray 
crystallographic structure of Norwalk virus capsid (323).  
 
The Caliciviridae family is divided into five genera: Vesivirus, Lagovirus, Sapovirus, Norovirus and the 
recently classified Nebovirus (94, 154), Figure 1.2. Four unclassified tentative calicivirus genera have 
also been identified, these are: Recovirus, which includes the Tulane virus, an enteric virus of rhesus 
A B
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macaques, and a novel strain recently identified in human stool (134, 370); Valovirus, which includes 
the swine St-Valérien-like viruses (222); and the Nacoviruses and Bavoviruses, both of which infect 
poultry (448, 449).  Of the classified genera, the Vesivirus genus contains feline calicivirus (FCV), a 
common cause of respiratory infections in cats with the potential to cause severe systemic disease 
from highly virulent strains (337). Another prominent vesivirus is the San Miguel sea lion virus, which 
causes vesicular lesions, abortion and encephalitis in marine mammals and is similar to the vesicular 
exanthema of swine virus (291). The Lagovirus genus members are restricted to lagomorph hosts 
(rabbits and hares) and include rabbit haemorrhagic disease virus (RDHV) that causes a disease from 
which the virus takes its name. The sapoviruses and noroviruses are both causative agents of 
gastroenteritis. Human sapoviruses, the prototype stain of which is the Sapporo virus, have typically 
been associated with gastroenteritis in young children, although adult infections have also been 
reported (202). Porcine sapoviruses are closely related to the human strains and novel sapoviruses 
have recently been found in bats (221, 419). 
The Norovirus genus displays remarkable genetic and antigenic diversity and is further divided into 
five genogroups (GI-V), based on the sequence of the major capsid protein (VP1), Figure 1.2. Human 
norovirus (HuNV) was first observed in 1968 in an outbreak of gastroenteritis in a school in Norwalk, 
Ohio, USA. This gave rise to the prototypical HuNV strain, named Norwalk Virus. Norwalk virus was 
not identified as the etiological agent until 1972, when volunteers fed filtered stool samples from 
infected children suffered the same symptoms (208). This was the first observation that an enteric 
virus could directly cause gastroenteritis (208). Norwalk virus belongs to genogroup I (GI) but HuNVs 
have since also been classified into in GII and GIV, which can differ by up to 50% in nucleotide 
identity (132, 423). GII also contains the porcine noroviruses (395); GIII the bovine and ovine 
noroviruses (300, 450); GIV the canine and lion noroviruses (266, 277) and GV viruses are restricted 
to rodents (369, 418), Figure 1.2. The five genogroups can be further divided into genotypes. There 
are currently 14 in GI, 17 in GII, 2 in GIII and only 1 in both GIV and GV, although novel GV clusters 
have recently been identified (18, 341, 418). 
Introduction 19 
 
Caliciviridae 
 Norovirus      Vesivirus      Lagovirus      Sapovirus      Nebovirus 
Norwalk 
Virus 
FCV RDHV Sapporo- 
virus 
Newbury-1 
Virus 
       GI                  GII                GIII                  GIV                  GV     
   Human            Human           Bovine                Human                Murine 
                           Porcine           Ovine                 Canine 
  GI.1-14            GII.1-17             GIII.-2                 GIV.1                  GIV.1 
The full impact of the animal norovirus strains is only beginning to be investigated. For example, 
recent reports state that bovine norovirus is endemic in dairy herds in the UK and other European 
countries (301), although the full morbidity and economic impact is yet to be established. Likewise, 
porcine norovirus typically results in asymptomatic infections in healthy pigs but it has recently been 
found to cause diarrhoea in piglets (358).   
 
 
 
 
 
 
 
 
 
 
Figure 1.2. The Caliciviridae family of small positive strand RNA viruses. The family divided into 5 
genera and the prototypical virus is given for each genus, FCV: feline calicivirus, RDHV: rabbit 
haemorrhagic disease virus. There are 4 unclassified proposed genera of the family, the Recovirus, 
Nacovirus, Bavovirus and Valovirus, not shown here. The Norovirus genus is further divided into 5 
genogroups (G) whose strains exhibit a wide host tropism as shown. The genogroups are further 
divided into genotypes. 
 
 Epidemiology and transmission of HuNV 1.2
HuNV is a major cause of viral gastroenteritis worldwide resulting in an estimated 23 million 
infections in the USA every year (CDC, 2006) and at least 2 million in the UK (321). On average HuNV 
is responsible for 71,000 hospitalisations every year in the USA, which can surge to over 110,000 in 
epidemic years, at a cost of at least $493 million (255). Strains belonging to genotype GII.4 have 
been responsible for over 70% of outbreaks since 2001 and have caused epidemics in 1995-96, 2002, 
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2004, 2006, 2007-8, 2009 and 2012, which have coincided with the emergence of new GII.4 variants 
(57, 254, 362, 420, 422). There is evidence of much wider strain diversity and prevalence in 
developing countries (8, 456), although difficulties in surveillance, sampling and the limited 
availability of molecular diagnostics in some settings are thought to hinder accurate comparison 
(216). In the UK the norovirus surveillance year runs from July to June to cover the winter season, 
when cases peak in the northern hemisphere, giving rise to the media’s nickname for norovirus: ‘The 
Winter Vomiting bug’.  The epidemiological seasonality of norovirus is not fully understood and 
whilst some studies have reported correlations between cold temperatures and rainfall with 
increased infection rates, it is likely a complex combination of factors also including social behaviour, 
winter hospitalisations from other infectious diseases and yearly waning herd immunity (53, 253). 
Outbreaks in developed countries typically occur in places with close living environments, such as 
hospitals, schools, care homes, military bases and notoriously cruise ships (24, 329, 345, 416, 444). In 
hospitals, outbreaks result in ward closures, staff illnesses and up to 47,000 lost bed days a year 
(Health Protection Agency 2009). In 2002-2003, a year of high incidence, the total cost to the NHS 
was estimated at £115 million (256), making HuNVs economically significant pathogens with the 
potential to jeopardise hospital services.  
The ability of HuNV to thrive in enclosed environments is due to a number of properties, which 
combine to result in large fast spreading epidemics. Firstly, HuNV is highly infectious and only a very 
low infectious dose (<102 viral particles) is required to establish infection (411). Secondly 
transmission can occur by multiple routes. The primary route is faecal-oral via contaminated 
surfaces (79), however airborne transmission is also possible by viral particles contained within 
droplets of aerosolised vomit (264). Studies suggest that up to 3x107 viral particles can be spread as 
an aerosol by projectile vomiting induced by HuNV, and some reports have found an inverse 
correlation between attack rate and proximity to the symptomatic individual (66, 264). Finally, 
noroviruses are highly stable in the environment and are resistant to the majority of common 
disinfectants, with the exception of high chlorine concentrations. Thus they can persist on 
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contaminated surfaces despite regular cleaning practices (79). Most studies on the stability of HuNV 
have however been based solely on detection of the viral genome after surface cleaning and only 
more recently have culturable surrogates for HuNV (discussed later) been used to determine that 
this correlates with infectivity (37). There are numerous accounts that illustrate the combined effect 
of these properties on the efficient spread of HuNV. One representative example concerns an 
outbreak in which 9 of 11 members of a football team were infected after handling a contaminated 
carrier bag (328).  The carrier bag, which tested positive for norovirus, had been kept in the 
bathroom of a symptomatic individual and was later passed around the team containing food. 
Contamination occurred via aerosolised vomit as the original patient had not been in direct contact 
with the bag or the rest of the team and the virus was stable on the surface of the bag for a number 
of days (328). This example also highlights the importance of vigilant hygiene as the only existing 
control measure for HuNV. 
The environmental stability of HuNV also facilitates spread via contaminated food and as such it 
accounts for approximately 50% of all foodborne gastroenteritis in the USA (443). The most common 
sources of infection are contaminated seafood, lettuce and berries, as high cooking temperatures 
are required for inactivation and HuNV remains stable in water and during refrigeration (163, 181). 
HuNV can also survive in water mixed with the majority of pesticides, which represents a potential 
point of introduction into the food chain, alongside direct contact with infected food handlers (29, 
426). Seafood contamination generally occurs more directly from sewage contaminated water, from 
which oysters and other filter feeders are able to concentrate HuNV. It was recently reported that 
over 75% of all sampled oysters in the UK tested positive for HuNV, and often for multiple 
genogroups, highlighting the scale of this problem (257, 292). Both oysters and lettuce leaves have 
been found to express carbohydrates that can serve as attachment factors for HuNV allowing 
specific binding and bioaccumulation, which challenges elimination by conventional purification 
methods (128, 231).  
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The possibility of zoonotic norovirus transmission has also been raised. These concerns arise mainly 
from the close clustering of HuNVs and porcine noroviruses in GII (395, 434). The theory has been 
supported by the finding of strains resembling HuNV GII.4 in pigs and in retail meat and the 
observation that some HuNV strains are able to infect gnotobiotic pigs and calves (80, 270, 381). 
Human GII.4 strains have also recently been found in stool samples from pet dogs in contact with 
symptomatic owners, suggesting dogs could be a potential transmission route, although as yet there 
is no evidence that HuNV can replicate in the canine gastrointestinal tract (398). Overall the zoonotic 
hypothesis has been largely dismissed due to the lack of evidence for animal strains in humans, in 
addition to the large genetic differences and different attachment factor usages between many 
human and animal strains (133, 300, 306, 352, 462, 463). Neither is there evidence as yet for 
recombination between strains from different species, although inter- and intra-genogroup 
recombination between HuNV strains has been observed (224, 320). The continual emergence of 
new GII.4 variants capable of causing fresh epidemics also suggests that the success of HuNV is not 
reliant on interactions with animal strains. 
 Disease 1.3
HuNV infection is characterised by severe diarrhoea and projectile vomiting, often accompanied by 
fever, stomach cramps, bloating and aching limbs. The virus has a short incubation period ranging 
from 12-48 hours and thus symptoms are typically of rapid onset. Increased severity of symptoms 
has been reported for GII.4 infections, resulting in a higher percentage of hospitalisations (100). A 
number of more serious symptoms have been associated with HuNV infection, particularly in high 
risk target groups such as the very young and elderly. These include necrotising enterocolitis in 
neonates (391, 421), seizures in children (69, 81), acute liver dysfunction in adults (288, 467) and 
links have also been established with Crohn’s disease (59), chronic gastrointestinal disease (322) and 
post-infectious irritable bowel syndrome (PI-IBS) (465). However there are mixed reports regarding 
HuNV as a trigger for PI-IBS (267, 465), and no underlying mechanisms have been established to 
directly implicate HuNV in the exacerbation of these conditions. It is worth noting however that 
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there have only been two studies investigating the mechanisms behind HuNV-induced diarrhoea. 
Examination of infected duodenal biopsies concluded that diarrhoea is driven by epithelial barrier 
dysfunction resulting from enterocyte apoptosis (in part mediated by cytotoxic T cell infiltrates) and 
down-regulation of tight junction proteins that seal the epithelial layer (417). Loss of function 
therefore results in leak flux of water back into the intestinal lumen. Increased anion secretion is 
also thought to contribute and has been shown to cause severe watery diarrhoea arising from other 
intestinal pathogens (417).   
In the majority of cases infection is self-limiting and clears within several days. However prolonged 
viral shedding after the resolution of clinical disease has been described in otherwise healthy 
individuals, as have asymptomatic infections (19, 139). Whilst asymptomatic shedders represent a 
continued risk of transmission, the likely occurrence of this is thought to be low (397). There are 
increasing reports however of chronic symptomatic infections in the immunocompromised, such as 
transplant recipients, cancer chemotherapy patients and HIV-infected patients with severe 
immunosuppression (232, 351, 445). In these cases infection can result in treatment complications, 
including transplant failure (338), and increased mortality often linked to malnutrition (46, 333). The 
severity of infection has been observed to correlate with the degree of immunosuppression and 
HuNV illness may often be resolved by cessation of immunosuppressive treatments (350), albeit at 
the risk of transplant rejection. To date, the longest reported infection is 898 days of persistent virus 
shedding and intermittent diarrhoea (350), although there are unpublished reports of infections 
lasting over 8 years (I. Goodfellow, personal communication). Hospitalised chronically infected 
patients can act as a regular source of nosocomial transmission and continued viral evolution (218, 
350, 396). 
It has recently been reported that HuNV is the second largest cause of gastroenteritis-associated 
mortality in developed countries, behind Clostridium Difficile (162). Despite this mortality rates are 
generally low and only target groups such as the immunocompromised, young and elderly are 
typically at risk, with an estimated 80 deaths in the elderly occurring each year in England and Wales 
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(171). Data from the USA suggests however that HuNV mortality rates can double in epidemic years 
(162). In contrast, estimates from developing countries suggest that HuNV may be responsible for at 
least 200,000 deaths in children under 5 each year, although this is likely to be a substantial 
underestimate due to limited epidemiological surveillance and difficulties in conclusive diagnosis 
(311). 
 The challenges of studying HuNV in vitro 1.4
Despite the identification of Norwalk Virus over 4 decades ago and complete sequencing of the 
genome in 1990 (208, 452), all attempts to establish an efficient cell culture system have failed, 
making the study of HuNV highly challenging. Efforts to culture HuNV have been initiated in a 
number of labs and have involved testing a wide variety of cell lines and culture conditions. Of the 
reported attempts (and there are likely to have been as many unreported), most have focussed on 
human gastrointestinal tract epithelial cell lines, in addition to a selection of common cell lines of 
human and animal origin (116). The use of differentiation factors and cell culture supplements has 
also been trialled without success, including insulin and DMSO for differentiation, and gastric juices, 
bile acids, human intestinal contents and digestive enzymes (116).  
Following the discovery of a murine norovirus (MNV) which replicates in macrophage and dendritic 
cells (discussed later), the focus has shifted to testing HuNV in cells of the haematopoietic lineage.  
As MNV was originally isolated in mice deficient in the signal transducer and activator of 
transcription 1 (STAT1) interferon (IFN) pathway, suppression of IFN signalling has also been tested 
in haematopoietic cell lines  (209, 230, 239, 447). To date these attempts have not yielded success 
and whether HuNV shares a similar immune cell tropism remains unclear. It has been shown that 
transfection of HuNV RNA, either isolated from stool or expressed from a DNA vector, is able to 
replicate and produce viral particles in mammalian cells (15, 158). These studies suggest that the 
barrier to cell culture is at the level of viral entry or uncoating, and may be due to the absence of an 
unidentified cellular receptor for HuNV in the cell lines tested thus far. 
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It is possible that a specific receptor or factor required for infection is only expressed upon full cell 
differentiation in a 3D milieu as found in vivo, for example with apical and basolateral polarisation of 
epithelial cells. In support of this theory is the observation that an ex vivo human adult duodenal 
culture was fully permissive for HuNV GII.4 infection. Active viral replication was observed by an 
increase in genomic RNA levels, expression of non-structural viral proteins and detection of negative 
sense viral RNA, the replication intermediate (239). Staining for viral antigens was found to be most 
intense in glandular epithelial cells, however a glandular epithelial cell line subsequently only 
supported limited  HuNV replication (239). This model has not yet been adopted for further studies, 
perhaps due to the limited availability of ex vivo duodenal cultures.  
On the basis that a 3D environment may provide a more physiologically relevant system to support 
infection, Straub et al developed a 3D small intestinal epithelial model (INT-407) (388). The system 
was originally established for the study of Salmonella pathogenesis and involves cell culture in a 
rotating wall vessel that allows formation and differentiation of 3D aggregates (293). This system 
was reported as the first cell culture system for HuNV, following observations of cytopathic effect 
after inoculation with GI and GII viruses, isolated from infected stool samples (388). Two other 
human intestinal cell lines cultured in the same 3D manner were also shown to support limited RNA 
replication, however the reproducibility of these systems was later reported to be problematic even 
within the same laboratory (387, 389). Furthermore attempts to replicate this system by others have 
failed and this model has been widely questioned and dismissed (180, 308).  
In the absence of a cell culture system, several alternative methods have been established to 
facilitate the study of HuNV in vitro. The first of which is the replicon system, which consists of a 
human hepatoma cell line (Huh-7) expressing self-replicating Norwalk virus genomic RNA (74). This is 
generated by transfection of the viral RNA, engineered to carry a neomycin resistance gene in place 
of the viral ORF encoding the major capsid protein. Selection with G418 then results in stable 
maintenance of the RNA, accompanied by viral protein expression and RNA replication (74). The 
main use of the replicon system has been to assay potential antiviral compounds and identify 
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cellular factors associated with norovirus replication (47, 70, 71, 74). A complementary system to the 
replicon is the use of recombinant virus-like particles (VLPs), which provide the opportunity to study 
the viral capsid, the only component missing from the replicon system. VLPs self-assemble upon 
expression of the major capsid protein (VP1) and have been generated by a variety of expression 
systems including baculoviruses, human cells, venezuelan equine encephalitis virus replicon particles 
and plants (27, 155, 191, 201, 404). Irrespective of the production method, VLPs are in-
distinguishable from native virions in terms of morphology and antigenic properties (201). As such 
they have largely been used to study antibody responses and interactions with cellular attachment 
factors (169, 170, 191, 195). 
 In vivo models for HuNV 1.5
Much of what is known about norovirus pathogenesis and immunity has come from experimental 
infection of human volunteers. Typically volunteers are administered with stool filtrates from 
infected patients and then monitored for disease outcome, duration of infection, duration and type 
of immunity (also resulting from inoculation with VLPs) and the mixed role of serum antibody 
responses in protection (102, 153, 203, 244, 310, 331, 401, 414). The biological properties of the 
virus have also been investigated by volunteer studies in addition to the duration and magnitude of 
shedding, which were found to be on average 28 days and 9.5 x10^9 genome copies per gram of 
faeces, respectively (19). Perhaps the most significant outcome of volunteer studies has been the 
identification of histo-blood group antigens as host susceptibility factors, which will be discussed in 
more detail in section 1.8.1 (193, 245). Whilst studying a virus in its native host clearly provides the 
most relevant model of infection, the HuNV volunteer model has a number of limitations, the most 
obvious of which being sample size and recruitment of volunteers. Furthermore, many of the early 
volunteer studies were complicated by the potential inclusion of genetically resistant individuals and 
the absence of pre-exposure histories. Experiments depend on the availability of safety-tested 
norovirus innocula and are of great expense. Finally, studies at the cellular level are hindered by the 
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invasive nature of biopsy during the acute phase, alongside biocontainment problems when taking 
samples.  
Given the difficulties in implementing human volunteer experiments, a robust animal model of 
infection has been long sought after. A number of nonhuman primate species have been tested for 
permissibility to HuNV with mixed results. Rhesus macaques were found to be susceptible to 
Norwalk virus (332) but infections were asymptomatic and sporadic (332). Infection of newborn 
pigtail macaques resulted in transmissible clinical illness including diarrhoea and vomiting (394) but 
this model has not yet been used to probe any aspect of HuNV infection. Chimpanzees were 
originally demonstrated to be permissive to asymptomatic infection by Norwalk virus in 1978 (451) 
and have more recently been proposed as a model to evaluate vaccine candidates as they develop 
antibody responses (48). In chimpanzees, viral antigen was detectable in the cytoplasm of cells in the 
small intestine lamina propria and in particular in cells of the dendritic lineage expressing DC-sign. 
This supports the idea of an immune cell tropism, and although HuNV does not replicate in PBMC-
derived dendritic cells, a specific intestinal cell expressing DC-sign could still be involved (230).  
Gnotobiotic pigs have also been developed as an animal model for HuNV, following the finding of 
strains resembling human GII.4 viruses in domestic pigs (80, 434). Infection with a GII.4 HuNV, 
closely related to porcine noroviruses, consistently produces mild diarrhoea in approximately 75% of 
inoculated gnotobiotic pigs (80, 382). Translation of non-structural viral proteins has been detected 
in enterocytes, which indicates active viral replication but further confounds the issue of cell tropism 
of HuNV (80). This model has since been used to evaluate the type, magnitude and kinetics of 
cytokine and antibody responses following HuNV infection and vaccination with VLPs (382, 383).  
Similarly, gnotobiotic calves are permissible to infection by HuNV GII.4 as well as bovine norovirus 
strains (165, 381), however the large size of these animal models precludes widespread use. 
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 Surrogate models for HuNV 1.6
Efficient cell culture systems have been established for a small number of caliciviruses, which have 
contributed to understanding of calicivirus and norovirus biology. These include porcine enteric virus 
(PEC), feline calicivirus (FCV), rabbit haemorrhagic disease virus (RDHV), the Tulane virus (TV) and 
murine norovirus (MNV). PEC, a member of the Sapovirus genus which produces gastroenteritis in 
pigs, can be manipulated by reverse genetics and grown in porcine kidney continuous cell lines (LLC-
PK). Cell culture is only possible with the addition of bile acids, which result in suppression of IFN 
signalling mediated by STAT1, a key player in innate immunity (72, 73). TV, a member of the 
proposed Recovirus genus, can be cultured in monkey kidney cells and also has a reverse genetics 
system available (134, 437). TV has recently been shown to cause gastroenteritis in rhesus macaques 
(354), altogether making it a strong model to study calicivirus replication, pathogenesis and 
immunity. Due to the early availability of reverse genetics and a cell culture system, FCV has been 
most widely used in studies of calicivirus replication, translation, inactivation and environmental 
stability (217, 376). Although FCV does not provide a suitable in vivo model for HuNV gastroenteritis, 
as infection manifests as respiratory or systemic disease, it shares many protein orthologs with 
noroviruses and similarities at the level of replication. In terms of genetic conservation, the 
nucleotide identity between all of these surrogate models and HuNVs range from 32-42% (423). 
MNV was discovered in 2003 and is to date the only norovirus that can be propagated in cell culture, 
displaying a tropism for macrophage or dendritic cells (447).  Both DNA- and RNA-based reverse 
genetics systems are now available to allow the study of genetically defined noroviruses (10, 78, 435, 
461). MNV-1 was first identified as the cause of a lethal infection in immunocompromised (STAT1/ 
RAG2-/-) hosts, where infection was systemic and lead to encephalitis, vasculitis of cerebral vessels, 
meningitis, hepatitis and pneumonia. The severity of infection was attributed to the absence of 
STAT1 as STAT1-/- mice succumbed to infection with similar symptoms within the course of 7 days. In 
contrast MNV-1 infection in RAG1/2-/- mice resulted in a persistent infection with viral genomic RNA 
still detectable in the faeces and multiple visceral organs at 90 d post infection. In 
Introduction 29 
 
immunocompetent hosts, MNV-1 infection is subclinical and can be cleared within 5 days (209). The 
majority of other MNV strains identified since cause persistent infections in immunocompetent 
hosts (189, 190, 413). For example, MNV-3 causes an asymptomatic infection in wild type mice and 
viral RNA can be detected in the caecum, colon, mesenteric lymph node and in the feces for at least 
56 days (10). MNV has since been isolated from wild mice, indicating its natural widespread 
distribution (368). Moreover it is a highly prevalent pathogen in laboratory mice, with some facilities 
reporting 50-70% seroprevalence (294). In terms of a surrogate model, MNV shares over 50% nt 
identity with HuNV, which is similar to the identity between HuNV strains from different genogroups 
(423). Like HuNV, MNV is an enteric pathogen and is spread by the faecal-oral route. MNV provides a 
model for both acute and persistent HuNV infections, although disease manifestation can differ as 
MNV infections in immunocompetent mice are largely asymptomatic and mice do not possess an 
emetic response, nor do they routinely develop diarrhoea. However as with HuNV, MNV has also 
been linked to the exacerbation of irritable bowel conditions (59). Whilst MNV strains display large 
biological diversity, there is limited genetic diversity as all strains fall within a single genogroup and 
serotype (413), which hinders the use of MNV as a model for vaccine development. However due to 
the high conservation at the genetic and protein levels, MNV has become a valuable tool to probe all 
aspects of the norovirus lifecycle. 
 Norovirus genome organisation 1.7
The norovirus genome is a single stranded positive sense RNA of approximately 7.4kB. The 5’end is 
covalently attached to a viral genome-linked protein (VPg), whilst the 3’ end is polyadenylated, 
Figure 1.3. The 5’ and 3’ untranslated regions (UTRs) are extremely short (for examples, 5 and 78 nt 
in MNV respectively (209)) and contain evolutionarily conserved RNA secondary structures that 
extend into the coding regions and can be found throughout the genome (366). These structures are 
known to be important for viral replication, translation and pathogenesis (22, 274, 366).           
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Figure 1.3 Organisation of the murine norovirus genome. The genome is covalently attached to VPg 
(NS5) with a polyA tail and is divided into 4 ORFs. ORF1 is translated as a polyprotein which is 
cleaved by the viral protease NS6 to produce the non-structural proteins. ORFs 2,3 and 4 are 
translated from a subgenomic RNA. HuNV shares a similar genome organisation but does not 
possess ORF4. 
 
The norovirus genome is organised into 3 conserved open reading frames (ORFs), and MNV has a 
fourth ORF that is not present in HuNV, Figure 1.3. Human sapovirus is the only other member of the 
Caliciviridae family to have an equivalent fourth ORF (248). The norovirus ORF1 is translated as a 
large polyprotein, which is co- and post-translationally cleaved by the virus-encoded protease (NS6) 
to release 6 mature non-structural (NS) proteins including NS6 itself (378). The other NS proteins 
include the viral RNA dependant RNA polymerase (NS7), VPg (NS5), the putative NTPase/RNA 
helicase (NS3) and NS1-2 and NS4, which have both been implicated in replication complex 
formation (198). ORF2 and ORF3 are translated from a subgenomic RNA and encode the major and 
minor capsid proteins, VP1 and VP2 respectively. The subgenomic RNA is identical to the last 2.4kB 
of the genome and is also covalently attached to VPg at the 5’end with a polyA tail at the 3’ end 
(179). For MNV, ORF4 is translated from an alternative reading frame within ORF2 and encodes the 
recently identified protein virulence factor 1 (VF1), a novel innate immune regulator (45). The 
nomenclature for the proteins of HuNV and MNV has yet to be unified in the literature and is 
summarised in Table 1.1. The names stated here relate to MNV and will be the principal ones used 
throughout this thesis. The orthologs for FCV are also listed as they will be referred to for 
A(n)
A(n)
ORF1
ORF2 ORF3
ORF4
VPg
VPg
NS1-2  NS3  NS4  NS5   NS6    NS7 
VF1
VP1             VP2
MNV
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comparisons of the viral proteins. The genome structure and organisation of FCV is largely conserved 
with HuNV with just 3 ORFs. However post-translational processing of ORF2 results in the expression 
of an additional protein named the leader of the capsid protein (LC), which has been associated with 
the induction of cytopathic effects (3). The functions of the viral proteins will be discussed in the 
context of the viral lifecycle and are also analysed in greater detail in Chapter 3. 
 
MNV Protein HuNoV ortholog FCV ortholog 
NS1-2 p48 p32 
NS3 NTPase p39 (NTPase) 
NS4 p22 p30 
NS5 (VPg) VPg VPg 
NS6 Pro Pro 
NS7 Pol Pol 
VP1 VP1 VP1 
VP2 VP2 VP2 
VF1 
No equivalent 
No equivalent 
No equivalent 
No equivalent 
LC 
Table1.1 The murine norovirus proteins and their HuNV and FCV orthologs. 
 
 The norovirus lifecycle 1.8
Due to the lack of a cell culture system for HuNV understanding of the norovirus lifecycle, including 
the molecular mechanisms behind each stage and the role of the viral proteins, is limited compared 
to other RNA viruses. Studies with MNV have begun to address this and much information can be 
gained through comparisons to the lifecycle of FCV, which has been more extensively characterised. 
An overview of the norovirus lifecycle is given in Figure 1.4.  
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Figure 1.4 Outline of the norovirus lifecycle. 1. HuNV and MNV are thought to attach to the cell 
surface using different carbohydrate attachment factors (purple diamonds). This is not sufficient to 
mediate entry and binding to an unidentified protein receptor is thought to be required (2.). 3. Entry 
and uncoating (4) proceed through as yet undefined pathways. 5. The incoming viral genome is 
translated, through interactions with VPg at the 5’ end of the genome (red pentagon) and the 
cellular translation machinery. 6. The ORF1 polyprotein is co- and post-translationally cleaved by NS6 
(purple).7. The replication complex is formed by recruitment of cellular membranes (grey crescents) 
to the perinuclear region, through interactions in part with NS1-2 (orange) and NS4 (yellow). 8. 
Genome replication occurs via a negative strand intermediate and genomic and subgenomic RNA are 
generated by the viral RNA dependent RNA polymerase, NS7 (green circle), using VPg as a protein 
primer. 9. The replicated genomes are translated (within the replication complex) or packaged into 
the capsid, VP1, for virion assembly. (10.) The exit pathway has not yet been characterised. * 
indicates steps that have not yet been fully characterised.  
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1.8.1 Viral attachment and entry  
The non-enveloped norovirus virion is a proteinaceous capsid that is responsible for mediating cell 
binding and entry. Electron microscopy studies of HuNV VLPs revealed that the capsid is composed 
of 180 copies of VP1, stabilised by just 2 copies of the minor capsid protein VP2, Figure 1.5 (41, 324). 
The structure of VP1 is divided into an N terminal arm, a shell (S) domain and a protruding (P) 
domain (323). The S domain forms a smooth shell around the viral genome, whilst the P domain 
extends from the surface of the capsid and dimerises into arch-like structures (323). The P domain is 
further divided into the P1 domain, which forms the base of the arch and is heavily involved in 
dimerisation interactions, and the P2 domain, the top of the arch, which is the least conserved 
domain and contains the binding sites for cellular carbohydrate attachment factors and also sites for 
antigenicity, Figure 1.5 (62, 210, 251, 407).   
 
 
Figure 1.5. The HuNV capsid. The norovirus capsid is composed of 180 copies of VP1, the major 
capsid protein, and 2 copies of VP2, the major capsid protein. VP1 is composed of a shell (S) domain, 
shown in blue, which encases the viral genome. The protruding (P) domain is divided into a P1 
domain (red) involved in dimerization interactions and P2 (yellow) which contains the sites for 
attachment factor binding and antigenicity. The structures of the intact capsid and monomeric VP1 
have been determined by a cryo-EM and x-ray crystallography respectively (323, 324)  
Histo-blood groups antigens (HBGAs) expressed on intestinal epithelial cells have been identified as 
attachment factors for HuNV. There is however no direct evidence that binding mediates entry and 
P2 domain
P1 domain
S domain
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overexpression of HBGAs does not facilitate successive rounds of infection in transfected non-
permissive cells (158), suggesting an additional receptor may be involved. The role of HBGAs in 
attachment was clearly demonstrated in a large scale study of naturally acquired infections, in which 
secretor negative individuals were resistant to HuNV infection (415). This finding has been supported 
by numerous volunteer studies and in vitro binding assays with VLPs (263). Secretor negative 
individuals do not express a functional fucosyltransferase 2 enzyme (FUT2) and consequently are 
unable to produce H antigens, which are a precursor to the A, B and O blood group antigens. Over 
20% of the European population is thought to be secretor negative (415), suggesting they should be 
resistant to infection by Norwalk virus. There is also evidence that blood group type can influence 
susceptibility to Norwalk virus (194), although this is more complex for the GII.4 strains (115, 226). 
GII.4 viruses are able to infect secretor negative individuals, suggesting that they can use alternative 
attachment factors (63, 343, 402). The wider binding profile of GII.4 strains has been proposed to 
account, in part, for their greater epidemiological success compared to GI viruses (115, 246).   
Animal noroviruses and other caliciviruses have also been found to use HBGAs as cellular attachment 
factors (296, 463). Like HuNV, MNV also uses cell surface glycans for attachment but with a 
preference for terminal sialic acids on either glycolipids, such as the ganglioside GD1a expressed on 
murine macrophages, or on N- and O-linked glycoproteins (405, 406). Binding to these different 
ligands is again virus-specific and influences tissue tropism in vivo (405). Glycan-binding is also not 
sufficient to mediate internalisation of MNV and a protein receptor has not yet been found. FCV is 
the only calicivirus for which a receptor capable of mediating entry has been identified. FCV also 
uses glycans for attachment, specifically α2,6-linked sialic acids in the upper respiratory tract, before 
binding and engaging the junction adhesion molecule 1 (JAM-1) for internalisation (260, 390).  
The entry pathway and mechanisms for uncoating following receptor binding have yet to be fully 
elucidated. Studies with MNV have shown that entry and uncoating in macrophage cells is pH-
independent (314), as may be expected given the infection route through the acidic pH of the 
stomach.  Entry of MNV is not dependent on clathrin- or caveolin-mediated endocytosis but requires 
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cholesterol and dynamin II, and phagocytosis and macropinocytosis have been excluded as the major 
routes (143, 315).  
1.8.2 Viral protein translation 
The first event after genome release is thought to be translation of the viral proteins from the 
incoming positive strand RNA genome, which resembles mRNA. Translation of calicivirus genomes 
occurs by a unique mechanism that is not found in other animal RNA viruses, but is thought to be 
similar to that used by some plant viruses, such as the Potyviridae family (238). Translation is 
mediated by VPg covalently bound to the 5‘ end of the genome, which acts as a cap-substitute, 
interacting with host cell translation initiation factors. The VPg of HuNV and MNV have both been 
shown to interact with components of the eIF4F translation initiation factor complex, in particular 
eIF4E, the direct cap-binding protein, and eIF3, which is recruited to the complex and in turn helps to 
recruit the 43S ribosomal pre-initiation complex (95, 147). MNV translation has also been shown to 
require eIF4A, the RNA helicase component of eIF4F, potentially for unwinding RNA structures 
present in the 5’ end of the genome (77), and eIF4G, a scaffold component of the complex that helps 
to recruit other factors (96). However it should be noted that only direct interactions have been 
demonstrated for eIF3 and eIF4E. Translation of FCV differs in its functional requirements, as in 
comparison to norovirus translation it requires all components of the eIF4F complex (77).  
The extremities of calicivirus genomes contain highly ordered RNA structures that are thought to 
interact with host cell factors to promote viral replication and translation (366, 424). For example, 
structures in the Norwalk virus 5’ and 3’ ends are thought to interact with the cellular proteins La, 
the polypyrimidine tract binding protein (PTB) and the poly(A) binding protein (PABP) and these 
proteins have also been identified in binding RNA structures in the MNV genome (159, 160, 424). 
Binding of these and other factors may serve to enhance viral protein translation, perhaps through 
stabilisation of long range RNA interactions that promote circularisation of the genome (346). 
However the direct effects of each cellular protein on norovirus translation have yet to be 
determined.  
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Translation of the ORF1 polyprotein and post-translational processing by NS6 releases the non-
structural proteins and their precursors, some of which are known to be functionally active in 
replication (38, 438). Translation of the viral proteins VP1 and VP2 (and VF1 in MNV) is thought to 
occur primarily from the subgenomic RNA. This may be a strategy to produce higher levels of the 
major capsid protein for virus assembly, in comparison to the lower requirement for non-structural 
proteins. Translation of VP2 is thought to occur by a termination-reinitiation strategy, which has 
been demonstrated using MNV and FCV (278, 289). Upon termination of ORF2 translation (VP1), 
ribosomes are thought to remain associated with the RNA to reinitiate at the start of ORF3 (VP2). 
This is achieved by overlapping stop and start codons of ORF2 and ORF3 respectively, for example 
UAAUG in MNV. An upstream RNA motif known as the termination upstream ribosomal binding 
sequence (TURBS) is also required, which is in part complementary to 18S ribosomal RNA and is 
thought to tether the ribosome through base pair interactions (289). 
1.8.3 Genome replication 
Similar to other positive strand RNA viruses, norovirus replication occurs in membrane bound 
complexes in the cytoplasm (40, 199). MNV infection induces the formation of membranous vesicle 
clusters, derived from membranes of the secretory pathway (the ER, trans-Golgi network and 
endosomes), which serve as a platform for replication (199). The NS1-2 and NS4 proteins in MNV 
(and their equivalents in FCV), have been implicated in formation of the replication complex through 
localisation to different membranous organelles, although the mechanisms driving assembly of the 
complex are unknown (21, 198). The MNV replication complex locates to the perinuclear region at 
the mitochondrial organising centre (MTOC) and positioning of the complex is thought to be 
mediated by interactions between VP1 and acetylated tubulin, although a direct interaction has not 
been demonstrated (197).  
 As for all positive sense RNA viruses, genome replication occurs via a negative strand intermediate 
and is performed by the viral RNA dependent RNA polymerase (RdRp). The norovirus RdRps contain 
active site residues conserved among other positive strand RNA virus RdRps, and are thought to be 
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structurally and functionally conserved (183). The replicative properties of the MNV RdRp (NS7) are 
comparable in vitro to those of the HuNV RdRp (3Dpol), supporting the use of MNV for studies of 
replication (54).  
Initiation of RNA synthesis by norovirus RdRps is thought to occur by 2 different mechanisms. For 
initiation on positive sense genomic and subgenomic RNA, the polymerase uses VPg as a protein-
primer for RNA synthesis. This mechanism is also employed by other animal caliciviruses and 
members of the Picornaviridae family of positive strand RNA viruses (258, 290, 312, 334). The 
polymerase covalently attaches VPg to the genome by guanylation of VPg, whereby a phosphodiester 
bond is formed between the guanine at the 5’end of the genome and a conserved tyrosine residue in 
VPg (Y26 in MNV and Y27 in HuNV) (392). This linkage is essential for infectivity (39, 158). 
Biochemical and structural studies have indicated that the conformation of VPg and its helical core is 
central in facilitating the VPg-RdRp interaction, and an element at the 3’ end of the genome is 
thought to enhance the efficiency of nucleotidylylation (39, 235). The second mechanism of initiation 
is VPg-independent and involves de novo initiation on antigenomic and antisubgenomic templates, 
suggesting that features in the RNA may determine the mode of initiation (334).The de novo 
initiation of norovirus RdRps is enhanced through direct interactions with the shell domain of VP1, in 
a species specific manner. Species-specific interactions with NS1-2 were also found to promote RdRp 
activity, whereas interactions with VP2 proved inhibitory (392, 393). Taken together this suggests 
that the viral proteins may play alternative regulatory roles, perhaps at different stages in the 
norovirus lifecycle. The HuNV 3Dpol is also thought to be regulated by phosphorylation by the 
cellular survival kinase Akt (120). Akt phosphorylates 3Dpol on residue T33, which is conserved 
among pandemic HuNV GII.4 strains but absent in non-pandemic strains (120). However the 
implications of Akt regulation of 3Dpol activity on infection have not been fully investigated. 
Two theories have been put forward to explain the initial production of subgenomic RNA during 
norovirus replication. The first involves premature termination during synthesis of the antigenomic 
RNA, arising from an unidentified termination signal. The resulting negative sense subgenomic RNA 
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would then serve as a template for the production of positive sense subgenomic RNA. The second, 
more widely accepted model is that an RNA secondary structure upstream of ORF2 in the 
antigenomic RNA acts as a promoter for synthesis of positive strand subgenomic RNA. Bioinformatic 
and mutational analysis of antigenomic RNA within our laboratory has identified the presence of a 
small stem loop structure, which is thought to act as a promoter sequence for production of 
subgenomic RNA by NS7 (Amir Yunus, unpublished data).  
1.8.4 Interactions with host cell factors and pathways. 
Interactions with host cell proteins and cellular pathways are essential for achieving productive 
replication for many positive strand RNA viruses (286), yet knowledge of host cell interactions 
involved in the norovirus lifecycle lags behind that of other RNA viruses. Several studies have 
demonstrated interactions between host cell proteins and structures in the viral RNA, which may 
play an essential role (22, 159, 160, 346, 424). One such study used riboproteomics to identify host 
cell factors that interact with the 5’ and 3’ ends of the MNV genome (424). Some of the interaction 
partners were shown to localise with the replication complex during infection and RNA-inhibition 
(RNAi) mediated knockdown of the cellular factors DDX3, La and PTB inhibited MNV replication in cell 
culture, confirming a role for these factors in the viral lifecycle. The precise function of the 
interaction with each viral protein is still under investigation (424). PTB is known to interact with the 
polypyrimidine tract in a stem-loop structure at the 3’ end of the MNV genome (22). Mutation of the 
binding site reduces PTB binding and was sufficient to attenuate MNV in vivo further demonstrating 
the essential role of RNA-protein interactions in norovirus replication and as possible determinants of 
pathogenesis (22).  
To create a beneficial cellular environment for replication, noroviruses are thought to disrupt a 
number of host cell pathways. The host cell protein secretion pathway is one such target that is 
disrupted during replication of both HuNV and MNV (356, 357, 447) to modify and recruit 
membranes for replication, Figure 1.6. The disruption has been attributed to disassembly of the Golgi 
apparatus induced by the MNV NS4 protein and its HuNV equivalent, p22 (356) (356) (357). The 
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HuNV protein p48 (equivalent to MNV NS1-2) may also contribute to disassembly of the Golgi 
apparatus and has been found to disrupt expression and trafficking of cell surface proteins when 
transfected in isolation (129, 135, 440). It is possible that this also interferes with antigen 
presentation or cytokine secretion, as has been seen for other RNA viruses (99, 101).  
A study of HuNV replication in the replicon system identified a role for both cholesterol and 
carbohydrate synthesis pathways in the norovirus lifecycle. From DNA microarray analysis, 
cholesterol biosynthesis was down-regulated in cells containing the replicon and the use of statins to 
lower cholesterol was found to promote replication (71). Likewise, simvastatin was found to increase 
HuNV replication in the gnotobiotic pig model (205) and epidemiological data has since raised 
concerns regarding the use of statins as an increased risk factor in the elderly (336). The enhanced 
replication resulting from treatment with statins in vivo is thought in part to be mediated through 
suppression of innate immunity (205), however the direct molecular basis for the interaction 
between norovirus and cholesterol synthesis has yet to be determined. 
 
 
Figure 1.6. MNV induces rearrangements in membranes of the secretary pathway components. 
Ultrastructural studies of MNV-1-infected RAW 264.7 Cells. Cells were infected with MNV-1  at high 
MOI (J–L) or were mock-infected (A–C) and electron microscopy was  performed at 24 hpi. Arrows 
indicate MNV-1 particles and arrowheads indicate adjacent membranes. VA, vesiculated areas (which 
are not observed in the mock); Nuc, nucleus; rER, rough endoplasmic reticulum. Scale bars represent 
200 nm for (A) and (J), 500 nm for (B) and (K), and 2 μm for (C) and (L). Figure taken from.(447) 
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Antagonistic interactions with the innate immune system are a well-known feature of RNA virus 
infections. Given the short time course of HuNV, innate immunity has been highly implicated in the 
control of infection, which has been supported by studies with HuNV and MNV. Treatment with 
IFNα/β reduced HuNV RNA replication in the replicon system and in gnotobiotic pigs and decreased 
replication of MNV in vitro (70, 74, 75, 205). The role of STAT1 signalling in IFN-mediated innate 
immune response has also been well documented to control the appearance of clinical disease and 
viral dissemination during MNV infection in vivo (209, 283, 447). Initial detection of norovirus is 
thought to primarily occur by the cellular helicase MDA-5, which senses double stranded RNA 
(dsRNA) (272). Accordingly, MNV replicates to higher titres in MDA-5-/- mice, and also, to a smaller 
extent, higher in TLR3-/- mice, suggesting it may also contribute to detection of dsRNA (272). The 
signalling cascade initiated by MDA-5 is mediated by the mitochondrial antiviral signalling protein 
(MAVS), which results in activation of the transcription factors interferon regulatory factor (IRF) 3, 
IRF-7 and NF-kappaB. This in turn results in the production of type I IFNs and the upregulation of IFN 
stimulated genes (ISGs) (211, 355).  Both IRF-3 and IRF-7 have been shown to be critical for IFN-
mediated control of MNV infection (412). It has recently been found that MNV is able to interfere 
with innate immune signalling at the cellular level through the actions of VF1, the product of ORF4 
(275). In vitro VF1 was found to delay the upregulation of INFβ and other ISGs, and loss of VF1 
resulted in a fitness cost in vitro and attenuation in vivo. Interestingly attenuation was observed in a 
STAT1-/- model of infection, suggesting that STAT1 independent signalling pathways may also be 
involved but are not sufficient to control MNV infection alone (275). VF1 was found to localise to the 
mitochondria and thus is expected to interfere with signalling through the MAVs complex or 
downstream affecting IRF-3 and IRF-7 activation, although further studies are underway in our 
laboratory to elucidate the direct target (275). As HuNV does not express a homolog to VF1 it is 
unknown at present if it has the same capacity as MNV to antagonise the innate immune response, 
however functional duplication of VF1 has not been excluded.  
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1.8.5 Assembly and exit 
The processes behind viral assembly, encapsidation and the exit of noroviruses are largely unknown. 
The ability of VP1 to self-assemble into VLPs morphologically indistinct from native virions suggests 
that it may be sufficient to drive capsid assembly (42), although the involvement of cellular proteins 
cannot be excluded. Whilst VP2 is not required for VLP assembly, it is thought to promote the 
stability of VP1 and is essential for the production of infectious virions (41, 377). The highly basic 
nature of VP2 has formed the basis of a long-held theory that it may be involved in encapsidation 
(377). Accordingly, VP1 and VP2 have been shown to interact and in a recent biochemical study the 
binding of VP2 was mapped to a conserved motif in the shell domain of VP1. This places VP2 in the 
interior of the capsid, consistent with a role in encapsidation (431). However to date there is no 
evidence of a direct interaction of VP2 with the viral genomic RNA.  
There have been no direct studies on the exit and release of the assembled norovirus virion to 
complete the viral lifecycle. One proposed exit strategy for other caliciviruses involves the induction 
of apoptosis (7, 379). Whether noroviruses may employ a similar strategy is unknown however 
accumulation of apoptotic epithelial cells has been observed in intestinal biopsies from infected 
patients (417). Furthermore, apoptosis is induced with active MNV replication (49, 275). The 
induction is associated with down regulation of survivin, a pro-apoptotic factor, followed by 
cytochrome c release and caspase activation. Whether the down regulation of survivin occurs by a 
direct interaction with a viral protein or as a response to indirect effects of MNV on the host cell has 
yet to be determined (49). Instead VF1 has been shown to delay the onset of apoptosis through its 
localisation at the mitochondria (275), although it could be argued that this may serve to prolong the 
window for replication prior to the final stages of exit and release. Inhibition of apoptosis results in 
reduced MNV production, either way demonstrating a clear requirement of apoptosis for an aspect 
of the norovirus lifecycle (138).  
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 Characterising viral proteins and genomes by insertional mutagenesis 1.9
The apparent gaps in understanding the norovirus lifecycle have hindered the development of 
antivirals and to date there are no licensed norovirus inhibitors. The long term rational development 
of antivirals for HuNV is dependent on detailed characterisation of the remaining viral protein 
functions as well as identification of their viral and cellular interaction partners. Since the discovery 
of MNV, studies on the function of the norovirus proteins have increased, however the specific 
activities of at least 5 of the 9 proteins remain unknown and to date there has not been a systematic 
functional study of an entire norovirus genome. Transposon (Tn)-mediated insertional mutagenesis 
is an approach that has been widely used not only to identify the essential functional domains of 
viral proteins (137, 227, 339, 408) and cis-elements (13, 14, 227), but has also been extended to 
characterising entire viral genomes (13, 35, 212, 279). 
Following the discovery of Tns as mobile genetic elements and the development of in vitro 
transposition reactions, Tn mutagenesis has been employed as a molecular tool to dissect and 
characterise gene and protein functions in a variety of different applications (reviewed in (173)). In 
comparison to site-directed or targeted mutagenesis, typically used to study protein function, Tn-
mediated insertional mutagenesis confers a number of advantages for characterising previously 
unknown viral proteins and entire genomes. Firstly, whereas site-directed mutagenesis is most 
effective with prior knowledge of the protein function and suspected key residues, Tn-mutagenesis 
can be used to randomly probe the importance of entire regions and can identify potential 
functional domains. Conversely, if a function is known it can also be used to identify the domain 
responsible (137). Secondly, whilst residue-scanning mutagenesis can also be used over large 
regions, individually generating and characterising each mutant can be labour-intensive and time-
consuming and as such it is not suitable for genome-scale studies. In contrast, Tn-mutagenesis 
reactions can simultaneously generate large libraries of insertion mutants, which can then be 
screened en masse and the effect of each insertion on viral replication determined in parallel by use 
of various insertion-profiling techniques (13, 14, 35, 279). Furthermore, Tn-mediated insertional 
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mutagenesis can involve either insertion of a the whole Tn element (approximately 1kB), useful for 
disrupting entire viral ORFs (279), or with systems such as the MuA transposon there is the option to 
remove a large portion of the Tn by restriction digest, leaving a smaller residual insertion ranging 
from 4-93 amino acids, depending on the Tn used (reviewed in (173)). These smaller insertions are 
more appropriate for probing the importance of different regions of a viral protein, viral cis-element 
or smaller viral genomes. The MuA transposon system, which leaves a 5 amino acid insertion, has 
been used to identify the essential regions of HIV and Moloney murine leukemia virus proteins (227, 
339),  Gammaherpesvirus, HCV and HIV cis-acting elements (13, 14, 227) and the entire potato virus 
A, HCV and Venezuelan equine encephalitis virus (VEEV) genomes (13, 35, 212) , to name a few.  
 Characterising viral protein function by use of reporter and epitope tags.  1.10
Determining the subcellular localisation of viral proteins during infection, imaging infections in real-
time and identifying cellular interaction partners are all ways to begin characterising the function of 
viral proteins during replication. These approaches rely on the ability to ‘tag’ the protein of interest 
with either a reporter protein or an epitope tag, in such a way that it does not interfere with viral 
replication or the function of the protein of interest. This approach has been used to study the 
infection dynamics of many viruses and the roles of numerous viral proteins in replication by 
successfully engineering those viruses to express reporter or epitope tags.  
There are a plethora of examples that demonstrate the variety of uses of reporter- and epitope-
tagged RNA viruses in particular, all of which could be applicable to the study of MNV. To illustrate 
this, polioviruses with the reporter protein Discosoma sp. Red (DsRed) inserted into a site in the viral 
protease 2A were used to identify its subcellular localisation during infection (409). FCVs expressing 
DsRed or GFP have been used to observe the progression of single and co-infections in vitro (1). A 
murine leukaemia virus expressing GFP fused to the envelope protein was used to monitor viral 
attachment at the cell surface by flow cytometry (367). For in vivo studies, pathogenic and 
attenuated measles viruses were engineered to express GFP to determine the differences in tropism, 
alongside identifying initial cell tropism following different transmission routes (98, 237). Reporter 
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proteins can also provide a means of quantifying viral replication in a high-throughput manner 
compared to determining viral titre by tissue culture infectious dose 50 (TCID50) or plaque assay. For 
example a dengue virus carrying Renilla Luciferase fused to the capsid protein demonstrated 
quantifiable luciferase activity linked to replication, which facilitated a high-throughput screen for 
antivirals (470). Whilst epitope tags cannot be used for real-time imaging, they facilitate purification 
of the viral proteins from infected cells, often in complexes with their interaction partners. Coupled 
with quantitative proteomic approaches and mass spectrometry this can be used to identify the viral 
and cellular interaction partners of the protein of interest. For example, viral and cellular interaction 
partners of the poliovirus 3A protein were identified using polioviruses carrying different epitope 
tags (c-myc, FLAG and hemagglutinin) in the 3A protein (410).  Identifying interaction partners can 
not only reveal the function of the viral protein but can dissect the interactions needed for 
replication complex formation, identify the essential cellular components required for replication, 
reveal how the viral proteins hijack cellular pathways or subvert the innate antiviral response and 
demonstrate how the virus modifies the cellular environment to achieve replication. Ultimately, with 
follow up depletion studies to confirm which interactions are essential, it can lead to identification of 
new antiviral targets by design of small molecule inhibitors to block host-cell interactions and inhibit 
viral replication. 
To date there are no reported studies using infectious reporter- or epitope-tagged noroviruses. This 
is largely due to the fact that it is not known where in the HuNV or MNV genomes an insertion can 
be made without compromising viral replication. Furthermore, MNV presents many challenges to 
the techniques traditionally used for generating reporter-tagged viruses. For example, large 
insertions of a reporter gene under control of an internal ribosome entry site (IRES) in the UTRs are 
not thought to be possible due to the compact nature of the genome and the restricted size of the 
MNV 5’ and 3’ UTRs (5nt and 78nt respectively). The UTRs and various regions of the genome are 
also known to contain RNA structures that play functional roles in the norovirus lifecycle by 
interacting with host cell proteins, and whose integrity is essential for efficient replication (22, 366, 
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424). The norovirus non-structural proteins are translated as a polyprotein in which the precursors 
are also thought to be functional and essential for replication (38), so this precludes insertion of 
reporter proteins or tags within the cleavage sites or within artificially inserted cleavage sites. 
Finally, limited structural and functional information available on the norovirus proteins does not 
support a targeted approach to directly fuse a reporter protein and a viral protein in a way that will 
not interfere with viral protein function.  
Identification of tolerated insertion sites by Tn mutagenesis provides an alternative approach to 
engineering exogenous nucleotide sequences into a viral genome, including reporter proteins or 
small peptide tags (1, 16, 280, 409, 410). This strategy has been particularly successful for labelling 
small positive strand RNA viruses (408, 409), which present similar challenges as MNV with respect 
to the traditional approaches for generating a reporter-tagged virus. To date, FCV is the only 
calicivirus which has been engineered to express reporter proteins. The insertion site was identified 
by Tn-mediated insertional mutagenesis and was shown tolerate both GFP and DsRed (1, 4). This 
tolerated site was located in the leader capsid protein, which is the only protein of FCV that does not 
have an equivalent in noroviruses (1, 2). The success of this approach with FCV indicates that it could 
be applicable for generating a tagged-MNV to study norovirus replication. 
 Development of a norovirus vaccine 1.11
There is currently no licensed vaccine for HuNV. Development of a vaccine would be of particular 
benefit to target populations such as healthcare workers, military personnel, individuals with 
underlying gastrointestinal disorders and highly susceptible individuals, including the young, elderly 
and immunocompromised. Vaccination of these high risk groups may be more appropriate than 
blanket immunisation of the population should a vaccine be developed.  
Whilst there has been continued interest in a norovirus vaccine, progress has been limited by several 
factors. Human challenge studies to address norovirus immunity have presented a complex picture 
with inconsistencies in the role of neutralising antibodies in protective immunity and a lack of 
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consistent long term protection (varying between 6 months to 2 years) (203, 245, 299, 310). The high 
degree of antigenic diversity between different HuNV strains has also challenged the feasibility of a 
vaccine and may be responsible for repeated infections and short-term immunity. Cross protection 
between genogroups has not yet been demonstrated in human volunteer studies (244), suggesting 
that multivalent vaccine formulations may be necessary to target all norovirus genogroups (249). An 
alternative approach could be to vaccinate against the prevailing genotype, currently GII.4, with 
continued surveillance, genotype sampling and vaccine reformulation. Recent studies with MNV have 
begun to address the complexities surrounding norovirus immunity. For example it has been shown 
using MNV that effective vaccination must elicit a broad concerted response involving neutralising 
antibodies, B cells and CD4 and CD8 T cells (67, 68). The MNV challenge model has also been used to 
investigate cross-protective responses against MNV from multivalent HuNV VLPs and the duration of 
protective immunity from MNV infection (67, 249, 250). 
HuNV VLPs have been proposed as a potential vaccine candidate. They have proven to be 
immunogenic in mice, gnotobiotic pigs, chimpanzees and humans, eliciting mucosal and serum 
antibody responses (48, 249, 383, 401). In one study aimed to test the ability of VLPs to protect 
against HuNV, volunteers were immunised with a monovalent Norwalk virus (GI.I) VLP preparation 
prior to challenge with the same strain (17). VLPs induced serum antibody responses and significantly 
protected against HuNV-induced illness, however protection was not complete and 37% of 
vaccinated individuals still developed symptoms, albeit less severe. This preliminary study did not 
examine the duration of protection, cross protection or the ability to vaccinate the young or elderly. 
Nevertheless it demonstrated that vaccination against norovirus disease may be possible (17).  
Live attenuated vaccines have proven effective against a variety of RNA viruses including polio, 
measles, mumps and yellow fever and often elicit a stronger and broader immune response than 
inactivated or viral protein based vaccines by activating all arms of the immune system (151, 229). 
Traditional approaches to attenuation have involved passage of the virus in tissue culture to induce 
attenuating mutations that may reduce fitness, replication capacity or pathogenesis in the host (150), 
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as has been achieved accidentally for MNV-1 (23, 447). However the mechanism of attenuation is 
often unknown and there is potential for reversion to a pathogenic phenotype and viral shedding (5). 
Furthermore, without a cell culture system for HuNV this is not yet a viable approach for producing a 
live attenuated HuNV vaccine. Two recently described rational approaches to attenuation, 
successfully applied to other RNA viruses, circumvent many of these problems and have great 
potential to be applied to MNV. Studying rational approaches to the attenuation of MNV could 
ultimately lay the groundwork for design of a live attenuated HuNV vaccine if the hurdle of 
developing a cell culture system can be overcome in the future. Furthermore these approaches 
provide insight into what is important for the replication of norovirus  in vitro and in vivo.  
 Rational approaches to attenuation 1.12
1.12.1 Attenuation by insertion of exogenous sequences 
One rational approach to attenuation, successfully demonstrated for several RNA viruses, involves 
insertion of an exogenous sequence into the viral genome. The basis for attenuation is then 
determined by the functional properties of the exogenous sequence (28, 52, 365). For many viruses 
insertion of a reporter gene leading to the direct fusion of the reporter and viral proteins has been 
sufficient for attenuation, in most cases by reducing the activity of the tagged protein in vivo (52, 
365). This approach has the advantage that the resulting tagged-virus can be also used to study 
viral replication as described above.  
Exogenous sequences in the form of microRNA target sequences have also been shown to lead to 
viral attenuation. MicroRNAs (miRNAs) are small non-coding RNAs of approximately 20-24nt in 
length. They mediate post-transcriptional regulation of gene expression and are involved in 
regulating all aspects of cellular function from the innate immune response to differentiation and 
tissue development (174). miRNAs exert a regulatory function by binding to perfect or near-perfect 
complementary sequences in the 3’ end of messenger RNAs (174). Binding of a miRNA to a target 
results in recruitment of an RNA-induced silencing complex (RISC), which in turn either results in 
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translational silencing or degradation of the mRNA. When binding with perfect complementarity 
occurs, the mRNA may be cleaved by an endonuclease component of the RISC complex, Argonaute 
2 (31).  
The regulatory capacity of miRNAs can be harnessed to control viral replication by inserting a 
miRNA target sequence into the viral genome. Due to the tissue-specific expression of miRNAs, 
replication can be restricted in a tissue specific manner to control viral tropism. This was first 
demonstrated with poliovirus, which was engineered to carry a neuronal-specific miRNA 
complementary sequence (28). In neuronal cells expressing the corresponding RNA, the genome 
was targeted for degradation, Figure 1.7. By this mechanism, in vivo replication of the miRNA-
targeted virus was prevented in the central nervous system, where it results in severe disease. Loss 
of neurovirulence corresponded to attenuation but replication in non-neuronal cells, Figure 1.6, 
resulted in a robust protective immune response (28).  
Attenuation by means of the miRNA machinery has since been shown for several other highly 
pathogenic RNA viruses, including influenza, Semliki Forest virus and members of the Flaviviridae 
family (176, 177, 313, 459). As such it has been proposed as a general rational approach to 
generating attenuated vaccines for RNA viruses. To date this approach has only been used against 
viruses which cause acute infections, therefore MNV now provides a suitable model to determine 
whether a similar approach could be used to attenuate noroviruses, and in particular whether 
miRNA-mediated attenuation can occur in persistent infections. The added advantage of applying 
this approach to norovirus is that it allows the importance of particular cell tropisms to be probed 
for the maintenance of acute and persistent infections.  
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Figure 1.7. Attenuation by the cellular miRNA machinery. Schematic diagram of the work 
performed on poliovirus. The poliovirus genome was engineered to carry a neuronal-specific miRNA 
target sequence (28). (A) In neuronal cells expressing the particular miRNA, the virus carrying the 
cognate miRNA target sequence was degraded by recruitment of an RNA induced silencing complex 
(RISC). (B) In gastrointestinal epithelial cells which do not express the same miRNA, replication of 
the virus carrying the miRNA target sequence was unaffected.  
1.12.2 Rational attenuation by manipulating polymerase fidelity  
The second rational approach to attenuation exploits a characteristic thought common to all RNA 
viruses; the ability to mutate and to exist as a quasispecies. RNA viruses are thought to exist not as a 
single clone but as a spectrum of genetically related variants, collectively known as the viral 
quasispecies (108, 110, 112, 386). These dynamic populations arise primarily due to the high error 
rates of viral RNA dependant RNA polymerases (RdRps) or reverse transcriptase enzymes, coupled 
with high rates of replication. The mutation rates of RNA viruses have been estimated to be 10-4 to 
10-6 substitutions per nt per round of replication (347). This is several orders of magnitude greater 
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than that of DNA viruses, which have been estimated to be between 10-6 and 10-8 substitutions per 
nt per round of replication (347). The difference can be accounted for by the exonuclease 
proofreading function of DNA polymerases (11), which RdRps do not possess; RNA viruses instead 
favouring faster, less accurate replication, as error-correction incurs a time penalty (385). However it 
is worth noting the exception that RNA viruses with genomes over 10kB, such as the coronaviruses, 
employ proofreading mechanisms and have higher fidelity (119). Other mechanisms can also 
contribute to RNA virus quasispecies diversity, such as genomic recombination (107, 185), segment 
reassortment and changes induced by host cell RNA editing enzymes, such as APOBEC (349). 
The concept of a quasispecies emanated from a mathematical theory proposed by Manfred Eigen in 
1977 (124). It was originally formulated to explain the evolution of error-prone self-replicating RNA 
entities of the pre-cellular RNA world (123, 124). In 1978, using the Qβ RNA bacteriophage, Domingo 
and Weissman presented the first direct experimental evidence for error-prone replication of an 
RNA virus, demonstrating the high mutation rate and expanding diversity within a phage population 
(33, 111). This work established a link between RNA viruses and Eigen’s theoretical quasispecies 
model, and began to change the view of RNA viruses as clonal entities (113, 186). The theory was 
subsequently extended to be applicable to RNA virus populations (covered in (104)) and the term 
was adopted by virologists. Following the pioneering work on the Qβ phage, evidence of a 
quasispecies quickly emerged for the foot and mouth disease virus (FMDV) and the vesicular 
stomatitis virus (VSV) (106, 184, 371, 384). Since then, high mutation rates and quasispecies diversity 
have been experimentally demonstrated for a wide range of RNA viruses, including HIV, HCV, 
influenza, poliovirus, dengue virus and Coxsackie viruses (109, 146, 219, 265, 326, 428).  
The quasispecies theory is based on a number of founding principles. Firstly, the whole population 
acts like (quasi-) a single species and selection occurs on the entire population rather than its 
individual variants (122, 228). The variants within a quasispecies will have differing degrees of fitness 
in each environment and the population will contain a consensus sequence, which is not necessarily 
the fittest, highest frequency virus nor may it actually exist as an individual variant (104). All variants 
Introduction 51 
 
in the spectrum are genetically linked by mutation, as is shown in Figure 1.8, where an initial founder 
genome can quickly generate a diverse population within several rounds of replication (228). 
However as variants can regenerate one another by mutation, the relationship between variants is 
likely more complex, particularly when there are multiple founder genomes. The number of founder 
genomes can be influenced by various bottlenecks during infection, which represent physical or 
immunological barriers to transmission between hosts or between different tissues or cell types 
(220). Passage through a bottleneck is a stochastic event and can serve to shrink diversity, fix certain 
mutations in a population and can affect the course of an infection, depending on the fitness of the 
individual variants that gain access (83, 317).  
 
 
Figure 1.8 RNA viruses exist as quasispecies. An initial viral genome will rapidly expand into a 
diverse quasispecies through several rounds of replication, due to high error rate and low copying 
fidelity of RdRps. A simplified chain is shown here with one founder genome (black line) that 
acquires a mutation (coloured shape) with each round of replication (arrows). In reality the situation 
would be more complex with multiple founder genomes, multiple new variants produced from each 
genome, and variants can regenerate one another through mutation. 
A viral quasispecies is more than just a population of individual variants, but rather should be 
considered as a dynamic population, where interactions between its members can affect 
quasispecies behaviour and the outcome of infection.  For example, cooperative interactions have 
been shown to occur between variants to facilitate access to a particular tissue, thereby determining 
tissue tropism (428). Likewise negative interactions are also possible, where replication deficient 
variants, known as defectors, can interfere with the replication of other variants, resulting in 
suppression of overall fitness or pathogenesis of the quasispecies (145, 348).  
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Existing as a quasispecies confers a number of benefits to RNA viruses. The pre-existence of variants 
enables them to rapidly adapt and evolve in the face of selective pressures such as host neutralising 
antibodies, herd immunity and antiviral agents (110, 287, 295), which complicates the use of 
antivirals and vaccines against RNA viruses. Furthermore, high quasispecies diversity has been 
shown to promote virus transmission, widen tissue tropism, enhance persistence, pathogenesis, 
virulence, and resistance to antivirals (50, 84, 144, 241, 318, 425, 428).  
A caveat of the high mutation rate is that it places RNA viruses in a precarious position. There is 
thought to be an intrinsic limit to the degree of variability a viral genome can tolerate before virus 
viability is compromised (114, 123). This limit has been termed the threshold of error catastrophe. 
When a mutation frequency exceeds this limit, a lethal accumulation of errors occurs, resulting in 
extinction of the quasispecies in process known as lethal mutagenesis (105, 121-123), see Figure 1.9. 
Due to the high error rates of RdRps, RNA viruses are thought to exist at the edge of the threshold of 
error catastrophe. This allows them to strike a balance between genomic flexibility and maintaining 
genomic integrity (114). In this position the quasispecies can incur large losses of variants (the grey 
shaded area in Figure 1.9), but can be maintained as long as a sufficient proportion of the population 
remains viable (122). However this position leaves RNA viruses susceptible to extinction by modest 
increases in mutation rate resulting in drastic losses of viability and lethal mutagenesis (105, 121). 
The concept of lethal mutagenesis has been experimentally demonstrated with the use of chemical 
mutagens, such as ribavirin, which drive lethal mutagenesis by increasing RdRp error rates (88, 152, 
364). 
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Figure 1.9. RNA viruses exist as a quasispecies at the edge of error catastrophe. An RNA virus 
population is composed of a spectrum of genetically related variants, or quasispecies (white, normal 
population), due to the high error rate of the RNA dependent RNA polymerase (RdRp). Chemical 
mutagens promote an increase mutation frequency, which can drive the virus past the threshold of 
error catastrophe (red dotted line) beyond which lethal accumulation of errors occurs and virus 
viability is lost in the majority of the population (grey, mutagenised population). A high fidelity 
polymerase produces fewer errors during replication, thereby restricting quasispecies diversity and 
shifting the virus population away from the threshold of error catastrophe (blue, quasispecies 
restricted). Adapted from (427). 
 
Given that quasispecies diversity plays a large role in determining viral pathogenesis and that RdRp 
fidelity has been so finely tuned for this benefit, it is perhaps not surprising that altering quasispecies 
diversity can lead to viral attenuation. The first studies to demonstrate this however were highly 
significant not only in demonstrating the role of quasispecies diversity in pathogenesis but also in 
revealing the potential of manipulating quasispecies diversity as a rational approach to attenuation.  
During screens for ribavirin resistant polioviruses, two groups simultaneously isolated a high fidelity 
RdRp (3DPOL) mutant, with a single change from glycine to serine at position 64. This change was 
sufficient to confer resistance not only to ribavirin but to a number of different mutagens (316, 428). 
The 3DPOL G64S mutant was found to have a general increase in copying fidelity and as a result 
generated less genomic diversity and produced a restricted quasispecies, Figure 1.9. Consequently, 
the 3DPOL G64S mutant was attenuated in vivo with restricted neurotropism and reduced viral 
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shedding (318, 428). The inability of this mutant to invade the central nervous system was not due to 
the absence of specific neurotropic variants, but rather due to insufficient cooperation within the 
restricted quasispecies, required for neurotropism (428). In a follow-up study, the 3DPOL G64S 
mutant was found to generate a protective immune response, comparable in efficacy to the current 
live attenuated poliovirus Sabin vaccine strain (429). The high fidelity mutant had the advantage of 
being stable and did not revert to a more pathogenic wild-type phenotype throughout the five day 
period of infection (429).  
The concept of attenuation by manipulating quasispecies diversity has since been supported by 
studies on a number of other RNA viruses. A high fidelity arbovirus (Chikungunya virus) was recently 
isolated with restricted quasispecies diversity. In the natural mosquito host, the high fidelity mutant 
attained lower titres and dissemination than the wild-type virus and displayed restricted viremias in 
a mouse model of infection (84). It is not only restricting diversity that can result in attenuation, 
conversely increasing mutation frequency and diversity can achieve the same affect. In a 
comprehensive study on the Coxsackievirus B3, a panel of low fidelity mutants, or mutator viruses, 
were generated, each carrying a single point mutation in the RdRp (144). Whilst there was no loss of 
fitness for these mutants in vitro, in vivo they were attenuated with restricted tissue tropism, and in 
some cases the low fidelity mutants failed to establish persistent infections. The authors concluded 
that an increased mutation rate, which would result in a population of largely replication-defective 
variants, was a disadvantage only in vivo where population size is restricted by infection bottlenecks 
(144). Similarly, FMDV populations treated with mutagens to increase the RdRp mutational 
frequency and expand quasispecies diversity (rather than to drive lethal mutagenesis) were 
attenuated in the mouse model of FMDV. The observed attenuation was attributed to suppression 
of virulence by the defective or less fit members of the quasispecies, as individual variants capable of 
achieving wild-type virulence could be isolated from the quasispecies (348). Collectively these 
studies demonstrate that RdRp fidelity has been fine-tuned and not only is there an upper limit of 
mutational frequency for maintaining in vivo fitness, but also a lower limit. Given the conservation 
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between RdRps, it suggests that manipulating polymerase fidelity and quasispecies diversity could 
be a general approach to rational attenuation for RNA viruses.  
The presence of a quasispecies has been reported for several different members of the Caliciviridae 
family, including San Miguel Sea Lion viruses, (441), FCV, (325) and RDHV (149). For HuNV however, 
evidence for a quasispecies is largely indirect. The error rates of HuNV and MNV RdRps are 
comparable to the HCV RdRp in in vitro fidelity studies (55), suggesting that HuNV RdRps may have 
similar potential to generate a diverse quasispecies. Also, the RdRp of the prevailing HuNV GII.4 
genotype was found to have higher in vitro mutation rates than strains found only in sporadic 
outbreaks, suggesting that the ability to generate genetic diversity may be important in determining 
epidemiological fitness and could contribute to the success of the GII.4 genotype (55). The regular 
emergence of genetically diverse HuNV strains in the face of herd immunity (361) implies that host 
selection pressures may be acting on a pre-existing spectrum of viral mutants to drive evolution, as 
predicted by the quasispecies theory (122). Direct evidence for HuNV quasispecies comes from 
sequencing of viral isolates taken from chronically infected patients, where the quasispecies may 
facilitate evasion of host immune responses (56, 64, 182). Likewise minor variants have been 
identified in chronically infected patients, which are capable of transmission (218). In contrast, in 
acute infections the HuNV population is thought to remain largely homogenous (56). This is contrary 
to what may be expected, as given that the HuNV RdRp has low fidelity, infection over 10 days 
should allow sufficient rounds of replication for quasispecies expansion to occur, unless strong 
purifying selection is at play. This study was limited to 2 samples and next generation sequencing of 
just the ORF2 and partial ORF3 region, with highly stringent technical error thresholds applied. As 
such it is possible that low level variants and the full quasispecies were not detected (56). 
MNV now provides a suitable model to address the importance of quasispecies diversity in acute and 
persistent MNV infections and to determine whether manipulating quasispecies diversity could also 
be a rational approach to attenuating noroviruses. It is worth noting that generating a high fidelity 
MNV mutant may not only provide a rational approach to attenuation itself but could be combined 
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with other approaches to attenuation and for example could serve to increase the genomic stability 
of a virus carrying non-viral sequences such as reporter tags or miRNA target sequences for the 
purposes above.  
 Project aims  1.13
As described herein, the long term rational development of antivirals is dependent on further 
detailed characterisation of norovirus replication and elucidation of the functions of the remaining 
viral proteins. Using MNV as a model for HuNV replication, the aims of the first half of this thesis 
were therefore to use transposon mutagenesis to identify regions of the genome and of the viral 
proteins that are essential for norovirus replication and in doing so identify important functional 
domains in the uncharacterised viral proteins. The second aim was then to generate noroviruses 
carrying protein tags to study replication and to identify cellular interaction partners of the viral 
proteins that contribute to the norovirus lifecycle. 
The second half of this thesis was concerned with assessing the potential of generating attenuated 
noroviruses by two rational approaches developed for other RNA viruses. More specifically the aim 
of the first approach was to determine whether the miRNA regulatory machinery could be used to 
attenuate norovirus infections by generating and characterising MNV carrying macrophage-specific 
miRNA target sequences. Finally, the aim of the second approach was to determine whether 
norovirus could be attenuated by altering quasispecies diversity through manipulating the fidelity of 
the norovirus RdRp.   
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2. Materials and Methods 
 Cells and viruses 2.1
2.1.1 Cells  
Murine macrophage cell lines RAW264.7 and IC21 were maintained in Dulbecco’s modified Eagles 
Medium (DMEM, Gibco) containing 10% fetal calf serum (FCS), penicillin (P) (100 SI units/mL) and 
streptomycin (S) (100 µg/mL) and 10 mM HEPES (pH7.6) at 37°C with 10% CO2. The murine microglial 
BV-2 cell line (45) was provided by Jennifer Pocock (University College London). BV-2 cells were 
maintained in DMEM supplemented with 10% FCS (Biosera), 2 mM L-glutamine, 0.075% sodium 
bicarbonate (both Gibco) and antibiotics penicillin and streptomycin as above. BHK cells engineered 
to express T7 RNA polymerase (BSR-T7 cells, obtained from Karl-Klaus Conzelmann, Ludwid 
Maximillians University, Munich, Germany) were maintained in DMEM containing 10% FCS, penicillin 
(100 SI units/mL) and streptomycin (100 µg/mL) and 0.5 mg/mL G418. For preparation of bone 
marrow derived macrophage (BMDM), bone marrow cells were harvested from female C57BL/6 
mice and were cultured in DMEM containing 10% fetal calf serum (FCS), penicillin (100 SI units/mL) 
and streptomycin (100 µg/mL). For differentiation the supernatant from CMG14 cells, which 
contains macrophage colony stimulating factor (M-CSF), was added to the media for 5-7 days. 
2.1.2 Infectious clones 
The cDNA clone pT7:MNV 3’ RZ, containing the WT MNV-1 genome under control of a truncated T7 
polymerase promoter were previously constructed alongside modified versions that contained 
either a frame shift in the NS7 region of ORF1 (pT7:MNV 3’ RZ F/S), or an active site mutation in NS7 
(NS7 YGGG) (78, 393). The pT7:MNV 3’ RZ P1b (P1b-WT) clone had previously been constructed to 
contain the changes (A5941) and (2151) as described (23). The cDNA clone pT7:MNV3 3’RZ (MNV3-
WT) contains the MNV-3 sequence under control of a the T7 promoter as is described in (10). 
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2.1.3 Reverse genetics  
Virus was rescued from cDNA clones (as indicated in the results chapters) using the reverse genetics 
system based on recombinant Fowlpox expressing T7 RNA polymerase, as previously described (78). 
Briefly, 1 µg of each cDNA clone was transfected, using Lipofectamine 2000 transfection reagent 
(Invitrogen), into BSR-T7 cells previously infected with recombinant Fowlpox virus expressing T7 RNA 
polymerase at an MOI of approximately 0.5 pfu per cell. Where indicated, the RNA-mediated reverse 
genetics system was used as recently described (460). In short, RNA was produced by an in vitro 
transcription reaction containing 200 mM Hepes pH 7.5, 32 mM magnesium acetate, 40 mM DTT, 
2 mM spermidine, 7.5 mM of each NTP, 60 ng of linearised DNA template and 50 μg/mL of T7 RNA 
polymerase. Reactions were incubated at 37°C for 5-7 h then RNA was precipitated with lithium 
chloride and resuspended in RNA storage solution (Ambion). Post-transcriptional enzymatic capping 
was performed using the ScriptCap system from Epicentre, according to manufacturer’s instructions. 
After the reaction, RNA was again precipitated in lithium chloride and stored in RNA storage solution 
(Ambion). 1 µg of RNA was transfected into BSR-T7 cells using Lipofectamine 2000 (Invitrogen).  
After 48 h post transfection of cDNA or RNA, cells were freeze-thawed at -80°C to release virus 
particles.   
2.1.4 Viral TCID50 
Fifty percent tissue culture infectious dose (TCID50) titrations were performed on RAW264.7 cells 
using 10-fold serial dilutions typically over a range of neat to 10-7. The viral TCID50/mL was 
determined by scoring for signs of cytopathic effect (CPE) at 5 days post infection by visual 
inspection. The TCID50/mL was then calculated according to the formula described in (327). 
2.1.5 Sequencing of viral genomic RNA 
To confirm the stability of an insertion of a mutation, viruses were typically sequenced following 
passage in RAW264.7 cells at low MOI (0.01 TCID50/cell). Following each passage, RNA was 
extracted using the GenEluteTM Total mammalian RNA system (Sigma-Aldrich), which is based on 
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nucleic acid column purification and was performed according to manufacturer’s instructions. Unless 
stated below, reverse transcription was performed using Moloney murine leukaemia virus reverse 
transcriptase (M-MLV RT, Promega). Typically 5 µL of cDNA was then PCR amplified with primers 
covering the region of interest by either KOD Hi-Fidelity polymerase (Merck Biosciences) or GoTaq 
Flexi DNA Polymerase (Promega), as recommended in the manufacturer’s instructions. PCR products 
were analysed by agarose gel electrophoresis and either gel purified where necessary or column 
purified by GFXTM PCR and Gel Band Purification (GE Healthcare). Sanger sequencing was performed 
by the Imperial College Genomics Core Lab or Source Biosciences. Chromatograms were analysed 
using ContigExpress Software (Invitrogen).  
2.1.6 Generation of viral stocks 
To make passage 1 high titre stocks of mutant viruses, RAW264.7 cells were seeded at a density of   
1x105 in 6 well plates. Cells were inoculated with 700 µL of recovered virus for 1 h, cells were washed 
and media was replaced with DMEM, 10% FCS and P/S. To make passage 2 high titre stocks 1.5x107 
RAW264.7 cells were seeded into T75 flasks and were infected at an MOI of 0.01 TCID50/cell. From 
each method virus was harvested at 48-72 hpi by 2 rounds of freeze-thawing at -80 °C and then 
clarified by centrifugation to remove cell debris. This was passed through a 0.2 µm filter prior to 
titration by TCID50. Each stock was then passaged in RAW264.7 cells at low MOI (0.01 TCID50/cell) 
for sequence verification (as above). 
2.1.7 Viral growth analysis 
Multistep growth curve analysis of insertion viruses and polymerase mutants was performed by 
infecting RAW264.7 cells with sequence-verified virus at an MOI of 0.01 TCID50/cell. Virus was 
harvested at various time points post infection, typically 0, 6, 9, 12, 24 and 48 hpi. Following a single 
freeze-thaw cycle, virus titre was determined by TCID50 on RAW264.7 cells. Total RNA was also 
extracted at each time point using the GenEluteTM Total Mammalian RNA System to determine the 
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genomic RNA copy number for each mutant by two-step reverse transcriptase quantitative PCR (RT-
qPCR) (section 2.1.8). 
Virus yield assays were performed by infecting either RAW264.7 or BV-2 cells (as indicated in the 
results chapters) with sequence-verified viruses at an MOI of 0.01 TCID50/cell. Virus was harvested 
at 12, 24 or 48 hpi and titred by TCID50. 
2.1.8 Quantification of viral RNA by RT-qPCR  
Quantification of viral genome copies from infected cells or faecal samples (see section 2.8.3) was 
performed by two-step RT-qPCR. From infected cell samples, 20 ng of RNA was used for reverse 
transcription. The amount of RNA used from faecal samples corresponded to that extracted from 0.5 
mg of stool. Viral RNA of known copy number was generated by in vitro transcription of the MNV-1 
or MNV-3 cDNA clones (as above) and was serially diluted to generate a standard curve. Reverse 
transcription was performed with M-MLV using random hexamers, as per manufacturer’s 
instructions. qPCR was then performed on the cDNA using a Taqman Low Rox qPCR mastermix 
(Primer design), with primers and probes given in Table 2.1. The ViiaTM 7 Real time PCR machine was 
used with an initial denaturation step of 8 min at 95 °C, followed by 50 cycles of 95 °C for 10 s and   
60 °C for 1 min. The genome copy number was interpolated from the standard curve and was 
calculated per ng of RNA or per mg of stool depending on the sample, using Microsoft Excel. All 
graphs were produced using Graph Pad Prism V.5 Software.  
 
 
 
Table 2.1. Primer and probes used for qPCR determination of viral genome copies. 
  
Primer Residues Primer sequence 
Sense 5028 - 46 CCGCAGGAACGCTCAGCAG 
Antisense 5137 - 56 GGCTGAATGGGGACGGCCTG 
TaqMan Probe 5062 - 76 ATGAGTGATGGCGCA 
Fluorophore  FAM 
Quencher  TAMRA 
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 Cloning insertion viruses and mutants  2.2
The cloning of 15 nt insertions, the FLAG tag coding sequences and microRNA target sequences into 
specific sites in the MNV genome was all achieved by overlap mutagenic PCR. This was also used for 
the cloning of MNV polymerase mutants. Briefly, for each mutant 2 first round PCR reactions were 
carried out using KOD Hi-Fidelity polymerase with either the MNV-1, MNV-1 P1b, or MNV-3 cDNA 
clones as a template (indicated for each mutant in the relevant results chapters), Figure 2.1. For each 
reaction a primer specific for the MNV cDNA clone was used in combination with a primer of 
opposite polarity spanning the genome sequence of the desired insertion site flanked by the 
insertion sequence or carrying the mutation, Figure 2.1. The products of each first round reaction 
were mixed and used as templates for a second round of PCR using the forward and reverse primers 
specific for the MNV genome, to produce an insert carrying the desired mutation or insertion 
sequence. This insert was digested by restriction enzymes that have unique cleavage sites within the 
MNV genome. The appropriate MNV cDNA clone was also digested with the same enzyme pair and 
both digested insert and vector were gel purified. The vector was dephosphorylated with Antarctic 
Phosphatase (New England Biolabs), prior to ligation using T4 DNA ligase (New England Biolabs).  
Each ligation was transformed into alpha-select chemically competent bronze efficiency cells 
(Bioline).Mini preps were performed following standard procedures using a TENS lysis buffer (1M 
Tris pH7.5, 5M NaOH, 0.5M EDTA and 10%SDS) and a neutralisation buffer (Sodium acetate pH5.2), 
followed by ethanol precipitation. Individual clones were screened for the presence of each insertion 
or mutation by either differential digest or PCR. Plasmid DNA was then prepared from larger cultures 
using the Pure Yield Plasmid Midi Prep System (Promega) and the inserted region was sequenced in 
its entirety. 
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Figure 2.1. Cloning strategy based on overlap mutagenic PCR. In the first round a forward primer or 
reverse primer against the MNV genome (F/R) was used with a reverse or forward primer specific for 
the site for insertion and carrying the insertion sequence or mutation (R-ins/F-ins). An MNV cDNA 
clone was used as a template. The 2 first round products were used as templates in a second round 
of PCR with the F and R primers. The product from the second round was then subjected to 
restriction digest with 2 enzymes that have a unique site in the MNV cDNA clone. The digested 
product was ligated with MNV cDNA vector that had been digested with the same restriction 
enzymes. 
 
 Transposon mutagenesis 2.3
2.3.1  Generation of mutagenised insertion libraries 
The HyperMuATM transposase enzyme (Epicentre Biotechnologies) was used as detailed in 
manufacturer’s instructions for transposition of a kanamycin resistant transposon M1-KanR (Tn) 
(Mutation Generation Systems Kit, Finnzymes) into the MNV-1 infectious clone pT7:MNV 3’ RZ.  The 
Tn was composed of inverted terminal repeats of the modified bacteriophage Mu right end 
sequence with a NotI site, flanking the selectable marker gene. The transposition reaction was 
performed using the recommended ratio of transposon to pT7:MNV 3’ RZ.  The ratio was optimised 
to increase clone numbers and 450 ng pT7:MNV 3’ RZ was used with 50 ng Tn. This was similar to 
F
R
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that recommended to promote a single transposition event per copy of the infectious clone, but the 
possibility of a double insertion cannot be entirely excluded. The reaction was transformed into XL10 
Gold® Ultracompetent Cells (Stratagene) and selected through resistance to kanamycin and 
carbenicillin, to create the original Tn library. The resulting library contained an estimated 225,000 
clones, each containing a single randomly inserted kanamycin resistant transposon (Tn). 10 µg of this 
library was subsequently digested with 1 of 5 different pairs of restriction enzymes (New England 
Biolabs) to release a defined region of the genome (Table 3.1 and Figure 3.1). Non-mutagenised pT7: 
MNV 3’ RZ was digested with the same enzyme pairs and ligated to each mutagenised insert. Each 
library was screened by digest with the same pair of enzymes to confirm all clones had a Tn in the 
appropriate fragment. To create the 15nt insertion libraries, the five Tn mutagenised libraries were 
extensively digested with NotI and the Tn removed, before self-ligation and transformation into 
XL10- Gold® Ultracompetent Cells. Ten clones were screened of the 15nt insertion by restriction 
digest with NotI and an enzyme that cleaves either side of the specific region for each library (Table 
2.1). The library was also digested with the same enzyme combinations. RNA transfections were 
performed for each 15nt insertion library (see above for details) in triplicate and recovered virus was 
titred by TCID50.   
Library Library region Enzyme used with NotI for 
library screening 
NS1-2 6-843 EagI (2471 & 7445) 
NS3/4 843-2566 DraIII (3032 & 7956) 
NS5/6/7 2566-3948 XhoI (4597 & 7510) 
NS7/VP1/VF1 3948-5768 DraIII (3032 & 7956) 
VP1/VP2/3’UTR 5768-7410 XhoI (4597 & 7510) 
Table 2.2. Restriction enzymes used to screen clones from each 15 nt insertion library for the 
presence of the 15nt insertion. Numbers in brackets refer to cleavage sites in the pT7:MNV 3’ RZ 
clone. 
 
2.3.2 Insertion profiling 
For tissue culture selection of tolerated insertions, virus recovered from each 15nt insertion library 
was passaged 3 times in RAW264.7 cells at an MOI of 0.01 TCID50/cell for the first passage and 0.1 
thereafter, for 16 h, with 2 independent biological replicates. Virus was titred in between each 
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sequential passage and total RNA was extracted using the GenEluteTM Total Mammalian RNA 
System. Reverse transcription of the extracted RNAs, the in vitro transcribed library input RNA and 
wild-type RNA was performed using Superscript III (Invitrogen). The cDNAs were then used as 
templates for PCR amplification of overlapping fragments spanning the mutagenised region of each 
library, using KOD Hot Start DNA polymerase (Novagen). Primers are given in Appendix 1. In the case 
of the VP1/VP2/3’UTR library, the original DNA library was also PCR amplified and profiled to control 
for a loss of library diversity during in vitro transcription. All fragments were approximately 400bp in 
size and overlapped with the following fragment by around 100bp. The pT7:MNV 3’RZ clone was also 
used as a template to generate corresponding PCR products to later control for non-specific 
products in the second round of PCR and detection of the insertions. Each RT-PCR or PCR product 
was gel purified and 50ng was used as a template in a second round of PCR using the same virus 
specific forward primer (from the first round of PCR) and a NotI mini primer (5’TGCGGCCGCA3’), 
labelled at the 5’ end with the fluorescent dye FAM. 1 µL of each fluorescently-labelled product was 
then mixed with 8.6 µL HiDi formamide (Applied Biosystems) and 0.4 µL ROX 400HD size markers 
(Applied Biosystems) and analysed in three technical replicates using an ABI 3730xl DNA Analyzer at 
the Genomic Core Facility (Hammersmith Campus, Imperial).  
2.3.3 Insertion profiling: data analysis  
The data generated by the DNA Analyzer was processed using Peak Scanner Software (Applied 
Biosystems), using modified Amplified Fragment Length Polymorphism analysis settings. The 
minimum fluorescence intensity of detection was set according to the background peaks observed 
for WT DNA across the same mutagenised region of each library, which presumably occurred due to 
GC-rich regions in the WT non-mutagenised genome. These were typically 600 arbitrary units for all 
libraries except the VP1/VP2 insertion library for which the background was set at 200 arbitrary units 
and the NS1-2 library for which it was set to 400 arbitrary units. Any peaks that were greater than 
this limit in the WT were later excluded from the library data sets to exclude the possibility of false-
positives. The data was visualised as an electropherogram, with each peak representing a 15nt 
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insertion. Data regarding the fragment lengths (bp) and corresponding peak heights in each 
fragment were exported into Microsoft Excel for further analysis. Fragments smaller than 65bp in 
size typically corresponded to primer noise and were excluded from the data set as this region was 
be covered by the overlapping nature of the PCR amplicons. The data from triplicate analyses of 
each fragment was compiled and the peak heights were averaged for insertions appearing in all 3 
replicates. Insertion profiles were also compiled for the duplicate passages. To calculate the position 
of each insertion within the genome, the size of the peak was added to the genome position of the 
virus specific forward primer and 10nt were subtracted to allow for the size of the 3’ NotI 
miniprimer.  The final whole genome insertion map was compiled from each passage of each of the 
libraries in Graph Pad Prism. The Chimera modelling software was used (UCSF) to map the positions 
of insertions onto the MNV NS7 structure (PDB ref 3NAH), VPg (PDB ref 2M4G), NS6 (PDB ref4ASH) 
and the P domain of VP1 (PDB ref 3lq6B). Sequence alignments were performed with Align X 
software and protein sequence structure predictions were performed using TMPred, PHDht, and 
PSIPRED, all available online. 
2.3.4 Isolation of 15nt insertion mutants 
To isolate individual insertion mutants, limiting dilutions of the virus recovered from each 15nt 
library were performed on RAW264.7 cells seeded in a 96 well plate. RNA was extracted from wells 
showing cytopathic effect using Trizol. The mutagenised region was amplified by RT-PCR using the 
One-Step Access QuickTM RT-PCR system (Promega) and primers to span the relevant mutagenised 
region. PCR products were then digested with NotI to confirm the presence of the 15nt insertion and 
the insertion sites were sequence-verified to determine the genomic position. The sequence of 
selected insertion sites from the profiling were predicted using Vector NTI Software (Invitrogen).  
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 Engineering reporter- tagged viruses  2.4
2.4.1 Generation of GFP-insertion libraries  
All 5 Tn mutagenised libraries were extensively digested with restriction enzyme NotI (New England 
Biolabs) to remove the Tn. Antarctic Phosphatase (New England Biolabs) was used to remove 5’ 
phosphate groups from the pT7 MNV:3’ RZ NotI ends to prevent circularisation in the ligation step. A 
GFP insert was amplified using primers IGIC477 (TAAACTATTGCGGCCGCATGGTGAGCAAGGGCGA 
GGAGC) and IGIC478 (TAAACTATTGCGGCCGCCTTGTACAGCTCGTCCATGCCGAGAGTGATCCC) to 
introduce NotI cleavage sites into either end of the GFP coding sequence (using plasmid pEGFP-C1 as 
a template). The purified product was ligated with pETM11-eIF4e, previously linearised by NotI 
digestion. GFP was then excised from the vector by NotI digestion, to ensure both ends contained a 
NotI site. The NotI-GFP insert was subsequently ligated with each of the libraries, and transformed 
into XL10 Gold® Ultracompetent Cells, selected on carbenicillin only. This produced 5 GFP-insertion 
libraries, each composed of clones containing GFP in place of the Tn. Randomly selected clones from 
each library were screened for the GFP insert by NotI digestion, in combination with a second 
enzyme that cleaved either side of the region containing GFP, Table 2.2.  
Virus was recovered from each GFP-insertion library using the DNA-based system detailed above. 
Virus was harvested at 48hpi and cell lysates were prepared and analysed for GFP, NS7 and GAPDH 
expression by western blot (described below).  Five independent rescues were performed for each 
GFP-insertion library and were then pooled and concentrated by ultracentrifugation at 100,000 x g 
for 4 h prior to resuspension in tissue culture media. The pooled and concentrated viruses were then 
used to infect RAW264.7 cells, seeded into a 10cm dish, at low MOI to increase the chance of 
isolating GFP-tagged virus. Fluorescence microscopy was used to search for GFP-positive cells. 
2.4.2  Engineering reporter protein coding sequences into the MNV genome 
A plasmid containing the coding sequence for the improved light, oxygen and voltage sensing 
domain (iLOV) was kindly provided by Professor John Christie (University of Glasgow) and Dr. 
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Fernando Abaitus (Imperial College London) kindly provided a plasmid containing the coding 
sequence for Gaussia Luciferase (G.Luciferase). The iLOV and G.Luciferase coding sequences were 
inserted into cDNA clones carrying a 15 nt insertion at a specific location in the genome containing a 
NotI restriction enzyme site (details of each insertion site are provided in Chapter 4). For this the 
coding sequence of each reporter protein was amplified to be flanked by NotI restriction enzyme 
sites and to be in-frame for each specific insertion site. For each insertion site an insert was also 
amplified to contain the coding sequence for 2A peptide from the Foot and Mouth Disease virus 
(FMDV) (nt sequence: CTGTTGAATTTTGACCTTCTTAAGCTTGCGGGAGACGTCGAGTCCAACCCTGGGCCT, 
protein sequence: NFDLLKLAGDVESNPGP). This mediates co-translational cleavage to release one 
side of the reporter protein from the viral protein. It was therefore positioned to cause minimal loss 
of the viral protein, as is detailed in Chapter 4.  
Each insert and vector was then digested with NotI prior to gel purification. The vectors were 
dephosphorylated with Antarctic phosphatase and ligated with the appropriate insert for 
transformation into alpha-select chemically competent bronze efficiency cells. Clones were screened 
for the presence of each insertion by NotI restriction digest and agarose gel electrophoresis. Plasmid 
DNA was prepared from midi preps and sequenced as described above. To measure the activity of G. 
Luciferase activity during virus recovery, the media was removed, cells were washed and the media 
replaced to be able to monitor the amount of G. Luciferase secreted in 30 min. The supernatant 
from each transfected cell was collected and 40 µL were incubated with the G. Luciferase substrate 
coelenterazine (NanoLight Technology). G.Luciferase activity was measured using an Autolumat Plus 
LB 953 machine (Berthold). 
The coding sequence for the FlAsH tag (TGCTGCCCAGGATGCTGC) was introduced directly into the 
specified positions in the MNV-1 genome (after nt 218 and 6686, Chapter 4) by overlap mutagenic 
PCR, following the outline described above. This strategy was also used for inserting the coding 
sequence for the small split GFP fragment (AGAGATCACATGGTCTTGCACGAGTACGTCAATGCTGC 
TGGTATCACA), which corresponds to the 16 terminal amino acids of GFP, as described in (20, 58).  
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 Protein techniques and microscopy 2.5
2.5.1  Western blotting 
Samples were prepared for western blot by harvesting the cells directly into RIPA buffer (50 mM 
Tris/HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS). The cell lysates were 
resolved by SDS-PAGE (either 12.5% or 15% gels) and transferred to a polyvinylidene fluoride (PVDF) 
Immobilon-P membrane (Millipore), which had been activated with methanol. Transfers were 
performed using a Trans-Blot SD semi-dry electrophoretic cell, 15V for 50 min (BIO-RAD). The 
membranes were blocked (5% milk with 0.1% Tween-20 in PBS). The antibodies used against the 
viral proteins throughout this thesis were rabbit polyclonal anti-NS7 and rabbit anti-NS3 (non-
commercial antibodies). NS1-2 was detected using mouse immune sera provided by Professor 
Herbert Virgin and Dr Larissa Thackray (Washington University in St Louis). Antibodies used against 
cellular proteins include anti-cofilin (Abcam), anti-VDAC (Abcam), anti-TRIM21 (Sigma-Aldrich), and 
anti-GAPDH (Ambion). Rabbit polyclonal antiserum against DDX3 was kindly provided by Dr Aravind 
Patel (Glasgow University). These were followed by goat anti-mouse and anti-rabbit HRPO-
conjugated secondary antibodies (Sigma-Aldrich). For detection of the FLAG tag HRPO-conjugated 
anti-FLAG was used. HRPO-conjugated primary and secondary antibodies were detected by 
chemiluminescence (ECL, Amersham, GE Healthcare). 
2.5.2  Immunoprecipitation 
RAW264.7 cells were infected with passage 1 sequence verified stocks of NS4-FLAG, VP2-FLAG, NS1-
2 FLAG or WT MNV-1 at an MOI of 0.01 TCID50/cell. At 36 hpi, cell lysates were harvested (lysis 
buffer 50 mMTris HCl, pH7.4, with 150 mM NaCl, 1 mM EDTA and 1% Triton X-100) and a proportion 
was kept aside as the total cell input. Immunoprecipitations were then performed using Anti-FLAG 
M2 Affinity Gel (Sigma-Aldrich), as per manufacture’s instructions. Briefly, the anti-FLAG affinity gel 
was incubated with the cell lysates overnight at 4 °C. The samples were then centrifuged at 4 °C at 
5000 rpm for 30s to pellet the agarose beads and the supernatant was removed and was retained as 
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the ‘flow-through’ fraction. The agarose was washed 3 times with Tris buffered saline (pH 7.5) prior 
to elution into SDS-PAGE sample buffer by heating at 95 °C for 3 min. Input, flow through and elution 
fractions were then analysed by western blot (see above).  
2.5.3 Confocal microscopy 
For confocal microscopy of the GFP-insertion libraries, BSR-T7 cells were seeded onto glass 
coverslips at a density of 1.5 x 106 and recovery of each cDNA GFP-insertion library was performed as 
described above using the DNA based system. eGFP was also transfected as a positive control. After 
24hpi, cells were fixed using 4% Paraformaldehyde:PBS and mounted onto glass slide with Mowiol 
containing DAPI stain.  For confocal microscopy of the FLAG-tagged viruses, BV-2 cells were seeded 
onto glass coverslips at a density of 5 x 105 and infected the same day at an MOI of 1 TCID50 per cell. 
After 12hpi, cells were fixed using 4% paraformaldehyde (PFA) in PBS, permeabilised with 0.2% 
Triton X100 in 4% PFA in PBS and quenched with 200 mM glycine in PBS. PBS washes were 
performed in between each step. Cells were blocked in 10% FCS in PBS and stained with monoclonal 
anti-FLAG M2 (Sigma-Aldrich) and rabbit anti-NS7 serum, followed by donkey  anti-mouse and anti-
rabbit antibodies (Jackson Laboratories), conjugated with Alexa Fluor 546 and Alexa Fluor 488 
respectively, using the Molecular Probes Conjugation Kit (provided by Michael Hollinshead, Imperial 
College London). Cells were then mounted onto a glass slide with Mowiol containing DAPI stain. 
Images were captured using a Zeiss 510 Meta laser confocal microscope.  
 SILAC proteomics  2.6
2.6.1 Sample preparation 
BV-2 cells were maintained in SILAC-DMEM (Dundee Cell Products) supplemented with arginine and 
lysine amino acids labelled with different stable isotopes (Cambridge Isotope Labs). The 
combinations of labelled amino acids for each media condition are given in Table 2.3. The DMEM 
also contained P/S and dialysed FCS (Dundee Cell products). BV-2 cells were passaged in each media 
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for at least 5 cell divisions to ensure over 95% of proteins contained the correctly labelled amino 
acids.  
Media Stable isotope labels 
Arginine                                             Lysine  
Light (R0K0)   - - 
Medium (R6K4)  13C 2H 
Heavy (R10K8)  15N, 13C 15N, 13C 
Table 2.3 Composition of arginine and lysine residues containing different stable isotopes. Only the 
labelled atoms are shown.  
 
SILAC experiments were performed for NS4-FLAG and NS1-2-FLAG (Chapter 4). For the first NS4-
FLAG experiment, 1 x 107 BV-2 cells labelled with either light, medium or heavy amino acids were 
seeded into 10cm2 dishes and infected with NS4-FLAG or MNV-1 WT at an MOI of 1.5 TCID50/cell. 
This MOI was as high as could be used to maintain a low volume of innoculum, to avoid the potential 
effects of pulse labelling from the unlabelled virus innocula. At 10 hpi protein was harvested directly 
into cell lysis buffer (50 mM Tris HCl, pH 7.4, with 150 mM NaCl,1 mM EDTA, and 1% Triton X-100) 
with protease inhibitors added (Promega). Cell lysates were centrifuged at 13.2krpm for 10 min to 
remove cell debris and the soluble fraction was collected as the input for immunoprecipitation. The 
protein concentration from each sample was determined by Pierce BCA protein assay (Thermo 
Scientific), as per manufacturer’s instructions. Equal protein amounts were incubated with anti-FLAG 
M2 affinity gel (Sigma-Aldrich) and immunoprecipitation was performed as described above in 
section 2.5.2. The immunoprecipitation was validated by western blot analysis for NS4-FLAG and 
GAPDH, as described above. The eluted fractions from each sample (light, medium and heavy) were 
then combined in a 1:1:1 ratio and were analysed by mass spectrometry. 
For the second SILAC experiment for NS1-2 FLAG, small optimisations were made to this protocol. 
Firstly, high titre virus stocks of each virus were generated by infecting differentially labelled BV-2 
cells. Each stock therefore contained the appropriately labelled amino acids and so a larger volume 
of innoculum could be used without the problem of pulse labelling. As a result a higher MOI could be 
used (3 TCID50/cell) for the SILAC experiment. Secondly cell lysates were treated with an RNase 
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cocktail (New England Biolabs) to remove viral RNA that may have been precipitated with NS1-2 
FLAG as part of the replication complex and any cellular RNA binding proteins.  
2.6.2  Mass spectrometry  
Mass spectrometry was performed by Dr Kate Heesom at the Proteomics Facility of the University of 
Bristol. Each combined sample was resolved by SDS-PAGE and the lane of each sample was cut into a 
single slice and in-gel tryptic digestion was performed using a ProGest automated digestion unit 
(Digilab UK).  The resulting peptides were fractionated using a Dionex Ultimate 3000 nanoHPLC 
system in line with an LTQ-Orbitrap Velos mass spectrometer (Thermo Scientific).  In brief, peptides 
in 1% (vol/vol) formic acid were injected onto an Acclaim PepMap C18 nano-trap column (Dionex). 
After washing with 0.5% (vol/vol) acetonitrile 0.1% (vol/vol) formic acid peptides were resolved on a 
250 mm × 75 μm Acclaim PepMap C18 reverse phase analytical column (Dionex) over a 150 min 
organic gradient, using 7  gradient segments (1-6% solvent B over 1min., 6-15% B over 58min., 15-
32%B over 58min., 32-40%B over 3min., 40-90%B over 1min., held at 90%B for 6min and then 
reduced to 1%B over 1min.) with a flow rate of 300 nl min−1.  Solvent A was 0.1% formic acid and 
Solvent B was aqueous 80% acetonitrile in 0.1% formic acid.  Peptides were ionized by nano-
electrospray ionization at 2.1 kV using a stainless steel emitter with an internal diameter of 30 μm 
(Thermo Scientific) and a capillary temperature of 250°C. Tandem mass spectra were acquired using 
an LTQ- Orbitrap Velos mass spectrometer controlled by Xcalibur 2.1 software (Thermo Scientific) 
and operated in data-dependent acquisition mode.  The Orbitrap was set to analyze the survey scans 
at 60,000 resolution (at m/z 400) in the mass range m/z 300 to 2000 and the top six multiply charged 
ions in each duty cycle selected for MS/MS in the LTQ linear ion trap.  Charge state filtering, where 
unassigned precursor ions were not selected for fragmentation, and dynamic exclusion (repeat 
count, 1; repeat duration, 30s; exclusion list size, 500) were used.  Fragmentation conditions in the 
LTQ were as follows: normalized collision energy, 40%; activation q, 0.25; activation time 10ms; and 
minimum ion selection intensity, 500 counts. 
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The raw data files were processed and quantified using Proteome Discoverer software v1.2 (Thermo 
Scientific) and searched against the UniProt Mouse database and MNV-1 protein sequences 
including the sequence of the NS4-FLAG and NS1-2 FLAG tagged proteins using the SEQUEST (Ver. 28 
Rev. 13) algorithm.  Peptide precursor mass tolerance was set at 10ppm, and MS/MS tolerance was 
set at 0.8Da.  Search criteria included carbamidomethylation of cysteine (+57.0214) as a fixed 
modification and oxidation of methionine (+15.9949) and appropriate SILAC labels (2H4-Lys, 
13C6-Arg 
for duplex and 13C6
15N2-Lys and 
13C6
15N4-Arg for triplex) as variable modifications.  Searches were 
performed with full tryptic digestion and a maximum of 1 missed cleavage was allowed.  The reverse 
database search option was enabled and all peptide data was filtered to satisfy false discovery rate 
(FDR) of 5%.  The Proteome Discoverer software generates a reverse “decoy” database from the 
same protein database and any peptides passing the initial filtering parameters that were derived 
from this decoy database are defined as false positive identifications.  The minimum cross-
correlation factor (Xcorr) filter was readjusted for each individual charge state separately to 
optimally meet the predetermined target FDR of 5% based on the number of random false positive 
matches from the reverse decoy database. Thus each data set has its own passing parameters.  
Quantitation was done using a mass precision of 2ppm.  After extracting each ion chromatogram the 
Proteome Discoverer software runs several filters to check for, among other things, interfering peaks 
and the presence of the expected isotope pattern.  Peptides which do not pass these filters are not 
used in calculating the final ratio for each protein.  Protein ratios presented in table X represent the 
median of the raw measured peptide ratios for each protein.  
2.6.3 Data Analysis 
The mass spectrometry results for each SILAC experiment were analysed using Microsoft Excel. 
Single peptide hits were firstly excluded and the ratios between each labelled samples were 
calculated to give the ratios for either NS4-FLAG/WT or NS1-2-FLAG/WT. The log2(SILAC ratio) was 
then determined and the mean log2(SILAC Ratio) and standard deviation (SD) was calculated for each 
protein. A log2(SILAC ratio) of 1 indicates a 2-fold enrichment of in the FLAG-virus samples compared 
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to the WT sample, which was set as a threshold for specific interactions. Proteins with a mean 
log2(SILAC ratio) of less than 1 were excluded as non-specific interactions and experimental or 
environmental contaminants. High confident interactions were defined as proteins identified in all 
replicate experiments that were over 2 fold enriched with a mean log2(SILAC ratio) or 1 and a SD that 
did not cross the threshold. Low confidence interactions were defined as those present in at least 2 
of 3 replicates, also with a mean log2(SILAC ratio) of 1 and a SD that did not cross this threshold.   For 
the NS1-2 FLAG SILAC experiment, Ingenuity Pathways Analysis (IPA) was also performed on the high 
and low confidence results combined.  
 MicroRNA (miRNA) techniques 2.7
2.7.1 miRNA extraction 
To analyse miRNA expression RAW264.7 and BV-2 cells were infected with MNV-1 WT at an MOI of 
0.1 TCID50/cell or were mock infected and the small cellular RNA fraction was harvested at 20 hpi. 
For the same purpose BMDM cells were infected at an MOI of 10 TCID50/cell and small RNA species 
was harvested at 24 hpi. Furthermore a DNA-based recovery of MNV-1 was performed in BSR-T7 
cells, for small RNA species to be extracted at 24 h post transfection. In each case the small cellular 
RNA fraction (<200bp) was harvested using the miRVana RNA isolation kit, as per manufacturer’s 
instructions. In brief, cell lysis is followed by an acid-phenol:chloroform extraction to obtain the 
soluble fraction. This was then mixed with ethanol and passed over a glass fibre filter to immobilise 
large RNA species. The small RNA species were collected in the filtrate and mixed with a higher 
percentage of ethanol to be immobilised on a second glass fibre filter. Following washes the small 
RNA fraction was eluted in a low ionic strength solution. This retains RNA molecules as small as 10 
nt. 
2.7.2  MiRNA RT-qPCR and Taqman Low Density Arrays  
For cDNA synthesis the Taqman miRNA reverse transcription kit was used (Life Technologies), 
according to manufacturer’s instructions. 1000 ng of RNA extracted from infected and uninfected 
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RAW264.7 cells and BV-2 cells were used with Megaplex RT primers, Rodent Pool A (Life 
Technologies). The pool contains primers specific to 335 and 238 mature unique mouse and rat 
miRNAs respectively, alongside primers for 4 specific endogenous controls. The cDNA was then used 
for qPCR using Taqman Rodent miRNA Array A cards (TDLA, Life Technologies). The Taqman Rodent 
miRNA Array A is a pre-configured 384 well card that can amplify and detect 381 mature rodent 
miRNAs and 3 control small RNAs (that are common to those in the Megaplex primer pools). As 
recommended in the manufacturer’s instructions, 6 µL of cDNA was mixed with Taqman Universal 
PCR 2X Master Mix (no UNG) (Life Technologies) into a final volume of 900 µL. 100 µL of each mix 
was loaded into a port on the TLDA card which covered two rows of the 384 well card. The cards 
were then centrifuged for 1 min at 1200 rpm to load the mastermix into each well. The TLDA cards 
were run on the 7900HT T Fast Real-Time PCR System and the data was visualised and analysed for 
the Ct value of each miRNA by RQ manager software (Life Technologies). Further analysis was 
performed using Microsoft Excel. The Ct value for each miRNA was normalised against the Ct value 
for the endogenous control small nuclear RNA, U6. To do so, the delta Ct value was calculated for 
each miRNA in each sample, by subtracting the Ct value of U6 from the Ct value of the specific 
miRNA. To compare the fold change in each miRNA resulting from MNV infection in RAW264.7 cells 
and BV-2 cells, the delta Ct of a miRNA in uninfected cells was subtracted from the delta Ct value for 
the corresponding miRNA in infected cells. This gives the delta delta Ct value (DDCt). The relative 
quantity (RQ) was then calculated by 2-(DDCt). The RQ value equates to a fold change where an RQ 
value of 2 means a 2-fold increase in the level of miRNA, whereas an RQ value of 0.5 indicates a 2-
fold decrease in the level of the miRNA. A two-fold change was used to indicate a significant change, 
as suggested in the manufacturer’s instructions.  
RT-qPCR was also performed using RT and PCR primer-probes specific to a selection of miRNAs.  The 
RT-qPCR was performed using the same enzymes and master mixes but with individual primers for 
miR-155, miR-467a, miR-467c, miR-126, miR-125-5p, miR-124, miR-10a and the control RNA U6. 
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10ng of RNA was used in each RT reaction and 5 µL of cDNA was used in the qPCR reaction. The delta 
Ct value was calculated and compared for each miRNA in different cell lines.  
 Techniques for generating and characterising polymerase mutants 2.8
2.8.1  Generating mutagen resistant viruses 
WT MNV-1 was serially passaged in the presence of chemical mutagens ribavirin (50 µM), 
azacytidine (50 µM), MnCl2 (1mM) or MgCl2 (5mM). For each passage, RAW264.7 cells were pre-
treated with each mutagen for 2 h prior to infection. For the first passage, RAW264.7 cells were 
infected at an MOI of 0.01 TCID50/cell but thereafter blind passage was performed by inoculating 
cells with 300 µL of the previous passage. The mutagen was present for the duration of each 
infection and did not reduce cell viability by more than 50% as recommended (34). Virus was 
harvested at 16 hpi. WT MNV-1 was also passaged in the absence of any mutagen to account for any 
changes that may occur with repeated serial passage in RAW264.7 cells.  At passages 10 and 20, 
total RNA was extracted and the polymerase region of ORF 1 (nt 3537-5066) was amplified by RT-
PCR using M-MLV RT and GoTaq Flexi DNA polymerase (as described in section 2.5.1). At passage 10 
this region was consensus sequenced and at passage 20 clonal sequencing was performed (see 
section 2.8.4). For clonal sequencing the PCR products were TA cloned using the pGEM-T Easy 
system (Promega), as per manufacturer’s instructions. For each mutagen treatment 28 colonies 
were picked and were sent for DNA preparation and sequencing by GATC Biotech. Sequences were 
analysed with Contig Express for non-synonymous changes in NS7.  
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2.8.2  Monitoring tissue culture adaptive changes 
The polymerase mutants P1b-P72S and P1b-E75S were serially passaged alongside P1b-WT in 
RAW264.7 cells at either high (>2 TCID50/cell) or low (0.01 TCID50/cell) MOI. At 24 hpi virus and 
total RNA were harvested. Virus was titred in between each passage by TCID50 in RAW264.7 cells. 
The regions of the genome encoding NS7 (3537-5066), VP1 (5056-6678) and NS4 (2121-2615) were 
amplified by RT-PCR using M-MLV and GoTaq Flexi DNA Polymerase. These regions were consensus 
sequenced for the polymerase mutations at nucleotide positions 3750 (P72S) and 3759/60 (E75S) in 
NS7 and for the genetic markers of tissue culture adaptation at positions 5941 (VP1) and 2151 (NS4).  
2.8.3  Cell viability and mutagen sensitivity assays 
The non-specific cytotoxicity of ribavirin (Sigma-Aldrich), 5-fluorouracil (5FU) (Sigma-Aldrich), 
azacytidine (AZC) (Sigma-Aldrich) and amiloride (Sigma-Aldrich) in RAW264.7 cells or IC21 cells was 
monitored using a Cell Titre-Blue Viability Assay (Promega), as per manufacturer’s instructions. Cell 
viability is determined by the ability to metabolise a test compound resazurin to resorufin, which 
absorbs at 570nm. To calculate % cell viability, the difference in absorbance at 570nm in the 
presence and absence of cells was measured for each mutagen concentration, which corresponds to 
the degree of metabolism of the resazurin and takes into account any influence of the mutagen on 
absorbance. For each mutagen this was expressed as a percentage of the difference observed for 
untreated cells. To test the sensitivity of P1b-WT, P1b-P72S and P1b-E75S to ribavirin, AZC and 
amiloride RAW264.7 or IC21 cells were seeded at 3x105 in 24 well plates and were mock-treated 
with complete media or with concentrations of each mutagen that retained more than 80% cell 
viability. Cells were pre-treated for 2 h prior to infection with either P1b-WT, P1b-P72S or P1b-E75S 
at an MOI of 0.01 (TCID50/cell).  The mutagen was present for the duration of infection and virus 
was harvested at 20 hpi for titration by TCID50.  
  
Materials and Methods 78 
 
2.8.4 Determination of viral mutation frequencies 
The P1b-P72, P1b-E755S and P1b-WT viruses were serially passaged at an MOI of 0.01 TCID50/cell in 
RAW264.7 cells. Virus was harvested at 24 hpi and titred in between each passage. At passage 5 
total RNA was extracted and the coding sequence spanning part of VP1 and VP2 (nt 6252-7229) was 
amplified by RT-PCR with M-MLV RT and GoTaq Flexi DNA polymerase. Each PCR amplicon was 
cloned using the pGEM-T Easy vector system. For each virus, 96 clones were picked and sent for 
sequencing by GATC Biotech. The sequences were aligned and analysed using Simmonics Software. 
For each virus the number of mutations per clone and in total was determined over a region of 880 
bp which showed consistent coverage. Short reads were excluded from the analysis. The mutation 
frequency was calculated by dividing the total number of mutations by the total number of nt 
sequenced and is expressed as mutations per 10k nt. 
2.8.5 In vivo studies  
Three-to-four week old female C57BL/6 mice were inoculated with 1000 TCID50 of MNV3-P72S, 
MNV3-E75S and MNV3-WT virus by oral gavage. Each group contained 6 mice and a control group 
was mock infected. Mice were weighed and faecal samples were collected on days 1-7, 14, 21, and 
28 post infection and mice were euthanized on day 28. Faecal pellets were homogenised in PBS 
(100mg/mL), followed by centrifugation at 4000 rpm for 5 min, 4 °C. RNA was extracted from 100 µL 
of supernatant using the GenElute mammalian total RNA kit and viral genome copy numbers were 
determined as described in section 2.1.8. The RNA from faecal samples taken on d28 was also used 
for cDNA synthesis with SuperScript III enzyme (Life Technologies), as per the manufacturer’s 
instructions. A pool of reverse primers were used including those which bound at genome nt 
positions 5058, 5367, 5738 and 6026, which are all close to the NS7 coding region (3537-5066). 
cDNA was then treated with RNase H (New England Biolabs) at 37 °C for 15 min and used as a 
template for nested PCR with KOD High Fidelity Polymerase. The primers used in the first round of 
nested PCR covered the region nt 3394 to 4451. 5 µL of the first round product was then used as a 
template in the second round with primers spanning the region of nt 3687 to 4128. This product was 
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gel purified and consensus sequences to confirm the polymerase mutations for P72S (at nt 3750) 
and E75S (at nt position 3759/60). 
The in vivo studies performed with the MNV-1 strain in immunocompromised mice were carried out 
by Dr. Larissa Thackray at the University of Washington. 129v STAT1-/- mice were inoculated by oral 
gavage with 3 x 104 plaque forming units (PFU) of MNV-1 P1b-P72S, MNV-1 P1b-E75S and MNV-1 
P1b-WT. There were 5 mice in each group and lethality was observed over 7 days post infection. 
129V RAG1-/- mice were inoculated by oral gavage with 3 x 105 PFU of MNV-1 P1b-P72S, MNV-1 P1b-
E75S and MNV-1 P1b-WT. Each group contained 7 mice, 5 of which were euthanized on day 5 post 
infection and lung, liver, spleen, mesenteric lymph node, distal intestine and colon tissue samples 
were harvested. The same tissues were collected from the 2 remaining mice in each group on day 35 
post infection. One mouse in the MNV-1 P1b E75S group died after day 5 post infection from 
unrelated causes. The viral titre in each of the tissues was determined by plaque assay on RAW264.7 
cells. 
To extract RNA from the day 35 colon samples, tissues were homogenised into RNA lysis buffer using 
ceramic beads (BioSpec Products) with a Fast Prep-24 homogeniser (MP Biomedicals). RNA was then 
extracted using the (GenElute total mammalian RNA kit. Reverse transcription was performed using 
SuperScript III and random hexamers, followed by PCR amplification of the genomic region 3625-
4012 using KOD High fidelity polymerase. Products were gel purified and consensus sequenced for 
the P72S and E75S mutations. 
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3. Identification of the essential elements required for MNV replication 
  Background 3.1
3.1.1 Transposon mutagenesis 
Tn-mediated insertional mutagenesis has been widely used to identify the essential and non-
essential regions of viral proteins, cis elements and entire viral genomes (13, 14, 36, 408). In each 
case a similar methodology has been followed, whereby the target gene or genome is first 
mutagenised in a simple reaction mediated by a transposase enzyme to generate a Tn-mutagenised 
library. The transposons can then be removed by restriction digest and religation of the vector 
leaves smaller signature tag. This library is subsequently screened en masse for the effect of each 
insertion on either viral replication or on a specific aspect of the viral lifecycle. The insertions that 
were present before and after selection are then identified by one of a number of possible insertion 
profiling techniques. From the insertions that are missing from the selected pool, a footprint of 
essential regions can be established.  
3.1.2 Aims 
The aim of this chapter was therefore to identify the essential regions of the MNV genome by firstly 
developing a transposon-mediated insertional mutagenesis strategy for MNV. It was then to apply 
an insertion profiling technique to map the regions that do and do not tolerate insertions and 
generate a footprint of essential regions for each viral protein and RNA element.  
 Results 3.2
3.2.1 Transposon-mediated insertional mutagenesis of the MNV genome 
In order to use Tn-mutagenesis to identify the essential regions of the MNV genome, an in vitro 
transposition system based on the MuA bacteriophage machinery was selected. The advantage of 
the MuA system is that removal of the Tn leaves a small insertion signature which results in an in-
frame insertion of 5 amino acids. This small insertion is preferable for probing different regions of a 
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viral protein, as opposed to larger inserts left by other Tn systems. For this reason the MuA-based 
system has been used for the mutagenesis of various viral proteins, cis elements and entire genomes 
(13, 14, 35, 212, 227). A MuA-compatible Tn was selected with the criteria that it had to carry an 
alternative selectable marker gene (kanamycin) to the MNV infectious clone (carbenicillin), such that 
transposed clones could be obtained by double selection. Importantly, the selected transposon was 
flanked by a restriction enzyme site that is not present in the MNV infectious clone (NotI) to allow 
excision of only the transposon. Trial reactions were initiated with 2 different MuA transposase 
enzymes and varying ratios of target to transposon DNA, to attain the highest possible yield of 
insertion clones. The HyperMuATM transposase enzyme was consistently found to be the most 
efficient. The most effective ratio of target to Tn DNA (see Methods and Materials) was similar to 
that suggested by the enzyme manufacturer to ensure the transposition of a single Tn per copy of 
the MNV infectious clone. Whilst the possibility of double insertions cannot be excluded, subsequent 
excision of 2 Tns would result in loss of the intervening portion of the viral genome, unlikely to 
produce infectious virus.  
Using the optimised conditions, the full length MNV-1 infectious clone (pT7:MNV 3’RZ (78)) was 
subjected to in vitro transposition to create a Tn-mutagenised library, Figure 3.1. This library 
contained an estimated 225,000 insertion clones. To exclude clones containing a Tn in the backbone 
of the vector, which would later produce WT virus likely to dominate in a population of insertion 
mutants, 5 adjacent regions of the Tn-mutagenised library were sub-cloned into the non-
mutagenised MNV-1 infectious clone. For this purpose, 5 different pairs of restriction enzymes were 
used to divide the genome into regions spanning NS1-2, NS3/4, NS5/6/7, NS7/VP1/VF1 and 
VP1/VP2/3’UTR, covering the whole genome without overlaps (Figure 3.1 and Table 3.1). Ligation of 
the mutagenised insert with the non-mutagenised backbone was performed followed by 
transformation to again collect all mutagenised clones through selection on kanamycin and 
carbenicillin. This generated 5 Tn-mutagenised libraries, each containing Tns only in a well-defined 
portion of the genome. To confirm the presence of the Tn, each library was digested with the same 
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restriction enzymes that were used to generate it. The mutagenised fragments could be identified by 
an apparent shift in molecular weight (corresponding to the size of the Tn) compared to the parental 
non-mutagenised clone, Figure 3.2A.  
 
 
 
Figure 3.1. Strategy for Tn mutagenesis of the MNV-1 genome. A HyperMuATM transposase 
enzyme was used to insert one Tn per MNV-1 infectious clone to generate a Tn-mutagenised library. 
This was sub-cloned to generate 5 libraries containing Tns only in a well-defined region of the 
genome (grey shading).*SpeI cleaves at a position within the plasmid vector, other numbers indicate 
genome position. Removal of the Tns from each library leaves signature 15nt insertion (black 
shading). Dashed lines represent the vector of the MNV-1 infectious clone. 
 
The Tns were next removed from each library by NotI digestion, to leave behind a signature 15nt 
insertion. Religation and retransformation of the libraries resulted in the production of 5 15nt 
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insertion libraries. The 15nt insertion is composed of 10 nt derived from the Tn, containing a GC-rich 
NotI site, and 5 nt that originate from target DNA adjacent to the insertion site, which is duplicated 
during the original transposition event (Figure 3.3A). The amino acid sequence of each insertion 
depends on the reading frame in which it is inserted and the sequence of the duplicated target DNA, 
although importantly insertions never result in a stop codon (212). Ten individual clones were picked 
from each library and screened for the presence of 15nt insertions, alongside each library as a 
whole. This was done by restriction digest with an enzyme that cut either side of the mutagenised 
library region, in combination with NotI, which would further digest the library fragment if an 
insertion was present. For example, for the library spanning VP1/VP2/3’UTR XhoI was used to 
release a 2.9kB fragment containing VP1/VP2/3’UTR from the infectious clone. If an insertion was 
present this product was further cleaved by NotI compared to a non-mutagenised clone, Figure 3.B. 
The size of the NotI restriction digest products can be used to indicate the possible positioning of the 
insertion within the library region. In each case, this revealed seemingly unbiased differential digest 
patterns amongst the clones and a ladder of products resulting from cleavage of the whole library, 
suggesting that insertion sites were spread throughout each library region. The results of a 
representative screen are shown in Figure 3.2C.  
Library 
 
Nt position Enzyme 
Pair 
Size of Tn library 
(no. of clones) 
 
Size of 15nt library* 
(no. of clones) 
NS1-2 1 -843 SpeI – FseI 106,000 227,340 
NS3/4 843- 2566 FseI – BamHI 190,032 208,140 
NS5/6/7 2566- 3948 BamHI- AfeI 1520 504,000 
NS7/VP1/VF1 3948- 5768 AfeI- SacII 40,000 296,930 
VP1/VP2/3’UTR 5768-7410 SacII - NheI 89,809 510,050 
Table 3.1. Creation of the Tn and 15nt insertion libraries. For each library, the genome positions are 
given, alongside the enzyme pairs used to clone the mutagenised library fragment. The size of the Tn 
libraries are estimated to the nearest 10 clones. Large multiplication of target sites must occur to 
account for the increases in library size from the Tn- to 15nt-insertion libraries. 
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To recover virus from the 15nt cDNA insertion libraries, in vitro transcribed capped RNA was 
generated for direct transfection into BSR-T7 cells. The RNA reverse genetics system, recently 
developed in our lab (460), was employed over the DNA-based reverse genetics system due to its 
higher efficiency, which is preferable for recovering a complex library. Furthermore initial virus 
rescues performed with the DNA-based reverse genetics system had failed to recover insertion 
viruses, suggesting recombination between clones may have occurred within this system. Using the 
RNA-based system infectious insertion viruses were recovered from each of the 15nt insertion 
libraries, although at significantly lower titres in comparison to RNA derived from the non-
mutagenised WT cDNA clone, with the exception of the NS1-2 library (Figure 3.3B).  
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Figure 3.2 Characterisation of Tn and 15nt insertion libraries. (A) The 5 libraries contain Tns only in 
specified fragments of the MNV-1 genome. Each library of was digested with the restriction enzyme 
pair used to generate it (see Table 3.1), alongside the wild type MNV-1 cDNA clone. Tn - : Wild type 
MNV-1 cDNA; Tn + ; Library containing transposon in the specified fragment. Size of Tn: 1254bp. (B) 
Schematic diagram of the restriction digests used for screening the 15nt insertion libraries. The 
example is shown for the library spanning part of VP1/VP2/3’UTR, shaded in grey. XhoI was used to 
release the mutagenised fragment and if a 15nt insertion was present, containing a NotI site, then 
digestion by NotI should further cleave the mutagenised fragment. (C) Representative results from 
screening the VP1/VP2/3;UTR insertion library for 15nt insertions, using the scheme in (B). Digestion 
of the library reveals a ladder of digest products suggesting insertions were spread throughout the 
region.  
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Figure 3.3 Recovery of infectious 15nt insertion viruses. (A) Composition of the 15nt insertion. 
Numbers in italics represent the 5 nt target site for the original transposition (underlined numbers), 
10 nts originate from the transposon and contain a NotI restriction site highlighted in bold. (B) 
Recovery of infectious virus from 15nt insertion libraries. BSR-T7 cells were transfected with in vitro 
transcribed, enzymatically capped RNA produced from each cDNA 15nt insertion library. Virus was 
harvested at 48 h post transfection and the yield of recovered infectious virus was determined in 
RAW264.7 cells. FS carries a frame-shift in NS7 and was used as a negative control. The limit of 
detection is 11.2 TCID50/mL. Transfections were performed in triplicate; error bars represent the 
standard error of the mean. Significance was tested using One Way ANOVA and compared to WT 
using a Dunnett post-test, ***: p< 0.001; *p<0.5. 
 
3.2.2 Passage of insertion libraries 
To simultaneously identify and determine the effect of each insertion on viral replication, an 
insertion profiling method using insertion-specific fluorescent-PCR was established for MNV-1 
(Figure 3.4). The virus recovered from each 15nt insertion library was first subjected to tissue culture 
selection by 3 serial passages in RAW264.7 cells, performed as 2 independent biological replicates. 
Each passage was performed at low MOI to reduce the possibility of trans-encapsidation and 
complementation of defective RNAs which may result after coinfection of cells with multiple viruses. 
Virus and RNA were harvested at 16 hpi from each passage and were used to identify the insertion 
sites present within the population. Multiple RT-PCR reactions were performed on the extracted 
RNA, alongside the unselected input RNA for each library, to generate overlapping fragments 
spanning the appropriate mutagenised region. The purified products were then used as a template 
for a second round of PCR using a fluorescently-labelled insertion-specific primer and the same virus-
5’ NNN12345TGCGGCCGCA12345NNN 3’
3’ NNN12345ACGCCGGCGT12345NNN 5’
5’ NNN12345NNN 3’
3’ NNN12345NNN 5’
A B
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specific forward primer. The resulting fluorescently labelled products were analysed by capillary 
electrophoresis to determine the size (in nt) of each peak corresponding to an insertion, from which 
the genome position could be calculated (see Materials and Methods for details of data handling). 
To ensure that library complexity was maintained during in vitro transcription of the cDNA libraries 
(prior to recovery), the VP1/VP2/3’UTR cDNA 15nt insertion library was also profiled and was found 
to be comparable to that of the corresponding in vitro transcribed RNA. Example electropherograms 
from a region of the VP1/VP2/3’UTR library are shown for the cDNA library, input RNA and each of 
the 3 passages (Figure 3.5).  
A list of insertions detected prior to selection and at each stage thereafter was compiled for each 
15nt insertion library to generate an insertion map covering the entire MNV-1 genome (with the 
exception of the first 55 nt) (Figure 3.6 and Appendix 1). In the unselected input population 2,049 
insertions were detected, corresponding to approximately 1 insertion every 3-4 nt, although the 
distribution was not entirely even. After the first passage the number of detected insertions was 
reduced to 918, and then 468 and 324 after the second and third passages respectively, indicating 
the selection of stable and viable insertion mutants. The immediate loss of insertions during the first 
round of selection reveals which regions of the genome encode protein domains that must be intact 
for viral replication. Conversely insertions that are tolerated for all 3 passages must not significantly 
compromise protein function or replication, and as such this rationale can be used to narrow down 
regions that encode important functional protein domains across the entire genome. 
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Figure 3.4. Schematic diagram showing selection and the insertion profiling method for the 15nt 
insertion libraries. RNA was produced from each 15nt cDNA insertion library by in vitro transcription 
and enzymatic capping of the DNA library, and virus was recovered using the RNA-mediated reverse 
genetics system, in duplicate. For selection in tissue culture, the recovered virus was sequentially 
passed (in duplicate) 3 times in RAW264.7 cells at low MOI. RNA was extracted after each passage, 
and, alongside the input RNA, was used as a template for RT-PCR amplification of overlapping 
fragments, covering the respective mutagenised region of each library. Each fragment was used as a 
template in a second round of PCR with a virus-specific primer and the insertion-specific NotI 
miniprimer, labelled with a fluorescent tag (black circles). Fluorescently labelled products were 
detected and analysed by capillary electrophoresis.  
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Figure 3.5. Example electropherograms showing the detection and positioning of 15nt insertions in 
the fragment covering nt 6546-6931 (ORF2) during selection in tissue culture. Peak size is depicted 
on the X-axis (measured in nt) and fluorescence intensity on the Y-axis. The similar insertion profiles 
of the cDNA library and the RNA input suggest that diversity was not lost during in vitro 
transcription. Comparison of sequential passages reveals selection occurring within the insertion 
mutant populations. Insertions within the solid box are maintained whereas the dashed box 
highlights a group of insertions that are rapidly lost. Preliminary studies indicated that peaks under 
65 nt in size may correspond to primer oligomerisation and so were excluded from the analysis and 
the displayed electrophoregrams. 
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Figure 3.6. Genome-wide insertion profiling of the MNV genome. (A) Insertion sites detected in 
each passage (P1-P3) for each library were compiled to generate a map of insertion sites across the 
entire genome with the exception of the first 55 nt. 2,089 insertions were detected in the input 
profile with only 324 remaining after the 3 passages, indicating selection of viable mutants. Insertion 
sites found in the input and passage 3 populations at the C-terminus of NS4 (B) and the C-terminus 
of VP2 (C) are shown in greater detail. The insertions highlighted in red correspond to the position a 
FLAG tag was later inserted in the NS4 and VP2 coding regions, see Chapter 4. 
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3.2.3 Mapping of insertion sites and interpretation 
NS1-2: The NS1-2 protein is highly divergent between noroviruses and is the only norovirus protein 
that lacks sequence homology with any other viral protein therefore providing no clue as to its 
function (167). In a recent study NS1-2 was found to be associated with the replication complex in 
MNV-1 infected cells and it has been implicated in complex formation by recruiting cellular 
membranes, although a definitive function has not yet been established (198). NS1-2 was found to 
have the highest percentage of tolerated insertions remaining after the 3 passages (22% of those 
detected in the input) of all the non-structural proteins, Table 3.2. This is in line with the observation 
that it is the least conserved of the norovirus non-structural proteins. The insertions remaining after 
passage 3 were almost entirely located in the N-terminal half of the protein (residues 1-144), 
recently reported to account for the high sequence divergence of NS1-2 between norovirus 
genogroups, that at least in isolation behaves as an intrinsically  disordered region (25). In particular 
the insertions clustered between nt positions 57-90, 154-185 and 350-404, corresponding to amino 
acid residues 18-29, 50-60 and 111-133 respectively. Nearly all insertions between the second and 
third cluster were lost at the first passage, suggesting this region encodes an important functional 
domain. It is also worth noting that the first 250 nt of the MNV genome contains predicted RNA 
secondary structures that may interact with cellular proteins (366), which suggests that the 
tolerated insertions within the first 2 clusters do not compromise the RNA structures or any RNA-
protein interactions essential for replication in cell culture. 
The second cluster of tolerated insertions overlaps with 2 caspase 3 cleavage sites previously 
described in MNV, 118DXXD121 and 128DXXD131, which are thought to be cleaved late in infection (378). 
Three insertions were tolerated for all 3 passages in the first site and 2 in the second site, all of 
which disrupted the cleavage sites by introducing 5 amino acids between the aspartic acid residues. 
This indicates that cleavage of these sites is not essential for replication in permissive cells and, as 
previously suggested, may simply be a result of the induction of apoptosis at late stages of infection 
(378). However it is interesting to speculate that as many MNV strains appear to have maintained 
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these sites (378), perhaps the cleavage sites and the subsequent cleavage products play a role in vivo 
that is not apparent in cell culture. A third protease site in NS1-2 has been reported (100DXXD103) and 
is thought to be cleaved by an unknown cellular proteinase (378). Interestingly, all insertions that 
disrupted the positioning of the aspartic acid residues relative to one another were lost at the first 
round of selection, suggesting cleavage of this site is important for replication and that the cleavage 
products may have a specific function.  
The C-terminal half of NS1-2 exhibits a greater degree of sequence conservation between norovirus 
genogroups (25). Accordingly only several insertions were detected in this region after the third 
passage, indicating that disruption of its structure or function must compromise viral fitness or 
replication. The largely hydrophobic C-terminus contains a predicted transmembrane domain 
spanning residues 266-318 (25). All insertions in this region, except for 3, were lost after the first 2 
passages, suggesting disruption of the putative transmembrane domain compromises viral fitness. 
The C-terminus of the HuNV NS1-2 equivalent protein (p48) is also largely hydrophobic and contains 
a predicted TM domain between residues 361-379 (129, 135). This TM domain is thought to 
potentially act as a membrane anchor and be involved in intracellular membrane rearrangements 
and Golgi apparatus disassembly (135). In contrast, the MNV NS1-2 localises to the ER with no 
apparent Golgi association and promotes ER reorganisation into distinct vesicular structures when 
transfected in isolation (198). It is therefore possible that the TM region of NS1-2 and p48 mediate 
similar functions but in different organelles or that NS1-2 may also affect the Golgi but only in the 
presence of the other viral proteins. Finally, as regions that did not tolerate any insertions were 
located within both the C- and N-terminal halves, MNV NS1-2 may contain 2 separate functional 
domains. This is consistent with the recent report that NS1-2 appears to be comprised of 2 distinct 
halves with differential properties, which may afford the protein multiple functions (25).  
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Region  Genome  
Location 
Size  
(nt) 
Total insertions in region 
(% coverage) 
Insertions tolerated  
at P3  
NS1-2 6-1028 1023 279 (27.3%) 62 (22.1%) 
NS3 1029-2120 1092 340 (31.1%) 45 (13.2%) 
NS4 2121-2615 495 143 (28.9%) 21 (14.7%) 
NS5 2616-2987 372 93 (25%) 14 (15.1%) 
NS6 2988-3536 549 109 (19.9%) 11 (8.3%) 
NS7 3537-5066 1530 411 (26.9%) 57 (13.9%) 
VP1 5056-6678 1623 444 (27.3%) 48 (10.8%) 
VP2 6681-7304 624 204 (32.7%) 61 (29.9%) 
3’UTR 7305-7400 96 24 (25%) 8 (33.3%) 
Table 3.2 The percentage and number of insertions before and after selection in different regions 
of the MNV genome. 
 
NS3: NS3 is the putative helicase, due to the presence of 3 canonical superfamily 3 helicase motifs 
(motifs A, B and C), however its role in replication has not yet been clearly demonstrated. In vitro 
characterisation of HuNV NS3 (p41) demonstrated that the protein had NTP binding and hydrolysis 
activity, as conferred by canonical superfamily 3 helicase motifs A and B (319). All insertions that 
disrupted Motif A (GXXGXGKS/T) were lost at the first passage, although an insertion that changed 
the last 2 residues (K-N and S-A respectively) was tolerated for the first passage but subsequently 
lost, most likely due to a reduction in viral fitness. It is also possible however that the virus altered 
this insertion to restore the motif, meaning that it could no longer be detected. Only 1 insertion was 
detected in motif B (DD/E), which is involved in Mg2+ binding, and it appeared to be tolerated until 
passage 3. However prediction of the insertion sequence revealed that the motif should remain 
unaltered due to duplication of the target site nts. Together this data provides the first evidence that 
the NTPase activity of NS3 is essential for MNV replication. The proposed helicase activity of NS3 is 
thought to be conferred by motif C, although HuNV p41 failed to demonstrate unwinding during in 
vitro characterisation (319), but it is possible that an extra co-factor is required.  Motif C (S/TTN) 
contains an invariant asparagine residue located downstream of motif B. Whilst the preceding 
residues were found to tolerate insertions for the first 2 passages,  an insertion that changed the 
asparagine to methionine was lost immediately from the input profile upon passage in cell culture. 
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This indicates that this motif may also play an important role in replication, however further studies 
are required to confirm this observation and determine the exact function of motif C.  
NS4: Like NS1-2, NS4 has been associated with the replication complex in MNV-1 infected cells and is 
also thought to recruit cellular membranes to establish the complex (198), however its precise role 
in the MNV life cycle has not been determined. Both the N- and C-terminal regions of NS4 tolerated 
insertions throughout all 3 passages (see Figure 3.6B for the C-terminal profile). The central domain 
however did not tolerate any insertions through even the first passage and amino acids 64-129 
appeared to be essential for replication. Accordingly, sequence comparison of 4 different MNV 
strains (strains 1-4) revealed 95 % amino acid identity over these residues (data not shown). The 
central domain of the HuNV NS4 ortholog (p22) contains a predicted transmembrane helix involving 
residues 112-127, which is thought to mediate membrane association (357). Sequence analysis using 
3 different protein structure prediction tools (TMPred, PSIPRED and PHDhtm) predicted a 
transmembrane helix in the central domain of MNV-1 NS4, with the most agreement for its position 
involving residues 110-121 (data not shown). The TM domain of HuNV p22 is thought to be 
responsible for localisation of the protein to the Golgi apparatus, resulting in its dispersion and 
disruption of protein trafficking in transfected cells (357).  Similarly, the MNV NS4 protein has also 
been shown to localise to the Golgi, however only minor dispersion of the transGolgi apparatus has 
been observed in MNV-infected cells without gross changes in morphology (198, 200). Furthermore, 
NS4 has been observed to only mildly disrupt protein secretion in transfected cells, with mixed 
reports (198, 200, 356), which suggests that the predicted membrane associated domain of NS4 may 
exert an alternative function during MNV replication to its HuNV counterpart.  
NS5/VPg: VPg is found covalently bound to the 5’ end of the genomic and subgenomic RNAs and 
plays a role in translation initiation and also in RNA synthesis by acting as a protein primer for NS7 
(96, 164). For this role, VPg is guanylated on Y26 by NS7 and mutation of this residue has been 
shown to abolish viral replication (392). In accordance with this data, an insertion compromising Y26 
was immediately lost from the profile at the first passage, further validating the profiling results. VPg 
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mediates translation initiation by interacting with the cellular translation initiation factors eIF3, 
eIF4G1 and eIF4E in addition to S6 ribosomal protein, although it is worth noting that direct 
interactions have only been demonstrated for VPg and eIF3 and VPg and eIF4E (77, 96). Insertions 
tolerated through passage 3 were largely found in the C-terminus of VPg by mapping the insertion 
sites onto the recently solved structure of MNV VPg, as shown in Figure 3.7 (235). Unpublished data 
from our laboratory suggests that binding sites for eIF4G map to the C-terminus, indicating that 
tolerated insertions must not disrupt these interactions and that this data could support on-going 
studies to identify the translation initiation factor binding sites on VPg. Many sites in the N-terminal 
half of the protein were still detectable at passage 2, however the majority were not maintained 
through the third passage suggesting that they in some way compromise viral fitness and are altered 
or lost from the population. The central helical domain is known to be essential for the interaction 
between VPg and NS7 (235), which may account for the loss of nearly all insertions in this domain, as 
is evident by structural mapping of the insertion sites, Figure 3.7.  
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Figure 3.7. Structural mapping of the 5 aa insertion sites on VPg. The insertions found in the input 
(A) and passage 3 (B) profiles were mapped onto the structure of MNV VPg (PDB accession code 
2M4G). The structure was solved for residues 11-85 of 124 in total. Blue residues highlight positions 
after or at which an insertion was detected, where two insertions were found in a single codon with 
different outcomes, the most tolerated one was marked. Only 15.1% of insertions were tolerated 
until passage 3 and most of these were towards the C-terminus. The structures were mapped using 
Chimera Software (UCSF).  
 
NS6: The viral protease NS6 tolerated the fewest insertions, with only 8.3 % of input insertions still 
detectable after 3 passages in cell culture (see Table 3.2). The structure and function of the HuNV 
protease (3CLpro) has been extensively characterised and the active site is thought to be a catalytic 
triad of H30, E54 and C139, although E54 is largely thought to determine substrate specificity rather 
than being essential for catalysis (372, 373, 466). The HuNV 3Cpro and MNV NS6 share over 60 % 
amino acid identity (234) and sequence alignments showed that H30 and C139 are conserved, 
whereas position 54 is aspartic acid rather than glutamic acid in MNV-1 NS6 (data not shown), 
although this implies it has a similar function. Of the catalytic triad residues, only C139 contained an 
NH2
COOH
NH2
COOHA
B
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insertion in the input profile, which as expected was lost at the first passage. Taken together, this 
indicates that the catalytic triad and mechanism of catalysis may be conserved between the HuNV 
3CLpro and MNV NS6, which has not yet been established although it has been indicated by structural 
studies (234).  
The structure of the MNV NS6 has recently been determined to high resolution (234), allowing the 
insertion positions to be mapped, Figure 3.8. The structure of NS6 was adventitiously solved with the 
C-terminus of an adjacent NS6 molecule bound in the active site as a peptide substrate, which 
facilitated identification of the key residues involved in peptide binding and specificity (234). The 
specificity of norovirus NS6 cleavage has previously been questioned, as other studies have 
demonstrated unbiased cleavage (168). The residues found to form contacts with the peptide 
substrate in the ‘specificity’ and ‘hydrophobicity’ pockets of NS6 are highlighted in Figure 3.8A, 
alongside the catalytic triad. All insertions in these residues are lost by passage 3 (Figure 3.8B and C), 
with the exception of hydrophobicity pocket residue Y166, however this insertion is not predicted to 
alter the identity of Y166. As such, these results support the structural data suggesting that MNV 
NS6 may display specificity in cleavage site recognition, which is required for uncompromised 
replication. The low degree of tolerated insertions would imply that the majority of the NS6 
structure is important for maintaining protease activity.  
The polyprotein cleavage sites of MNV NS6 have been well mapped (378).  Within the input profile 
at least 1 insertion was identified in every cleavage junction within ORF1. Interestingly, none of 
these insertions would result in a change in the identity of the immediate cleavage site residues 
adjacent to the scissile bond, due to duplication of the target DNA within the insertion. However the 
position of the cleavage site would be shifted 5 aa downstream and the identity of the preceding 
residues altered. None of the insertions in the cleavage junction residues were tolerated beyond 
passage 1 or 2, suggesting that altering the positioning or the surrounding residues may affect 
cleavage efficiency and viral fitness. This further supports the evidence from the recent MNV NS6 
crystal structure, which showed that peptide residues in N-terminal positions P1, P2 and P4 to the 
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scissile bond form close contacts with NS6 and are largely phenotypically conserved between 
noroviruses (234). Whilst there is some variation, which suggests that specificity is not absolute and 
explains the initial tolerance of the insertions, it is likely that mutated residues form less-optimal 
interactions with NS6 and affect cleavage efficiency and specificity.  An insertion at the NS4-VPg 
cleavage site predicted to result in a duplicated cleavage site and potentially release of a tripeptide 
(composed of 3 alanine residues), was lost during the first round of selection.  
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Figure 3.8. Structural mapping of the 5 aa insertion sites on NS6. (A) The structure of MNV NS6 
(PDB accession code 4ASH) with key residues highlighted in stick format and coloured. Green 
residues are the catalytic triad H30, D54 and C139 (mutated to A in the structure), orange residues 
(H157, T134 and Y143) comprise the specificity pocket and purple residues (I107, I109, V114, V158, 
A159,T161, T166, I168) alongside H30 and D54 are form two substrate recognition hydrophobicity 
pockets. The insertions found in the input (B) and passage 3 (C) profiles were mapped onto the 
structure. Blue residues highlight positions after or at which an insertion was detected, where two 
insertions were found in a single codon with different outcomes, the most tolerated one was 
marked. Active site residue C159 did not tolerate an insertion, validating the profiling. Only  8.3 % of 
insertions were tolerated until passage 3. The structures were mapped using Chimera Software 
(UCSF).  
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NS7: NS7 is the viral RNA-dependent RNA polymerase (RdRp), which synthesises the genomic, 
subgenomic and antigenomic viral RNAs during replication. The structure of MNV NS7 has been 
determined (183), which allowed the insertions present in the input and passage 3 profiles to be 
mapped (Figure 3.8A and B). The majority of insertions were lost by passage 3, particularly those 
surrounding the active site motifs near the centre of the protein and loops involved in RNA binding 
and adjacent to the NTP binding site (residues 433-440 and 374-381 respectively), which as expected 
would likely compromise viral replication. The majority of the insertions remaining after passage 3 
can be found in unstructured loops and in the bundle of 8 α-helices on the left hand-side of the 
structures in Figures 3.7A and B. This bundle of  α-helices  comprises the finger domain of NS7, 
which like other RdRps is described as having a right-hand conformation (Figure 3.8A) (183).  
VP1 and VF1: VP1 is the major capsid protein and is divided into an N terminal arm, a Shell (S) 
domain and a protruding (P) domain. The S domain forms a smooth shell around the viral genome, 
whilst the P domain extends from the surface of the capsid and dimerises into arch-like structures 
(323). The majority of insertions across VP1 were largely lost after a single passage in tissue culture 
(Figure 3.6A). Those that were still detected in the S domain after 3 passages clustered around 
residues 133-137, 176-177 and 195-199, suggesting that these regions may not be involved in tight 
intermolecular interactions within the capsid. The S domain of VP1 is also thought to stimulate NS7 
de novo initiation activity via interactions involving loops in the S domain (393). All insertions in the 
corresponding loops (loops 1,3,5 and 7 in (393)) were promptly lost during the first round of 
insertions, with the exception of 2 insertions in loop 7, providing evidence that VP1-stimulation of 
NS7 may be essential for replication. The core β-barrel structure of the S domain is thought to be 
required to stabilise the interactions between VP1 and NS7 (393), which further accounts for the loss 
of insertions in the S domain. The region of ORF2  which encodes the S domain also overlaps with 
the alternative reading frame ORF4 and has been shown to be highly conserved across MNV strains 
with suppression of synonymous site variability (275). Thus, in addition to the role of the S domain in 
capsid formation, it is unsurprising that the majority of insertions in this region were lost as any 
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insertions may affect the function of both proteins. The insertion clusters tolerated for 3 passages in 
the S domain correspond to amino acid residues 130-133, 172-173 and 192-196 in VF1.  It is worth 
noting however that VF1 it is not required for replication in cell culture (275) and as such functional 
analysis of this kind is of limited value. 
The P domain is further divided into the P1 domain, which forms the base of the arch and is heavily 
involved in dimerisation interactions, and the P2 domain, the top of the arch, which is the least 
conserved domain and contains the receptor binding sites and sites for antigenicity (210, 252, 407). 
The structure of the P domain of MNV VP1 has recently been determined to a high resolution (407), 
which allows structural mapping of the insertion sites present in the input and passage 3 profiles 
(Figure 3.9C and D respectively). After passage 3, the remaining insertions map largely to flexible 
loops or unstructured regions that may be able to better accommodate small additional sequences. 
One such cluster maps to the C’-D’ loop of the P2 domain, which is involved in capsid dimerisation 
interactions (407). This loop may therefore be sufficiently flexible to accommodate insertions whilst 
maintaining the interactions, or modification of the interactions of this loop does not significantly 
compromise the overall capsid structure. The remaining insertions appear to lie on the opposite side 
of the P1 domain to the dimer interface. Receptor binding sites and defined antigen sites have been 
mapped to the E’-F’ loop of the P2 domain (407). Four insertions in this loop were detected in the 
input RNA, however only 1 at the base of the loop was present at passage 3 (after amino acid 380), 
despite the reported high degree of diversity observed at the antigenic sites (282). As this domain is 
also thought to mediate cell attachment, it suggests that there may be some structural constraints 
to maintain and that insertions here may reduce the viral fitness.  Likewise, an insertion at amino 
acid 300, in the A’-B’ loop in the P2 domain, which is also recognised by neutralising antibodies, was 
not tolerated past passage 1 and neither was an insertion in R396, one of the residues thought to be 
involved in an ionic lock between P2 dimers in the capsid that may mediate conformational changes 
required for infection (407). 
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Figure 3.9. Structural mapping of the 5 aa insertion sites on NS7 and the VP1 P domain. 
The insertions found in the input and passage 3 profiles were mapped onto the structures of NS7 
(PDB accession code 3NAH) (A and B respectively) and the P domain of VP1 (PDB accession code 
3LQ6) (C and D respectively). Blue residues highlight positions after or at which an insertion was 
detected, where 2 insertions were made in a single codon with different outcomes, the most 
tolerated one was marked. In the P domain of VP1 the majority of insertions tolerated after 3 
passages lie within flexible loop regions. The catalytic centre in NS7 did not tolerate any insertions, 
further validating the profiling. The structures were mapped using Chimera Software (UCSF).  
  
C D
A B
S Domain
P1 Domain
P2 Domain
C’-D’ Loop
E’-F’ Loop
A’-B’ 
Loop
Palm 
Thumb
Fingers
Identification of the Essential Elements Required for MNV Replication 104 
 
VP2 and the 3’ UTR: VP2 is the minor capsid protein, with reports from FCV suggesting that 2 copies 
of it are incorporated into the capsid (375), although it is also possible VP2 plays other roles in the 
viral life cycle. VP2 tolerated the highest percentage of insertions after the 3 passages with 30 % of 
the insertions present in the input remaining after 3 passages in cell culture. Clusters of stable 
insertion sites were found in particular at the start of VP2, near the VP1/VP2 boundary, and at the 3’ 
end of the VP2 coding region (Figures 3.6 A and C). It is likely that the region in between these 
clusters contains a functional domain or structure important in capsid interactions. The same region 
has also been demonstrated to be essential for replication of related FCV (377). The basic nature of 
VP2 has led to the proposal that it may be involved in binding the viral RNA and also acidic regions of 
VP1 (431), suggesting a structural basis of genome encapsidation, although a direct interaction 
between VP2 and RNA has not yet been demonstrated.  
The cluster of stable mutations in the 3’ end of the VP2 coding region corresponds to the position of 
a putatative stem loop structure (22), Figure 3.10. Whilst the function of this structure is unknown, 
the nts involved have been found to be largely conserved between different strains of MNV (22). 
However insertions appear possible on both sides of the stem loop and 51 % of insertions tolerated 
at P3 were in invariant residues, suggesting this loop has a high degree of flexibility to maintain 
function. 
Two stem loop structures have been mapped to the 3’UTR, which were also able to tolerate 
insertions at specific locations, Figure 3.10. The integrity of these stem loops is essential for 
replication in tissue culture (22), which suggests that the stable insertions do not completely disrupt 
the structure of these stem loops. The second of these stem loops (otherwise called stem loop 3 in 
previous literature) contains a single stranded polypyrimidine tract that is the binding site for the 
cellular proteins polypyrimidine tract binding protein (PTB) and poly r(C) binding proteins isoform2 
(PCBP2) (22). An insertion in this region was lost after a single passage, which again validates this 
approach as disrupting this loop and its interactions has previously been shown to incur a fitness 
cost in RAW264.7 cells (22). It is likely that these RNA structures also bind other cellular proteins 
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during MNV replication and so the insertional mutagenesis data should aid future studies to map 
potential protein binding sites.  
 
Figure 3.10. Mapping the 15nt insertions on the 3 stem loops at the 3’ end of the MNV genome. 
The structure is based on that determined in (22). Highlighted residues had an insertion immediately 
after them. Nts coloured red indicate that an insertion was found in the input but lost by passage 3. 
Nts in blue correspond to the position of insertions that were tolerated for all 3 passages. Stem 
loops are numbered SL1-3 from left to right. 
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3.2.4 Validation of the insertion profiling 
Several approaches were taken in order to validate the results of the profiling and confirm that the 
insertions identified during tissue culture selection represent replication-competent insertion 
viruses. Firstly, a small selection of individual insertion viruses were isolated from each of the 15nt 
insertion libraries by limiting dilution and the insertion sites sequence-verified. All bar one of the 
sites identified in the isolated sequence-verified viruses were found to within 1nt in the tissue 
culture selected profiles,  which is similar to the accuracy previously published for this technique (13) 
(Table 3.3). The failure to identify one of these insertion sites in the profiling highlights that profiling 
using capillary electrophoresis is unlikely to identify all minority species within a complex population.   
 
Nt position Protein Amino acid sequencea Present in profilingb Viruses isolated 
218  NS1-2             WT: LAGLPV                                     
     Mutant: LAGCGRTGLPV  
No  2  
2523  NS4             WT: RPSFYW                                 
     Mutant: RPLRPQPSFYW  
Yes  2  
2604  NS4            WT: GWYHSE                               
    Mutant: GWLRPQWYHSE  
Yes  1  
2840  VPg             WT: ATRRSR                               
     Mutant: ATRCGRTRRSR  
Yes  2  
5073  VP1             WT: SDGAAP                            
     Mutant: SDGCGRNGAAP  
Yes  1  
5585  VP1             WT: QEESMR                              
     Mutant: QEDAAAEESMR  
Yes  1  
6688  VP2             WT: MAGALF 
     Mutant: MAGAAAAGALF  
Yes  1  
7229  VP2             WT: PRDHTP 
     Mutant: PRDCGRSDHTP  
Yes  1  
7239  VP2             WT: TPATQG 
     Mutant: TPVRPQPATQG  
Yes  1  
Table 3.3. Validation of insertion profiling by identifying insertions in viruses isolated from 15nt 
insertion libraries by limiting dilution. a Underlined residues correspond to the inserted residues; 
residues in italics indicate a change in residue identity due to insertion within a codon.  b Insertion 
detected within selected profiles to within 1nt. 
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A selection of insertion sites identified in the profiling were next validated by introducing them into 
the MNV-1 cDNA clone. All of those predicted to be stable tolerated insertions (on the basis that 
they could be detected in the passage 3 profile, Table 3.4) successfully yielded infectious virus by 
reverse genetics recovery (Figure 3.11) and were stable for 3 passages in RAW264.7 cells (data not 
shown). Importantly, a site that was not tolerated in the profiling and was lost at the first passage (nt 
position 6722), did not recover infectious virus (Figure 3.11). 
 
Nt position  Protein       Amino acid sequencea Profiling detectionb 
       Input                 Passage 3 
84 NS1-2            WT: SSKASV 4358 31032 
       Mutant: SSKVRPHKASV   
218c  NS1-2             WT: LAGLPV                                     
     Mutant: LAGCGRTGLPV  
-  - 
382 NS1-2            WT: RPSFYW                                 
     Mutant: RPLRPQPSFYW  
407 23352 
2600  NS4            WT: GWYHSE                               
    Mutant: GWLRPQWYHSE  
6348 31617 
6686  VP2             WT: MAGALF 
     Mutant: MAGAAAAGALF  
9181 17900 
6688d VP2           WT: MAGALF 
     Mutant: MAGAAAAGALF 
-  
7229  VP2             WT: PRDHTP 
     Mutant: PRDCGRSDHTP  
308 3399 
7239  VP2             WT: TPATQG 
     Mutant: TPVRPQPATQG  
283 4262 
Table 3.4. Sequence and detection of insertions cloned into the MNV-1 cDNA clone to validate the 
profiling. a Underlined residues correspond to the inserted residues; residues in italics indicate a 
change in residue identity due to insertion within a codon. b Numbers reflect detection of the insertion 
to within 1 nt and refer to fluorescence intensity of the corresponding peak. c Insertion was not 
detected in the profiling but isolated by limiting dilution. d Insertion 6688 was not identified in the 
input profile. 
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Figure 3.11. Validation of the insertion profiling data. Tolerated insertion sites maintained for 3 
passages were introduced into the MNV-1 cDNA infectious clone and yielded infectious virus by use 
of the DNA-based reverse genetics system. Numbers refer to the genome position after which the 
insertion was made. Insertions coloured white lie within NS1-2, light grey are insertions in NS4 and 
dark grey VP2. Importantly, introduction of an insertion at position 6722, which was deemed 
replication-incompetent in the profiling, failed to yield infectious virus by reverse genetics. The pT7 
MNV 3’RZ NS7 Frame Shift clone (FS) was used as a negative control for virus recovery. Significance 
was tested using One Way ANOVA and Dunnett’s Multiple Comparison Post-Test to compare each 
insertion virus to the WT control, n=3, **p<0.01.  
 
Whilst the use of low multiplicity infections during passage of the recovered libraries in cell culture 
would minimise co-infection, the occurrence of trans-encapsidation or complementation could not 
formally be excluded. To specifically address this, the detection of a replication incompetent 
insertion virus (position 6722, Figure 3.11) was examined when co-transfected and passaged with 
WT virus. The insertion at position 6722 had been found from the library profiling to produce a lethal 
phenotype, which was validated by reverse genetics. If trans-encapsidation or complementation 
could occur between WT virus and this replication incompetent virus, then the insertion at position 
6722 should be detectable after co-recovery and passage. To test this hypothesis, in vitro transcribed 
capped RNA was generated for WT and the replication incompetent virus 6722 and co-transfections 
were performed. The recovered virus was titred and passaged at an MOI of 0.01, as had been used 
Identification of the Essential Elements Required for MNV Replication 109 
 
for the first passage of each library. The 6722 insertion was detected in the profile from the input 
RNA but not after a single passage in the presence of WT virus (Figure 3.12), thereby confirming that 
detection of replication-incompetent insertion mutants is unlikely in this experimental setup. As a 
control, the replication competent insertion virus (6686) was also co-recovered with WT RNA, and 
could be detected after the first passage. 
 
 
 
Figure 3.12. Replication-defective insertion viruses cannot be detected when passaged in the 
presence of replication-competent viruses at low MOI. In vitro transcribed, capped RNA was 
generated for the WT MNV-1 and 6722 (replication-incompetent) and 6886 (viable) insertion viruses, 
and the replication-defective NS7 FS mutant. Co-transfections of each insertion virus with either WT 
or FS were performed in BSR-T7 cells, and the recovered virus mixtures were titred and passaged at 
low MOI (0.01TCID50/cell) in RAW264.7 cells, as was used in the profiling passages. Insertion 
profiling was performed as described in Materials and Methods and fluorescence intensity 
corresponds to either the peak for 6722 or 6686 as indicated, profiling was performed twice and 
representative results are shown. The replication-incompetent insertion at position 6722 could only 
be detected in the input RNA and not when passaged in combination with WT, confirming that 
complementation or trans-encapsidation does not readily occur in this system. 
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3.2.5 Investigating the loss of 15 nt insertions 
It is possible that insertions that compromise viral fitness are mutated during passage of the libraries 
to a more favourable sequence, given the high mutation rates of MNV NS7 (54). This would prevent 
detection of the insertion by the PCR-based insertion profiling, which was reliant on an insertion-
specific primer. To investigate whether this occurred, the composition of passage 3 of the NS1-2 
library was examined. Individual viruses were isolated by limiting dilution and the NS1-2 coding 
region was amplified by RT-PCR and sequenced to identify insertion sites. The sequence of each 
passage 3 insertion was then compared to the predicted sequence of the insertion that would have 
originally been left at the same position by removal of the Tn, which is composed of 10nt from the 
Tn and 5 nt duplicated from the target site DNA. Six of the 8 isolated viruses contained 15nt 
insertions whose sequence in passage 3 matched the predicted sequence for the original Tn-derived 
insertion. This was as expected as the passage should contain mainly tolerated insertions. One of 
these insertions was not apparent in the passage 3 profile from the library screening, suggesting that 
it may have fallen below the threshold of detection and that there may be detection limit problems 
with the insertion profiling technique. Only 1 virus was found to contain a 15nt insertion that had 
been mutated from the original sequence, although whether this affected detection cannot be 
verified it was within the first 55 nt of the genome which was not covered by the insertion profiling. 
Lastly, 1 virus was isolated that did not appear to contain an insertion and had a WT NS1-2 
sequence. As no WT clones should be present in the libraries, this may have occurred by 
recombination with a different insertion virus.  
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Virus 
 
Nt 
position 
Original Tn-derived 
insertion present? 
Amino acid sequence 
 
Present in 
profiling? 
1,2 368 Yes            WT: RPDAPS P3 
        Mutant: RPDCGRTDAPS  
3 367 Yes            WT:  RDPAPS                                     
     Mutant: RPDAAAPDAPS 
P3
4 52 Yes            WT:  RNTEKR                            
     Mutant: RNTDAAATEKR  
* 
5 - No - 
 
No 
6 50 Altered             WT: RNTEKR 
     Mutant: RNTCGRNTEKR              
P3 mutant: RNTEGGRHEKR 
* 
7,8 358 Yes             WT:  RPKEDRP 
     Mutant: RPKDAAAEDRPD 
P1 
 
Table 3.5. Composition of library 1 (nt 1-843, NS1-2) after passage 3. Viruses were isolated from 
passage 3 of library 1 by limiting dilution, RNA was extracted and the library region amplified by RT-
PCR and sequenced to identify insertion sites. Six of the eight viruses contained the original 15 nt 
insertion, one contained a 15nt insertion but with a mutated sequence and one was not found to 
contain an insertion at all. * The insertion profiling did not cover genome positions up to 55nt. 
Underlined residues correspond to the inserted residues; residues in italics indicate a change in 
residue identity due to insertion within a codon. 
 
3.2.6 Profiling of insertions at passage 5 
Passage 3 was selected as the practical point at which to identify tolerated stable insertions, 
however to investigate what happens in the library populations beyond passage 3, insertion profiling 
was performed on passage 5 of the VP1/VP2/3’UTR library. The 2 extra passages of this library were 
performed at the same low MOI and RNA was extracted after passage 5 for insertion profiling as 
before. The insertions that were present in the input, passage 3 and passage 5 for the region 
covering 5800-7400 nt are shown in Figure 3.13.  The fluorescence intensity of each peak (the y-axis 
value) may reflect the frequency of each insertion variant in the population and as such can indicate 
viral fitness and reveal the population dynamics. However the frequency could also be influenced by 
biased PCR amplification of different fragments and the number of identical insertion variant clones 
in the input population, so for screening the libraries this measure was used only to confirm the 
presence, rather than fitness, of individual insertion variants. From the input to passage 3, a large 
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number of insertion variants were lost from the population as negative selection occurs, whereas 
some appear to become enriched, based on large increases in fluorescence intensity. This pattern 
continues from passage 3 to 5.  As the fluorescence intensity of the prominent peak in passage 5 was 
above the detection range, the insertion-specific PCR products had to be diluted for capillary 
electrophoresis. This means that some of the lower level insertions may be diluted to below the limit 
of detection. Whilst the prominent insertions from passage 3 are still present in passage 5, 2 other 
insertions appear to increase in fluorescence intensity. The insertion after nt position 5920, which 
demonstrates the greatest increase, was present in both the input and passage 3 profiles, albeit at 
much lower levels. The second increase was in the insertion after nt position 6195, which was not 
detectable in passage 3, suggesting it may have fallen below the limit of detection. Whether the 
higher intensity of these viruses arise from increased replication in the less complex viral population 
in passage 5, or through preferential PCR amplification of the products in a less complex mixture 
would need to be addressed by further experiments and characterisation of the growth of these 
viruses in isolation and in mixed populations.  
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Figure 3.13. Insertion profiling beyond passage 3. Library 5 covering VP1/VP2/3’UTR was serially 
passaged 5 times and profiles are shown for the input, passage 3 and passage 5 for the region 
spanning 5800-7400 nt. Loss of insertion sites and enrichment of others during sequential passage in 
tissue culture shows selection occurring. Fluorescence intensity and insertion site information was 
compiled from all fragments spanning this region and from duplicate passages and duplicate capillary 
electrophoresis analysis. Fluorescence intensity gives an indication as to the abundance of the 
mutation in the population so increased measures may represent dominant insertions.  
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 Discussion 3.3
Despite significant recent advances in the study of norovirus replication, many of the viral protein 
functions have not been fully characterised and a systematic study of the entire genome had not yet 
been completed. Here, comprehensive Tn-mediated insertional mutagenesis was applied to the 
entire MNV-1 genome, coupled with insertion-specific fluorescent PCR profiling, to identify the 
essential and non-essential domains of each viral protein. Five 15nt insertion libraries of MNV-1 
infectious clones were generated by Tn mutagenesis, which were then subjected to selection of 
tolerated insertion sites in a permissive cell line. Functional analysis of over 2000 insertions across 
the genome indicated previously unknown functional domains and allowed the importance of 
known functional motifs to be probed, shedding light on the role of several of the viral proteins. 
Cloning insertion sites into the WT MNV-1 genome, alongside sequencing of individual insertion 
viruses served to validate the results of the profiling approach. This study represents the first study 
to perform functional analysis on an entire norovirus genome.  
Passage of the 15nt insertion libraries in permissive RAW264.7 cells resulted in selection of viable 
and stable insertion sites, whilst over 84 % of insertions were lost during the 3 passages. Reasons for 
loss of the insertions appeared to be multi-factorial.  Firstly, insertions that disrupt the function of a 
viral protein domain or an RNA structure essential for replication are likely to be lethal or seriously 
debilitating to the virus, and will therefore not be present within the replicating population. If an 
insertion results in a fitness cost, weaker viruses may eventually be outcompeted to undetectable 
levels, although the passages were performed at a low MOI to preclude competition.  Furthermore 
due to the high error rate of the RdRp (54), any changes in an insertion sequence that increase viral 
fitness may be favoured and changes to the NotI site within the insertion will prevent detection by 
the insertion-specific primer. Whilst these interpretations provide insights into which sites are 
required for viral replication it is also possible that non-homologous genomic recombination occurs 
within the complex population and contributes to the loss of insertions or generation of WT virus. 
This explanation may be particularly relevant to the NS7/VP1/VF1 and VP1/VP2 15nt insertion 
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libraries, as the sub-genomic RNA is thought to be a particular hotspot for genomic recombination in 
noroviruses (268). 
Profiling the large number of insertions across the genome allowed the essential and non-essential 
regions of the viral proteins to be probed and identified. As a strategy to narrow down the 
functionally important protein regions, the focus was placed on the insertions that are immediately 
lost during selection and those which are stabilised for 3 passages. Whilst insertions that were only 
present for the first or second passages most likely compromise viral replication, analysis is 
complicated by the numerous reasons for their loss within a large library population. However 
studying these insertions in isolation could also yield information on protein function and amino acid 
requirements and may contribute to future more detailed studies of the viral proteins. Likewise site-
directed mutagenesis provides a more direct, less disruptive mutagenesis strategy than 15nt 
insertional mutagenesis. Whilst site directed mutagenesis was not a feasible approach for a genome-
wide study, it could now be used for more targeted analysis of the regions identified here as 
functionally important.  
Insertion profiling techniques traditionally involved urea-polyacrylamide gel-based foot-printing,  
which was then replaced in more recent studies with insertion-specific fluorescent PCR coupled with 
capillary electrophoresis for a less labour-intensive, more rapid approach (13, 212). However this 
approach was also found to have certain limitations. Firstly, the accuracy of detection was to within 
1/2nt, although this is comparable to that previously reported for insertion profiling of the Hepatitis 
C genome by the same method (13). The genome coverage here (28.4 %) was slightly greater than 
that achieved in the Hepatitis C study (25.2%) (13). Each of the genome coding regions were fairly 
evenly mutagenised, with between 25-33% of nts covered, with the exception of NS6. In theory this 
should equate to nearly every codon containing an insertion, however the coverage was not entirely 
even, as has been observed previously (13, 35). This most likely arose from bias in the initial 
transposition reaction. Transposition mediated by the MuA transposase is thought to be essentially 
random and most DNA phosphodiester bonds can act as target sites, however preferential insertion 
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at different base pairs has been demonstrated which can be influenced by the surrounding base 
pairs and DNA structure (161). The resolution of these techniques was not sufficient to detect all the 
minority insertion variants within such complex library populations, indicating that this is not an 
exhaustive list of possible tolerated insertions. Whilst the precise reason for the lack of sensitivity 
was not determined, the need to use detection thresholds based on the background peak intensity 
for non-mutagenised WT will have undoubtedly contributed.  Finally, this approach to insertion-
profiling was used quantitatively in the study of the Hepatitis C genome by measuring the changes in 
fluorescence intensity ratios of peaks between passages to determine whether insertions are 
tolerated, attenuating or lethal (13). However without excluding the possibility that changes in 
fluorescence intensity can be influenced by PCR amplification bias and the frequency of identical 
insertion variants in the starting population, this method should only be confidently used in a 
qualitative manner to detect the presence or absence of insertions.  
The use of next-generation sequencing as an insertion profiling technique overcomes many of the 
above technical issues. This approach was recently developed for insertion-profiling and functional 
mapping of the entire Venezuelan Equine Encephalitis virus (VEEV) genome (35). The advantages of 
next-generation sequencing over capillary electrophoresis include higher capacity, the ability to 
cover stretches of the genome larger than 400nt fragments, the precise accuracy and that it could be 
used quantitatively by determining the number of sequences with the same insertion in the different 
selected populations. Thus if this study on MNV were to be repeated and next-generation 
sequencing was available, it may provide a more suitable approach.  
The 15nt insertion libraries generated in this study could be used in different ways to probe other 
aspects of norovirus replication. For example, other studies have screened libraries en masse for  
particular aspects of the viral lifecycle (227, 339). Processes that would be relevant to study for MNV 
could include viral entry, translation or replication, although this would require development of 
specific assays to isolate each of these processes. Likewise, if it is known that the virus harnesses or 
interferes with a host process or pathway, such as the innate immune response for MNV (275) or 
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perhaps the host secretion pathway (356), and a particular protein is suspected of mediating the 
interference, then the relevant insertion libraries could be passaged in cells defective in that 
pathway. Comparison of the profiles from defective and fully functional cells could reveal the 
regions of the protein that may be responsible for interacting with components of the pathway and 
mediating the interference. 
The insertion libraries could also be screened in vivo to look for regions that mediate essential 
functions that are not apparent or required in vitro. For instance, the libraries could be put through 
both the acute and persistent models of MNV infection which may help to identify regions that 
determine or contribute to virulence and persistence respectively. Furthermore identifying insertion 
variants that are absent from the secreted virus pools or present in lower levels (provided a 
quantitative method can be established) could reveal candidates for attenuated viruses. Another 
way to identify attenuated vaccine candidates from these libraries is to passage them at different 
temperatures to then select for temperature sensitive mutants from the different insertion profiles. 
This was successfully performed for VEEV, where a number of temperature-sensitive mutants were 
identified and were consequently attenuated for virulence in a mouse model of VEEV (35).  
Finally, identification of a large number of tolerated insertion sites in the MNV genome creates the 
possibility to now insert other exogenous sequences at these sites in order to engineer a reporter- or 
epitope-tagged virus for further studies of MNV replication.  
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4. Engineering tagged MNV to study replication and viral protein function. 
 Background 4.1
4.1.1 The potential uses of reporter- and epitope-tagged MNV. 
To date there are no studies using infectious reporter- or epitope-tagged MNV, most likely due to the 
perceived challenges in generating a tagged virus by traditional methods (as discussed earlier). 
Despite this, engineering MNV to express either a reporter protein or a small epitope tag would 
provide a versatile tool for characterising norovirus replication and investigating the unknown 
functions of the viral proteins. Concomitant expression of a reporter protein with MNV genome 
translation could facilitate live imaging of viral infections, in vitro and in vivo. In vitro it could provide 
an alternative means of quantifying viral replication for high-throughput screens of antivirals, as 
opposed to more labour intensive infectious virus titrations. In vivo, reporter-tagged MNV could be 
used to identify the full cellular tropism of MNV, the initial routes of infection and the cells in which 
some strains persist. It could also allow infections to be tracked non-invasively in real time, to 
monitor the course of infection and to assess the effectiveness of potential antivirals.  
Whilst epitope-tagged viruses are not suitable for live or in vivo imaging, the tag could facilitate 
characterisation of MNV proteins through microscopy to identify their subcellular localisation and by 
immunoprecipitation to purify the tagged viral proteins from infected cells. Immunoprecipitation can 
be combined with proteomic approaches to identify the viral and cellular interaction partners co-
precipitated with the tagged protein of interest. Mass spectrometry has often been used in this 
capacity to identify the co-purified proteins, however it is not inherently quantitative and even with 
the inclusion of controls for comparison (such as WT non-tagged viruses), it can be difficult to 
distinguish specific interaction partners from proteins that bind non-specifically to the bead matrix or 
the conjugated antibody. One high-throughput quantitative proteomics approach that overcomes 
these problems couples mass spectrometry with stable isotope labelling by amino acids in cell culture 
(SILAC). 
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Figure 4.1 Composition and combinations of differentially labelled amino acids used for SILAC. 
Light media is composed of R0KO which contain no stable isotope labels, medium contains R and K 
labelled with 13C and 2H (R6K4), and heavy labelled media contains R and K labelled with 13C and 15N 
(R10K8). 
 
SILAC was originally used in cell biology to study changes in the cellular proteome resulting from 
different conditions, such as differentiation (302), however it has become increasingly used to study 
changes in the cellular proteome induced by viral infection (125-127, 284, 285).  SILAC enables the 
relative quantification of proteins from different conditions such as infected versus uninfected cells 
or cells infected with a tagged virus versus an untagged virus. Thus when coupled with 
immunoprecipitation it can be used quantitatively to identify cellular interaction partners of the 
tagged protein. This is achieved by prior propagation of the different cell sets in media carrying 
amino acids differentially labelled with stable isotopes (302). The technique makes use of the fact 
that cultured cells will take up labelled amino acids from the media and incorporate them into 
nascent proteins, such that after a period of time all unlabelled amino acids will be replaced by their 
labelled counterparts (302). Stable isotope labelled arginine and lysine are typically used in 
compositions such as with 13C- and 15N-labels to make ‘heavy’ media (R10K8), 13C-arginine and 2D-
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lysine for ‘medium’ (R6K4) and unlabelled arginine and lysine (R0K0) for ‘light’ media, Figure 4.1. 
After sample preparation involving viral infection and immunoprecipitation, the proteins from each 
cell condition are mixed at a 1:1 ratio, resolved by SDS-PAGE and subjected to trypsin digestion prior 
to mass spectrometry. Trypsin cleaves after arginine or lysine residues (unless they are followed by 
proline or aspartic and glutamic acid residues) such that each peptide should contain at least one 
labelled amino acid. The advantage of the isotope labelling is that it enables the same peptide from 
each sample to be distinguished by a shift in the mass to charge ratio (m/z) identified in mass 
spectrometry. For example, a peptide with one R10 arginine will be shifted by 10 Da compared to an 
unlabelled peptide of the same chemical composition. The total shift is the sum of the labelled amino 
acids in each peptide. As the samples are combined to be analysed together, the relative abundance 
of the same peptide from each sample can be determined from the intensities of the two 
corresponding peaks, this is referred to as the SILAC ratio. Specific interaction partners should have 
high SILAC ratios and be highly abundant in one sample (for example the tagged protein sample) 
compared to the other (the untagged control). Non-specific interactions or environmental 
contaminants should be equally abundant in both samples and will have a SILAC ratio of 1 or less, so 
they can be easily discounted. Validation of the specific interaction partners identified by SILAC is 
then normally performed by independent techniques such as by western blot or 
immunofluorescence microscopy. 
4.1.2 Aims 
The identification of tolerated insertion sites by Tn-mutagenesis (described in the previous chapter) 
presents the opportunity for insertion of other exogenous sequences into the MNV genome, in an 
alternative approach to generating tagged viruses which has been successful for other small positive 
strand RNA viruses (1, 4, 409, 410).  The aim of this chapter was therefore to engineer an infectious 
reporter- or epitope-tagged MNV and to use the resulting virus to study MNV replication and protein 
function by a combination of the approaches described above, depending on the nature of the 
tolerated tag.  
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 Results 4.2
4.2.1  Generating and characterising MNV GFP-insertion libraries 
Given that a reporter-tagged virus confers the advantage of being able to study infection in vivo, 
attempts were first made to generate MNV expressing a reporter protein. A broad approach was 
initially taken to engineer GFP-tagged MNV by making use of the original Tn-mutagenised libraries, so 
as to target as many potential tolerated sites as possible. The presence of a NotI restriction enzyme 
site at either end of the Tn, which is absent from the MNV-1 infectious clone, enables removal of the 
Tn from each library. Instead of subsequent religation of the vectors to leave the 15nt insertion (as in 
Chapter 3), the Tns can be replaced with the GFP coding sequence, amplified to be flanked by NotI 
sites, Figure 4.2. Ligation and transformation of each NotI digested library with NotI-GFP was 
performed to generate 5 GFP-insertion libraries in which each clone should have GFP in place of the 
original Tn (Figure 4.2). The number of estimated GFP+ clones for each library is given in Table 4.1, 
however it should be noted that GFP would only be expressed if the cloning results in an in-frame 
fusion in the correct orientation, therefore by chance only 1 in 6 clones may contain GFP in-frame. 
Restriction analysis using NotI and an enzyme to cut either side of the region of interest verified the 
presence of GFP in 10 individual clones screened from each library (an example is shown in Figure 
4.3A). Digestion of each library with the same enzyme combination released GFP and produced a 
heterogeneous population of fragment sizes, as evident by the presence of a smear of DNA around 
the relevant size, indicating a spread of insertion sites (Figure 4.3A). Of those screened, a small 
number of clones within each library appeared to contain a NotI site but no GFP insertion (for 
example clone 6 in Figure 4.2A), where background religation of the library vector may have occurred 
to leave only the 15nt insertion, despite thorough dephophorylation of the vectors. This was 
estimated to be below 10% for all libraries except the library spanning NS3-NS4, where background 
ligation was around 28% (Table 4.1). 
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Figure 4.2 Strategy for generating GFP-insertion libraries from Tn-libraries. A HyperMuATM 
transposase enzyme was used to insert one Tn per pT7 MNV 3’RZ infectious clone to generate a Tn-
mutagenised library. This was sub-cloned to generate 5 libraries containing Tns only in a well-defined 
region of the genome (grey shading).*SpeI cleaves at a position within the plasmid vector, other 
numbers indicate genome position. The Tns were removed from each library by NotI digest and the 
vectors religated with GFP (green squares), PCR-amplified to be flanked with NotI sites (black 
triangles).  The resulting 5 GFP-insertions therefore each contain GFP only in the indicated region of 
the genome (green shading). Dashed lines represent the vector of the pT7 MNV 3’ RZ infectious 
clone. 
 
Infectious virus was recovered from each of the cDNA GFP-insertion libraries using the DNA-based 
reverse genetics system, with the exception of the NS5/6/7 GFP-insertion library where GFP 
insertions into these essential proteins were not tolerated and NS7 expression could not be detected 
by western blot (Figure 4.3B and C). Expression of GFP was not detected by western blot from any of 
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the GFP-insertion libraries during recovery, which may be due to a homogenous population of GFP-
fusion proteins in each library, or could indicate instability of the GFP-fusion proteins. However, by 
confocal microscopy expression of GFP was observed in BSR-T7 cells transfected with all libraries, 
with the exception of the VP1/VP2/3’UTR library (Figure 4.3), although capsid proteins are not 
normally at detectable levels in this system due to low levels of subgenomic RNA. Expression in this 
system is driven by the T7 polymerase and serves only to confirm that some clones within each 
library contain GFP inserted in-frame and in the correct orientation. 
To determine whether any viable GFP-tagged viruses could be isolated from the recovered GFP-
insertion libraries (excluding the NS5/6/7 library) RAW264.7 cells were infected at low MOI, to 
reduce super-infection and recombination between different insertion mutants, which may result in 
loss of the GFP insert. However, despite repeated attempts, no GFP positive cells were observed 
during a 48 h infection with virus from any of the GFP-insertion libraries, although the presence of 
infectious virus at 48 hpi could be detected by TCID50 (data not shown).  
  
Library  No. of independent 
cDNA clones a 
No. of clones 
with a Tn b  
Background ligation c Estimated GFP+  
clones  
NS1-2 11,550 290 130 11,130 
NS3/NS4 3,440 - 990 2,450 
NS5/NS6/NS7 17,770 8,990 1,280 7,500 
NS7/VP1 13,330 40 1,360 11,930 
VP1/VP2/3’UTR 20,000 - 730 19,270 
Table 4.1. Size and composition of the GFP-insertion libraries. a Clone numbers are given to the 
nearest 10 clones. b The number of clones containing a Tn was estimated by the number of 
kanamycin resistant clones. c Background ligation was estimated as from the vector and ligase control 
ligation and occurs from incomplete vector dephosphorylation. These clones are likely to just contain 
the 15nt insertion.  
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Figure 4.3. Characterisation and recovery of GFP-insertion libraries. (A) Example screening of clones 
in the NS1-2 GFP-insertion library by double digest, including NotI, to confirm the insertion of GFP. 
The different sized cleavage fragments from each clone and in digest of the whole library (lib) 
highlight different insertions of the original Tn throughout the region. (B) The yield of virus recovered 
at 24 h from each GFP-insertion library using the DNA reverse genetics system. GFP insertions in the 
NS5/6/7 library prevent recovery of infectious virus. The limit of detection is 11.2 TCID50/mL. Error 
bars represent the standard error of the mean. Significance was tested using One Way ANOVA and 
compared to WT with a Dunnett post-test, *** : p< 0.001, n=5. (C)  Western blot analysis was 
performed on lysates of transfected BSR-T7 cells, to assess translation of NS7, eGFP and GAPDH. FS: 
an MNV mutant containing a frame-shift mutation in the region coding for NS7 which serves as a 
negative control for recovery. Library 1: NS1-2; 2: NS3/NS4; 3: NS5/NS6/NS7; 4: NS7/VP1; 5: 
VP1/VP2/3’UTR. 
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Figure 4.4. Expression of GFP in during recovery of the GFP-insertion libraries using the DNA-
mediated reverse genetics system. Confocal microscopy was performed on BSR-T7 cells transfected 
with a GFP-insertion library, WT MNV-1 or eGFP controls. Cells were fixed and stained with DAPI. 
Expression of GFP was detected from the NS1-2, NS3/NS4, NS5/6/7 and NS7/VP1 GFP-insertion 
libraries, confirming that a proportion of these libraries have GFP inserted in-frame and in the correct 
orientation. Scale bars indicate 20µM. 
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4.2.2 Engineering reporter-viruses by a targeting tolerated insertion sites: site selection 
As it was not possible to isolate infectious GFP-tagged MNV using the previous strategy, a more 
direct approach was employed by targeting specific sites found to tolerate 15nt insertions. This 
approach was successfully used to generate GFP- and DsRed-tagged FCV, where only 2 sites were 
found to tolerate 15nt and 1 of these subsequently tolerated larger reporter gene insertions (1). As a 
starting point, sites in NS1-2 and VP2 were selected as these proteins were found to tolerate the 
greatest percentage of 15nt insertions (described in Chapter 3, see Table 3.1) and are both proteins 
of largely unknown function. Also as NS1-2 is the least conserved of the norovirus non-structural 
proteins and contains an inherently disordered N-terminal domain (25),  it seemed the most likely 
candidate to tolerate a larger insertion. To narrow down the possible sites within these proteins, a 
virus yield assay was performed using all of the previously cloned, validated, stable insertion viruses 
(described in Chapter 3). Insertions sites were selected from this assay from insertion viruses which 
displayed comparable growth characteristics to WT, Figure 4.5. These were nt 382 (NS1-2) and 6688 
and 7229 (VP2). The validated insertion site in NS4 (position 2600) was also later selected, which 
tolerated a 15nt insertion and seemed amenable to insertion of larger exogenous sequences given its 
position at the extreme C-terminus of NS4.  
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Figure 4.5. Comparison of the growth of a panel of 15nt insertion viruses. A virus yield assay was 
performed in which RAW264.7 cells were infected with each insertion virus or WT MNV-1at an MOI 
0.01 TCID50/cell. Insertion viruses are named with the genome position after which the insertion is 
made. Virus was harvested at 24 and 48 hpi and titred by TCID50. Insertion sites were selected from 
the viruses that displayed comparable growth to WT, specifically 382 (NS1-2), 6688 (VP2) and 7229 
(VP2).Significance was analysed with Two-Way ANOVA with a Bonferroni post-test to compare all 
insertion viruses to the WT at each time point, n=3, *: p< 0.05, **: p< 0.01, ***: p< 0.001. Error bars 
represent the standard error of the mean.  
 
4.2.3 Engineering a variety of reporter proteins into specific insertion sites 
In case the large size of GFP (850 bp) was too disruptive to viral protein function and contributed to 
the failure to isolate GFP+ viruses, reporter proteins with smaller coding regions were selected, 
starting with Gaussia Luciferase (G.Luc, 550bp) and the improved light oxygen and voltage sensing 
domain (iLOV, 350 bp) (403). G.Luc is the smallest of the luciferase genes yet displays the highest 
signal intensity, it can be used to provide a quantitative measure of viral replication and is suitable 
for in vivo imaging (403). The iLOV domain originates from the plant blue light receptor, phototropin, 
which has been modified for improved photophysical and fluorescence properties and its 
fluorescence is dependent on binding to a cellular cofactor chromophore (flavin mononucleotide) 
(353). iLOV has recently been used to generate fluorescent FMDV, a picornavirus similar in size to 
MNV (76, 353). The coding sequences for G.Luc and iLOV were engineered into each of the selected 
sites in the MNV genome, either alone and or in combination with the FMDV 2A peptide, Table 4.2. 
Engineering Tagged MNV to Study Replication and Viral Protein Function 129 
 
This acts as a co-translational cleavage peptide (97) and was included to release one terminus of the 
reporter protein to facilitate correct folding and to prevent secretion of the fused viral proteins with 
G.Luc, which is naturally secreted (403). G.Luc activity could be detected during DNA (Figure 4.6) and 
RNA recoveries (data not shown). Expression of iLOV was only observed during DNA recovery of an 
inadvertently cloned double iLOV insertion at position 382 (NS1-2), which showed weak fluorescence 
that was rapidly bleached to prevent imaging. However infectious virus could not be recovered from 
any of the G.Luc or iLOV insertion clones.  
 
 
Figure 4.6. Gaussia Luciferase activity during DNA-based recovery of the G.Luc insertion clones. At 
24 h post transfection of BSR-T7 cells, the media was replaced and the G. Luc. (GL) activity from each 
clone was measured from the amount secreted over a period of 30 minutes. Clones in light grey 
contain an insertion in the NS1-2 coding region, dark grey in NS4 and black in VP2. 2A refers the 
FMDV-2A peptide that was included in some clones to release G. Luc from the majority of the 
specified viral protein.  
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Genome position Viral Protein Insertions 
84 NS1-2 spGFP 
382 NS1-2 G. Luc., G. Luc.- 2A, iLOV, iLOV- 2A, iLOV-iLOV 
2600 NS4 G. Luc., 2A-G. Luc., iLOV, 2A-iLOV, spGFP 
6686 VP2 FlAsH tag, G. Luc., G. Luc- 2A, iLOV, iLOV-2A, 
spGFP 
7229 VP2 G. Luc., 2A-G. Luc.iLOV, 2A-iLOV, spGFP 
1028 End of NS1-2 spGFP 
2615 End of NS4 spGFP 
6681 Start of VP2 spGFP 
7304 End of VP2 spGFP 
Table 4.2. Summary of engineered reporter tagged insertion viruses. spGFP: split GFP, G.Luc: 
Gaussia Luciferase, iLOV: improved light oxygen and voltage sensing domain, FlAsH: Fluorescent 
Arsenical Hairpin tag, 2A: FMDV 2A co-translational cleavage peptide. 
 
The split-GFP (spGFP) protein tagging system was next explored as it has recently been proven 
successful for in vitro imaging of Influenza A, traditionally difficult to tag with larger reporter proteins 
(20). The spGFP system involves fusing the C-terminal 16 aa of GFP to the protein of interest, whilst 
supplying the complementary GFP fragment through transient transfection or by stable expression in 
cultured cells. Interaction of the 2 GFP components results in fluorescence localised with the target 
protein (58). The spGFP 16 aa fragment (S11) was directly cloned into the selected sites in NS1-2, NS4 
and VP2, but failed to yield infectious virus. As an alternative approach, the spGFP S11 fragment was 
also engineered into sites at either the start or end of NS1-2, NS4 and VP2, so as to generate N- or C-
terminal fusions respectively, Table 4.2. For the C-terminal fusions in ORF1, the last 3 residues of 
each protein were repeated directly after the spGFP insert in order to replicate the cleavage junction. 
This approach also failed to yield infectious spGFP-tagged viruses.   
The Fluorescein Arsenical Hairpin (FlAsH) technology has emerged as an alternative to protein 
labelling to circumvent the disruption to target protein activity resulting from fusion with large 
fluorescent proteins, and it has recently been used for super-resolution imaging of HIV (236, 259). 
Smaller than the spGFP S11 fragment, the FlAsH tag is comprised of just 6 aa containing a 
tetracysteine motif. The tetracysteine motif binds to an exogenously supplied, membrane 
permeable, bi-arsenical dye to result in fluorescence of the dye and labelling of the target protein 
(156). To trial this approach for MNV, the FlASH tag was directly inserted into a site in VP2 (after nt 
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position 6686) and this time infectious virus was recovered using DNA-based reverse genetics, albeit 
near to the limit of detection (11.2 TCID50/mL) (data not shown). However after 2 blind passages to 
amplify the recovered virus, the FlAsH tag insertion had been altered from CCPGCC to GAPVA. This 
result demonstrates the difficulty of introducing insertions given the ability of MNV to mutate and 
alter any sequence that compromises its replication. Furthermore given that the original 15nt 
insertion at this site was stable and displayed WT growth characteristics, it demonstrates how the 
specific sequence can determine whether an insertion is tolerated at a particular site. 
4.2.4 Engineering and characterisation of epitope-tagged viruses: NS4- and VP2-FLAG 
As insertion of larger exogenous sequences into the tolerated 15nt insertion sites failed to yield 
infectious reporter-tagged viruses, the FLAG epitope tag (DYKDDDDK) was next selected for insertion 
due to its small size and success with other small positive strand RNA viruses (410). The FLAG tag 
coding sequence was inserted into sites in NS4 (after nt 2600) and VP2 (after nt 7229) (Figure 4.7A). 
The 2600 insertion site seemed particularly suitable as it translates to the highly charged C-terminus 
of NS4 which has a similar sequence to the equally highly charged FLAG tag. Using the DNA-based 
reverse genetics system, infectious viruses were recovered for both NS4-FLAG and VP2-FLAG, 
although VP2 was at reduced titres compared to WT (Figure 4.7B).  
Western blot analysis of NS4- and VP2-FLAG infected cell lysates with an anti-FLAG antibody detected 
proteins of the expected molecular weights for NS4 (18kDA) and VP2 (29kDA) respectively (Figure 
4.7C). The NS4-FLAG insertion was stable for at least 3 passages in RAW264.7 cells as confirmed by 
western blot detection of the FLAG tag (Figure 4.7C) and sequencing of the insertion site (data not 
shown). In contrast, the VP2-FLAG insertion was only stable for 2 passages, after which it could no 
longer be detected by western blot with anti-FLAG antibodies. These passages were performed in 
duplicate and sequence analysis revealed that on one occasion the VP2 insertion had been entirely 
lost, whereas the second time it had been mutated from DYKDDDK to PRKDDEDK, which may prevent 
antibody recognition. 
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Figure 4.7. Engineering infectious FLAG-tagged murine noroviruses. (A)The FLAG epitope tag was 
inserted into sites in NS4 and VP2. (B) Infectious virus was recovered from NS4-FLAG and VP2-FLAG 
using the DNA-based reverse genetics system. Significance was tested using One Way ANOVA and 
compared to WT using a Dunnett post-test, **p<0.01, n=3. (C) Detection of the FLAG-tagged proteins 
in infected cell lysates by western blot after passages 2 and 3 in RAW264.7 cells.  Detection with an 
anti-FLAG antibody gave proteins at the expected molecular weight for NS4 (18kDA) and VP2 
(29KDa). The FLAG tag is no longer detectable in VP2 at passage 3. * A non-specific protein is 
detected by the anti-NS7 antibody with the same molecular weight as NS7.  
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To investigate the growth characteristics of the FLAG insertion viruses, a virus yield assay was 
performed. RAW264.7 cells were infected with NS4-FLAG, VP2-FLAG or WT virus at an MOI of 0.01 
TCID50/cell and virus was harvested at 12, 24 and 48hpi. At all times post infection both of the FLAG 
insertion viruses attained comparable titres to WT (Figure 4.8). This result was somewhat 
unexpected for VP2-FLAG as the instability of the insertion suggested a compromise to replication 
that is perhaps not evident by this assay. 
 
 
Figure 4.8. Growth characterisation of the NS4- and VP2-FLAG insertion viruses. A virus yield assay 
was performed by infecting RAW264.7 cells with either NS4-FLAG, VP2-FLAG or WT virus at an MOI 
of 0.01 TCID50/cell. Virus was harvested at 12, 24 and 48 hpi and viral titre determined by TCID50. 
There was no significant difference between the titres reached by the FLAG insertion viruses 
compared to WT. Significance was tested with Two-Way ANOVA and a Bonferronni post-test to 
compare the insertion viruses to WT at each time point, n=3.  
 
4.2.5 Characterising the subcellular localisation of NS4 and VP2 in infected cells 
To determine the subcellular localisation of NS4 and VP2 during replication, microglial BV-2 cells 
were infected with sequence-verified passage 1 stocks of NS4-FLAG, VP2-FLAG and WT MNV-1 at 
high MOI. BV-2 cells are permissive to MNV infection and are more suited to microscopy studies than 
RAW264.7 cells due to better adherence properties and larger cytoplasms (86).  At 12hpi, cells were 
fixed and stained with antibodies against the FLAG tag and NS7 and analysed by confocal 
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immunofluorescence microscopy. As previously reported for WT NS4, NS4-FLAG co-localised with 
NS7 in dense perinuclear foci (198) (Figure 4.9) in a position most likely consistent with the 
microtubule organising centre, the reported location for the replication complex (197). NS7 also 
appeared to show some diffuse staining throughout the cytoplasm of all infected cells, as has 
previously been observed (198). For the first time VP2-FLAG was also found to co-localise with NS7 in 
perinuclear foci (Figure 4.9). 
 
 
Figure 4.9. NS4 and VP2 localise with NS7 in infected cells. Permissive microglial cell line BV-2s were 
infected with NS4-FLAG, VP2-FLAG or WT virus at an MOI of 1 TCID50/cell, or were mock infected. At 
12hpi, cells were fixed and dual stained for the FLAG tag and NS7. Both NS4 and VP2 co-localised 
with NS7 in perinuclear foci.  
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4.2.6 The FLAG tag facilitates purification of NS4 and VP2 from infected cells 
To determine whether the FLAG tag could be used to immunoprecipiate NS4 and VP2, RAW264.7 
cells were infected with passage 1 stocks of NS4-FLAG, VP2-FLAG or WT MNV-1 and the tagged 
proteins enriched using anti-FLAG agarose. Immunoprecipitation and subsequent western blot 
analysis of the input lysates and eluted proteins with an anti-FLAG antibody confirmed that NS4 and 
VP2 could be detected in the appropriate eluted fractions (Figure 4.10). In addition NS4 was found to 
co-immunoprecipitate NS1-2, suggesting they interact as has previously been reported for the FCV 
orthologs p30 and p32 respectively (206). This work confirmed that the epitope tagged viruses could 
be used to identify the interaction partners of these proteins and to dissect the molecular 
interactions that occur within the viral replication complex.  
 
 
 
Figure 4.10. Immunoprecipitation of NS4 and VP2 from infected cells via the FLAG tag. RAW264.7 
cells were infected with NS4-FLAG, VP2-FLAG or WT at MOI of 0.01 TCID50/cell or were mock 
infected (M). At 36 hpi cell lysates were prepared and anti-FLAG agarose was used to 
immunoprecipitate NS4 and VP2 respectively, as confirmed by western blot analysis. NS1-2 was co-
immunoprecipitated with NS4 only. 
 
4.2.7 Sample preparation for SILAC based proteomics of NS4-FLAG 
The immunoprecipitation of NS4- and VP2-FLAG from infected cells provided the opportunity to 
identify their viral and cellular interaction partners by SILAC based quantitative proteomics, 
beginning with NS4. BV-2 cells were firstly passaged at least 5 times in media substituted with either 
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light (R0K0), medium (R6K4) or heavy (R10K8) stable isotope labelled amino acids (Figure 4.11). Five 
cell divisions are recommended to ensure over 95% of all proteins are correctly labelled (302) and 
this had previously been confirmed for BV-2 cells (Edward Emmott, unpublished data). Passage in the 
different isotope-labelled media appeared to have no effect on the growth of BV-2 cells as observed 
by cell morphology and division times. For this experiment, high titre passage 1 stocks of NS4-FLAG 
were prepared and verified by sequencing and western blot analysis to confirm expression of the 
FLAG tag. 
Light, medium and heavy labelled BV-2 cells were then infected with either NS4-FLAG or WT at an 
MOI of 1.5 TCID50/cell (Figure 4.11), in the combinations listed in Table 4.3. The MOI was as high as 
could be achieved given the titre of the stock whilst maintaining a low volume of inoculum to avoid 
pulse labelling effects from the unlabelled media present in the inoculum. WT virus was included as a 
negative control to account for the non-specific interactions of cellular proteins with the anti-FLAG 
beads and to induce similar changes in the cell as during infection with the tagged virus. Duplicate 
experiments were performed, which taken together included triplicate infections of each virus as 
shown in Table 4.3. Protein samples were harvested at 10 hpi and equal protein amounts from each 
infection were used for immunoprecipitation by anti-FLAG agarose. Extracts from the input, flow-
through and elution stages were taken for validation by western blot analysis of the enrichment of 
NS4-FLAG during immunoprecipitation (Figure 4.12). NS4-FLAG was detectable in the appropriate 
eluates, whereas GAPDH, not expected to interact with NS4, was lost in the flow-through. Equal 
volumes of each elution were subsequently mixed in a ratio of 1:1:1 (L:M:H) for each experiment and 
were sent for liquid chromatography tandem mass spectrometry (LC-MS/MS) by the University of 
Bristol Proteomics Facility. 
 Light Medium Heavy 
Experiment 1 WT NS4-FLAG WT 
Experiment 2 NS4-FLAG WT NS4-FLAG 
Table 4.3. Infection combinations for the duplicate NS4-FLAG SILAC experiments. 
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Figure 4.11. The NS4-FLAG SILAC experiment. BV-2 cells were passaged for at least 5 cell divisions in 
media substituted with either light (R0K0), medium (R6K4) or heavy (R10K8) stable isotope labelled 
amino acids. Cells were then plated out and infected with either NS4-FLAG or WT at an MOI of 1.5 
TCID50/cell, performed in duplicate. At 10 hpi, cells were lysed and equal amounts of protein were 
used for immunoprecipitation on anti-FLAG agarose. Enrichment of the FLAG proteins was confirmed 
by western blot analysis. Light, medium and heavy samples were then pooled in a ratio of 1:1:1 and 
sent to the University of Bristol for resolution by SDS-PAGE prior to analysis by LC-MS/MS (stages 
below the horizontal dashed line) to identify interaction partners of NS4-FLAG. 
 
  
Light 
(R0K0)
Medium 
(R6K4)
Heavy 
(R10K8)
Passage for 5 cell divisions
NS4-FLAG WT-MNV NS4-FLAG
Lysis and α-FLAG Immunoprecipitation
Western blot validation
Combine samples 
1:1:1 (L:M:H)
Resolve by SDS-PAGE and analyse 
by LC-MS/MS
Infect at MOI 1.5 TCID50/ml
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Figure 4.12. Western blot validation of NS4-FLAG SILAC immunoprecipitation. Protein samples were 
collected at the input, flow-through and elution stages of immunoprecipiation for WT and NS4-FLAG 
(F) infected cells grown in the light (L), medium (M) and heavy (H) labelled media. All samples from 
the duplicate experiments are shown. Samples were analysed for FLAG and GAPDH expression. NS4-
FLAG was enriched in the eluates from all NS4-FLAG infected cells, although at different levels, 
whereas GAPDH, which is not expected to interact with NS4, was lost in the flow-through. 
 
4.2.8 Results of the NS4-FLAG SILAC experiment 
In total 253 proteins were identified and quantified between the 2 experiments, including only those 
identified by at least 2 unique peptide hits for reliability. The mean log2(SILAC ratio) was calculated 
for each protein (see Materials and Methods for data handling), where a value of 1 equates to 2-fold 
enrichment of that protein in the NS4-FLAG sample compared to the WT sample. This was used as a 
threshold above which proteins were considered specific interaction partners. The 2-fold threshold is 
in line with what has previously been used although it is a fairly conservative cut-off (126). Of the 253 
proteins, 137 were then excluded with mean log2(SILAC ratio) ratios of 0 or below, as these were 
considered contaminants or non-specific interactions (equally enriched in both samples).  
Of the remaining proteins, only 5 were classed as high confidence interaction partners on the basis 
that they were identified in both of the duplicate experiments and in all of the FLAG:WT 
comparisons. The most enriched of these was the viral protein NS1-2, followed by NS5 and NS6, in 
addition to NS4 itself, which indicates identification of the bait protein or the possibility that it 
dimerises. On this basis, the only cellular protein to be classed as a high confidence interaction 
partner was TRIM21, although it had a mean log2(SILAC ratio) close to 1, and a high standard 
anti-FLAG
anti-GAPDH
40kDa
20kDa
WT  F    WT    F     WT   F   WT  F    WT      F    WT   F   WT  F    WT   F    WT   F 
L            M             H           L              M              H          L           M             H
Input                                 Flow-through                         Elution
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deviation that crosses the 2-fold cut-off (Table 4.4). Fourteen proteins were identified as lower 
confidence interaction partners on the basis that they were only found in 1 of the duplicate 
experiments but in at least 2 of the FLAG:WT SILAC ratios. In many cases these proteins had smaller 
standard deviations between replicates than the high confidence interactions (Tables 4.4 and 4.5).  
Five of these proteins are known to play a role in translation, which may have been precipitated 
indirectly through interactions with VPg, and 2 are known mitochondrial proteins. 
 The remaining proteins from the original 253 were excluded from the analysis on the basis they 
were found to have large standard deviations that significantly crossed the mean log2(SILAC ratio) 
threshold, or that they were only found in 1 SILAC ratio or were background contaminants such as 
antibody light and heavy chains.  
Accession Description Mean log2(SILAC ratio) STDEV 
(log2) 
MNV |NS1-2| MNV |NS1-2| 5.73 1.05 
MNV |NS4| MNV |NS4| 5.56 1.60 
MNV |NS5| MNV |NS5| 4.69 2.26 
MNV |NS6| MNV |NS6| 4.40 2.59 
Q3U7K7 E3 ubiquitin-protein ligase TRIM 21 1.08 0.66 
Table 4.4 SILAC ratios of proteins identified as high confidence interactions in the NS4-FLAG 
immunoprecipitation experiments. 
 
Accession Description Mean log2  
(SILAC ratio) 
STDEV 
(log2) 
MNV |NS7| MNV |NS7| 6.64 0.00 
Q8C845 EF hand domain containing 2 3.86 1.19 
E9PVC6 Eukaryotic translation initiation factor 4 gamma 1 2.15 1.92 
F6ZQM8 Glyceraldehyde-3-phospate dehydrogenase 1.71 0.25 
Q3THU8 Putative uncharacterised protein GN= Slc25a3 1.58 0.21 
Q8CGH5 Iqgap1 protein 1.48 0.14 
G3UX26 Voltage-dependent anion selective channel protein 2 1.51 0.07 
P18760 Cofilin-1 1.48 0.14 
Q9D8N0 Elongation factor 1-gamma 1.43 0.06 
D3Z5M2 Protein GM10110 1.35 0.07 
Q3THW7 Putative uncharacterised protein GN= eIF3H 1.22 0.08 
Q8BTU6 Eukaryotic initiation factor 4A-II 1.20 0.10 
Q9D4E6 Protein PABPC6 1.16 0.11 
Q3U931 Putative uncharacterised protein GN= G3BP2 1.13 0.15 
Table 4.5 SILAC ratios of proteins identified as lower confidence interaction partners in the NS4-
FLAG SILAC experiments. 
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4.2.9 Validation of the NS4-FLAG SILAC dataset 
In order to validate the SILAC data by an independent method, the samples were first analysed by 
western blot for the cellular proteins, TRIM21, cofilin and VDAC. These proteins were identified 
mainly as lower confidence interactions. Cofilin could not be detected in the NS4-FLAG eluate 
samples and the majority of VDAC and TRIM21 appeared to be lost in the flow-through, although a 
weak interaction cannot be excluded. This was also the case for samples taken from a direct 
independent repeat of the NS4-FLAG immunoprecipitation reaction (Figure 4.13).  
 
 
Figure 4.13. Investigating the validity of the SILAC data by western blot analysis. An independent 
repeat infection and anti-FLAG immunoprecipitation was performed in an attempt to validate the 
SILAC data. Protein samples from each stage of the process were analysed by western blot for the 
cellular proteins TRIM21, cofilin and VDAC, all identified in at least 2 replicates within the SILAC data 
set. However these could not be detected in the eluate fractions. 
 
4.2.10 Generation and characterisation of NS1-2 FLAG 
NS1-2 has been implicated in driving formation of the replication complex (198), although the 
mechanisms for this and any other functions of NS1-2 have not been characterised. Given the 
success in generating infectious FLAG-tagged NS4 and VP2, NS1-2 was also selected for insertion of 
an epitope tag to facilitate studies of its function. The coding sequence for the FLAG epitope tag was 
inserted into the NS1-2 coding region after nt 383. From the insertion profiling (described in Chapter 
3), nt position 382 had been found to tolerate a 15nt insertion, but an insertion at this site would not 
F    WT    M       F     WT     M      F    WT     M
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result in the FLAG tag being translated in-frame, so the closest in-frame position was used instead. 
This yielded infectious NS1-2 FLAG-tagged virus, using the DNA-based reverse genetics system 
(Figure 4.14A).  
To assess the stability of the insertion, the recovered NS1-2 FLAG virus was sequentially passaged 3 
times in RAW264.7 cells at low MOI. The FLAG insertion was stable for the 3 passages as evident by 
detection of the FLAG tag by western blot on infected cell lysates (Figure 4.14B) and sequencing of 
the insertion site (data not shown). The anti-FLAG antibody detected a protein of slightly higher 
molecular weight than that predicted for NS1-2 (50kDA compared to 40kDA), however it has 
previously been shown to migrate at a higher molecular weight due to the inherently disordered 
properties of the N-terminal domain (25).   
To investigate the growth characteristics of NS1-2 FLAG a multi-step growth curve experiment was 
performed. RAW264.7 cells were infected with NS1-2 FLAG or WT at an MOI of 0.01 TCID50/cell or 
were mock infected, and virus and protein were harvested at multiple times post infection over the 
course of 48 h, Figure 4.15.  NS1-2 FLAG displayed a small but significant defect compared to WT at 
the early stages of replication, but attained comparable titres by 24 hpi. The viral proteins could only 
be detected from 24 hpi, at which point there was no difference in the levels of NS7 between NS1-2 
FLAG and WT, although the level of NS7 appeared reduced in NS1-2 FLAG compared to WT at 48 hpi. 
NS1-2 was also detected via the FLAG tag at 24 hpi from NS1-2 FLAG infected cells. At 48 hpi, the 
anti-FLAG antibody detected a smaller protein of 30KDa, consistent with cleavage of NS1-2, as has 
previously been observed (378). NS1-2 contains several caspases 3 cleavage sites, which are known 
to be cleaved late in infection with the induction of apoptosis (378). The loss of GAPDH in infected 
cells corresponded with observations of excessive cytopathic effect.  
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Figure 4.14. Recovery and characterisation of the NS1-2 FLAG virus. (A) Infectious virus was 
recovered from NS1-2 FLAG using the DNA-based reverse genetics system at comparable levels to 
WT at 48 h post transfection , with no significant defect. Significance was tested using One Way 
ANOVA and compared to WT using a Dunnett post-test, n=3. (B) Detection of the FLAG-tagged 
protein in infected cell lysates by western blot after passages 1 and 3 in RAW264.7 cells. Cells were 
infected at an MOI of 0.01 TCID50/cell and protein lysates were harvested at 24 hpi. Detection with 
an anti-FLAG antibody gave a protein at a higher molecular weight than that expected for NS1-2 
(40KDa), as has been previously published (25).  
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Figure 4.15. Characterisation of the growth of the NS1-2 FLAG virus. A multi-step growth curve 
analysis was performed by infecting RAW264.7 cells with NS1-2 FLAG or WT at low MOI. Virus (A) 
and protein samples (B) were harvested at different hours post infection throughout the course of 
48 h. (A) NS1-2 FLAG displays delayed replication prior to 24 hpi, at which comparable titres to WT 
were attained. Significance was tested with Two-Way ANOVA and a Bonferroni post test to compare 
NS1-2 FLAG to the WT at each time point, ***: p < 0.001, n =3. (B) Infected cell lysates were analysed 
with anti-NS7, anti-FLAG and anti-GAPDH antibodies. NS7 levels were not detectable prior to 24 hpi 
at which point NS7 was at comparable levels between NS1-2 FLAG and WT, although it appeared 
reduced in NS1-2 FLAG infected cells at 48 hpi. NS1-2 was detected by the FLAG tag and appeared to 
be cleaved at 48 hpi, as previously observed (378). The cleavage product of NS1-2 FLAG is indicated 
by an *.M indicated mock infected cells. 
 
To determine the subcellular localisation of NS1-2 FLAG, BV-2 cells were infected at high MOI with 
passage 1 sequence-verified stocks of NS1-2 FLAG and WT or were mock infected. At 12 hpi cells 
were fixed and stained with antibodies against the FLAG tag and NS7, Figure 4.16. NS1-2 FLAG was 
found to co-localise with NS7 at the perinuclear region, the known location of the replication 
complex. This localisation has previously been reported for untagged NS1-2 in infected cells (198), 
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and serves to confirm that the FLAG tagged protein should as behave as WT NS1-2. More diffuse 
cytoplasmic staining of NS1-2 FLAG was also observed, which did not appear to co-localise with NS7. 
NS1-2 has previously been reported to localise to the endoplasmic reticulum in transfected cells 
(198), which may correspond to the pattern observed here, although this requires further 
investigation.  
 
 
 
Figure 4.16. NS1-2 FLAG localises to the replication complex in infected cells. Permissive microglial 
cell line BV-2s were infected with NS1-2 FLAG or WT virus at an MOI of 5 TCID50/cell, or were mock 
infected. At 12hpi, cells were fixed and dual stained for the FLAG tag and NS7. NS1-2 FLAG co-
localised with NS7 in perinuclear foci but also displayed wider cytoplasmic localisation which did not 
overlap with NS7.  
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4.2.11 Sample preparation for SILAC based proteomics of NS1-2 FLAG 
To be able to use SILAC based proteomics to identify interaction partners of NS1-2, it was first 
confirmed that NS1-2 could be immunoprecipitated from infected cells using the FLAG tag (data not 
shown). Next high titre virus stocks were generated for NS1-2 FLAG in each differentially labelled 
SILAC growth media. This was to avoid later pulse labelling effects of the otherwise unlabelled viral 
inoculum on labelled cells. Each stock was sequence verified and expression of NS1-2 FLAG was 
confirmed by western blot (data not shown).  
As for the SILAC experiment performed on the NS4-FLAG virus, BV-2 cells were passaged at least 5 
times in the presence of media containing light, medium and heavy labelled amino acids. The 
experiment set up was similar to that shown in Figure 4.11 and Table 4.3 for NS4-FLAG. Cells were 
infected with either WT or NS1-2 FLAG (prepared in the appropriately labelled media) at an MOI of 3 
TCID50/cell, higher than that achievable for NS4-FLAG. Cell lysates were collected at 10 hpi and were 
treated with an RNase enzyme, so as to degrade viral RNA that may be precipitated with NS1-2 
through the replication complex and thus reduce co-purification of host RNA-binding proteins. 
Immunoprecipitation using anti-FLAG agarose was then performed using equal amounts of protein 
from each set of infected cells. Extracts from the input, flow-through and elution stages were taken 
for validation of the purification of NS1-2 FLAG by western blot analysis (Figure 4.17). NS1-2 FLAG 
was detectable in the appropriate eluates, whereas GAPDH, which is not thought to interact with 
NS1-2, was lost in the flow-through. Equal volumes of each elution were subsequently mixed in a 
ratio of 1:1:1 (L:M:H) for each replicate experiment and were again sent for liquid chromatography 
tandem mass spectrometry (LC-MS/MS) by the University of Bristol Proteomics Facility. 
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Figure 4.17 Validation of the immunoprecipitation of NS1-2 FLAG for SILAC proteomics. Protein 
samples were collected at the input, flow-through and elution stages of immunoprecipiation for WT 
and NS1-2 FLAG infected cells grown in the light (L), medium (M) and heavy (H) labelled media. The 
western blot shown is representative of results from the triplicate experiments. Samples were 
analysed for FLAG and GAPDH expression. NS1-2-FLAG was enriched in the eluates from all NS1-2 
FLAG infected cells. A band at a similar size to NS1-2 FLAG was detected in the WT eluates, which is 
either a non-specific band or may be a cleavage product of NS1-2. GAPDH, which is not expected to 
interact with NS1-2, was lost in the flow-through. 
 
4.2.12 Analysis of SILAC results for NS1-2 FLAG  
Between the triplicate SILAC experiments 180 proteins, identified with at least 2 peptide hits, were 
over 2-fold enriched in the NS1-2 FLAG samples compared to WT. The 2-fold cut-off was again 
applied as the threshold for a specific interaction. Of these proteins, 71 were deemed high 
confidence interactions on the basis that they were identified in all 3 replicates (Table 4.7) and 34 
were identified in 2 of 3 NS1-2 FLAG infections and were thus considered low confidence 
interactions (Table 4.8). The viral proteins NS4, VPg and NS6 were among those identified as high 
confidence interactions. NS7 was not identified, suggesting the replication complex was not isolated 
in its entirety as perhaps expected from RNase treatment of the samples.  
To begin analysis of the large number of cellular factors identified as high and low confidence 
interactions, Ingenuity Pathway Analysis (IPA) software was used. Through the accession numbers of 
the identified proteins, IPA is able to assign proteins to different groups based on function and 
protein type. The software works by matching identified proteins of interest against the Ingenuity 
Knowledge Base, a database of protein:protein interactions and functional gene annotations. Using 
IPA to analyse the type of proteins identified revealed that the majority were enzymes, followed by 
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transcription and translation regulators, kinases and phosphatases (Table 4.9). Ribosomal proteins 
were found to be the most represented protein family, with the DEAD Box helicase protein family 
the second most abundant (Table 4.10). A number of the associated proteins could be classified by 
IPA into a several canonical signalling pathways. The EIF2 signalling pathway was the most strongly 
associated, succeeded by regulation of eIF4 and P70S6K signalling (Table 4.11). 
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Accession Description Mean log2 
(SILAC Ratio) 
STDEV 
(log2) 
mnv|NS4| mnv|NS4| 3.54 0.45 
P14148 60S ribosomal protein L7 3.29 0.80 
mnv|NS1-2| mnv|NS1-2| 3.27 0.22 
D3Z3R2 Protein Gm10268 3.19    0.61 
 
Q3V3N5 Putative uncharacterized protein (Fragment) 3.14 0.68 
P62754 40S ribosomal protein S6 3.12    0.70 
 
Q0QEW9 60S ribosomal protein L18 (Fragment) 3.10 0.83 
Q3THJ6 Putative uncharacterized protein 3.09   0.65 
 
P62911 60S ribosomal protein L32 3.02 0.44 
P62918 60S ribosomal protein L8 2.99 
 
0.92 
Q91VR5 ATP-dependent RNA helicase DDX1 2.95 0.66 
P14115 60S ribosomal protein L27a 2.89 0.68 
P27659 60S ribosomal protein L3 2.89   0.52 
 
Q6ZWN5 40S ribosomal protein S9 2.89 0.58 
P62242 40S ribosomal protein S8 2.88 0.55 
Q9JJF3 Lysine-specific demethylase NO66 2.87 0.42 
Q9D8E6 60S ribosomal protein L4 2.84 0.50 
A2A547 Ribosomal protein L19 2.83    0.73 
 
P83882 60S ribosomal protein L36a 2.83 0.32 
Q8VI94 2',5'-oligoadenylate synthetase-like 9 2.82 0.33 
P47911 60S ribosomal protein L6 2.81 0.58 
O35295 Transcriptional activator protein Pur-beta 2.8 1.37 
P12970 60S ribosomal protein L7a 2.78 0.69 
P41105 60S ribosomal protein L28 2.76 0.39 
E9PWH9 Ribosomal protein L15 2.75 0.55 
P19253 60S ribosomal protein L13a 2.75 0.26 
P62267 40S ribosomal protein S23 2.75 0.51 
P47963 60S ribosomal protein L13 2.71 0.67 
P62900 60S ribosomal protein L31 2.70 0.39 
P62717 60S ribosomal protein L18a 2.69 0.64 
P62855 40S ribosomal protein S26 2.68 0.40 
P62281 40S ribosomal protein S11 2.65 0.55 
D3Z2T7 MCG123716 2.58 0.47 
Q9CR57 60S ribosomal protein L14 2.58 0.60 
Q497D7 Rpl30 protein 2.57 0.43 
E9Q132 60S ribosomal protein L24 2.56 0.57 
D3Z4H3 Protein Gm10154 2.53 0.41 
O70569 Ribosomal protein S14 2.49 0.72 
P62849-2 Isoform 2 of 40S ribosomal protein S24 2.48 0.47 
D3Z3R1 60S ribosomal protein L36 2.47 0.61 
P61358 60S ribosomal protein L27 2.47 0.62 
Q5M9N6 Rpl37a protein 2.47 0.35 
Q3TK27 Putative uncharacterized protein 2.45 0.41 
P62830 60S ribosomal protein L23 2.44 0.54 
Q6ZWV7 60S ribosomal protein L35 2.43 0.64 
Q9JIK5 Nucleolar RNA helicase 2 2.43 0.73 
Q8BTI8-3 Isoform 3 of Serine/arginine repetitive matrix 
protein 2 
2.42 1.54 
D3YTQ9 40S ribosomal protein S15 2.36 0.56 
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B7ZWF1 Ddx3x protein 2.35 0.62 
Q545F8 40S ribosomal protein S4, X isoform 2.30 0.57 
P14131 40S ribosomal protein S16 2.20 0.67 
Q3TVV6 Putative uncharacterized protein 2.17 0.68 
mnv|NS5| mnv|NS5| 2.16 0.05 
Q8VC94 Rpl11 protein 2.15 0.45 
Q569Z6 Thyroid hormone receptor-associated protein 3 2.12 0.86 
A2AVJ7 Ribosome binding protein 1 1.97 0.73 
Q3TWW8 Protein Srsf6 1.89 0.33 
mnv|NS6| mnv|NS6| 1.87 0.33 
Q8K363 ATP-dependent RNA helicase DDX18 1.85 0.55 
Q3TGI9 Putative uncharacterized protein 1.83 0.70 
E9QN31 Putative ribosomal RNA methyltransferase NOP2 1.80 0.63 
P51881 ADP/ATP translocase 2 1.75 0.50 
P84104-2 Isoform Short of Serine/arginine-rich splicing factor 
3 
1.75 0.36 
Q91YK6 Rpl23a protein (Fragment) 1.75 0.72 
P62983 Ubiquitin-40S ribosomal protein S27a 1.74 0.46 
Q8BL97-3 Isoform 3 of Serine/arginine-rich splicing factor 7 1.73 0.16 
P67984 60S ribosomal protein L22 1.70 0.55 
Q08288 Cell growth-regulating nucleolar protein 1.65 0.64 
Q61656 Probable ATP-dependent RNA helicase DDX5 1.60 0.43 
Q501J6 Probable ATP-dependent RNA helicase DDX17 1.54 0.47 
P60867 40S ribosomal protein S20 1.29 0.27 
 
Table 4.7. High confidence interactions with NS1-2 FLAG identified by SILAC. High confidence 
interactions were those identified in triplicate experiments. A mean log2(SILAC ratio) of 1 indicates a 
2-fold enrichment, which was used as a cut-off for specific interaction. 
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Accession Description Mean log2 
(SILAC ratio) 
STDEV 
(log2) 
Q3TKR5 Ribosomal protein L5 5.05 1.29 
Q6ZWY3 40S Ribosomal protein S27-like 4.97 2.36 
E9Q7G0 Protein Numa1 4.83 2.57 
Q9CYH6 Ribosome biogenesis regulatory protein homolog 4.63 2.82 
Q9ESV0 ATP-dependant RNA helicase DDX24 4.42 2.85 
Q8K1N4-2 Isoform 2 of Spermatogenesis-associated serine-rich 
protein 2 
4.17 3.15 
Q9Z204-4 Isoform 4 of Heterogeneous nuclear ribonucleoproteins 
C1/C2 
4.17 3.50 
Q8BL36 Putative uncharacterised protein 3.92 0.60 
Q80VD1 Protein FAM98B 3.55 0.23 
Q921R2 40S ribosomal protein S13 3.24 0.11 
P42669 Transcriptional activator protein Pur-alpha 3.01 1.61 
Q1W5Q7 Putatitive gag-pol protein 2.99 0.91 
Q640L9 MCG7614, isoform CRA_a 2.67 0.68 
Q6ZWU9 40S ribosomal protein S27 2.67 0.89 
E9PV46 Protein Gm8841 2.52 0.62 
O09167 60S ribosomal protein L21 2.36 0.59 
Q3TFP0 FUS interacting protein (Serine-arginine rich 1) 2.21 0.16 
Q5F2E7 Nuclear fragile X mental retardation-interacting protein 
2 
2.06 0.09 
Q9D7S7-2 Isoform 2 of 60S ribosomal protein L22-like 1 1.97 0.44 
P62245 40S ribosomal protein S15a 1.83 0.04 
P97351 40S ribosomal protein S3a 1.82 0.50 
Q3TPJ4 Putative uncharacterized protein (Fragment) 1.82 0.11 
Q91VM5 RNA binding motif protein, X-linked-like-1 1.81 0.50 
Q3TW40 Putative uncharacterized protein 1.78 0.46 
Q9JJI8 60S ribosomal protein L38 1.78 0.54 
G3X926 MCG1407, isoform CRA a 1.70 0.59 
D3YXG3 Protein Gm4963 1.63 0.55 
Q5SQB0 Nucleophosmin 1.53 0.17 
P15864 Histone H1.2 1.51 0.42 
 
Table 4.8. Low confidence interactions with NS1-2 FLAG identified by SILAC. Low confidence 
interactions were those identified in 2 of 3 replicative experiments. A mean log2(SILAC ratio) of 1 
indicates a 2-fold enrichment, which was used as a cut-off for specific interaction. 
  
Engineering Tagged MNV to Study Replication and Viral Protein Function 151 
 
 
Type of Molecule Number of Proteins 
Enzyme 30 
Kinase 2 
Phosphatase 2 
Transcription Regulator 18 
Translation Regulator 4 
Transporter 9 
Other 116 
 
Table 4.9. Summary from Ingenuity Pathway Analysis of the types of proteins specifically enriched 
with NS1-2 FLAG. 
 
Protein Family Number of Proteins 
DEAD box helicase (DDX) 9 
DEAH box helicase (DHX) 3 
Heterogeneous ribonucleoprotein 
(hnRPP) 
6 
Ribosomal proteins* 56 
* Large (60S) ribosomal proteins (RPL) (34) 
* Small (40S) ribosomal proteins (RPS) (22) 
Splicing factor PQ/RS-rich (SFPQ/RS) 7 
 
Table 4.10. The most represented protein families among NS1-2 FLAG interaction partners, as 
revealed by  Ingenuity Pathway Analysis. 
 
Pathways Number of 
molecules 
EIF2 Signalling 47 
Regulation of eIF4 and p70S6K Signalling 16 
mTOR signalling 16 
Granzyme A signalling 4 
Regulation of actin-based motility by Rho 6 
 
Table 4.11. The top 5 signalling pathways associated with NS1-2 FLAG interaction partners, as 
determined by Ingenuity Pathway Analysis. 
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4.2.13 Validation of the NS1-2 FLAG dataset 
The DEAD (Asp-Glu-Ala-Asp) Box helicases (DDX) were one of the most represented protein families 
in the SILAC dataset, and in particular DDX3 was identified as a high confidence interaction partner. 
At the time of this study an independent on-going project in the lab had demonstrated that DDX3 
plays a role in the replication of MNV (424), although the mechanism is unknown. With the 
availability of an antibody, DDX3 was first selected for validation of the SILAC dataset by western 
blot analysis of the immunoprecipitation samples.DDX3 could be detected in the eluate samples of 
NS1-2 FLAG infected cells, but not that from WT infected cells, which supports the SILAC data, Figure 
4.18.  
 
 
Figure 4.18. Validation of the immunoprecipitation of DDX3 with NS1-2 FLAG identified by SILAC. 
Protein samples from one of the WT and NS1-2 FLAG immunoprecipitations performed for the SILAC 
experiment were analysed for the presence of DDX3 by western blot. DDX3 was detected in the 
eluate sample from the NS1-2 FLAG infected cells and not in the corresponding WT sample, 
confirming the SILAC data. 
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 Discussion 4.3
4.3.1  Reporter-tagged MNV 
Reporter-tagged MNV would facilitate a large number of studies to characterise norovirus replication 
and the viral proteins and to answer some key outstanding questions about MNV infections in vivo, 
as discussed at the start of this chapter. Furthermore identifying a position in the MNV genome that 
tolerates a reporter gene would mean that a similar insertion could be trialled in a HuNV genome or 
replicon. Generating replication-competent reporter-tagged HuNV RNA could ultimately be used in 
experiments to identify the HuNV receptor, the main hurdle in developing a HuNV cell culture 
system. Transfection of reporter-tagged HuNV RNA would provide an easy read out for replication 
and viral spread in cells expressing cDNA libraries of potential reporter proteins, allowing large 
numbers to be screened in a high-throughput manner. Towards the end of this project a luciferase-
based replicon system was developed in our lab for MNV (393). The coding sequence for Renilla 
Luciferase was inserted after the VP1 coding region, under control of the MNV TURBS sequence for 
ribosome termination-reinitiation, followed by the FMDV 2A sequence and ORF3 encoding VP2. 
Renilla Luciferase activity was linked to replication and translation of the genome, and the replicon 
has been used for studying stimulation of NS7 activity by VP1 (393). However infectious virus carrying 
the luciferase gene was not produced within this system and there remains no infectious reporter- 
tagged norovirus. For all of these reasons, a number of different attempts were made to engineer 
reporter-tagged MNV, although none proved to be successful.  
In the first broad attempt, direct exchange for GFP in the Tn-insertion libraries did not lead to 
isolation of GFP+ MNV from 5 GFP-insertion libraries covering the entire genome. A number of 
factors most likely contributed to the failure to isolate a GFP-tagged virus by this approach. Firstly, 
although infectious viruses were recovered from the libraries, they were mainly 15nt insertion 
viruses resulting from background ligation during cloning, which would be expected to outcompete 
any GFP-tagged viruses with a replication defect. Secondly, a proportion of the GFP coding regions 
may have been lost by recombination occurring in the DNA-mediated reverse genetics system, as 
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was observed in recovery of the 15nt insertion libraries using this method (described in Chapter 3). 
Large copy numbers of the viral RNA are produced by T7-driven transcription, which may favour 
template switching and recombination by the viral polymerase. It is also possible that an appropriate 
site was not identified within the libraries as only 1 in 6 insertions would result in in-frame 
translation of GFP. Therefore using a combination of GFP inserts engineered to be expressed in all 
three reading frames could increase the likelihood of isolating GFP-MNV.  Finally, the GFP insertions 
may have simply been too large and disruptive to the viral proteins or the genome itself. It has been 
suggested for hepatitis A virus that there may be a limit to the amount of extra RNA that can be 
encapsidated given the limited size of the viral capsid (215). However the creation of GFP-tagged 
FCV, which is similar in capsid size to MNV, suggests that this should not be the limiting factor (1).  
As a second, more targeted approach, a number of sites previously found to tolerate 15nt insertions 
were trialled for their ability to accept insertions of larger exogenous sequences. The obvious caveat 
of selecting sites by this approach is that the sites are only known to tolerate small sequence-specific 
15nt insertions. Despite targeting a number of these sites and using different engineering strategies 
and multiple reporter proteins, all of smaller size than GFP (G.Luc., iLOV, spGFP and FlAsH), 
generation of a reporter-tagged virus could not be achieved. This suggests that the insertions at 
these sites were too disruptive to the viral protein structure or function and as such abolished viral 
replication. In total 7 sites were targeted out of a possible 144 tolerated sites spanning 3 selected 
proteins. Whilst this was a highly selective strategy it is over 3 times as many sites as were tested to 
successfully generate reporter-tagged FCV and poliovirus (1, 409). It has been suggested that 
generating a reporter-tagged virus in this way can be a largely empirical exercise of matching an 
appropriate reporter gene with an appropriate genome site and protein context (409). For example 
DsRed was stably inserted into a site in a poliovirus protein from which GFP was quickly expelled 
(409). Thus it is possible that other sites in the MNV genome that tolerate 15nt insertions could also 
tolerate insertions of reporter genes and more could be trialled, although cloning different insertions 
into each of the 324 tolerated insertion sites across the genome was beyond the time constraints of 
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this project. Future work could also include trying a broad library-based approach again but with a 
smaller insertion, such as the spGFP insertion.  
Since the beginning of this study, the structures of NS7, NS6 and VPg have become available, which 
in combination with the insertion profiling could now guide the choice of an appropriate site to make 
a direct reporter-protein fusion, as has been used to generate other reporter-tagged viruses (117). 
However as NS6 only tolerated a small percentage of 15nt insertions, this may be an unsuitable viral 
protein to target (see Chapter 3) and the other proteins are equally central to replication.  An 
alternative strategy to tagging viral proteins is to tag the viral RNA (305). This approach has been 
recently developed and is achieved by insertion of an RNA aptamer (of approximately 90nt) into 
either coding or non-coding regions of the genome. The RNA aptamer forms a particular RNA 
secondary structure in which is it able to bind an exogenously supplied fluorophore, resulting in 
fluorescence from the RNA-fluorophore complex (305). The most effective of these emits a green 
fluorescence, comparable in brightness to fluorescent proteins, and has been termed Spinach (305). 
The possibility of applying this approach to MNV is now under investigation. 
4.3.2  Epitope-tagged viruses 
The advantages of epitope tags over reporter proteins are the smaller size and relatively inert 
peptide sequences, for instance in comparison to the tetracysteine FlAsH tag, which should render 
them less disruptive to viral proteins and more likely to be tolerated. As such, the FLAG epitope tag 
was successfully inserted into NS4, VP2 and NS1-2, in sites that did not tolerate various reporter 
proteins. This yielded the first infectious FLAG-tagged noroviruses that were characterised through 
western blot, immunofluorescence and immunoprecipitation. All viruses were found to have similar 
growth characteristics to WT-MNV, although the NS1-2 FLAG virus displayed an early lag in 
replication and it is possible that the VP2-FLAG virus has an underlying defect to explain the loss of 
the FLAG tag after 2 passages in cell culture, which requires further investigation. In contrast NS4-
FLAG and NS1-2 FLAG were stable for at least 3 passages. Using the FLAG tag, NS4 and NS1-2 were 
found to colocalise with NS7 at the site of the replication complex, as has previously been 
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demonstrated (198), confirming that the FLAG-tagged proteins behave as their WT counterparts. VP2 
was also shown to co-localise with NS7 in infected cells for the first time, suggesting it also associates 
with the replication complex. The subcellular localisation of these proteins could now be further 
probed to identify the cellular components with which they co-localise outside of the replication 
complex. For NS1-2 and NS4 this may shed light on the mechanisms by which they drive complex 
formation. The FLAG tags could also be used for further characterisation of these proteins, such as to 
determine the topology of the predicted transmembrane domains in NS4 and NS1-2 by antibody 
binding selective permeabilisation studies.  
NS4, VP2 and NS1-2 were immunoprecipitated by means of the FLAG tag and NS1-2 was co-
immunoprecipitated with  NS4, an interaction previously demonstrated for the equivalent FCV 
proteins p32 (NS1-2) and p30 (NS4) (206). This interaction was later confirmed by SILAC identification 
of NS4 and NS1-2 interaction partners (see discussion below). Immunoprecipitation of the FLAG-
tagged viral proteins suggested that characterisation of the viral and cellular interaction partners of 
these proteins, and thus the interactions that comprise the replication complex, could be 
investigated by SILAC based quantitative proteomics and this work was begun with NS4 and NS1-2.  
 
4.3.3 Analysis of NS4 interaction partners identified by SILAC proteomics 
Immunoprecipitation of NS4 coupled with SILAC and mass spectrometry identified 4 high confidence 
interaction partners of NS4 (excluding NS4 itself) and 14 lower confidence interaction partners. There 
was little reproducibility between the duplicate experiments which may be due to the lower levels of 
NS4-FLAG in the elution in one experiment (Figure 4.11, elution, medium NS4-FLAG sample). This in 
turn may have resulted in lower levels of its interaction partners for detection or in SILAC ratios that 
fell below the 2-fold enrichment cut-off. As there were 2 NS4-FLAG repeats within the other 
experiment, confidence could still be gained from the proteins identified within just this one 
experiment. 
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Of the high confidence interactions, NS1-2 was the most enriched protein and conversely NS4 was 
the most enriched protein in the NS1-2 FLAG SILAC data. As mentioned earlier, this interaction was 
first independently identified by western blot following immunoprecipitation of NS4-FLAG. Both of 
these proteins have been implicated in formation of the replication complex (198, 200). They are 
both thought to be membrane bound and localise to different organelles whose membranes can be 
found in the replication complex and serve as a platform for replication (198, 200). Therefore it is 
possible that the interaction between NS4 and NS1-2 brings the complex together. To investigate this 
and their co-localisation during the course of infection, a double tagged virus carrying a c-myc tag in 
NS1-2 and the FLAG tag in NS4 was engineered and is undergoing characterisation for future studies. 
Furthermore the interaction domains of these two proteins could now be mapped by co-transfection 
of tagged truncation mutants coupled with immunoprecipitation reactions. The other viral proteins 
that were highly enriched with NS4-FLAG were VPg, NS6 and NS7, whose interactions with NS4 may 
also contribute to formation of the replication complex. However it is possible that the proteins were 
precipitated as part of the ORF1 polyprotein if NS4-FLAG is pulled down as it is being synthesised in 
the replication complex, although higher molecular weight precursors were not apparent by 
detection of NS4 with the anti-FLAG antibody. Whether these interactions are direct therefore 
requires further investigation.  
The only cellular protein that was enriched with NS4-FLAG in both experiments was the tripartite 
containing 21 protein (TRIM21). TRIM21 has E3 ubiquitin ligase activity and thought to play several 
roles within the cellular antiviral response, mainly as an intracellular receptor for antibodies that 
remain bound to virions as they enter the cell (261). Via its ubiquitin ligase activity, TRIM21 promotes 
degradation of the bound virion by the proteasome in combination with a segregase and unfoldase 
enzyme, required to tackle the challenging virion structure (172). This action neutralises viral 
infection prior to translation of viral genes (261, 273). Whilst it is interesting to speculate as to 
whether TRIM21 mediated antibody dependent intracellular degradation may play a role in MNV 
infection, it should be noted that large standard deviation was identified in the levels of TRIM21 
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between replicate experiments, suggesting that it may not be a specific interaction. It must also be 
considered that given TRIM21 is thought to have higher affinity for antibodies than any other human 
antibody receptor (261), it is possible that it was immunoprecipitated through interactions with the 
conjugated antibody. However in this case it should have been equally abundant in the WT samples 
and would have been excluded as a contaminant. From western blot validation of the TRIM21 SILAC 
data, it appeared that it was largely lost in the unbound fraction, although there was a very low level 
in the NS4-FLAG eluate and a weak interaction cannot yet be excluded. 
There were a number of interesting proteins identified as low confidence interactions of NS4-FLAG. 
Cofilin is required for sorting of secretory proteins in the trans-golgi network (TGN), where it localises 
and interacts with a Ca2+ ATPase via actin (430). Knock-down of cofilin prevents uptake of Ca2+ into 
the TGN and leads to mis-sorting of secretory proteins (430). MNV infection and NS4 in particular are 
known to result in mild disruption of the protein secretory pathway (198, 356, 447), thus cofilin 
appeared to be an attractive target for NS4, however the interaction could not be validated by 
western blot analysis. G3BP2 was also identified as a low confidence interaction partner of NS4-
FLAG. It is an RNA binding protein involved in formation of cytoplasmic mRNA stress granules, which 
arise in response to cellular stresses including viral infections (269). Stress granule formation 
sequesters many cellular housekeeping mRNAs to make way for translation of stress-inducible 
mRNAs. This is also thought to be part of a cellular defence particularly against RNA viruses, whose 
genomes resemble mRNA and on which stress granules can form to prevent viral translation (87, 
307). As such many RNA viruses employ strategies to disrupt stress granule formation by binding and 
sequestering G3BP isoforms (1 or 2) in the replication complex, or by cleavage of G3BP-1 (87, 307, 
442). Given the similarities with other RNA viruses, it is likely that stress granule formation also 
occurs as a result of MNV infection and thus it is conceivable that NS4 or one of the other viral 
proteins may interact with G3BP-2 to disrupt this process. However this requires further studies as 
the SILAC data on this interaction has yet to be validated.  
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Two of the proteins identified as lower confidence interaction partners of NS4-FLAG were 
mitochondrial proteins, Slc25A3 and voltage-dependent anion selective channel protein 2 (VDAC2). 
NS4 is not known to localise to the mitochondria, although this has never been examined throughout 
the course of infection. NS6 however has been shown to localise to the mitochondria in transfected 
cells (198), thus it is possible that the 2 mitochondrial proteins were indirectly immunoprecipitated 
with NS6, provided NS4 was in contact with mitochondrial NS6. The localisation of NS4-FLAG and NS6 
at the mitochondria could now be further investigated to contribute to validation of this interaction 
and to identify a potential direct interaction partner. In either case, identification of these proteins 
could provide insight into how MNV may maintain a beneficial cellular environment for replication. 
Slc25A3 is a phosphate carrier in the inner mitochondrial membrane, which transports inorganic 
phosphate into the matrix and is essential for oxidative phosphorylation and synthesis of ATP (271). 
VDAC2 is a porin in the outer mitochondrial membrane that allows the movement of solutes but has 
more recently been found to play a central role in mitochondrial-mediated apoptosis (360). The 
opening and closing of VDAC2 is regulated by direct binding of pro- and anti- apoptotic factors 
respectively (340, 359). Opening of VDAC2 results in efflux of cytochrome c, which in turn activates 
cellular caspases and triggers apoptosis. MNV is known to trigger apoptosis via the mitochondrial 
pathway involving release of cytochrome c (49), although it also employs strategies to delay the 
onset of apoptosis via the viral protein VF1 (275). An interaction with VDAC2 by one of the viral 
proteins could therefore also serve to delay the onset of apoptosis. Conversely it could be possible 
that interactions with VDAC2 stimulate apoptosis, as found for the Infectious Bursal disease virus 
viral protein 5 (IBDV) (243), which interacts with VDAC2 to induce apoptosis late in infection and 
promote viral release (243). The induction of apoptosis as an exit strategy has also been proposed for 
MNV and FCV (49, 379). As for the other low confidence cellular proteins, a clear interaction between 
VDAC and NS4-FLAG could not be observed by western blot. The majority of VDAC was lost in the 
flow-through but a small proportion appeared to be eluted with NS4-FLAG suggesting a weak 
interaction, although this was confounded by high background staining.  
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Whilst all of the above proteins could provide interesting hits for follow up studies, it is clear that 
using SILAC with the FLAG-tagged viral protein requires optimisation to be able to validate the 
interactions. It is possible that the levels obtained in this preliminary study were sufficient for 
detection by SILAC-based mass spectrometry but not by western blot and therefore the 
experimental set needs to be optimised. For instance, the MOI for this experiment was limited by 
the titre of the NS4-FLAG stock, whereas using a higher MOI may provide greater input material and 
higher enrichment of NS4-FLAG and its interaction partners, as proved more successful in the NS1-2 
FLAG experiment described below. Furthermore using a greater input may allow a higher threshold 
for specific interactions to be applied. The identification of GAPDH as a low confidence interaction 
partner of NS4-FLAG, which appeared to be lost in the unbound fraction of the IP by western blot, 
demonstrates perhaps the need for more stringent specificity cut-offs. The buffer conditions of the 
IP are now also under optimisation to ensure that the replication complex isolated is enzymatically 
active to ensure the interactions are functionally relevant and that protein:protein interactions are 
maintained throughout the entire process. Alternative independent validation methods could also 
be used to confirm a role for the identified proteins in MNV replication, such as reverse 
immunoprecipitation of the target protein, depletion studies or immunofluorescence colocalisation 
studies.  
4.3.4 Analysis of NS1-2 FLAG interaction partners identified by SILAC proteomics 
In comparison the NS4-FLAG experiment, SILAC proteomics identified a greater number of 
interaction partners of NS1-2 FLAG, suggesting that NS1-2 may play multiple roles throughout the 
cell. This may also have been a result of initial optimisation of the protocol including using a 
specifically labelled virus inoculum to allow larger inoculum volume and thus a higher MOI. RNase 
treatment was also included to reduce the precipitation of cellular RNA binding proteins with NS1-2 
through interactions with viral RNA in the replication complex.  
As mentioned the most enriched protein was NS4, which further supports an interaction between 
NS4 and NS1-2, and VPg and NS6 were also identified as high confidence interactions. As before, 
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there is the possibility that these proteins may have been isolated as a precursor with NS1-2, 
although higher molecular weight species were not observed with the anti-FLAG antibody by 
western blot of the eluted samples (data not shown) nor was NS3 detected.  
The presence of the other viral proteins, and indeed so many cellular proteins, suggests that not all 
of the proteins identified will interact directly with NS1-2, but may be purified through association 
with other proteins. Nonetheless identification of these factors can still reveal proteins involved in 
the replication of MNV. For example, 2 of the top 5 canonical signalling pathways associated with 
the identified proteins were involved in the regulation of protein translation (EIF2 signalling and 
regulation of eIF4 and p70S6K signalling). Proteins associated with these pathways may have been 
purified through association with VPg, known to interact with cellular translation factors (77). 
Likewise, ribosomal proteins were the most represented protein family and were some of the most 
enriched proteins identified. These would be expected to be highly abundant in the replication 
complex, the site of viral protein translation, and may have also been isolated through interactions 
with VPg. It is also possible that RNase treatment did not proceed to completion or that regions of 
the viral RNA were protected from degradation through interactions with RNA binding proteins or 
ribosomes, such that some ribosomal proteins may have been co-precipitated with viral RNA. One 
RNA binding protein that was specifically enriched with NS1-2 FLAG was 2’5’ oligoadenylate 
synthetase-like 9 (2’5’ OAS-L9). 2’5’OAS-L9 is involved in antiviral signalling by binding to double 
stranded RNA, the replication intermediate of MNV (207). Validation of the interaction of 2’5’OAS-L9 
either with the double stranded viral RNA or with NS1-2 could reveal a role for this signalling 
pathway in the cellular response to norovirus infection and perhaps a novel mechanism of innate 
immune antagonism by NS1-2 or one of the co-purified viral proteins.  
Surprisingly for an RNA virus whose replication is thought to be cytoplasmic, a large number of the 
specifically enriched proteins play nuclear roles as splicing factors, transcriptional regulators, histone 
modification proteins and nucleolar proteins. There are no published reports of norovirus proteins 
localising to the nucleus, although this may be worth investigating. Alternatively it is known that 
many nuclear proteins, and particularly transcription and splicing factors, shuttle between the 
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nucleus and the cytoplasm, which could make them available for interaction with the cytoplasmic 
norovirus proteins. Some cytoplasmic RNA viruses, such as poliovirus, even employ strategies for 
influencing the localisation of nuclear proteins to the cytoplasm through viral protease-mediated 
cleavage of the nuclear pore complex (309). It is also worth considering whether disruption of the 
nuclear envelope may have occurred during lysis to allow factors to bind to NS1-2 FLAG or its 
interaction partners post-lysis, therefore the functional relevance of these observations needs be 
confirmed and the interactions validated. Norovirus replication has however been shown to alter 
patterns of cellular gene expression, particularly of genes involved in carbohydrate and lipid 
metabolism (71). It is also possible that such changes in gene expression could also be mediated at 
the level of upstream cytoplasmic signalling pathways, such as through the mTOR pathway, which 
was one of the canonical signalling pathways most associated with the proteins purified with NS1-2 
FLAG. Signalling through mTOR regulates many cellular processes, including lipid metabolism (225). 
Further studies into these interactions could hence shed light on how MNV modulates cellular gene 
expression.  
The DEAD box (DDX) RNA helicase family was identified as one of the most represented protein 
families associated with NS1-2 FLAG, second only to the ribosomal proteins. The co-
immunoprecipitation of DDX3 could be detected by western blot, which served to validate the SILAC 
data. By SILAC, DDX3 was on average 5.1 fold enriched with NS1-2 FLAG, which is much greater than 
the interactions of NS4-FLAG that could not be validated.  
Members of the DEAD Box RNA helicase family are involved in a multitude of cellular processes 
involving RNA, from transcription and translation to mRNA export (reviewed in (330)). More 
recently, through studies of interactions with different viruses, novel functions of the DDX proteins 
have emerged. In particular, DDX3 has been implicated in antiviral signalling as a cytosolic sensor of 
viral nucleic acids (281). However it is also thought to play an antiviral role downstream of pattern 
recognition, as a scaffold protein to facilitate the activation of IkappaB kinase ɛ and the TANK 
binding kinase I (TBK1), and promote subsequent signalling through IRF3 (157). As such, many viral 
proteins are reported to interact with DDX3 to antagonise this function and antiviral signalling (298, 
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304, 432). Conversely DDX3 has been identified as an essential cellular factor for viruses including 
HIV and HCV, mainly through enhancement of viral translation initiation (141, 142, 380). DDX3 has 
been shown to bind to the 5’ end of both cellular and viral mRNAs and induce unwinding of local 
RNA secondary structure to facilitate translation initiation. Additionally, DDX3 interacts with the 
translation factors eIF4G and PABP to assist in recruitment of the translation initiation eIF4F complex 
and assembly of the functional 80S ribosome (142, 380). Consequently targeting the activity of DDX3 
has been proposed as a potential antiviral strategy, particularly against HIV (141). Previous studies in 
our group have identified a role for DDX3 in the MNV lifecycle, through interactions with genomic 
RNA and with VPg ((424) and Lilianne Chung, unpublished data). Therefore it seems plausible that 
DDX3 was co-purified with NS1-2 FLAG through association with either un-cleaved viral RNA or VPg, 
although a direct interaction cannot be ruled out. siRNA-mediated depletion of DDX3 and small 
molecular inhibitors of DDX3 helicase activity (originally developed against HIV (141)) have both 
been shown to result in reduced replication of MNV ((424) and Luis Urena, unpublished data). 
Studies are underway to determine the precise involvement of DDX3 in MNV replication with the 
hypothesis that it may facilitate translation initiation, given the association between DDX3 and VPg 
and the viral RNA. Although whether recruitment of DDX3 to the replication complex has a two-fold 
effect by sequestering its antiviral activity is also a possibility. Studies in the lab have also been 
initiated into the role of other DDX proteins in MNV replication, such as DDX1, which was found to 
be highly enriched with NS1-2 FLAG.  
It is evident from these preliminary studies on NS4 and NS1-2 that, with optimisation, SILAC based 
proteomics on FLAG-tagged viruses could provide valuable insights into the cellular factors involved 
in norovirus replication. As has been demonstrated with targeting DDX3 to inhibit HIV and MNV (141, 
424), this has the potential to identify novel targets for antiviral intervention. Optimisation of the 
SILAC immunoprecipitation is required to consistently yield interactions that can be validated by 
independent methods. Following this, SILAC proteomics could also be applied the VP2-FLAG virus to 
identify the interaction partners of VP2. Although the insertion sites used for engineering these 
FLAG-tagged viruses were carefully selected, it is also possible that many of the other stable insertion 
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sites identified in the profiling could accommodate a FLAG tag or a similarly sized tag such as the His 
or c-myc tags. This would allow other lesser characterised norovirus proteins to be studied in a 
similar way. It is also possible that these insertions could be engineered into the HuNoV proteins at 
similar sites, for example the C-terminus of HuNoV p22 is also highly charged suggesting it may 
similarly accommodate a FLAG tag to generate replication competent RNA for transfection studies. 
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5.  Rational attenuation by the cellular microRNA machinery 
 Background 5.1
5.1.1 Production of miRNAs and harnessing the miRNA machinery  
Despite their small size microRNAs (miRNAs) play a significant role in cellular gene expression by 
negatively regulating over 50% of human mRNAs involved in many aspects of cellular function (32, 
118). The expression pattern of miRNAs is specific to each cell and tissue type and can change with 
differentiation status, infection and can be aberrant in cancer (30, 60, 223, 247). The production of a 
miRNA begins in the nucleus, where RNA Pol II transcribes a primary miRNA either from introns or 
from sequences corresponding to the 3’UTR of mRNAs (233). This primary miRNA is approximately 
80nt and forms an imperfect stem loop structure, in which form it is cleaved by a nuclear RNase III 
enzyme, Drosha (Figure 5.1) (91). This generates what is known as the precursor miRNA 
(approximately 60 nt), which is exported to the cytoplasm for further cleavage by another RNase III 
enzyme, Dicer. Cleavage and unwinding by Dicer releases a mature miRNA (20-24nt), which is loaded 
into an RNA-induced silencing complex (RISC) and guides the complex onto target mRNAs (374). 
Recognition of a target mRNA is directed by an essential  7 nt ‘seed sequence’ in the miRNA (usually 
bp 2-8), which must be homologous to the target (31). The fate of the target mRNA is then 
influenced by the degree of complementarity with the rest of the miRNA sequence. Partial 
complementarity typically results in translational silencing by RISC, whereas perfect 
complementarity is less common in mammalian cells and promotes mRNA cleavage by Argonaute 2, 
an endonuclease component of the RISC (31), Figure 5.1. 
Interactions between miRNAs and viruses have become the focus of intense research over the past 
decade. Many viruses encode their own miRNAs to regulate both cellular and viral gene expression 
(148). These are largely double-stranded DNA viruses whose miRNAs are transcribed in the nucleus, 
although the first miRNA-like small RNA from a cytoplasmic RNA virus (West Nile Virus) has recently 
been identified and is capable of modulating cellular gene expression to promote viral replication 
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(192, 399). Based on the finding of cellular miRNA target sites in some RNA virus genomes, it has 
been proposed that certain cellular miRNAs may directly target viral genomes as part of an innate 
antiviral response (342, 468). This concept has been subject to some debate and it is generally 
considered that RNA viruses may have evolved to avoid homology with cellular miRNAs expressed in 
permissive cells (92, 468). Similarly, some viruses employ strategies that globally inhibit miRNA 
biogenesis and silencing (92, 342). Cellular miRNAs do however play an indirect role in the antiviral 
response by regulating processes from IFN signalling through to antigen presentation (44). 
Conversely, cellular miRNAs can in fact promote replication by modulating the expression of host cell 
proteins involved in the viral lifecycle (82). Likewise direct interactions between a miRNA and a viral 
genome can be essential for replication (204). To date there is just one example of this, where liver 
specific miR-122 binds directly to target sites in the 5’ end of the HCV genome to promote 
replication in part by stabilising the genome and enhancing viral translation (242). 
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Figure 5.1. The generation and effector functions of cellular miRNAs. miRNA production begins in 
the nucleus, where RNA Pol II (RNAPII) produces a primary miRNA. This forms into imperfect stem 
loop structures, in which conformation it can be cleaved by an RNase III enzyme, Drosha, to release a 
pre-miRNA. The pre-miRNA is exported to the cytoplasm, where it is further cleaved by a second 
RNase III enzyme (Dicer), which also unwinds the pre-miRNA to release a mature single stranded 
miRNA that is loaded into the RNA induced silencing complex (RISC). Depending of the degree of 
homology between the mature miRNA and a target sequence in the 3’ end of mRNAs, the target will 
either be degraded by RISC (perfect homology) or translation of the target will be suppressed (partial 
homology).  
 
The regulatory capacity of the cellular miRNA machinery can be harnessed to control viral tissue 
tropism and modulate virulence. This concept exploits the cell- and tissue-specific expression of 
miRNAs and has been well documented. Control of viral tropism is achieved by engineering a viral 
genome to encode a cell-specific artificial miRNA target sequence, otherwise known as a miRNA 
response element (MRE). In cells expressing the cognate miRNA, the viral genome will be targeted 
by RISC for either translational silencing or degradation, consequently restricting viral replication in 
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that particular cell lineage or tissue. This strategy of regulating viral tropism has been applied for a 
number of purposes. It was first developed as a potential means to increase the safety of oncolytic 
viruses by preventing replication in non-tumour cell lineages and in tissues where replication causes 
disease. For example, insertion of a muscle-specific MRE into the Coxsackie A21 virus genome 
prevented replication in muscle cells and alleviated lethal myositis without compromising the 
oncolytic potential of the targeted virus (213). The approach has also been used for oncolytic DNA 
viruses, where insertion of the liver-specific miR-122 target sequence into the ORF of an adenovirus 
protein suppressed replication in hepatic cells (but not in tumour cells) to prevent liver cytotoxicity 
(458).  
The main application of controlling tropism through miRNA regulation is the generation of potential 
live attenuated vaccines. Ideally a live attenuated vaccine candidate should not be able to replicate 
in tissues where it produces disease, but should replicate to sufficient levels elsewhere to elicit a 
protective immune response. Viral attenuation has traditionally been achieved by passage of the 
virus in cell culture to introduce changes that can alter tissue tropism in the host, but the mechanism 
of attenuation is often unknown and alterations to the virus can be unpredictable (151). Harnessing 
the miRNA machinery to restrict replication in a cell-specific manner therefore provides a rational 
approach to viral attenuation. This concept has been demonstrated for a number of highly 
pathogenic RNA viruses. For example, species-specific attenuation of Influenza A H5N1 and H1N1 
was achieved by insertion of a mammalian MRE into each genome, which resulted in attenuation of 
the targeted viruses in mice but not in eggs, to allow production of the vaccine candidate (313). 
Attenuation through restricting neurotropism has been achieved in a similar way for poliovirus, 
Japanese encephalitis virus, Semiliki Forest virus, vesicular stomatitis virus and a pseudeotyped 
dengue virus (28, 176, 177, 214, 457, 459). In each case insertion of a neuronal specific MRE into the 
viral genome suppressed replication in the central nervous system by recruitment of RISC to the 
targeted genome, which in turn prevented neurovirulence and alleviated the associated mortality. 
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Replication in peripheral tissues was unaffected and served to elicit robust, protective immune 
responses (28, 176, 457).  
5.1.2  Aims 
Restricting viral tropism using the cellular miRNA machinery has since been proposed as a general 
strategy for generating live attenuated RNA virus vaccine candidates. However to date this concept 
has only been demonstrated for viruses that cause acute infections and largely with a well-defined 
neuronal tropism. The aim of this chapter was therefore to determine the potential of this approach 
to generate attenuated noroviruses, and to address in particular whether it can be used to attenuate 
persistent viruses.  
 Results 5.2
5.2.1 Identification of miRNAs expressed in MNV-permissive cell lines  
To be able to determine the potential of targeting the miRNA machinery against MNV in vitro, it was 
first necessary to identify the miRNAs that are expressed in MNV permissive cell lines. To do so, a 
screen was performed using Taqman RT-qPCR Low Density Arrays (TLDAs) to identify the miRNAs 
expressed in both RAW264.7 and BV-2 cells. Both cell types were first infected with MNV-1 at an 
MOI of 0.1 TCID50/cell, or were mock infected. At 20 hpi post infection, the small RNA fraction (less 
than 200 nt) was harvested from infected and uninfected cells (see Materials and Methods for 
details). This time point was selected to coincide with the innate immune response against MNV-1 
(indicated by previous work in the lab (275)) as many macrophage miRNAs are thought to be 
involved in regulating interferon responses (446). Reverse transcription was performed on the small 
RNA population using a pool of primers specific for 380 mature murine miRNAs and 4 other small 
RNAs as endogenous controls. To confirm that the extraction and reverse transcription of miRNAs 
had been successful qPCR was performed to detect miR-155, known to be expressed in macrophage 
(data not shown) (297, 400). qPCR was then performed on each sample using the TLDA cards, which 
contain preloaded primer-probe sets for the same 380 miRNAs and small RNA controls. Each 
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infection and RT-qPCR card analysis was performed in duplicate. The level of each miRNA was 
normalised against the level of a non-coding small nuclear RNA (U6) as an endogenous control, 
which did not appear to be altered with infection. For normalisation, the Ct value of U6 was 
subtracted from the Ct value of the miRNA, which is invariably expressed at lower levels than U6 and 
therefore has a higher Ct value. This gives the Delta Ct value (as plotted on the y-axis in Figure 5.2). A 
miRNA expressed at high levels will therefore have a lower Delta Ct value, as the Ct of the miRNA 
will be closer to the highly expressed control Ct value.  
The miRNA expression profile of infected RAW264.7 cells was first compared to infected BV-2 cells. 
This was to identify an miRNA that is only expressed in one of the cell lines, so that the other cell line 
would remain permissive to a virus carrying the specific MRE and could be used for virus titrations 
and production of virus stocks. It was expected that not all of the murine miRNAs present on the 
TLDA would be detected given the cell-specific nature of miRNA expression. As such in total 136 
miRNAs of the 380 were detected and compared between the 2 cell lines. Of the 136 miRNAs, the 
majority were expressed in both cell types at similar levels, Figure 6.2. However 15 miRNAs were 
found to be expressed only in BV-2 cells, whilst 6 miRNAs were detected solely in RAW264.7 cells, 
highlighted in Figure 5.2.  
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Figure 5.2.(A) miRNA expression profiles of RAW264.7 cells infected with MNV-1 compared to infected BV-2 cells.  Results are shown for the first 66 miRNAs. 
RAW264.7 and BV-2 cells were infected with MNV-1 at an MOI of 0.1 TCID50/cell. The small RNA fraction was harvested at 20 hpi. Reverse transcription was 
performed using a set of primers for 380 miRNAs and control small RNAs, followed by qPCR analysis using TLDA miRNA cards. The Ct for each specific miRNA is 
normalised against the Ct of the U6 control RNA to give the Delta Ct value shown on the Y-axis. The higher the Delta Ct the lower the expression. Boxed points 
indicate miRNAs that are expressed in only one of the cell lines during MNV-1 infection.  
 
 
A
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Figure 5.2.(B) miRNA expression profiles of RAW264.7 cells infected with MNV-1 compared to infected BV-2 cells.  Results are shown for the remaining 70 
miRNAs. RAW264.7 and BV-2 cells were infected with MNV-1 at an MOI of 0.1 TCID50/cell. The small RNA fraction was harvested at 20 hpi. Reverse transcription 
was performed using a set of primers for 380 miRNAs and control small RNAs, followed by qPCR analysis using TLDA miRNA cards. The Ct for each specific miRNA 
is normalised against the Ct of the U6 control RNA to give the Delta Ct value shown on the Y-axis. The higher the Delta Ct the lower the expression. Boxed points 
indicate miRNAs that are expressed in only one of the cell lines during MNV-1 infection.  
 
 
B
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5.2.2  MNV-1 infection results in changes in cellular miRNA levels. 
The TLDA miRNA screen also allowed the effect of MNV-1 infection on cellular miRNA levels to be 
investigated. This was first analysed for RAW264.7 cells where the fold change in each miRNA was 
determined for MNV-1 infected cells compared to uninfected cells. For any miRNAs that were 
undetected in either sample, a Ct value of 32 (the limit of detection) was assigned to be able to 
calculate a fold change. As an initial guide, changes greater than 2-fold were considered to be 
significant. The greatest increase was observed in miR-124 which was not detected in uninfected 
cells. This was followed by miR-687 and miR-155 which were increased by 20.5 and 10.3 fold 
respectively. In total, 7 miRNAs were increased with MNV-1 infection in RAW264.7 cells, Table 5.1. 
Whilst no miRNA showed more than a 2-fold reduction, MNV-1 infection appeared to reduce the 
level of miR-107 and miR-199a-3p to below the detection threshold, corresponding to a 1.3 fold 
reduction in both, Table 5.1. 
Similarly, MNV-1 infection in BV-2 cells resulted in increased expression of 5 miRNAs. The greatest 
increase was observed in miR-687 (6.2 fold), and a 2-fold increase was observed in miR-155, which 
together were the only miRNAs to be increased in both cell lines. As in RAW264.7 cells, miR-107 was 
decreased by 1.3 fold but this was sufficient to again prevent detection in infected cells. The largest 
fold change was in miR-17, which was highly expressed in uninfected cells but could no longer be 
detected in infected cells, resulting in over a 1,576 fold reduction, Table 5.1  
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Figure 5.3 (A) Changes in the level of miRNAs with MNV-1 infection of RAW264.7 cells. RAW264.7 cells were infected with MNV-1 at an MOI of 0.1 TCID50/cell. 
The small RNA fraction was harvested at 20 hpi. Reverse transcription was performed using a set of primers specific for 380 miRNAs, followed by qPCR analysis 
using TLDA miRNA cards. The relative quantity value on the y-axis is equivalent to fold change. The dashed lines indicate a 2-fold increase and decrease, above or 
below which the change is considered significant. + miR-124 was not detected in the uninfected samples, therefore to calculate the fold change a Ct value of 32 
was assigned, which is the limit of reliable detection. Results for the first 63 miRNAs are shown here. In total, the levels of 6 miRNAs were increased by more 
than 2-fold, whereas only miR-107 was decreased by more than 2-fold. 
A
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Figure 5.3 (B) Changes in the level of miRNAs with MNV-1 infection of RAW264.7 cells. RAW264.7 cells were infected with MNV-1 at an MOI of 0.1 TCID50/cell. 
The small RNA fraction was harvested at 20 hpi. Reverse transcription was performed using a set of primers specific for 380 miRNAs, followed by qPCR analysis 
using TLDA miRNA cards. The relative quantity value on the y-axis is equivalent to fold change. The dashed lines indicate a 2-fold increase and decrease, above or 
below which the change is considered significant. + miR-124 was not detected in the uninfected samples, therefore to calculate the fold change a Ct value of 32 
was assigned, which is the limit of reliable detection. Results for the remaining 63 miRNAs are shown here. In total, the levels of 6 miRNAs were increased by 
more than 2-fold, whereas only miR-107 was decreased by more than 2-fold. 
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Figure 5.4 (A) Changes in the level of miRNAs with MNV-1 infection of BV-2 cells. BV-2 cells were infected with MNV-1 at an MOI of 0.1 TCID50/cell. The small 
RNA fraction was harvested at 20 hpi. Reverse transcription was performed using a set of primers specific for 380 miRNAs, followed by qPCR analysis using TLDA 
miRNA cards. The relative quantity value on the y-axis is equivalent to fold change. The dashed lines indicate a 2-fold increase and decrease, above or below 
which the change is considered significant. Results are shown for the first 62 miRNAs. + miR-17 was not detected in the infected samples, therefore to calculate 
the fold change a Ct value of 32 was assigned, which is the limit of reliable detection. The results are shown for the first 63 miRNAs. miR-17 and let-7b were 
decreased by more than 2-fold. 
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Figure 5.4 (B) Changes in the level of miRNAs with MNV-1 infection of BV-2 cells. BV-2 cells were infected with MNV-1 at an MOI of 0.1 TCID50/cell. The small 
RNA fraction was harvested at 20 hpi. Reverse transcription was performed using a set of primers specific for 380 miRNAs, followed by qPCR analysis using TLDA 
miRNA cards. The relative quantity value on the y-axis is equivalent to fold change. The dashed lines indicate a 2-fold increase and decrease, above or below 
which the change is considered significant. Results are shown for the remaining 60 miRNAs. Here, the levels of 3 miRNAs were increased by more than 2-fold.  
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miRNA Fold Change in RAW264.7 Fold Change in BV-2 
miR-124+ 46.5 ↑ - 
miR-687 20.5 ↑ 6.2 ↑ 
miR-155 10.3 ↑ 2.0 ↑ 
miR-345-5p 5.5 ↑ - 
miR-685 4.5 ↑ - 
miR-132 3.1 ↑ - 
miR-210 2.6 ↑ - 
miR-199a-3p* 1.5 ↓ - 
miR-107* 1.3 ↓ 1.3 ↓ 
let-7b - 4.0 ↑ 
miR-207 - 3.9 ↑ 
miR-146a - 2.1 ↑ 
miR-744 - 2.1 ↑ 
miR-17 + - 1575.6 ↓ 
Table 5.1. Average fold change observed in miRNAs with MNV-1 infection in RAW264.7 and BV-2 
cells. +miR-124 was not detected in the uninfected RAW264.7 samples and miR-17 was not detected 
in the infected BV-2 samples, therefore to calculate the fold change of both of these a Ct value of 32 
was assigned for the undetected samples, which is the limit of reliable detection. *miR199a-3p and 
miR-107 were detected in infected RAW264.7 cells and although less than a 2-fold change was 
observed. 
 
5.2.3 Validation of the TLDA miRNA data 
A panel of miRNAs was selected for validation of the TLDA data from those that were found only in 
one particular cell line. These were miR-10, miR-124 and miR-125a-5p from RAW264.7 cells and miR-
126-5p, miR-467a and miR-467c from BV-2 cells. For validation, RAW264.7 and BV-2 cells were again 
infected with MNV-1 under the same conditions (at an MOI of 0.1 TCID50/cell) and the small RNA 
fraction was harvested at 20 hpi. RT-qPCR was performed using individual primers specific for each 
miRNA and the control RNA U6. In support of the TLDA data, the miRNAs identified in BV-2 cells 
were all only detected in BV-2 cells, and the same was true for the RAW264.7 miRNAs, with the 
exception of miR-124, Figure 5.5. By TLDA analysis, miR-124 had been identified only in infected 
RAW264.7 cells but this time was also detected in infected BV-2 cells. Likewise, by the TLDA analysis 
miR-124 was not present in uninfected RAW264.7 cells and had displayed the greatest fold-increase 
ith MNV-1 infection. This data could not be validated and miR-124 was instead detected at similar 
levels in both infected and uninfected RAW264.7 cells (data not shown). This suggests that the 
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apparent increase in miR-124 observed with the TDLA cards may have been due to failed 
amplification of miR-124 in the uninfected RAW264.7 samples.  
 
 
Figure 5.5 Validation of the TDLA data. RAW264.7 cells and BV-2 cells were infected with MNV-1 at 
an MOI of 0.1 TCID50/cell. Small RNA species were harvested at 20 hpi and RT-qPCR was performed 
with individual primer sets specific for each miRNA. The Ct for each miRNA was normalised by 
subtracting the Ct value of endogenous U6 RNA in each sample to give the Delta Ct value on the y-
axis. The higher the Delta Ct, the lower the expression of the miRNA. All miRNAs identified in 
RAW264.7 cells by TDLA were detected in only in infected RAW264.7 cells only and vice versa for BV-
2 miRNAs. The only exception was miR-124, originally detected on in RAW264.7 cells but that was 
also present here in infected BV-2 cells. 
 
5.2.4  Selection of a miRNA for use against MNV-1 
The candidates for use against MNV-1 were narrowed down to the 5 miRNAs that had been 
identified and validated as being only expressed in one of the permissive cell lines. However it was 
also important to determine whether these miRNAs were expressed in the cells used for recovery of 
MNV, BSR-T7 cells. Expression of the specific miRNA in these cells could prevent recovery of a virus 
carrying the cognate MRE. To investigate the expression of the candidate miRNAs during virus 
recovery, BSR-T7 cells were infected with FPV-T7 and transfected with the MNV-1 WT cDNA clone. 
At 24 h post transfection, the small RNA species were harvested for analysis of each miRNA by RT-
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qPCR using the individual miRNA primer sets.  Only 3 of the candidate miRNAs were not detected in 
transfected BSR-T7 cells, miR-126, miR-467a and miR-467c (Figure 5.6A), all of which are expressed 
only in BV-2 cells. 
The expression of the 6 candidate miRNAs was also assayed in infected bone-marrow derived 
macrophages (BMDM), which could later be used to investigate miRNA-driven restriction in primary 
cells. BMDMs were generated from 4 individual mice and cells from each individual were infected 
with MNV-1 at an MOI of 10 TCID50/cell, due to the lower infectivity of BMDMs, or were mock 
infected. The small RNA population was harvested at 24 hpi for RT-qPCR. All miRNAs except for miR-
126 could be detected in infected BMDMs. Taking all of this data into account, miR-467c was 
selected as the target miRNA as it is highly expressed in infected BV-2 cells and is present in BMDMs 
but not in RAW264.7 cells or BSR-T7 cells. 
 
Figure 5.6. miRNA expression in BSR-T7 cells (A) and BMDMs (B). Expression of the panel of 
candidate target miRNAs for use against MNV-1 was determined by RT-qPCR. (A) BSR-T7 cells were 
infected with T7-FPV and transfected with the WT MNV-1 cDNA clone and small RNA species were 
harvested at 24 hpi. Only 3 of the miRNAs were not detected in BSR-T7 cells, all of which are 
expressed only in infected BV-2 cells. (B) BMDMs generated from 4 individual mice were infected 
with MNV-1 at an MOI of 10 TCID50/cell and the small RNA population was harvested at 24 hpi. All 
of the miRNAs except for miR-126 were detected in infected BMDMs and the level of each was not 
altered by infection. 
 
 
 
 
A B
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5.2.5 Engineering MNV-1 to carry the miR-467c target sequence 
To determine whether miR-467 could be used to restrict MNV-1 replication, complementary miR-
467c target sequences were engineered into the MNV-1 cDNA clone. The target sequences (22nt) 
were introduced at 2 positions in the genome that had previously been found to tolerate insertion of 
the FLAG tag coding sequence, which is of a similar size (24 nt) (described in Chapter 4). These were 
nt position 383 in the NS1-2 coding region and nt position 7229 in ORF3 encoding VP2, Figure 5.7A. 
As the miR-467 sequence is only 22nt, 2 additional nt were added to prevent the insertion resulting 
in a frame shift in the downstream protein. At each site a target sequence was introduced with 
either perfect or partial (64%) complementarity to miR-467c, to direct different effector functions of 
RISC against the target genome, Figure 5.7B. Importantly the amino acid sequence of each insertion 
was kept the same. The viruses generated were designated as NS1-2-467c, NS1-2-467cM, VP2-467c 
and VP2-467cM, where M indicates a modified partial complementary target sequence, Figure 5.7B. 
To determine the effect of targeting positive and negative sense genomic RNA (gRNA), the same 
miR-467c target sequences were introduced to be complementary to miR-467c in MNV-1 negative 
sense gRNA. These viruses were named: NS1-2-467c-A/S, NS1-2-467cM-A/S, VP2-467c-A/S, VP2-
467cM-A/S, where M again refers to a modified partially complementary sequence and A/S indicates 
that the MRE is in the anti-sense genomic RNA, Figure 5.B.  
The DNA-based reverse genetics system was employed to recover virus from each of the clones with 
miR-467c target sequences. For those with target sequences in the positive sense gRNA, infectious 
virus was only recovered from clones carrying the MRE in the NS1-2 coding region and not in VP2. In 
the negative sense, infectious virus could be recovered from each of the clones, including VP2. This 
may be accounted for by the difference in amino acid sequence resulting from the insertions in the 
positive sense gRNA compared to negative sense gRNA. To be able to test a complete set, only the 
viruses carrying MREs in NS1-2 were taken forward for characterisation.  
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Figure 5.7 Generating MNV-1 carrying miR-467c target sequences. (A) The miR-467c target 
sequences were inserted into positions in the coding region for NS1-2 and VP2, previously found to 
tolerate FLAG-tag and 15 nt insertions. (B) The miR-467c target sequence was inserted to be 
complementary to miR-467c in the positive sense gRNA (NS1-2-467c, VP2-467c) and with modified 
(M) sequence complementarity (NS1-2-467cM, VP2-467cM). The perfect and modified target 
sequences were also inserted to be present in the negative sense gRNA (NS1-2-467c-A/S, NS1-2-
467cM-A/S, VP2-467c-A/S, VP2-467cM-A/S). (C) and (D) Recovery of the targeted viruses was 
performed in BSR-T7 cells using the DNA reverse genetics system. (C) Virus was only recovered from 
the clones carrying the miR-467c target sequences in NS1-2 in the positive sense and not in VP2. (D) 
Virus was recovered from all clones carrying the target sequence in the negative sense. Significance 
was tested using One Way ANOVA with a Dunnett post-test to compare each insertion virus to the 
WT control ***:  p< 0.001, n=3. NS7 YGGG was included as a negative control.  
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5.2.6 Viruses carrying miR-467c target sequences are restricted in cell culture. 
To determine whether carrying the miR-467c target sequences inhibits MNV replication in cell 
culture, BV-2 and RAW264.7 cells were firstly infected with the viruses carrying miR-467c target 
sequences in the positive sense gRNA. Infection was performed at low MOI (0.01TCID50/mL), virus 
was harvested at 24 hpi and viral titres were determined by TCID50 in RAW264.7 cells. If miR-467c is 
able to recognise a target in the genome and recruit the miRNA machinery, then replication of a 
virus carrying the target sequence should be inhibited in BV-2 cells, which express miR-467c, but not 
in RAW264.7 cells where miR-467c is absent, Figure 5.8A. In line with this prediction, the replication 
of NS1-2-467c carrying a perfect target sequence was significantly reduced in BV-2 cells compared to 
RAW264.7 cells, whereas the titre of WT-MNV was the same between cell lines, Figure 5.8C. 
Similarly, replication of a virus carrying an imperfect target sequence (NS1-2-467cM) was also 
significantly reduced in BV-2 cells compared to RAW264.7 cells, suggesting that the restriction 
applies for both perfect and imperfect MREs in the MNV genome, Figure 5.8B. The same restriction 
pattern was observed for viruses carrying the miR-467c target sequences in the negative sense gRNA 
(NS1-2-467c-A/S and NS1-2-467cM-A/S), suggesting both the positive and negative strands of MNV 
gRNA can be targeted to a similar degree, Figure 5.8C.  
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Figure 5.8. Carrying a miR-467c target sequence restricts MNV-1 replication in cell culture. (A) The 
restriction hypothesis. MNV carrying a miR-467c target sequence with perfect homology (NS1-2-
467c) should be restricted in BV-2 cells, which express miR-467c, but not RAW264.7 cells which do 
not have miR-467c. The same would be expected for a virus carrying an imperfect target sequence 
(NS1-2-467cM) but the predicted mechanism of restriction would be translational repression rather 
than degradation. BV-2 and RAW264.7 cells were infected with each virus carrying a miR-467c target 
sequence in either the positive sense gRNA (B) or the negative sense gRNA (C). A/S signifies viruses 
with target sequences in the antisense gRNA in (C). Viruses with the target sequence had 
significantly reduced replication in BV-2 cells compared to RAW264.7 cells, whereas growth of WT-
MNV was comparable between cell lines. Significance was tested using Two Way ANOVA and 
Bonferronni post-tests, ***: p< 0.001, n=3.   
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  Discussion 5.3
Each cell expresses a specific miRNA signature and contains the machinery to silence or degrade a 
target mRNA under the direction of a cognate miRNA. It is well documented that the cellular miRNA 
machinery can be harnessed to attenuate the replication of viruses carrying artificial miRNA 
response elements (MREs) and in theory this approach could be widely applicable, irrespective of 
viral tropism. It is thought to be particularly effective against positive strand RNA viruses, whose 
genomes resemble cellular mRNAs (28, 176, 214). However to date it has only been demonstrated 
for RNA viruses that cause acute infections and largely for those that display a well-defined 
neurotropism (28, 176, 457). By contrast noroviruses are known to cause both acute and persistent 
infections and to date only an immune cell tropism has been established for MNV (413, 447). 
Therefore to investigate whether this approach could also be applied to generate live attenuated 
noroviruses, MNV was engineered to carry the target sequence of a miRNA expressed only in 
permissive microglial BV-2 cells. The presence of a perfect or an imperfect miRNA target sequence at 
one site in the genome (in the positive or negative sense) was found to be sufficient to inhibit 
replication only in BV-2 cells expressing the cognate miRNA, which demonstrated the potential of 
this approach to obtain to attenuated noroviruses.   
To demonstrate this approach in vitro it was necessary to first identify cellular miRNAs that are 
expressed in MNV-1 permissive cell lines and that could be used against MNV. Although a number of 
publications have reported miRNAs that are expressed in macrophage cell lines that may have been 
suitable (297, 446), it was important to identify a miRNA that was only expressed in 1 of the MNV-1 
permissive cell line for practical purposes, such as being able to titre the MRE-viruses. A screen of 
the miRNAs expressed in BV-2 and RAW264.7 cells by miRNA TLDAs identified a number of miRNAs 
that were only expressed in 1 cell line during MNV-1 infection. This data was validated by individual 
RT-qPCR for 6 different miRNAs, all of which were confirmed to be present only in the respective cell 
line except for miR-124. The failure to detect this miRNA in both cell lines by TLDA may have been 
due to biased reverse transcription with the pool of primers, or errors in TLDA card loading which 
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would prevent amplification. This result highlights the need to validate the other TLDA data 
regarding changes in particular miRNAs resulting from MNV infection (discussed below).  
One particular miRNA, miR-467c, fulfilled the criteria of being highly expressed in BV-2 cells only and 
was selected for use against MNV. The function of miR-467c in macrophage cells is unknown and the 
only function of the miR-467 cluster of miRNAs (miR467a-e) is a reported role in endothelial cells 
during angiogenesis control (43). It is more than likely that miR-467c plays additional roles in 
macrophage as most characterised miRNAs appear to regulate multiple targets in different cell 
types. A number of miRNA target prediction programs are available which largely search gene 
databanks for targets based on sequence homology. Comparison of 4 different target prediction 
programs for miR-467c (TargetScan-Vert, miRDB, DIANA-MICROT, and microRNA.org) gave results 
ranging from 20 to 5,625 predicted targets, and not a single match could be found in the top 10 hits 
of all 4 prediction algorithms, which suggests that experimental approaches would be required to 
characterise the function of this miRNA. 
Insertion of miR-467c target sequences into the MNV genome at a site in the NS1-2 coding region 
resulted in a significant reduction in replication in BV-2 cells compared to RAW264.7 cells, which was 
not observed with WT-MNV. A similar reduction was observed for viruses carrying target sequences 
in both the positive and negative sense gRNA, suggesting that miR-467c is able to access and target 
both strands. Additionally, a similar reduction in replication was observed for viruses carrying 
imperfect compared to perfect target sequences, suggesting that miR-467c can direct both the 
cleavage and translational silencing functions of RISC onto the MNV genome. However further 
characterisation is required to establish the specific mechanism of inhibition for each of the MRE-
containing viruses. A single-step growth curve should now also be performed for each virus in the 
different cell lines to include determining the copy numbers of positive and negative strand gRNA. 
This may also shed light on whether each viral genome is degraded or silenced. Characterisation of 
the stability of each target sequence is also underway in both BV-2 and RAW264.7 cells. Given that 
the target sequences are under selective pressure in BV-2 cells, escape mutations may be expected 
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to occur more rapidly in this cell line compared to RAW264.7 cells. This may also reveal the 
minimum target sequence that is required for miR-467c-mediated restriction of MNV.  
It will then be important to demonstrate that the reduction in replication of these viruses is due to a 
specific effect of the miR-467c sequence and not a disruptive effect of the insertions on the function 
of NS1-2. All MRE-containing viruses attained comparable viral titres to WT-MNV in RAW264.7 cells, 
which would suggest that the function of NS1-2 is not compromised. However an alternative 
explanation is that the insertion could disrupt a specific interaction of NS1-2 that is required in BV-2 
cells but not in RAW264.7 cells. To exclude this possibility, inhibitors of miR-467c could now be used 
to test whether the restriction in BV-2 cells can be rescued by antagonism of miR-467c, which would 
indicate that it is specific to the presence of the miR-467c target sequences. Other studies have 
employed knock out cell lines or siRNA depletion of core components of the miRNA machinery (such 
as Drosha and Argonaute 2) to demonstrate their specific role in the inhibition of MRE-containing 
viruses (28, 313). This option could also be used to study the restricted MRE-MNVs, although the 
effects of global inhibition of the miRNA machinery on cellular function and on replication of WT-
MNV must be controlled. 
To enhance the miRNA-mediated suppression of MNV it may be possible to introduce another 
miRNA target sequence at a second location in the genome. Identification of over 300 sites in the 
MNV genome that tolerate 15 nt insertions (described in Chapter 3) means that a number of other 
sites and insertion combinations could be trialled to obtain a viable double insertion virus. Inclusion 
of an alternative miRNA target sequence may also reduce the likelihood of viral escape from miRNA-
mediated restriction. Studies on miRNA-targeted flaviviruses have suggested that extending the 
genomic distance between multiple target sequences not only increases suppression but reduces 
the occurrence of viral escape (177). This optimisation to produce a stronger restricted phenotype 
may be important prior to in vivo characterisation.   
Due to time constraints, the restriction was not tested in primary cells or in vivo. However the 
presence of miR-467c in bone marrow derived macrophage (BMDM) provides the opportunity to 
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determine whether the miRNA machinery can also restrict MNV in primary cells. MiR-467c was not 
as highly expressed in BMDM cells as some of the other miRNAs screened. It has been suggested 
that a minimum threshold of miRNA copy numbers must be reached for gene silencing to occur (51), 
therefore it may also be necessary to quantify absolute copy numbers of miR-467c in each cell line. 
An alternative option may be to engineer the target sequence of one of the more highly expressed 
miRNAs (such as miR-125-5p, Figure 5.6B) into the MNV genome. In vivo MNV is also thought to 
replicate in dendritic cells (447), therefore prior to in vivo studies the expression of miR-467c and the 
growth of the viruses carrying the corresponding MREs should also be determined in primary 
dendritic cells. 
If the suppression observed in cell culture is specific to the miRNA machinery, then viruses carrying 
miRNA target sequences that display the most significant restriction in vitro could be used to 
determine whether this results in attenuation in vivo. Due to the availability of MNV strains that 
manifest differently in mice with range of immunological backgrounds, attenuation could be 
assessed in both acute and persistent infections. The viruses carrying miR-467c target sequences 
have been generated in the MNV-1 strain which causes acute asymptomatic infections in 
immunocompetent mice and lethal systemic infections in immunocompromised STAT1-/- mice (209). 
To also look at persistence it would be necessary to introduce the target sequences into the MNV-3 
strain, which causes persistent infections in immunocompetent mice (10). Whether the same 
insertion sites will be tolerated in MNV-3 has not yet been investigated, although the sequences of 
MNV-1 and MNV-3 are largely conserved in NS1-2. The other RNA viruses that have been attenuated 
by this method, such as poliovirus, have had a clearly defined dual tropism, for example in neuronal 
and enteric cells, and attenuation was defined as a loss of neurotropism and the associated mortality 
(28, 176, 457). As MNV has only been shown to infect immune cells of the myeloid lineage and 
infection of MNV-3 is asymptomatic (10, 447), attenuation may be defined by whether the targeted 
viruses are able to establish a persistent infection, whether they are secreted at reduced levels and 
whether dissemination from the intestine to the mesenteric lymph nodes and spleen is observed. If 
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these mutants fail to establish a persistent infection but elicit a protective immune response, it 
would indicate the potential of this approach to generate attenuated vaccine candidates for 
persistent viruses.  
In vivo infection of viruses carrying a macrophage-specific MRE would also allow the importance of 
replication in macrophage cells to be probed in the maintenance of persistent norovirus infections. If 
miR-467c is expressed in primary dendritic cells then their contribution could also be assessed. 
Otherwise selection of an alternative miRNA that is expressed in both cell types may be more likely 
to lead to attenuation and would allow the role of immune cell tropism to be assessed as a whole. 
This could reveal whether there are other cell reservoirs that contribute to persistent MNV 
infections, such as epithelial cells, which to date has not been excluded.  
During this study it was also possible to identify the changes that occur in miRNA expression as a 
result of MNV infection. For other viruses this has led to identification of miRNAs that contribute to 
the viral lifecycle either by promoting or counteracting replication by indirect effects on host cell 
protein expression (82). The TLDA analysis allowed the expression of 380 miRNAs to be determined 
during MNV infection in both BV-2 and RAW264.7 cells. This selection of miRNAs corresponded to a 
pool of the better characterised, more highly expressed rodent miRNAs but it is not an exhaustive 
list. A second pool of rodent miRNA primers and the corresponding TLDA cards are available and 
could be used for a complete study of the changes in miRNA expression. Similarly, deep sequencing 
provides an alternative approach for a fully comprehensive study of all miRNAs and is often 
compared to microarray analysis of the changes in miRNA expression, although these techniques are 
not without limitation (26). For this study, TDLA was the most appropriate method based on its 
speed, reliability and the wide dynamic range over which changes can be observed (26).  
Only 2 miRNAs (miR-687 and miR-155) were found to be increased by MNV infection in both cell 
lines, although to a greater extent in RAW264.7 cells. The increase in miR-155 was validated in both 
cell lines by RT-qPCR performed prior to the TLDA analysis, as it is known to be expressed in 
macrophage and was therefore used to confirm the miRNA extraction procedure. However the 
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increase in miR-687 still remains to be validated. Whether an increase in these miRNAs facilitates 
replication or is part of a response against it could be addressed by specifically inhibiting miR-687 
and miR-155 to determine the outcome of infection. The increase in miR-155 is most likely part of an 
innate antiviral response against MNV infection, as has been observed in macrophage cells infected 
with VSV (433). Upregulation of miR-155 was found to occur in a RIGI/JNK/NFkappaB dependent 
manner and miR-155 in turn promoted type I IFN signalling by decreasing the expression of a 
negative regulator (suppressor of cytokine signalling 1) (433). Increased expression of miR-155 has 
also been shown to be accompanied by increased expression of pro-inflammatory mediators (439). 
As part of an inflammatory response the expression of miR-155 can be increased indirectly through 
miR-342-5p (439), which was also increased in infected RAW264.7 cells and may have therefore 
contributed to the increase in miR-155 following MNV infection. MiR-155 is a well characterised 
miRNA and PCR arrays are available for 84 of its known target genes which could be used in future 
studies to determine the effect of increased miR-155 expression in MNV infection. This in turn may 
highlight cellular proteins involved in the innate immune response against norovirus. A similar role in 
promoting inflammation and antiviral chemokine signalling has been demonstrated for miR-146a in 
microglial cells (335), which was accordingly upregulated in BV-2 cells.  
In contrast nothing is known about the function of miR-687. Four bioinformatic prediction 
algorithms gave results of between 100 and 4,700 predicted targets for miR-687 (TargetScan-Vert, 
miRDB, DIANA-MICROT, and microRNA.org), ranging in the degree of sequence homology, 
depending on the software used. Therefore experimental approaches would be required to establish 
its function in macrophage cells and during MNV infection. For other unknown miRNAs, broad 
target-searching experimental approaches have typically involved microarrays to observe 
upregulation of genes in the absence of the specific miRNA, mass spectrometry to observe increases 
in protein levels, or immunoprecipitation of the specific miRNA-RISC complex followed by mRNA 
sequencing. 
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MiR-107 was the only miRNA that was decreased in both MNV-infected BV-2 and RAW264.47 cells. 
As should be stated for all of the miRNAs following in the discussion below, the TLDA data for miR-
107 requires validation and the effect of each miRNA on viral replication must be demonstrated to 
certify that it plays a role in the norovirus lifecycle. However a number of studies have been 
published on miR-107 that could give insight into its function in MNV infection. Firstly it is known to 
regulate hypoxia signalling by decreasing the expression of hypoxia-inducible transcription factor 1 
beta (HIF1-β) (453), such that a reduction in miR-107 would promote hypoxia signalling by relieving 
the suppression on HIF1-β. The level of HIF1-β in MNV infection could therefore be used to 
investigate and validate the changes in miR-107 in infected cells. HIF1 has been shown to play a 
novel role in innate antiviral signalling and promotes the upregulation of antiviral genes in response 
to double stranded nucleic acids (although through HIF1-α activation) (187). Therefore it is possible 
that an increase in HIF1-β resulting from reduced miR107 could be part of an innate response 
against MNV. A role for miR-107 in innate immunity has been established following TLR-4 activation 
and as part of an antimicrobial response driven by INFγ and TNFα which decrease miR-107 to 
promote expression of immune effector proteins (178, 455), although a link with antiviral immunity 
has not yet been established. 
The most significant change was observed in the level of miR-17 which was decreased by 1,575 fold 
in infected BV-2 cells. There are no published studies on the role of miR-17 in microglial cells, 
although one report of miR-17 in macrophage suggests that it may be involved in modulating the 
inflammatory response (469). MiR-17 has also been shown to regulate autophagy through the 
suppression of Atg7 translation (85). Atg7 is known to be required for the IFNγ antiviral response 
against MNV as it promotes assembly of a complex of autophagy proteins that in turn prevent 
formation of the MNV replication complex, although a direct mechanism linking IFNγ and Atg7 has 
not been established (196). Neither has a link been made between miR-17 and IFNγ but it is possible 
that the decrease in miR-17 during MNV infection could be part of an antiviral response and be the 
missing link in this pathway, although many studies would be required to support this speculation.  
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As discussed above caution is required in these interpretations until the change in each miRNA is 
validated. Performing a similar study to determine the miRNA response to MNV infection in primary 
BMDMs may further support the changes observed here. Further study of these altered miRNAs may 
reveal a role of miRNAs in the norovirus lifecycle and through identification of their target factors 
could identify cellular proteins that either contribute to replication or form part of the antiviral 
response.  
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6. Rational Attenuation by manipulating polymerase fidelity 
 Background  6.1
6.1.1 The determinants of RdRp fidelity  
It is well established that a variety of RNA viruses exist as diverse quasispecies, a dynamic population 
which results from the low fidelity and intrinsically high error rate of viral RdRps or reverse 
transcriptases. Quasispecies diversity has been shown to give RNA viruses the advantage against 
their hosts in everything from evading host immune responses to invading multiple tissues and 
increasing pathogenesis. However it has also been clearly demonstrated that altering viral RdRp 
fidelity, in particular increasing fidelity to restrict quasispecies diversity, can result in viral 
attenuation and may be a generally applicable approach to rationally attenuating RNA viruses.  
The concept of rationally attenuating RNA viruses by manipulating polymerase fidelity was originally 
demonstrated with a high fidelity poliovirus 3Dpol G64S mutant, isolated through resistance to the 
chemical mutagen ribavirin (318, 428, 429). Ribavirin is a guanosine analog, whose primary 
mechanism of action against poliovirus is lethal mutagenesis (88). Once inside the cell, ribavirin is 
triphosphorylated by cellular enzymes and can then be misincorporated into nascent viral genomes 
by the viral RdRp, opposite both cytidine and uridine. As opposed to causing chain termination, the 
incorporated ribavirin will then act as a template in synthesis of the opposite strand and can 
hydrogen bond with either C or U, causing A to G and G to A transition mutations (90). The 
resistance to ribavirin of the 3Dpol G64S mutant was achieved by a general increase in fidelity, which 
was accompanied by restricted quasispecies diversity. The loss of diversity in turn resulted in 
attenuation of the mutant in vivo with restricted tissue tropism due to a loss of positive cooperative 
interactions within the population, required to pass through infection bottlenecks between tissues. 
This concept has since been demonstrated with a number of other RNA virus polymerase mutants, 
either isolated through screens for resistance to ribavirin and other chemical mutagens or by 
rational design (84, 144, 344). In each case studying the mechanisms of resistance or the impact of 
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different mutations on fidelity has increased understanding of the molecular mechanisms governing 
polymerase fidelity. 
Biochemical and structural studies of the poliovirus 3Dpol G64S mutant have paved the way in 
identifying the determinants of both WT 3Dpol fidelity and the higher fidelity of 3Dpol G64S (12). The 
fidelity checkpoint was identified as a conformational change in 3Dpol that occurs prior to 
phosphodiester bond formation for correct orientation of the incoming nt and this step was found to 
be slower for 3Dpol G64S (12). The structure of the poliovirus 3Dpol (along with other RdRps) is 
thought to resemble a cupped right hand, with a thumb domain, a bundle of α-helices known as the 
fingers domain and a palm domain containing the active site and 5 conserved structural motifs 
(motifs A to E), Figure 6.1A. Motifs A and C contain conserved active site residues that stabilise the 
incoming nt and chelate two divalent metal ions (usually Mg2+) involved in catalysis (61). The 
conformational change occurs in the active site however control of the fidelity checkpoint in 3Dpol is 
achieved from a remote site, notably the finger domain in which G64 resides, Figure 6.1A. The 
backbone of G64 forms part of an extensive network of hydrogen bonds that link the finger domain 
to the nearby amino terminus of the protein, which in turn stabilises active site residues in motif A, 
Figure 6.1B. The G64S mutation precludes correct formation of this hydrogen bond network and 
consequently perturbs the positioning of motif A residues, resulting in reduced rates of nt 
incorporation and increased fidelity (12). 
Remote site connections to active site residues are a conserved feature of many RdRps including the 
Norwalk virus NS7. Instead of a concerted hydrogen bond network involving the amino terminus, in 
the Norwalk virus NS7 the interaction is mediated directly by an arginine residue (R74) in the 
equivalent fingers domain helix, which forms multiple hydrogen bonds with residues of motif A, 
Figure 6.1C (12). 
 
Rational Attenuation by Manipulating Polymerase Fidelity 197 
 
 
Figure 6.1 Remote site control of the fidelity checkpoint is a conserved feature of RdRps. (A) 
Structure of the poliovirus 3Dpol G64S mutant, indicating the conserved right hand conformation of 
the RdRp. The G64S mutation is highlighted in magenta. The five conserved structural motifs are also 
highlighted, motifs A (red) and C (yellow) contain active site residues. Motif B is highlighted in green, 
motif D in blue and motif E in purple, motifs are as described in (166). The structure was modelled 
using UCSF Chimera Software, PDB 2IJF, as solved in (262). (B) In poliovirus 3Dpol G64 in the fingers 
domain forms a network of hydrogen bonds with the amino terminal residue (G1) and active site 
residues in motif A, involved in nt triphosphate orientation and catalysis and as such the fidelity 
checkpoint. (C) The remote site control of the fidelity checkpoint from the fingers domain is 
predicted to occur in the HuNV Norwalk virus RdRp, by virtue of an arginine residue (Arg74) that 
forms multiple hydrogen bonds to residues in motif A. The figures are coloured as follows: motif A, 
red; motif C, yellow; key residues in the fingers domain, blue; hydrogen bonds, dashed lines. Figures 
A and B are taken and adapted from (12). 
G64S
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C
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Building on the fidelity insights gained from the 3Dpol G64S mutant, other determinants of fidelity 
have since been identified. Again these have been based on the poliovirus 3Dpol which has become 
the model of choice for RdRp mechanistic, biochemical and kinetic studies. Motif D of the palm 
domain (Figure 6.2A) is also thought to be involved in the fidelity checkpoint conformational change 
(454). Following nt binding, changes in motif D result in closure of the active site into the catalytically 
active conformation required for phosphodiester bond formation. The movement of motif D is 
thought to position its residue K359 in close proximity to the incoming nucleotide, so that the lysine 
side chain stabilise the triphosphate moiety through hydrogen bonds. In the presence of an incorrect 
mismatched nt, motif D cannot achieve the correct closed conformation and as such the rate of 
misincorporation is reduced in comparison to the rate of correct nt incorporation (454). In other 
words, the harder it is for the RdRp to achieve the correct catalytically active conformation and the 
longer it takes, the more faithful nt incorporation will be.  
K359 was originally identified in 3Dpol as a general acid catalyst which protonates the pyrophosphate 
leaving group to sufficiently enhance its rate of release and catalytic efficiency (65). Mutation of 
K359 to arginine not only results in a slower polymerase but also increases fidelity, above that of the 
G64S mutant (436, 454). The impact of this change on quasispecies diversity in vitro was not directly 
measured, but in a mouse model of poliovirus infection the 3Dpol K359R mutant was highly 
attenuated, to a greater extent than 3Dpol G64S (436). The enhanced attenuation could be a 
combined effect of slower replication and increased fidelity, whereas the 3Dpol G64S mutant exhibits 
WT-like growth kinetics (429). Infection with the 3Dpol K359R mutant elicited a protective immune 
response, albeit slightly less efficacious than the live attenuated vaccine Sabin-1 strain, but was 
genetically stable (436). Motif D is conserved among all RdRps and residues orthologous to K359 are 
present in the RNA polymerases of many RNA viruses, including Norwalk Virus (K374) (65, 436). 
Therefore, manipulating motif D residues has been proposed as a potentially general approach to 
attenuating RNA viruses (436).  
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6.1.2  Aims 
The MNV RdRp (NS7) shares many properties with the RdRp of HuNV GII.4, in terms of activity, 
structure and mutation rate, suggesting that MNV provides a good model to study the HuNV 
polymerase (54). The mutation rates of the MNV and HuNV GII.4 polymerases are comparable to 
those of the poliovirus 3Dpol and the HCV RdRp, and the polymerases are structurally and 
mechanistically conserved, indicating that similar manipulation of polymerase fidelity could result in 
attenuation of norovirus (136). The aim of this chapter was therefore to determine the potential of 
this approach to rationally attenuate norovirus, by engineering and characterising a MNV NS7 
mutant with increased fidelity. Such a mutant could then also be used to probe the importance of 
quasispecies diversity in acute and persistent norovirus infections in vivo.   
 Results 6.2
6.2.1 Engineering high fidelity MNV NS7 mutants: Rational targeting of key residues involved in 
poliovirus 3Dpol fidelity 
Remote-site control of the fidelity checkpoint point in the Norwalk Virus NS7 is predicted  to be 
mediated by an arginine residue in the fingers domain (R74) (12). This residue is conserved between 
the Norwalk and MNV NS7 proteins (data not shown) and as such the corresponding arginine in 
MNV (R77) was first targeted as a rational approach to altering MNV NS7 fidelity. R77 was mutated 
to serine, alanine, lysine and asparagine in the MNV-1 cDNA clone. The mutations were selected for 
the varying capacity of each residue to hydrogen bond to the residues of motif A, predicted to be the 
main stabilising interaction from R77 (Figure 6.2A and B). To predict the number of hydrogen bonds 
each residue may form in this capacity, the structures of WT NS7 and each mutant NS7 protein were 
modelled, Figure 6.2C (PDB accession code 3NAH).  The R77K mutation appeared to be the only one 
that may allow formation of a hydrogen bond directly spanning the distance to the active site. 
However none of the mutations allowed recovery of infectious virus. Reduced levels of the mutant 
NS7 proteins were detected by western blot of the transfected cell lysates (Figure 6.2D). NS3 protein 
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levels were comparable to WT (Figure 6.2D), suggesting poor transfection efficiency was not 
accountable for the reduction in mutant NS7 levels compared to WT NS7, with the exception of the 
R77S mutant, where NS3 levels were significantly lower.  Five blind passages of the R77 mutants did 
not produce any reversion or suppressor mutants as evident by the absence of visible cytopathic 
effect and the failure to detect MNV RNA by RT-PCR (data not shown), suggesting these mutations 
were non-viable. 
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Figure 6.2. Rational targeting of R77 to alter MNV NS7 fidelity. (A) The structure of the MNV NS7 was 
modelled (PDB accession 3NAH) and the position of R77 (green) highlighted in relation to active site 
residues of motif A (red). (B) R77 is predicted to form multiple hydrogen bonds (blue lines) to residues 
of motif A. (C) R77 was mutated to serine, alanine, lysine and asparagine. The hydrogen bonds (blue) 
between the mutant residue (green) and residues of motif A were predicted for each mutant. 
Modelling was performed using Chimera Software (UCSF) (D) Western blot analysis was performed on 
lysates of transfected BSR-T7 cells, to assess translation of NS7 and NS3. FS: an MNV mutant 
containing a frame-shift mutation in the region coding for NS7 (pT7: MNV-GFS) which serves as a 
negative control for recovery alongside mock transfected cells.  
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Motif D and K359 of poliovirus 3Dpol are also conserved with HuNV and MNV (Figure 6.3 and Figure 
6.4A), and as such K377 of MNV NS7 was targeted as a second region of interest. K377 was mutated 
to arginine, histidine, glutamine and leucine. Arginine and histidine were firstly selected as they 
should be able to replicate the function of K377 as a general acid catalysis during nt incorporation 
and this substitution produced a slower, higher fidelity poliovirus 3Dpol (436). Glutamine was chosen 
on the basis that it may be able to form stabilising hydrogen bonds with the phosphate moiety of the 
incoming nt, if correctly orientated in motif D. Thirdly, leucine was selected due to its hydrophobic 
side chain which should exclude any water molecules from the site that could also act as proton 
donors. However none of the K377 mutants yielded infectious virus. NS7 and NS3 protein levels 
during transfection were equivalent to that of the WT (data not shown), suggesting all 4 mutations 
abolished viral replication.  
 
 
Figure 6.3. Norwalk virus and MNV contain orthologous lysine residues to 3Dpol K359. The 
conserved lysine is highlighted by the box and arrow head and amino acid numbers are given at the 
end of each sequence. * indicates residues conserved throughout all sequences, : indicates that a 
residue is functionally conserved and .indicates partial conservation of a residue. Alignments were 
performed using Clustal Omega Software from EMBL-EBI. 
 
 
6.2.2 Generating high fidelity MNV NS7 mutants: Altering structurally conserved domains 
implicated in fidelity 
The deleterious effect of mutating R77 and K377 suggested that fine tuning NS7 fidelity may require 
more subtle rearrangements in the finger domains to alter the position of active site residues 
involved in nucleotide selection. Initial sequence alignments between 3Dpol and norovirus NS7 
sequences revealed that G64 in 3Dpol aligns with E75 in MNV NS7, conserved between Norwalk virus, 
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the prototypical HuNV, and various MNV strains, Figure 6.4A. Modelling of the MNV NS7 structure, 
revealed that E75 lies within an outer finger domain (Figure 6.4B), equivalent to the finger domain in 
which G64 resides in 3Dpol (12, 316). E72 and 5 nearby amino acids in the same finger domain (V65, 
D68, L70, P72 and G78) were mutated to serine on the basis of its propensity for hydrogen bonding, 
Figure 6.4B. Recovery yielded infectious virus from 3 mutants, P1b-D68S, P1b-P72S and P1b-E75S, 
Figure 6.5A and B. The yield of recovered virus was significantly lower in comparison to P1b-WT for 
each viable mutant. Five blind passages did not generate any virus from the non-viable mutants, 
based on the absence of visible cytopathic effects and confirmation by RT-PCR (data not shown).  
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Figure 6.4. Design of MNV high fidelity mutants. (A) Sequence comparisons between norovirus and 
poliovirus RdRps. Poliovirus residue G64 is highlighted in red and aligns with E75 which is conserved 
in norovirus RdRps. * indicates residues conserved throughout all sequences, : indicates that a 
residue is functionally conserved and . indicates partial conservation of a residue. Alignments were 
performed using Clustal Omega Software from EMBL-EBI. (B) E75 lies within the fingers domain of 
MNV NS7, the same domain that G64 is found in the poliovirus 3Dpol. NS7 also takes on a right 
handed conformation. Five residues surrounding E75 in the fingers domain were mutated to serine, 
highlighted in red. K377 is also highlighted in blue. Structural modelling was performed using 
Chimera Software (UCSF), MNV NS7 PDB accession code 3NAH.  
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Figure 6.5. Recovery of MNV RdRp polymerase mutants in tissue culture. BSR-T7 cells were infected 
with Fowlpox virus expressing the T7 RNA polymerase and subsequently transfected with a plasmids 
containing the specified mutation in NS7, where expression of the genome is under control of a T7 
promoter. (A) The yield of recovered infectious virus was determined in RAW264.7 cells and 
expressed as TCID50/mL and compared to WT. The limit of detection is 11.2 TCID50/mL. 
Transfections were performed in triplicate; error bars represent the standard error of the mean. 
Significance was tested using One Way ANOVA and compared to P1b-WT with a Dunnett’s post-test, 
*** : p< 0.001. (B) Western blot analysis was performed on lysates of transfected BSR-T7 cells, to 
assess translation of NS7 and NS3. FS: an MNV mutant containing a frame-shift mutation in the 
region coding for NS7 (pT7: MNV-GFS) which serves as a negative control for recovery.  
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6.2.3 Generating mutagen-resistant viruses. 
The majority of other high fidelity RNA polymerase mutants have been isolated from screens for 
mutagen-resistant viruses, rather than having been generated by attempts at rational engineering. 
Recently, the generation of a high fidelity Coxsackie B3 virus was achieved by serial passage in the 
presence of ribavirin, aza-cytidine (AZC), MnCl2 and MgCl2 (240). This was the first paper to 
demonstrate the mutagenic effects of increasing cellular concentrations of Mn2+ and Mg2+ and each 
of the 4 mutagenic treatments resulted in isolation of the same high fidelity mutant (240). Therefore 
as an alternative approach to generating high fidelity MNV, WT MNV-1 was serially passaged in the 
presence of 50µM ribavirin, 50µM AZC, 1mM MnCl2 and 5mM MgCl2. The selected concentrations 
were the same as those used for generating mutagen resistant Coxsackie virus (240), and had no 
effect on cell viability for the 16 h infection.   
At passage 20 clonal sequencing of each population was performed (no changes were observed by 
consensus sequencing at passage 10). Coding changes were detected only in the MnCl2 treated 
population, where 3 non-synonymous nt changes were observed corresponding to A198T (G4128A), 
C305S (G4450C) and S392P (T4710C). None of these mutations had been fully selected within the 
population and all 3 occurred in different sets of clones with only 4 clones carrying 2 of the 
mutations (A198T and S392P). A198T and C305S map to the fingers region of NS7, in close spatial 
proximity to P72S, whereas S392P is located in the palm domain, Figure 6.6. 
To investigate the effect of these mutations, all 3 were introduced into the WT MNV-1 cDNA clone. 
Rescues were then performed in the presence and absence of 1mM MnCl2, as it was also possible 
that passage in the presence of MnCl2 resulted in a Mn-dependant polymerase. Infectious virus was 
not recovered for any of the mutants in the absence of MnCl2 and the presence of MnCl2 was found 
to inhibit recovery of WT virus (data not shown). Attempts were made to titre the recovery 
supernatants in the presence of MnCl2 which may allow detection of a Mn-dependent virus. 
However this was prevented by the high cytotoxicity 1mM MnCl2 over the course of 5 days for the 
TCID50. The recovery supernatants for each virus (from the recovery in the absence of MnCl2) were 
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blind passaged in RAW264.7 cells in the presence and absence of 1mM MnCl2, however no visible 
cytopathic effect was observed in either condition. Due to time constraints I was unable to attempt 
the use of other approaches or further optimisation of these recoveries 
 
 
 
 
Figure 6.6. Mapping and recovery of the mutations that arise from passage in the presence of Mn. 
(A)Three coding changes were identified after 20 passages of WT MNV-1 in the presence of 1mM 
MnCl2. A198T (top left red residue) and C305 (inner red residue) map to the fingers domain and 
C305 is in close proximity to P72S. S392 maps to the palm domain. Modelling was performed with 
Chimera Software (UCSF), MNV NS7 PDB accession code 3NAH. (B) BSR-T7 cells were infected with 
FPV and transfected with cDNA clones of A198T, C305S, S392P, WT and an NS7 mutant carrying 
active site mutation YGGG as a negative control. This was performed in the presence and absence of 
1mM MnCl2. Cell lysates were harvested and analysed for the presence of NS7, NS3 and GAPDH by 
western blot. 
 
 
Clone  + MnCl2  - MnCl2 
A198T - - 
S392P - - 
C305S - - 
WT 2.1 x 102 3.72 x 104 
NS7-YGGG - - 
Table 6.1 Recovery of viruses carrying polymerase mutations generated by passage in MnCl2. The 
recoveries were performed in the presence and absence of MnCl2 and virus was titred in the 
absence of MnCl2.The mean value is shown for the WT, n=3. - indicates that virus was not detected. 
The limit of detection is 11 TCID50/mL. 
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6.2.4 Characterising the fidelity of viable MNV NS7 mutants through tissue culture adaptation 
The viable MNV NS7 mutants D68S, P72S and E75S were taken forward for growth and fidelity 
characterisation. For an initial measurement of the fidelity, a known tissue culture adaptation 
marker in the MNV genome (an A to G transition at nucleotide position 5941) was monitored during 
serial passage. This marker reflects a lysine-to-glutamate change in the viral capsid protein VP1 (at 
residue 296) and confers tissue culture adaptation (23, 447). For the mutation to occur however it 
must be introduced into the original clonal population by an error made by NS7 and as such can be 
used as an indirect marker of mutation rate.  
In a preliminary experiment, the P1b-D68S, P1b-P72S and P1b-E75S mutants were serially passaged 
alongside the virulent MNV-1 strain (P1b-WT) at high MOI. At passage 5 the capsid region was 
amplified by RT-PCR and sequenced, which revealed a potentially slower mutation rate for the P1b-
P72S and P1b-E75S mutants, but not P1b-D68S, in comparison to P1b-WT (data not shown). For a 
more thorough comparison, P1b-P72S, P1b-E75S and P1b-WT were serially passaged 9 times at low 
MOI and viruses were titred and sequenced in between each passage, Figure 6.7. The P1b-P72S and 
P1b-E75S polymerase mutations, at nt positions 3750 and 3579 respectively, were also sequenced 
and remained stable throughout the 9 passages (data not shown). For P1b-WT, the A5941G 
transition occurred between passage 3 and passage 4, as has been previously observed (23). In line 
with preliminary observations, the A5941G transition occurred at a slower rate in the P1b-P72S 
population where it did not appear until passage 4 and did not dominate in the population until 
passage 9, Figure 6.7. In 2 independent repeats of this experiment, the P1b-E75S mutant did not 
acquire the A5941G mutation over 9 passages at low MOI, indicative of a low mutation rate.  
A second genetic marker implicated in tissue culture adaptation has been characterised as a G to A 
transition at position 2151, which translates to a valine to leucine change in NS4 (23, 447). As 
position 2151 has been shown to be under different selection pressures and may play an ancillary 
role to tissue culture adaptation to position 5941 (23), mutation at this position was followed as a 
second independent indirect indicator of polymerase fidelity. However in this instance the adaptive 
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nucleotide change was not observed at position 2151 during 9 passages of P1b-WT, P1b-P72S or 
P1b-E75S at low or high MOI (data not shown). 
 
 
Figure 6.7 P1b-P72S and P1b-E75S display slower mutation rates at position 5941, a marker of 
tissue culture adaptation. P1b-WT, P1b-P72S  and P1b-E75S were passaged 9 times at low MOI (0.01 
TCID50/cell) in RAW264.7 cells. After each passage, the nucleotide at position 5941 was determined 
by RT-PCR and sequencing. The P1b-P72S and P1b-E75S mutations, at positions 3750 and 3759 
respectively, were also sequenced and remained stable throughout all passages. RT-PCR and 
sequencing was performed in triplicate and a representative chromatogram is shown for each 
passage.  
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6.2.5 Characterising the fidelity of MNV NS7 mutants through sensitivity to chemical mutagens 
As a second measure of fidelity, the sensitivity of the NS7 mutants to different chemical mutagens 
was tested. This was on the basis that a high fidelity mutant should less frequently incorporate 
mutagenic nucleotide analogs and as such be less sensitive. This concept has been demonstrated for 
many other high fidelity mutants (84, 240, 316, 428) and may also be expected given that the MNV 
NS7 mutants were modelled on a ribavirin-resistant poliovirus 3Dpol mutant. It is necessary to test a 
number of mutagens as a polymerase mutant that is resistant to more than one mutagen is more 
likely to have a high fidelity phenotype, otherwise it is possible the resistance is specific to the 
mechanism of action of just one mutagen, which has also been observed (363).   
For each mutagen, it was firstly important to determine the non-specific cytotoxicity in order to 
select an appropriate concentration to test for anti-viral activity. Mutagen concentrations retaining 
over 80% cell viability have been most widely accepted (34). The concentration range assayed for 
each mutagen was based on concentrations shown to be effective against other RNA viruses. 
Cellular cytotoxicity was measured using the Cell Titre Blue Assay, which determines cell viability 
based on the metabolic capacity remaining to turn over the test compound reazurin. Cytotoxicity 
tests were performed over 24 h of treatment as used for the completion of low MOI MNV infections, 
which are recommended to test the cumulative impact of chemical mutagenesis over multiple 
rounds of replication (316). Ribavirin was first tested and was found to be highly cytotoxic in 
RAW264.7 cells with concentrations over 200µM resulting in 70% losses in cell viability, Figure 6.8A. 
Treatment with either 25 or 100µM produced a small but significant reduction in P1b-WT titres after 
a 24 h low MOI infection, although this may correlate with the increasing cytotoxicity, Figure 6.8A. 
Furthermore, no difference in sensitivity was observed for the P1b-P72S mutant in comparison to 
P1b-WT in these conditions (P1b-E75S was generated later and was not against ribavirin). In contrast 
to RAW264.7 cells, a second murine macrophage cell line (IC21) tolerated ribavirin concentrations 
up to 500 µM over 24 h as cell viability remained over 90%, Figure 6.8C. However treatment with 
500µM ribavirin did not significantly inhibit P1b-WT infection in IC21s (Figure 6.8D). 
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Figure 6.8. Determining the antiviral effects of ribavirin. The non-specific cytotoxicity of ribavirin in 
RAW264.7 cells was assessed over 21-24 h post treatment using the Cell Titre Blue Assay in 
RAW264.7 cells (A) and IC21 murine macrophage cells (C). Cytotoxicity tests were performed in 
triplicate, means are plotted and error bars represent the standard error of the mean.  (B) RAW264.7 
cells were pre-treated with 0, 25, or 100 µM ribavirin for 2 h prior to infection with P1b-WT or P1b-
P72S at low MOI. Virus was harvested at 24 hpi. The yield of infectious virus was determined by 
TCID50. A reduction in viral titres were observed with increasing ribavirin concentration, although 
there was no significant difference in the sensitivity of P1b-WT in comparison to P1b-P72S as tested 
by Two Way ANOVA and Bonferroni post-tests, n=3. (D) The effect of high concentrations of ribavirin 
against P1b-WT was also tested in IC21 cells, following pre-treatment and infection at low MOI. 
Inhibition of P1b-WT was not observed at 24 hpi. 
  
The mutagen 5-fluorouracil (5-FU) proved highly cytotoxic to RAW264.7 cells over the range of 
concentrations tested which reduced to around 40-50% by 24 h treatment, Figure 6.9A. This 
precluded the use of 5FU even at very low concentrations. RAW264.7 cells were equally sensitive to 
AZC, and large losses of viability occurred for concentrations greater than 5 µM over the course of 
24 h, Figure 6.9B). The anti-viral effect of 0-5 µM AZC was tested against P1b-WT, P1b-P72S and P1b-
A B
C D
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E72S, however this range of concentrations failed to significantly reduce the titre of the WT or 
mutant viruses, Figure 6.9C. 
Amiloride is a recently discovered mutagen, whose mutagenic activity is indirect through altering 
cellular concentrations of Mg2+ and Mn2+ (240). For concentrations under 100 µM, over 80% cell 
viability was retained following treatment for 24 and 48 h, Figure 6.9D. To determine if 
concentrations up to 100 µM exhibit anti-viral activity, RAW264.7 cells were pre-treated with 
amiloride for 2 h prior to infection with MNV at a low MOI, and virus was harvested at 24 h. 
However no significant inhibition was observed for P1b-WT or the mutant viruses following this 
treatment, Figure 6.9E. In summary none of the mutagen treatments could be optimised to exert an 
antiviral effect on P1b-WT and consequently could not be used to determine the relative sensitivity 
of each polymerase mutant as a measure of fidelity. 
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Figure 6.9. The effects of a panel of chemical mutagens against MNV NS7 mutants. The non-
specific cytotoxicities of 5FU (A), AZC (B) and amiloride (D) in RAW264.7 cells were assessed over a 
range of concentrations and at different times post-treatment as indicated, using the Cell Titre Blue 
Assay. 5FU was found to be too cytotoxic for use against MNV. (C) RAW264.7 cells were pre-treated 
with AZC (0-5 µM), and infected with P1b-WT, P1b-P72S and P1b-E75S at low MOI. Virus was 
harvested at 24 hpi. Treatment did not significantly inhibit any virus, nor were there differences in 
their response. (E) The effect of amiloride was tested against P1b-WT and the two NS7 mutants. 
Cells were pre-treated and infected at low MOI, virus was harvested at 24 hpi. Concentrations from 
0- 100 µM amiloride did not significantly reduce the titre of any virus. For all tests, viral titres were 
determined by TCID50, each sample was performed in triplicate and bars represent the mean with 
SEM error bars. For (C) and (E) significance testing was performed with Two Way ANOVA and 
Bonferonni post tests, n=3. 
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6.2.6 Growth characterisations of MNV NS7 mutants 
As slower replication kinetics can account for a seemingly lower mutation rate in a set amount of 
time, the growth of P1b-P72S and P1b-E75S were characterised by a multi-step growth curve 
analysis. P1b-P72S displayed similar growth kinetics to P1b-WT in the exponential phase of growth, 
albeit it with a small but significant defect in replication at 9hpi, although this was resolved by 12 hpi 
and P1b-P72S attained comparable final titres at 48hpi, Figure 6.10A. Production of P1b-P72S 
genomic RNA was significantly reduced in comparison to P1b-WT at all time points except for 24 hpi 
(as determined by quantitative RT-PCR), indicating that there may be a replication defect at the RNA 
level that is not evident in overall viral titres, Figure 6.10B. In comparison to the WT, P1b-E75S 
displayed significantly reduced growth during the exponential phase, despite attaining equivalent 
titres at 48hpi, Figure 6.10A. This defect was also significant at the RNA level throughout 48hpi, 
Figure 6.10B. 
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Figure 6.10 Growth characterisations of P1b-P72S and P1b-E75S.  (A) Multistep growth curve. 
RAW264.7 cells were infected at a low MOI (0.01TCID50/cell) and the virus titres were determined 
by TCID50 at 0, 6, 9, 12, 24, 48hpi. All assays were performed in triplicate and the average log is 
plotted ± SEM. The growth of P1b-P72S was significantly reduced at 9 hpi only (light grey stars), 
whereas P1b-E75S was significantly reduced at 9, 12 and 24hpi (dark grey stars). The limit of 
detection is 11.2TCID50/mL. (B) Levels of viral genomic RNA throughout infection. Total RNA was 
extracted at equivalent time points and genomic copy numbers were quantitated by qRT-PCR. qRT-
PCR was performed in triplicate, points represent the mean and error bars, the SEM. The defect in 
RNA levels of P1b-P72S and P1b-E75S was significant at all time points except 24hpi for P1b-P72S. 
For both viral titres and RNA levels, significance was analysed by Two way ANOVA and Bonferonni 
post-tests comparing each mutant to P1b-WT, n=3, *: p<0.05, **: p< 0.01, ***: p<0.001. 
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6.2.7 Determining the effect of altering polymerase properties on MNV pathogenesis in vivo  
The timing of this project coincided with relocation of the lab to Cambridge and during the transition 
animal facilities would not be available for the final 6 months of this project. On the basis that the 
P72S and E75S mutants had shown altered rates of mutation and replication (although more direct 
measures of fidelity were required), it was decided that small pilot animal studies would be 
performed to determine whether these altered polymerase properties could affect the outcome of 
infection in several in vivo models. Firstly, the virulence of the P1b-P72S and P1b-E75S mutants in 
acute infections was assessed using STAT1-/- mice, which are highly susceptible to infection by MNV-
1-P1b resulting in an acute lethal infection (447). This work was performed in collaboration with 
Larissa Thackray, University of Washington. 129Sv/STAT1-/- mice were orally inoculated with 3x104 
PFU of sequence-verified passage 1 stocks of P1b-WT, P1b-P72S and P1b-E75S. This dose of WT virus 
has previously shown to be lethal by 7 days post infection (dpi) (23). Here by 7 dpi, all bar one of the 
animals had succumbed to infection by P1b-WT. Infection with P1b-P72S and P1b-E75S also proved 
lethal to all mice over this time course and attenuation of virulence was not observed in this model, 
Figure 6.11A.  
To determine the ability of these mutants to establish persistent infections, sequence-verified 
passage 1 stocks of P1b-WT, P1b-P72S and P1b-E75S were inoculated into RAG1-/- mice. Inoculation 
of RAG1-/- mice with WT MNV-1 results in an asymptomatic persistent infection, which can last for 
up to 90 days during which time virus can be detected in multiple tissues and in the faeces (209). 
Again in collaboration with Larissa Thackray, RAG1-/- mice were orally inoculated with 3 x 104 PFU of 
P1b-WT, P1b-P722S and P1b-E75S with 5 mice in each group. At days 5 and 35 post infection the 
lung, liver, spleen, mesenteric lymph nodes (MLN), distal intestine and colon tissues were harvested 
and viral titres determined by plaque assay. At 5 dpi, a mixed picture of infection was observed for 
all viruses. Infection was not detected within members of each group, only 3 of 5 mice were infected 
with P1b-WT, whereas 4 and 2 mice were infected with P1b-P72S and P1b-E75S mice respectively, 
Figure 6.11B. In infected mice, wide variation was observed in viral titres in the tissues even within 
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the same virus group. As this was a small pilot study, by 35 dpi the sample size was reduced to just 2 
mice for P1b-WT and P1b-P72S and a single mouse for P1b-E75S, in addition P1b-WT failed to 
establish an infection in 1 of the mice. Whilst the highly restricted sample size precludes any 
statistical analysis, in each tissue examined P1b-P72S and P1b-E75S were detected at comparable 
titres to P1b-WT, with the exception of the distal intestine, where P1b-E75S could not be detected, 
Figure 6.11C. To investigate whether the NS7 mutants could have reverted during the course of 
infection, viral RNA was isolated from infected colon samples and was sequenced for the P72S and 
E75S mutations. At 35 dpi, the E75S mutation at nt positions 3759/3760 remained unchanged, 
however the P72S mutation at nt position 3750 appeared to display a mixed population with partial 
reversion to the WT genotype (C instead of T), Figure 6.11D.  Again as this was only performed on a 
single available sample, it is not apparent whether this reversion may occur in all mice infected with 
P1b-P72S or if reversion ever goes to completion. Taken together, the observations from this study 
would suggest that both mutants are capable of establishing persistent infections, although whether 
the mutants are attenuated regarding tissue tropism or viral titres could not be fully addressed. 
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Figure 6.11. Assessing the virulence and persistence of polymerase mutants in vivo. (A) 129 Sv/  
STAT1-/- mice were orally inoculated with a lethal dose of 3 x 104 PFU of P1b-WT, P1b-P72S and P1b-
E75S and percentage survival is shown. No significant difference was observed in lethal dose 50 
(LD50), as tested by One Way ANOVA. (B) and (C) RAG1-/- mice were orally inoculated with a 3 x 104 
PFU of P1b-WT, P1b-P72S and P1b-E75S. Tissues were harvested at days 5 (B) and 35 (C) post-
infection. Viral titre in each tissue sample was measured by plaque assay, dashed line indicated limit 
of detection. MLN: mesenteric lymph node, DI: distal intestine. No significant differences between 
mutant and WT infections were observed in any of the tissues, at either harvest day, as tested by 
Two Way ANOVA and Bonferonni post-tests to compare the mutants to P1b-WT. (D) Viral RNA was 
extracted from colon samples taken on day 35 for sequencing. The P72S and E75S NS7 mutations are 
indicated in the chromatograms. P1b-P72S showed signs of reversion to the WT genotype, whereas 
P1b-E75S remained stable.  
C3750T GA3759/60TC
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The MNV-3 strain provides a model of persistent infection in immunocompetent mice (10). To be 
able to assess the role of fidelity in this model of infection, the P72S and E75S mutations were first 
cloned into the MNV-3 cDNA clone (10), as the residues are conserved between MNV-1 and MNV-3 
strains, Figure 6.4A. The impact on growth of these mutations in the MNV-3 background were 
assessed by a multistep growth curve, and unlike in the P1b backbone, growth of these mutants did 
not appear to be compromised at the level of viral titres, in fact the replication of MNV3-P72S even 
appeared faster than that of the WT at early time points, Figure 6.12.  
 
 
Figure 6.12. Characterisation of the growth of the P72S and E75S NS7 mutants in the MNV-3 
backbone. RAW264.7 cells were infected at low MOI (0.01 TCID50/cell) with MNV3-P72S, MNV3-
E75S or MNV3-WT. Virus was harvested at indicated times post infection and viral titre was 
quantified by TCID50. Significance was tested by Two-Way ANOVA with Bonferonni post-tests to 
compare each mutant to MNV3-WT, *:  p<0.05, ***: p<0.001. Light grey stars on top refer to MNV3-
P72S and darker grey stars refer to MNV3-E75S, which were both significantly increased compared 
to MNV3-WT at early time points in infection. 
 
 
Immunocompetent 3-4 week old female (C57BL/6) mice were next inoculated orally with 1000 
TCID50 of sequence-verified passage 2 stocks of MNV3-WT, MNV3-P72S and MNV3-E75S, or were 
mock infected. On days 0-7, 14, 21 and 28 post infection, the weight of each mouse was monitored 
and faecal samples were collected, Figure 6.13A. Both groups infected with the mutant viruses were 
found to gain weight throughout the course of infection, with no significant difference from the 
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MNV3-WT or mock-infected groups (Figure 6.13B), similar to the weight gain previously reported for 
MNV3-WT infection (10).  
To determine whether the polymerase mutant viruses had established a persistent infection, RNA 
was extracted from stool samples initially taken from days 1, 3, 5, 7 (which are considered the acute 
phase of infection) and day 28, at which point the infection is considered persistent (10). The levels 
of genomic RNA were then established by quantitative RT-PCR. Viral RNA was detected in each 
group, throughout the course of infection, with the copy number peaking at days 2- 3 post infection 
(Figure 6.14A), consistent with what has previously been observed (9). There was no significant 
difference in the level of viral genomic RNA between MNV3-E75S and MNV3-WT, however a 
significant difference was observed for MNV3-P72S at days 1 and 7 post infection. At 7 dpi, the 
amount of viral RNA in MNV3-P72S infected samples was significantly reduced in comparison to 
MNV3-WT, although this difference was not observed at any other day. At 1 dpi infection the 
opposite effect was observed and the amount of MNV3-P72S was actually significantly higher than 
that detected in the MNV3-WT group, Figure 6.14A. To further investigate this significant increase, 
viral RNA was also quantified from samples taken on day 2 post infection, where a significant 
difference between MNV3-P72S and MNV3-WT was also observed although the difference was not 
as great, Figure 6.14A. Importantly, this increase was not due to differences in the inoculum of 
MNV3-P72S compared to MNV3-WT (Figure 6.14B), but is perhaps indicative of faster replication. 
This is similar to the growth characteristics observed for this mutant in the MNV-3 background in 
vitro, Figure 6.12.  
To confirm the stability of the P72S and E75S mutations throughout the course of infection, stool 
samples taken on 28 dpi were sequenced for the secreted virus. The E75S mutation was still present 
in the 5 sequenced samples and showed no signs of reversion by consensus sequencing, whereas the 
P72S mutation was stable in 4 of 5 animals but had fully reverted in one animal to the WT sequence 
(data not shown). This suggests the P72S mutation may confer a disadvantage in this model and 
could be under selection pressure, such that if a mutant with the original nt sequence is generated 
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within the quasispecies it may be selected. Overall however these results indicate that both mutants 
are able to establish persistent infections, with no apparent reduction in secreted viral titres.  
 
 
 
Figure 6.13. Characterising the persistence of MNV3-P72S and MNV3-E75S in immunocomptetent 
mice. (A) Outline of the experiment. Prior to infection mice were weighed and faeces were collected 
on day 0, following infection with 1000 TCID50 of the mutant and WT viruses, mice were weighed 
and faecal sample collected every day for 7 days post infection, and then on days 14, 21 and 28. 
Tissue samples were also harvested on day 28. (B) All infected mice gained weight throughout the 
duration of the study and significant differences were observed between groups infected with the 
mutants compared to WT, tested by Two Way ANOVA with a Bonferroni post-test to compare to WT, 
n =6. 
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Figure 6.14. MNV3-P72S and MNV3-E75S mutants can establish persistent infections in 
immunocompetent mice. Stool samples were collected and RNA was extracted for quantification of 
viral RNA by quantitative RT-PCR. (A) Data is shown for the acute phase (1- 7 dpi) and after 28 dpi 
which indicates a persistent infection. Significance was tested by Two-Way ANOVA, with a 
Bonferonni post-test to compare the mutants to WT, ***: p<0.001, **: p< 0.01, * :p<0.05, n=6. (B) 
Due to the observed increase in RNA for the P72S mutant at 1 dpi, the samples from 2 dpi post 
infection were also analysed as were the genome copies present in 1000TCID50 of each viral 
inoculum. 
 
6.2.8  Characterising the fidelity of MNV NS7 mutants by clonal sequencing 
To gain a more direct measure of the fidelity of the P72S and E75S NS7 mutants, population 
sequencing was performed on passage 5 of P1b-P72S, P1b-E755S and P1b-WT in RAW264.7 cells. For 
this type of analysis, structural regions known to tolerate variation have typically been sequenced 
A
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(34), accordingly, a region spanning the coding region for the P domain of VP1 and all of VP2 was 
cloned and sequenced. The mutation frequency (measured as the number of mutations per 10k nt) 
of P1b-P72S was not significantly different from the WT and a similar distribution of mutations was 
observed in both populations, Table 6.2 and Figure 6.15. By comparison P1b-E75S appeared to have 
a shift in the mutation distribution containing higher numbers of more mutagenised clones, Figure 
6.15. This was reflected in the overall mutation rate which was higher than that of P1b-WT, however 
the result did not display strong statistical significance (p<0.096), Table 6.2. The mutation 
frequencies fall within the high range of what is expected for RdRps, and may also be influenced by 
the error rate of the Taq polymerase used for cloning, in addition to sequencing error. It was later 
found that sequencing of a WT cDNA clone by the same method also gave a high error rate (on 
average 9.6 mutations per 10k nt), which was only 2-fold lower than those found for the virus 
populations, meaning that the virus mutation frequencies cannot be taken as absolute, however any 
differences should still have been apparent. 
 
Virus Total number of 
mutations 
Total number of 
nt sequenced 
Number of mutations 
per 10k nt 
Statistical significance 
from WT* 
WT 135 66,000 20.5 n/a 
P72S 138 74,800 18.4 p<0.464  
E75S 147 62,480 23.5 p<0.096 
Table 6.2. The mutation frequencies of the P72S and E75S NS7 mutants compared to WT, as 
determined by population sequencing. *Statistical significance was determined using the Mann-
Whitney U ranked sum test, to test for differences in the mutation distribution of the NS7 mutant 
populations compared to the WT. One-tailed test p values are given, to test the hypothesis that the 
P72S mutation frequency is lower than the WT and that the E75S mutant has a higher mutation 
frequency than the WT.  
  
Rational Attenuation by Manipulating Polymerase Fidelity 224 
 
 
Figure 6.15. Frequency distribution of the number of mutations found within each NS7 mutant 
population. The E75S mutant population was found to contain more clones with greater numbers of 
mutations compared to the WT and the P72S mutant populations. 
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 Discussion 6.3
For many RNA viruses, the existence as a viral quasispecies is thought to be important in various 
aspects of virus behaviour including pathogenesis, evasion of host immune responses and 
development of drug resistance (103, 107, 175, 287). Evidence is emerging for the existence of HuNV 
quasispecies (55, 64) and the pandemic GII.4 HuNV strains have recently been found to have higher 
mutation rates than strains from sporadic outbreaks, suggesting mutation rate may play a role in 
determining pandemic potential (55). However the importance of quasispecies diversity in acute or 
persistent norovirus infections remains uncharacterised. Such knowledge could potentially be used 
to attenuate noroviruses and elucidate other aspects of norovirus biology such as immune evasion 
and mechanisms of persistence. Here a panel of MNV NS7 mutants were designed and characterised 
towards the aim of identifying a high fidelity mutant that could be used to investigate the importance 
of norovirus quasispecies diversity and possibly lead to attenuation.  
The poliovirus 3Dpol has been extensively studied in terms of structure-function relationships, 
mechanisms of nt incorporation and determinants of fidelity.  Given the structural and mechanistic 
conservation between 3Dpol and the HuNV and MNV NS7 proteins (6, 136, 303), a rational approach 
to designing MNV NS7 fidelity mutants was first taken by targeting key residues known to control 
3Dpol fidelity. In particular, R77 was targeted on the assumption that it may play an analogous role to 
G64 in 3Dpol and remotely control fidelity through hydrogen bonding to active site residues (12). 
However, the failure to recover infectious virus from 4 different R77 mutants meant that its role in 
fidelity could not be addressed but suggested that it may play a pivotal role in the overall stability 
and activity of NS7. This was indicated by the reduced levels of the R77 mutant NS7 proteins from T7-
driven expression in the recovery cell lysates. Attempts made by our collaborators to crystallise the 
R77 mutant proteins were unsuccessful, also suggesting that mutating R77 may compromise NS7 
stability (E. Leen, unpublished data).  
K377 was the second residue in MNV to be rationally targeted as it is predicted to be orthologous to 
K359 in PV 3Dpol, which acts as a general acid catalyst in nt incorporation and influences fidelity (454). 
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Whereas mutation of K359 to arginine in 3Dpol resulted in a high fidelity mutant with slower 
replication kinetics (436), the same substitution in MNV (K377R) failed to recover infectious virus. 
K377Q, K377H and K377L mutations in NS7 also abolished replication, although this was expected for 
the latter. This finding suggests that there may be underlying mechanistic or structural differences 
between 3Dpol and NS7, despite the apparent enzymatic and structural conservation. Biochemical 
studies are now being undertaken by collaborators in the University of Pennsylvania (Craig Cameron) 
to determine the nt incorporation rate of these mutants and any other kinetic defects to determine 
why these changes were lethal to MNV and not PV. It is worth noting that this is not the first study to 
find that altering residues involved in 3Dpol fidelity can produce a different phenotype in related 
RdRps (144). 
The lethal effect of mutating key residues indicated that fine tuning NS7 fidelity may require more 
subtle rearrangements in the finger domains to alter the position of active site residues involved in nt 
selection. Through sequence alignments between MNV NS7 and poliovirus 3Dpol, the G64 position in 
poliovirus was found to align with E75 in MNV. E75 is conserved between MNV strains and numerous 
HuNVs, including Norwalk Virus and recent isolates from the currently prevailing GII.4 genotype (55). 
Modelling of MNV NS7 revealed that E75 resides in the equivalent fingers domain to G64 in 3Dpol and 
lies in close proximity to R77. Mutation of E75 and nearby residues to serine, selected for its 
increased propensity for hydrogen bonding, yielded recovery of 3 viable mutants, 2 of which (P1b-
P72S and P1b-E75S) were found to have reduced rates of tissue culture adaptation. An A to G 
transition at position 5941, which translates to a lysine to glutamate change in the region of VP1, 
confers tissue culture adaptation and attenuation in vivo. The change repeatedly occurs by passage 4 
of a virulent isolate of MNV-1 in RAW264.7 cells (23, 447).  In comparison, the A5941G transition did 
not occur until passage 5 of P1b-P72S at low MOI but then did not predominate in the population 
until passage 9. It is possible that a compensating mutation occurred to relieve the selection pressure 
exerted on position 5941, although none were detected in the surrounding P domain (data not 
shown). In contrast, P1b-E75S did not acquire the A5941G mutation during passage at low MOI, 
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which could have been due to increased fidelity but is more likely due to a significant growth defect 
(discussed below). It is also possible however that the selection pressure was no longer present 
during passage of P1b-E75S, as in later repeats of the same experiment P1b-WT also failed to acquire 
the mutation.  
It has previously been demonstrated that resistance to chemical mutagens can indicate higher 
polymerase fidelity (316, 428), however the use of chemical mutagens to study the fidelity of the 
MNV NS7 mutants was limited by the restricted tropism of MNV to highly sensitive macrophage cell 
lines. Several mechanisms of action of ribavirin have been reported, including inhibition of cellular 
enzymes and depletion of the GTP pool (188), which may have contributed to the high non-specific 
cytotoxicity observed here. Likewise 5-fluorouracil proved highly cytotoxic and unsuitable for use, 
which is perhaps unsurprising given that the cytotoxic effects of 5FU are well documented and can be 
harnessed for use against cancer (131). AZC and amiloride were found to be less cytotoxic at low 
concentrations but treatment did not reduce replication of WT MNV or the mutants. For both 
mutagens the tolerated concentrations were much lower than the range demonstrated to be 
effective against other RNA viruses (93, 240, 316). A second murine macrophage cell line (IC21s) was 
found to tolerate up to 10 fold higher concentrations of ribavirin than RAW264.7 cells, but inhibition 
of MNV replication was not observed. This suggests that either IC21 cells were not able to uptake 
ribavirin or could not metabolise ribavirin to the mutagenic triphosphate form.  
The lack of commercially available anti-norovirus agents means that there are few ways to exert a 
selective pressure on MNV replication, which can be used to indicate fidelity by the ability of each 
virus to generate escape mutations. The main agents that reportedly reduce norovirus replication are 
the alpha and gamma interferons (70), which limit viral replication through cellular mechanisms and 
are therefore unlikely to lead to viral escape mutations. One future possibility is to measure the 
ability of each virus to escape from neutralising antibody pressure, as a number of neutralising 
monoclonal antibodies have been developed against MNV (130, 252) and escape mutations have 
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been characterised (252). This may also demonstrate the importance of quasispecies diversity in a 
more physiological context such as evasion of the immune response. 
Replication rate is an important factor to consider whilst determining fidelity, as a decreased 
replication rate could result in a less heterogeneous population than a faster replicating virus in the 
same unit of time, given the same mutation rate. A slower replication rate could therefore account 
for slower rates of tissue culture adaptation at position 5941 and mask changes in fidelity. However it 
is worth noting that slower replication kinetics can be a desirable characteristic for a live attenuated 
vaccine candidate as it may contribute to attenuation (436). P1b-E75S displayed a significant growth 
defect, apparent in viral titres and RNA copy number, and it is therefore likely that the decreased 
replication rate reduced the likelihood of the 5941 mutation occurring. P1b-P72S was found to have 
comparable growth kinetics to P1b-WT suggesting that the slower mutation rate at position 5941 
was not a consequence of a slower replication rate. However it is also possible that the observed 
reduction in RNA levels generated by P1b-P72S could have resulted in a smaller pool of genomes 
from which to package and select the A5941G mutation. This is in line with more recent results from 
clonal sequencing of the P72S population, which would suggest that P72S does not have increased 
fidelity but a similar mutation frequency to WT. By comparison the E75S was found to have slightly a 
higher mutation frequency than WT and contained greater numbers of more mutagenised clones, 
although this result was not strongly statistically significant. Determination of the absolute mutation 
frequencies was confounded by the high error rates of the polymerase used for cloning, therefore 
this sequencing needs to be repeated with a system that is suitable for use with a higher fidelity PCR 
polymerase than Taq.  
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Figure 6.16. Structure of the P72S mutant compared to WT NS7. (A) The structure of WT MNV with 
motif A highlighted (green) and P72 (red). The structure is rotated from the normal right hand 
orientation to highlight these residues. (C) The P72S mutation (red) facilitates the formation of an 
additional hydrogen bond (blue) with the side chain of S251 in motif A (green), which is not present 
in the WT (B). The structure of the WT and P72S mutant were resolved by Eoin Leen (unpublished 
data). 
 
In order to gain a direct measure of the fidelity of the mutant polymerases, biochemical studies were 
recently performed by collaborators at the University of New South Wales (John Eden and Peter 
White). The P72S, E75S and WT NS7 proteins (in the MNV-1 background) were expressed and 
purified for in vitro characterisation, Table 6.3. It should be noted that that the final degree of purity 
was only 72–78 %, and the proportion of active polymerase in each preparation was not confirmed. 
The fidelity was measured using an in vitro assay that measures the rate of mis-incorporation of ATP 
on a poly-C template. In this assay, P72S was found to have a similar rate of mis-incorporation to WT, 
A
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whereas the rate was over 2-fold higher for the E75S mutant, Table 6.3. Taken altogether, the data 
thus far points towards a mild decrease in the fidelity of E75S accompanied by a significant defect in 
replication, and a defect in RNA production for the P72S mutant, with an unaltered fidelity 
phenotype. To confirm these results and for a definitive measure of fidelity, deep sequencing is now 
underway on the P72S, E75S and WT populations in both the MNV-1 and MNV-3 strains (in 
collaboration with Paul Kellam at the Sanger Institute).  
 
RdRp Average 
Concentration 
(mg/mL) 
RdRp Purity 
(%) 
RdRp Concentration 
(mg/mL) 
Mutation Rate 
(nt substitutions 
per site) 
WT 1.54 78.6 1.21 8.53E-04 
P72S 1.67 74.3 0.54 9.85E-04 
E75S 1.56 72.0 1.24 1.88E-03 
Table 6.3. Biochemical studies of the mutation rate of purified NS7 mutant proteins. P72S, E75S 
and WT NS7 proteins were expressed, purified and the mutation rate was studied by 
misincorporation of ATP onto a poly-C template in vitro. These experiments were performed by Peter 
White and John Eden at the University of New South Wales. 
 
Structural studies on the NS7 mutants, performed by collaborators at Imperial College (Eoin Leen and 
Stephen Curry), support the observation of altered polymerase properties for P72S in particular. 
From the structure of this mutant, an additional hydrogen bond was observed with residue S251, 
which is in the region of motif A and is adjacent to where nts bind in NS7, Figure 6.16. Therefore it is 
plausible that this extra hydrogen bond could alter or constrain the position of active site residues in 
motif A to influence replication rate. In contrast, no extra hydrogen bonds were observed in the 
structure of the E75S mutant, however given that RdRps are highly dynamic proteins and that the 
structure was determined in the absence of nts and template RNA, it is possible that changes in 
hydrogen bonding may not be observed in a single snapshot. Moreover, it has recently been argued 
that kinetic studies and molecular dynamics simulations are really required to gain a full insight into 
RdRp mechanisms (61).  
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Preliminary in vivo studies were performed prior to obtaining the clonal sequencing and biochemical 
data, due to constraints on the availability of animal facilities for the final months of this project. At 
that point both mutants had displayed altered replication and mutation rates, which can both result 
in attenuation in vivo (144, 428, 436). The availability of different MNV strains that exhibit biological 
diversity in mice of different immunological backgrounds provided the opportunity to examine the 
effect of these mutations in both acute and persistent infections, which should now be interpreted in 
terms of the importance of replication rate. In a lethal model of acute infection in STAT1-/- mice, both 
mutants were able to establish systemic infections with no change to lethality. It is possible that as 
STAT1-/- mice are highly permissive to MNV in the absence of type I, II and III interferon signalling, 
there may not be barriers or bottlenecks to infection and thus the need for fine-tuned replication 
rates may not be important.  
The RAG1-/- mouse model of persistent infections is highly relevant for studying norovirus infections, 
given the increasing reports of chronic HuNV infections in immunocompromised patients (140, 445). 
P1b-P72S and P1v-E75S were both able to establish persistent infections in RAG1-/- mice, which are 
deficient in both B and T cells. This would suggest that the compromised replication of the mutants, 
or the slightly lower fidelity of the E75S mutant, did not result in attenuation. The E75S mutant 
remained stable throughout the 35 day persistent infection whereas the P72S mutation showed signs 
of genotypic reversion. This was contrary to what may have been expected given that the E75S 
mutant displayed a more significant growth defect in vitro and was predicted to be under more 
pressure in vivo. Either the same growth defect was not apparent in vivo or replication rate is not 
important in this model. As this was a preliminary study and group size was very small, it is not 
possible to determine if the reversion of P72S is a representative result. Likewise, given the small 
sample size it was not possible to establish whether the mutants were attenuated in the sense of 
restricted tissue tropism. In the context of the MNV-3 strain, both mutants were capable of 
establishing persistent infections in immunocompetent mice, with no apparent attenuation in the 
levels of secreted virus. Surprisingly, the P72S mutant was in fact secreted at higher levels that the 
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WT virus at 1 and 2 dpi, potentially indicative of increased rates of replication. Higher rates of 
replication were also conferred by this mutation in the MNV-3 strain in vitro, in contrast to the 
reduced rates of replication when the same mutation was in the MNV-1 strain. NS7 differs between 
the 2 strains by only 9 amino acids, but one explanation is that the mutation has a different effect in 
each polymerase through interactions with these amino acids or other viral proteins. The inherent 
replication and mutations rates of the MNV-1 and MNV-3 polymerases have not yet been compared, 
but some insight on the mutation rate should be gained from the deep sequencing data. Again 
reversion of the P72S mutant was observed, but not within the whole group, suggesting it may 
compromise infection in some respect. MNV-3 has been shown to persist in the caecum and colon, 
where replication is presumably responsible for the levels of secreted virus (10) and thus it was 
assumed that the mutants did not have restricted tissue tropism. However it is possible that further 
dissemination of the mutants to the MLN may have been affected, although the contribution of 
replication in MLN to persistence has not been studied. MLN tissue samples were harvested at the 
end of the experiment which could now be used to address this.  
Towards the end of this project, an alternative strategy of generating fidelity mutants was employed 
by passaging WT virus in the presence of chemical mutagens, as has been successfully used to isolate 
a number of other RNA polymerase mutants. Although similar concentrations of ribavirin, azacytidine 
and magnesium were used, passage in the presence of these mutagens did not produce any changes 
in NS7, suggesting that there was not enough pressure on MNV in these conditions. Three mutations 
were identified in the population passaged in the presence of manganese, however when introduced 
into the WT MNV clone, none of the mutants recovered infectious virus. It is likely therefore that as 
opposed to generating a fidelity mutant, these mutations may confer a dependency on Mn2+. It has 
been observed for poliovirus 3Dpol that metal ion usage can be altered by mutations in the 
polymerase (89). This could not be fully tested for the NS7 mutations as the presence of MnCl2 was 
inhibitory to viral rescues and titrations. This is now being optimised to find a non-inhibitory 
concentration to potentially allow recovery of these mutants in the presence of MnCl2. Another 
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possibility is that as only the NS7 coding region was sequenced to identify these changes, 
complementary mutations may be required in other viral proteins. To address this, individual viruses 
should be now isolated from the population passaged in MnCl2 for whole genome sequencing.  
In summary, despite a number of attempts, it was not possible to generate a mutant with 
significantly altered fidelity to probe the importance of quasispecies diversity in norovirus infections 
or as a proof-of-concept that this approach can attenuate MNV. Studies are however on-going to 
definitely confirm the phenotype of the mutants described here. Besides the residues targeted in 
this study, it is likely that altering a large number of other residues could also affect polymerase 
fidelity. A recent study to generate Coxsackie virus B3 fidelity mutants targeted 18 residues and 
generated 126 mutants in total (144). Only 9 of these mutants were viable with WT growth kinetics, 
lower fidelity and attenuated phenotypes. The authors of this study not only targeted residues 
known to be involved in poliovirus fidelity, but also residues predicted from structural studies to be 
involved in many aspects of the nt incorporation cycle, such as conformational changes in motif A 
during catalysis, conformational changes in the palm and fingers domains for active site closure and 
positioning of the template RNA and incoming nt (144). With more structures of the MNV and HuNV 
polymerases now available, a similarly comprehensive study could be performed for MNV. For 
example, the structure of the Norwalk polymerase was captured in the catalytically active closed 
conformation with template RNA and the incoming NTP. This structure identified the conserved 
residue Arg182 of motif F as forming multiple hydrogen bonds to phosphate groups of the bound 
NTP, suggesting it stabilises the triphosphate moiety during catalysis (464) and may represent an 
interesting target to alter fidelity in a similar manner to Lys359 of 3Dpol. Similarly more studies on 
RdRp fidelity mutants have recently been published identifying novel residues involved in fidelity, 
many of which are functionally conserved. For example A372V confers high fidelity to Coxsackie 
virus B3 (240) and has a functionally analogous residue (I388) in MNV, which could be targeted. As 
seen within this study, targeting conserved residues will not necessarily generate the same 
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phenotype in different RdRps, but has the potential to provide further insights into the mechanisms 
of polymerase fidelity and replication and potentially lead to rational attenuation.  
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7. Summary and Future Directions 
Our understanding of the norovirus lifecycle lags far behind that of other RNA viruses. Although 
studies largely with MNV have begun to unravel the molecular mechanisms that govern each stage, 
including the interactions of norovirus with the host cell, much remains to be characterised. For 
instance it is fair to say that the function of 5 of the 9 viral proteins has yet to be fully determined. 
Characterising the function of the viral proteins and their interactions with host cell proteins is 
central to the long term rational development of antivirals and may contribute to rational 
approaches to attenuation. For these reasons the main objective of this study was to identify the 
regions of the viral genome and proteins that are essential for norovirus replication and to 
investigate the function of some of the uncharacterised viral proteins through the use of tagged 
viruses. This was with the aim of identifying interactions of the different proteins with host cell 
factors that may be essential for replication and could provide novel targets for antiviral 
intervention.  
The transposon-mediated insertional profiling represents the first functional study of a complete 
norovirus genome. This approach revealed the essential regions of each viral protein that must be 
intact for replication to be unaffected. For some proteins such as NS1-2, NS4 and VP2, large regions 
of the protein appeared to be essential, suggesting they may contain important functional domains 
or structural domains, such as the transmembrane domains identified in NS1-2 and NS4. Having 
identified these broad regions, more focussed site directed mutagenesis could now be applied to 
further characterise the function of role of each region in replication. For example it may be 
interesting to search within these regions of NS1-2 and NS4 for cellular localisation signals, to 
determine which organelles they reside in and whether localisation is essential for the role of each 
protein in establishing the replication complex. This approach also allowed the importance of known 
functional motifs to be probed, such as the helicase motifs in NS3 which all appeared to be required, 
and the caspase cleavage sites in NS1-2, of which only 1 was essential, which is cleaved by an as yet 
unidentified cellular protease. The mutagenesis was also applied to known RNA structures within the 
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3’ end of the genome. A number of studies are on-going in the lab to identify and determine the role 
of RNA binding proteins in norovirus replication and the mutagenesis data could contribute to 
mapping of the binding sites of cellular proteins. This use was demonstrated by the observation that 
insertions in the known RNA binding site of cellular protein PTB compromised replication.  
The 15 nt insertion libraries provide a useful resource that could also be used for further studies. For 
example infections of the libraries in vivo could be used to determine and compare the essential 
regions that are required for replication in either acute or persistent infections. The libraries have 
been generated in the MNV-1 background which is suitable for studies of acute infections so to 
study persistent infections transposon mutagenesis would also need to be performed on the MNV-3 
strain. For other viruses, in vivo characterisation of 15 nt insertion libraries has led to the 
identification of attenuating insertions that provide potential vaccine candidates (35). Requests for 
the 15 nt insertion libraries from others in the field suggest that they may have a wider contribution 
to studies on different aspects of norovirus replication and infection. 
Identification of over 300 tolerated insertion sites provided the opportunity to engineer the coding 
sequences for epitope tags into several tolerated sites to successfully generate the first epitope 
tagged noroviruses. Infectious viruses were generated carrying the FLAG tag in NS1-2, NS4 and VP2, 
selected as proteins which have not yet been fully characterised, although sites in other viral 
proteins could now be trialled. The FLAG-tagged viruses have also been requested by collaborators 
suggesting that they too may be a useful tool for the field in studying norovirus replication and 
protein function. 
The FLAG tag facilitated microscopy to show that all three proteins localised to the replication 
complex in infected cells. More detailed studies could now be performed to determine if these 
proteins localise to particular cellular organelles at different time points during infection. For NS1-2 
and NS4 this may give an idea of how they recruit cellular membranes for formation of the 
replication complex, and for VP2 this may indicate if it plays other roles in the viral lifecycle, as is 
thought, in addition to stabilisation of the capsid. The ability to immunoprecipitate the proteins via 
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the FLAG tag enabled SILAC-based proteomics to identify cellular interaction partners starting with 
NS4 and NS1-2. An initial experiment with NS4 identified a selection of cellular proteins, indicating 
the potential of this approach to identify cellular interaction partners that may play a role in 
replication and could reveal the function of NS4. However further optimisation of this approach is 
required to be able to validate the interactions by independent methods. With small optimisations a 
greater number of proteins were identified with NS1-2. Further studies are required to validate and 
investigate the interaction of NS1-2 with these proteins to determine a function. However the 
interaction between NS1-2 and cellular RNA helicase protein DDX3 could be validated by western 
blot. DDX3 was previously found to interact MNV genomic RNA and also VPg (L. Chung unpublished 
data and (424)), so whether the interaction with NS1-2 is direct remains to be confirmed, but this 
data indicates that the SILAC approach can identify proteins involved in replication. Previous studies 
found that inhibition of DDX3 activity with small molecule inhibitors reduces MNV replication, as has 
been observed for HIV (141). This demonstrates the potential of this approach to identify essential 
cellular interaction partners that may represent novel targets for antiviral intervention. The benefit 
of targeting cellular proteins to inhibit replication of RNA viruses is that treatment is less likely to 
result in generation of resistance or escape mutations in the viral population.  
The small size of the epitope tag sequences appeared most suitable for insertion into the MNV 
genome and despite a number of different attempts infectious MNV carrying a larger reporter 
protein could not be isolated. It is possible that the failure to isolate a reporter-tagged virus could be 
attributed to using only a selection of the tolerated sites and perhaps not in the right combinations 
with reporter proteins, although more sites were trialled here than for other tagged RNA viruses 
using the same approach (4, 409). A wider approach was also used to engineer GFP into the insertion 
libraries, although this also failed to yield an infectious GFP-tagged virus. This library-based approach 
could be further optimised to increase insertion site coverage using GFP-inserts engineered to be in-
frame for every site in combination with the RNA reverse genetics system for increased efficiency of 
recovery. It is also possible to directly insert GFP using a transposon that carries the coding sequence 
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alongside a selectable marker that can later be excised (276), which may provide an alternative 
broad approach. The insertion libraries could also be used in combination with a smaller reporter 
protein such as split GFP, which may circumvent the possible disruption of GFP to viral proteins due 
to its large size. An alternative option to tagging viral proteins may now be to tag the viral RNA with 
an RNA aptamer, named Spinach, which binds to and activates an exogenous fluorophore (305). 
Insertion of Spinach into tolerated sites in the 3’UTR could now be trialled. The possibility of making 
insertions in the small MNV 3’UTR has previously been excluded due to the large size a reporter 
construct requiring an IRES. Work within the lab has recently shown that a site in the third stem loop 
of the 3’UTR can tolerate insertions of up to 300 nt (S. Vashist, unpublished data), suggesting that 
although this is not sufficient for an IRES-reporter construct, the 90 nt of Spinach may be 
accommodated. However it is known that insertion at this site is likely to result in attenuation in vivo 
by interfering with interactions host cell binding proteins (22), so other tolerated positions should 
also be tested. It will also be important to determine whether the Spinach aptamer will be able to 
fold correctly within the context of the viral genome into a conformation in which it can bind the 
fluorophore to allow fluorescent labelling of the viral genome.  
The second half of this thesis was focussed on determining the potential of rational approaches to 
generating live attenuated noroviruses. Studying such rational approaches to attenuation can also 
give information on what is involved with or necessary for norovirus replication. The first approach 
was based on harnessing the cellular miRNA machinery to restrict norovirus replication by 
engineering cell-specific miRNA target sequences into the viral genome. This approach was also 
facilitated by identification of tolerated 15 nt insertion sites by the transposon-mediated 
mutagenesis performed in the first chapter. The site in NS1-2 that tolerated insertion of the FLAG 
coding sequence was also found to tolerate insertions of perfect and imperfect miRNA target 
sequences in the positive and negative sense genomic RNA. The miRNA selected for use against 
MNV (miR-467c) was highly expressed only in BV-2 cells and as such all viruses carrying a 
corresponding miRNA target sequence displayed reduced replication in BV-2 cells compared to a 
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second permissive cell line (RAW264.7 cells), which did not express miR-467c. This result highlighted 
the potential of directing the miRNA machinery against MNV to inhibit replication and suggests that 
this approach could lead to attenuation of MNV in vivo. Further in vitro characterisation is first 
required to demonstrate the specific nature and mechanism of inhibition and whether it is through 
cleavage of perfectly complementary target sequences and translational silencing of imperfect 
sequences, as is known to occur for cellular miRNA targets. If a specific involvement of the miRNA 
machinery can confirmed then in vivo studies of the viruses carrying the miRNA targets sequences 
could be performed in both the acute and persistent models of infection. This would be the first 
study to investigate whether this approach of harnessing miRNA machinery could be applied to a 
persistent virus to generate a live attenuated vaccine. From the perspective of norovirus infections, 
it would also allow the importance of replication in macrophage and dendritic cells to be established 
for maintaining persistent infections.  
In studying miRNA expression for this approach, the changes in miRNA expression resulting from 
MNV infection were also characterised in each permissive cell line. This revealed a number of 
miRNAs in each cell line that were either increased or decreased with infection, suggesting they may 
either form part of an innate antiviral immune response against MNV infection or could contribute 
to the viral lifecycle. Further studies are now required to investigate the involvement of each miRNA. 
To establish whether these changes are physiologically relevant, the changes in miRNA expression 
could be profiled in primary cell lines or infected versus infected tissues, which is possible by the 
Taqman based RT-qPCR array approach. This data could also be compared to changes in miRNA 
expression resulting from HuNV replication in the replicon cell lines or following transfection of 
HuNV RNA. Identification of the targets of any miRNA that can be confirmed to play a role in 
norovirus replication, may also reveal cellular protein factors that contribute to the virus lifecycle or 
that are involved in the norovirus immune response. For other viruses, changes in miRNAs have led 
to identification of factors that facilitate replication (82), and may represent potential antiviral 
targets alongside the miRNA itself. 
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The second rational approach to attenuation was centred on manipulating the replicative properties 
of the viral RNA dependent RNA polymerase, in particular altering fidelity. For a number of other 
viruses, the fidelity of the viral polymerase has been fine tuned to strike a balance between 
maintaining genomic flexibility and sequence conservation. Thus alterations to polymerase fidelity 
and quasispecies diversity, through mutating key polymerase residues, have been shown to 
attenuate RNA viruses (84, 428, 436) . However despite targeting a number of residues and regions 
of the polymerase that have been shown to regulate fidelity in other conserved RNA virus 
polymerases, MNV mutants with altered polymerase fidelity could not be isolated. It is possible 
therefore that much larger mutagenesis of the polymerase is required to obtain mutants with 
altered fidelity phenotypes.  Whilst the only viable mutants from this study, P72S and E755, did not 
appear to have altered fidelity they did have altered rates of replication, which has shown to be a 
contributing factor in the attenuation of other viruses (436). However P72S and E75S mutations 
were not sufficient to confer attenuation in several in vivo models of infection but partial reversion 
of P72S was observed following an increased replication during the initial stages of persistent 
infection in immunocompetent mice. Further larger scale studies are required to determine whether 
increased replication is therefore unfavourable for the maintenance of persistent infections and may 
drive reversion, at what stage reversion may happen or if indeed it occurs at a higher frequency in 
infected mice.  
Studies are on-going in the lab to identify other MNV polymerase fidelity mutants, not only as an 
approach to generating attenuated vaccine candidates, but also to be able to probe the importance 
of quasispecies diversity to acute and persistent infections, which could not be assessed here. With 
reports of pandemic HuNV strains having higher mutation rates than non-pandemic strains (55), this 
investigation is highly relevant to HuNV. Finally, obtaining a mutation that confers increased fidelity 
could be used to stabilise viruses carrying exogenous sequences, such as miRNA target sequences to 
decrease any likelihood of reversion, for a combined approach to attenuation.  
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9. Appendices 
 Appendix 1:  Primer pairs used for 15 nt insertion profiling 9.1
Library   Fragment Genome region Forward Primer Reverse Primer 
1.NS1-2 1 1-390 1F 
(GTGAAATGAGGATGGCAACGCCATCTTCTGCGCCC)   
390R  (CACAGGCTCCTTGGCATCCATAGC) 
 
 2 289-670 289F  (CGTGGCTACGGCTGGACATGTC) 670R (CCAGGTGTCCTTGATGCCAACAATCC) 
 3 542-929 542F  (GCTACACCTCTGGTGGCGGCCTG)   929R (GCTCAGCAAGCAAGATCAGGGCATTG) 
2.NS3/4 1 740-1139 740F  (CGTCCAGGACTGGAACGTCGACC) 
 
1139R  
(GGCGAACTTGCCCATCTCTTGGGCGGCCTT 
GAGAGCC) 
 2 1030-1424 1030F (GGCCCTTCGACCTTGCTCTTGACG) 1424R (GGGCCATGCTGATCCTGGCCAGC) 
 3 1320-1710 1320F (GCAGGGGCTGAATTCCTAAGGTCC) 1710R (GGGCACGTGTCGGCAAGCATCTG) 
 4 1608-2000 1608F (CCACGCGCTGATGTCGACCACTGGGATGC) 2000R (GTGTTTCCCTGACGGTCAAAG) 
 5 1899-2284 1899F (GATGATGCTCGGGCCAGAGCCCCTGG) 2284R ( GGCACCATTGTAGATCACCTGACAGG) 
 6 2180-2579 2180F (CGCCGGCATTCCATGGTACAAAATGG) 2579R 
(GGTACCACCCATCATCGTCATCCTCAAAG) 
3. NS5/6/7 1 2463-2852 2463F (CTGCAGGCGGCCGGCACGGCC) 2852R (CCAGGCCCAGTTTGGCTCTCTCTGCC) 
 2 2750-3142 2750F 
(CCTCGCTGACCGCGAGCGAGAAGAAGAACTCC) 
3142R 
(GGTGAAGTAGTACTTCAAGAAGTCCCCGC) 
 3 3045-3439 3045F (GTGAGCGGCCACGTCTTCATCACCG) 3439R (CCACGTGCACCCCAATCACAACCC) 
 4 3335-3728 3335F (GCAAACTGGCATGCTCCTGACTGG) 3728R 
(GAATAGGGCTTAAGCTGATCTCGCATGACC) 
 5 3625-4012 3625F (CCATGTTCTGGCGTACCTCGCC) 4012R (GGCAGCTGTATAAATGGGTCGCATGG) 
4. NS5/VP1/  1 3848-4244 3848F (GAAGCCCTGGACATTTAAGAAGGCTTG) 4244R (GCATCCATGTGGTACCTGAAATTG) 
VF1 2 4143-4539 4143F(GGCCCTTTCTGTGATGCTCTGAAAG) 4539R (GGAGAACTCAGATTCTTGCATCAC) 
 3 4439-4835 4439F (CCCATCCGGCTGCCCTTGCACCACACAGC ) 4835R 
(GGGAGGGTCTCTGAGCATGTCCAGGG) 
 4 4734-5129 4734F (GGTGACCAGTTTGGGTGGTACGGTCG) 5129R 
(GGTTGAATGGGGACGGCCTGTTCAACGG) 
 5 5024-5414 5024F (GACCCCGCAGGAACGCTCAGCAGTC) 5414R (GTACAAGGGCAACAACCACCTTGC) 
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 6 5311-5706 5311F (CCAGGGCTTAACCCCTACCTTGCC) 5706R (GGTTCTCTCTATGGGGGGAGTTAGG) 
 7 5607-5923 5607F (GCTGTACACGCCACTCCGCACAAACAGCC) 5923R (GGAACTCATAGGCAGCCTCCGCCGC) 
5.VP1/VP2/ 1 5666-6060 5666F(GCCTTCTTTCTAAGCCGGCGGCTGATTTC)  6060R (GGTCTCGGTCTGGACCTCGATCTCC) 
3’UTR 2 5958-6356 5958F (CGGTGAGGTGGCGACATTCACCC) 6356R (CCTACATGCGTCAGATCGACACC) 
 3 6256-6646 6256F (CGGTTTTCAGGACACCATCCC) 6646R (CGGCCTGTTGCCAAACTTCC) 
 4 6546-6931 6546F (CGCCTTGTCTTATTCCGGCTCAGG) 6931R (CGTTCTCCTGGGCCTGCGCCTGGG) 
 5 6831-7239 6831F (GCCCAGAAGGATCTCACTCTGATGG) 7239R (GGTGCCTTGAGTCGCCGGCGTATGG) 
 6 7114-7400 7114F (CCCCAACCTACACTCCAGGTAGG) 7400R  
(TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTAAAAT 
GCATCTAACTACCACAAAG) 
 
Appendices 271 
 
 Appendix 2: Insertion profiling across the MNV genome 9.2
Insertions detected prior to selection (input) and after each passage (P1-P3) are shown. The 
numbers given for the insertions at each stage refer to the fluorescence intensity (arbitrary units) of 
the corresponding peak detected by capillary electrophoresis. 
 
Genome Position (nt) Input P1 P2 P3 
57  934 1049 1047 
62  2082 2763 3408 
65 545  8017 10462 
66  1009   
68 447 2894 3129 7417 
70  510 408  
72  459   
73  20633   
74 4472 14472 10240 9249 
76  421 750 1487 
78 1020 13374 17063 23265 
80   982 1316 
81  1204 1200 1447 
82  1236  3244 
84 4358 26905 23451 31032 
86  492  423 
88 570 854 720 853 
90 2640 16933 12153 15873 
93 1922    
95   489  
96 5162 401   
97   433  
98  846 543  
100 484    
101  456   
103  472   
104 823    
105  2377 426  
108  662   
110  531   
111 1166    
112  1376   
113 980 4926 939  
115  7374 2153 987 
117 621  533  
119  8083 1242 588 
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120 1751 2857   
121  5542 824  
124 2287 2498 811  
125   1604  
126   1525  
128 689 942   
131 1271    
132  441   
134 2020    
144 1067    
145 1747    
146   505  
147   481  
148 3500  501  
149   499  
152 2594    
153  673   
154 6922 631 924 1155 
155    442 
156    456 
157 634    
159 1078 3438 3316 2050 
160  770 656 498 
162 755 12612 5695 2972 
164 1159 18945 9777 15353 
172  439   
176  12449  1455 
177   454  
181    1247 
185  2240 1078 480 
195  701 1923  
233 1774    
236 771    
250 442    
253 415    
255 2068    
259 1264    
261 476    
264 6586    
266 4327    
268 935    
270 1342    
272 2548    
273  1117 400 775 
275  730   
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283 461    
285 477    
287 10196    
289 3231    
293 991    
295 477    
300 7771    
303 664    
306 561    
307 3517    
310 13321    
313 4319    
314 904    
318 1522    
323 553    
335 1566    
338 8074 7034 3824 4880 
342 430    
343    425 
344   413 752 
347    562 
350  631 445 1097 
352  1153  939 
353 568   13914 
354  5088 5598 10144 
358  787   
362  3211 417 8770 
363  3958 5899 8669 
364 463 4641 3587  
365   4542  
367  965 926 1053 
368  1302 565 811 
369   1418  
370   579  
371  1073 1504 1542 
372  2032 3586 2055 
376  2021 1175 796 
377  947 479 597 
378  556 1264 433 
379  865 1367 1122 
380  6496 1677 7877 
381 1236 9602 6672 12768 
382 407 19292 19676 23352 
386  417 763 531 
387  687 774 750 
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394  5940 6719 6103 
395  7516   
397  5077 1576 2166 
400 429 6197 3223 1826 
403  3798 1022 2043 
404   6055 2641 
405  12146   
414  566   
416 411    
418  571   
427 2290  423  
433   946  
444 405    
445  671 1671 531 
453 1307 1399   
456 1071    
460 6586    
462 945    
471 1570    
473   751 464 
488 588    
490 485    
494 435    
503 954    
520 824    
537 9803    
540 1877    
541 650    
553 441    
576 2223    
585 1786    
592 1586    
596 2592    
599 2048    
602 1763    
607 474    
609 4847    
611 7125    
612 3104    
614 3953    
615 798    
617 532  436  
618 2757    
620 1823    
621 1212    
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622   528  
623 839    
626   588  
627 8030  472  
629 9436 413   
631 2820 516   
632 614    
633 1852 509   
636 486    
639 4067    
641 2528    
643 13030 467   
644 8761    
646 851    
647 950    
651 1017    
652 1101    
653 462    
654 1022    
656 2915    
657 3608    
663 651    
664 681    
666 2025    
667 1455    
668 3678    
669 2010    
674 413    
677 7196    
679 498    
683 1431    
686 480    
689 1732    
693 2408    
698 2160 404   
701 451    
703 2141    
707 819    
717  819   
723  3019 4507 915 
724 1088    
727 549    
732 793    
735 2114    
741 3602    
Appendices 276 
 
745 2887    
752 403    
757 433    
766 6572    
777 1035    
782 3793    
786 597    
792 11579 470   
793  470   
798 2395    
801 578    
803 5652    
808 609    
813 419    
816 9535    
819 3444    
825 1725    
827 11738    
848 729  763  
855    830 
857    625 
858 1393   641 
860 3735 3308   
862    1086 
865  2118   
866 2564 9088   
869 1437 1382   
874 970    
888 711    
894 1821    
895  648   
900 1009    
904  1722 824  
905 1587    
907 1234    
911 943    
921 14711 7561 5450  
928 1957    
931 1852    
936   1104  
937 6520 4884   
939 12425 9725 1304  
948 13716 9206   
952 8600 3837 2085  
961 8727 7854 11523  
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963 1708  3830  
971 3441 4656   
976 1339 4344   
980 5227 11358   
982 6674 4427 4590  
987 3181 3256   
990 2042    
993 2988    
995 11639 2901 3083  
999 907    
1004 5068 4124   
1005   2301  
1008 686    
1010  8678 5064  
1011  6144   
1012 28318  7226  
1021  1138   
1026 606    
1037 1268 969   
1043 736 2588   
1047 7907 7875 7211  
1049 3719    
1050  877   
1052 3309    
1053  5220   
1055 2404    
1056  6017   
1060  3399   
1061 3389 9641 2530  
1064  3768   
1074 1499    
1079  3340   
1080 3757    
1082 702    
1084  4692   
1085 1611    
1087  1255   
1088 4000   918 
1091 7784 2272 2968  
1092   1061  
1093   2067  
1096 2205    
1097 1076 7123  896 
1098  5559   
1099   2292  
Appendices 278 
 
1100 1985 6247   
1101  2185   
1102  3888  21070 
1103 2757 2257   
1104  1029   
1106 796    
1107 1160  751  
1108 2493  2196 2203 
1109  816   
1110 1036 2186   
1111 1653  600  
1112 1906 1828 1101  
1114  620   
1117    1855 
1127  1036   
1128 745 2057   
1129  2320   
1130 1518    
1131  1114   
1132 2199    
1137 800 1556   
1142   831  
1144  819   
1161    1166 
1171  1598   
1172 876 641 2089  
1175 2957 1000   
1178  891   
1182  782   
1184  1772   
1187 632    
1189  2650 913  
1199 776 665   
1204  2713   
1205 4225  1101 2068 
1210 756 1010   
1217  3298   
1219 1298 2477   
1221 1489    
1226 718    
1228 816 3865   
1232 3249 870 1343  
1237 616    
1239 829    
1241 1145    
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1245 2718 3826 3603  
1248 832    
1251 16063 11034 4011  
1255 652 648   
1256 839 2584   
1261 740    
1264 1505 783   
1268 665 644   
1274 1443    
1276    938 
1284    14601 
1285 28951 13830 16537  
1288 1165 5857   
1292 1000    
1297 2735 3064   
1299 3139 3161   
1309 879    
1310  1087   
1311 1891 1203   
1312  602   
1338 753    
1346 1028    
1348  622  1964 
1349 1860  769  
1352 6405 9104 2059 1083 
1354 10771 4590 4650  
1356    743 
1357 2480 2838   
1358   1683  
1361  1164   
1362 1988    
1363  601   
1369  605   
1370 2789 1750 695  
1372  745   
1384    801 
1385    616 
1387    685 
1388  694   
1395  1420  738 
1396  733   
1399   613  
1400 840 1113  1239 
1401  898   
1402   2404  
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1403   701  
1404  1170 2088  
1405   1752 1625 
1408   2584 1114 
1410 1324 632   
1415 2138 1538  982 
1418 6483 2333 2699  
1419   1006  
1422 622 1483   
1427 1950 1567   
1428    676 
1436 613    
1441    724 
1442 809    
1447 620   635 
1467 856    
1473 613    
1482  1298   
1486 1202 2771   
1492 1395    
1497 892    
1500 620 671   
1503 877    
1509 2641 5344 1503  
1514 2359 1885   
1516 642    
1524 651    
1531 737    
1535   656  
1540 973    
1546 643    
1549 1053    
1557 3827 2412   
1560 752 1821   
1579 985    
1581 4793 4598   
1582  1242   
1585 2804 3099 2225  
1588 871 1529 821  
1593  940   
1595 5112 3304   
1597 1643  2472  
1598 4427 5623   
1599   613  
1605 2969 6780   
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1610 1773 1448   
1611  3636   
1612 2997 797   
1617  1050   
1618 1742 1413 787  
1623 780 3768   
1627 2137 2130 1453  
1630 5655 8868   
1631   1362  
1633 1397    
1639 1900  1182  
1642 2660 6350 1203  
1643    1084 
1644 1179    
1645  3599   
1650 3772 2001   
1663  16115 2623  
1664 31727    
1669    3239 
1671 2708 1319 3984  
1673  2379   
1674 4134 663   
1677 3323 2291   
1679  3217   
1680 5497  1278  
1681 1223 1500   
1683 1731 1373 1102  
1686 11941 2266   
1687  13125 9951  
1688 17247 17454 4806  
1690 8091 4967 3842  
1691  8847   
1692 7648 7692   
1693  1627   
1694  1818   
1695 1722    
1698   1347  
1699 946    
1701 2840    
1702  762   
1703 5875 868   
1704 887 740   
1705 1677    
1709 809    
1711 1311 633   
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1714   1320  
1717 648    
1720   660  
1721 5205    
1722  2405   
1724 602 684   
1726  940   
1729 3787   4423 
1730  3698   
1731   1451  
1733 3530 2648   
1738 895 1129   
1742 1972    
1743  2992   
1746 1512  1546  
1749 1558    
1750  1277   
1752 4326 3337   
1753  3293   
1754 3015    
1755  1838   
1758 703    
1764 817 1339   
1765 1436 857   
1766  909  637 
1767 5395 2166   
1769   898  
1780 1006 3010   
1784 1624    
1786 20355 7727 3714  
1788 13069 8205 4985  
1791 3104 1861   
1792  3901   
1797 2069 1159   
1798  3054   
1800 5839 1844   
1801  4222 3542  
1804 24206 16274   
1805   3726  
1806 940    
1811 929 1561   
1821  1826   
1822 9828 7040 2828  
1824    5255 
1828 914  642  
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1830 8344  1425  
1831  3848   
1832  3373   
1841 1671    
1844 733    
1847 10281 6580 1804  
1876 2071 781   
1878  2029   
1886 1672 1327   
1894  1318   
1895 2316 1188   
1900 2124    
1901  1817   
1904 1105  1148  
1908  1547   
1910 8242 4964 1060  
1911  2613   
1914 771   1557 
1919    641 
1923 1109    
1927 612 1234   
1928    1501 
1930    2290 
1932 1830   31656 
1933  774   
1937    964 
1938 7251 8197 3477  
1941 1681 815 730  
1947 870    
1950 1921 1615   
1953 2050 1439   
1956    701 
1959 720    
1962 2257 1811   
1965   1345  
1966 4039 4572 729  
1968 2597    
1969 4115 1539 706  
1971 1663 875   
1974 1158  754  
1976    1397 
1979 930  889  
1982   1530  
1984  706  1087 
1985    643 
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1986 5801 3790 723  
1988 1075 1251  664 
1989    1362 
1990  622   
1991 652    
2006 1460    
2009 1181    
2012 626   1059 
2015    812 
2016    646 
2019    939 
2024 3712 6010   
2025  758   
2026  4230 1101 9856 
2027 4235  1252  
2031 1648 1858   
2032 1181    
2033  3270   
2038 958 723   
2042 3184    
2048  2269   
2052 3589 1334   
2057 821    
2060 1229 1892   
2064 696 3982   
2068   623  
2069  1219   
2070 1243 1018   
2072 1118    
2078 1411    
2081  833   
2085 640    
2087 3873 6869   
2091 7117 4463 4979  
2094 1465 3567   
2097 935 631   
2100 5265 4009   
2103 1514  2003  
2106 704    
2111 1588    
2114 637    
2118 2970  613  
2120 2642 1879 631  
2130  6151   
2131 5816 9493 1291  
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2134 1423 3785   
2140 1215    
2141 712 1377   
2144 3977 1318   
2145    697 
2146   792  
2149   1568 6630 
2150  1169 8383  
2157 2736 2074   
2159 1273 1128   
2165   704  
2166  1544   
2169 1463 1060   
2171  997   
2172 1263    
2177   2968  
2187  3457 3157 1217 
2190 2450 1029   
2193 3635 2154   
2203 603    
2206 666 841   
2213 1860 2938 698  
2215  2481   
2216  1006   
2220 934    
2227 1636 1451   
2229 771 1084   
2232 1711    
2233  2279   
2237 2816 2300   
2239 838    
2240 843    
2241 6859 1255   
2242 13922 8819 7817  
2244 1503  1188  
2245 2259 1266   
2248 919    
2249    678 
2250 693    
2252 662    
2253    724 
2261  971   
2264 4486 1706   
2267 770 2801 939  
2268   1615  
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2269   680 1569 
2270 829 1320   
2272 643 1922   
2273 1788    
2274    1839 
2275 1473 4578   
2277 1754    
2282 10811 4955 858 638 
2283 5197   8598 
2284  12374   
2286 4087    
2288 5429    
2289  1076   
2290 1412    
2295  724   
2298 4495    
2301 1960    
2304 9855 999   
2307    711 
2309 5686 917   
2312 7884    
2319 941    
2321 2887    
2326 1578    
2331 1591    
2342 4654    
2346 1037    
2358 3414    
2362 677    
2366 858    
2368 720    
2376 3417    
2377  880   
2389 3355    
2393 826    
2395 1446    
2397 6329    
2401 2235    
2402 2153    
2403 2226    
2423 1321    
2429 769    
2432 2244    
2435 2173    
2444 856    
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2447 1332    
2450 702    
2452 1556    
2455 1056    
2461 2304    
2497 3508    
2500 1738    
2505 927    
2507  707   
2514   1224  
2519  2093   
2521  2203 1165  
2522  31303  744 
2523 4031 1771   
2527  638   
2530  1722   
2531  1686   
2534 2346 3633 31588 30154 
2536  1397   
2539 1128 1344  1375 
2541  16652   
2542 5205 1303 31236  
2543  1440   
2546 755    
2549 1337 1515   
2554 2709 32037 32599 30948 
2557 2588  1082  
2560 3143    
2561  679   
2566 5616 10280   
2573 6167    
2574   1414  
2579   1249  
2582 768    
2583  4506 1994 1237 
2584 801    
2585   2565  
2586  747   
2588 2951    
2590   2487  
2591 5852  1762  
2592  1143  751 
2594 893 1054 1253 782 
2596  2278 2309 1627 
2598 2104   1805 
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2600  32192 32125 31617 
2601 6348  2311  
2604 844  652 854 
2605  798   
2606 2244    
2612 13804    
2615 786  1022  
2616   1015  
2617 708    
2619  4899 3488 671 
2621 695 5262 5074  
2622   7196  
2623 7594  675  
2627 4012 25267 22560 3788 
2630  624   
2631   735  
2632   1677  
2633  711   
2634   2780  
2637  1862 1486  
2638  734  855 
2639 642    
2654 729    
2655 728    
2661   779  
2663 815    
2665 694    
2673 691    
2676   1675  
2681 1379    
2683   937  
2685 6358  735  
2687 932    
2693 10953    
2695   3720  
2702 3510    
2710  908 969  
2711  1091 850 641 
2712 1161    
2713   1352  
2723   6058  
2726   1112  
2730 1359    
2736  1525 4678 1146 
2738 1873 679 700  
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2742 1199  1173  
2745 631    
2746  3127   
2749  1111 2430  
2751 858  3855  
2753 4447    
2757 2823    
2758   1568  
2760 1306    
2782   1105  
2783 2214    
2788 1373    
2795 872    
2798 1102    
2805 1127   948 
2807 1429    
2810 16750    
2811 5333    
2813 670    
2817 6020    
2820  623   
2822 5495    
2823 1500    
2826   604  
2828   2102  
2829  2219  1434 
2830  3167 2146  
2831  3995 3686  
2832  4295 3168 2039 
2833 2312 16289 16699  
2834  31255  26659 
2835  1140 990 1427 
2837  21498 20335 2431 
2838 1953   2012 
2841   658  
2843 17819    
2844  668   
2847 10581    
2852  6235 6778 6046 
2857 684    
2868 4354    
2879 1116    
2881 989    
2883 2188    
2885   645  
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2886  944   
2887  1102   
2891   956  
2893 843    
2898 812    
2931 3137    
2941    5679 
2942 2577    
2965 647    
2967 1482    
2991 4357    
2998 4727    
3001 3847    
3008 15465    
3014 1520    
3016 8017    
3022 1468    
3027 1165    
3033 1389    
3041 791    
3066 5082    
3070 2318    
3072  604 957  
3096 607    
3106 1003    
3114  1335   
3117 3059    
3118  14469   
3119 642    
3123   884  
3126    644 
3128  910 1348  
3129 1011   801 
3130   1276 961 
3131  1140 917 679 
3132 716    
3135   958  
3138 4647 813   
3139 3507    
3144 814    
3146 846    
3154 1990    
3161 2639 784   
3164 3148 845   
3170  900   
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3171 3480    
3175 853    
3181 634    
3185 1188    
3187 693    
3189 723    
3191  669   
3194 11412 1546   
3197 733    
3206 3161 633   
3213 784    
3216 684    
3220 1146    
3233 631    
3236  1127 1679  
3240 2149    
3249 22087 6350   
3253 762    
3260 4694 1155   
3276 2244    
3284 1848    
3289 949    
3293    687 
3294 1260    
3314 841    
3317 930    
3322 678    
3328 766    
3332 1904    
3341 899    
3346  1837   
3350 5900    
3352 642    
3356 806    
3359 719    
3367 783    
3376 749    
3383 1563    
3388 653    
3392  2352   
3393 2225    
3394 3197    
3400  1737   
3404 694    
3408 740    
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3413 6109 2139   
3416 694    
3421    863 
3422 749 624   
3424  615   
3425 779    
3427 857    
3431 1060 1399   
3439 3848    
3446  702   
3449 2056 3296   
3451 1010 729   
3469   879  
3471  1024   
3474    1127 
3475 777    
3477 1406    
3480 1521 662   
3483    688 
3485 1298 828   
3494 697    
3502 601    
3503 2114 645   
3505 2807 1453   
3513 1311 1211   
3515 2438 3519   
3526 16466 5722  20275 
3528 5013 3126   
3535 23194 10333   
3543 674    
3546  3010   
3547 2740    
3557 16723 1774  700 
3564 683    
3566 1033    
3571 5557    
3576 2231    
3583    705 
3586 1951    
3593 1059    
3609 1653    
3612 2451    
3616 846    
3619 1124    
3622 2093    
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3628 4134 768   
3636 1815    
3638 815    
3645 3643 685   
3648 4830    
3662 4357 681   
3665 4237    
3669 643    
3673 816    
3677 3766    
3682 820    
3684 1217    
3688 1453    
3689   638  
3690 1847 1427  618 
3692  996 1722  
3693 2358   32762 
3701 758 667   
3704 912    
3708 2032 676   
3709 1618 1403   
3712 1167 959 903  
3716 1163 1733  719 
3719 1247    
3724 663    
3735 4909    
3736  1422   
3741 1980 1210   
3745  679   
3747 3359 1638  865 
3752 7345 2489   
3758 627    
3759 1731    
3761    998 
3763 2998 1520  1004 
3765 1078    
3766 694   1312 
3768 1077    
3777 1184 999  618 
3778 1578 1003   
3779 1266    
3782 3153 1851  848 
3799 2796 1522  814 
3804 732    
3810 859    
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3823 1566 768   
3829 678    
3834    907 
3838 2297 1220   
3840 804    
3845 1554 923   
3855 855    
3857 6852 2229  806 
3868 1064    
3874  707   
3875 3567 1346   
3885 9823 3802  1188 
3888 1631 1097   
3897    14398 
3904 2630 1155   
3908  2733 3127  
3911 4005 3231 1111 605 
3913 6387 2367  1203 
3919 3258 1577   
3922 809    
3944 4341 1102   
3945 1830    
3946 1026    
3955   950  
3956 1558 1064   
3966 2131    
3969  675   
3972 2272 1401   
3974 776    
3977 709    
3981  1002   
3982 1978 806   
3983 1028 850   
3986   1449  
3987 1847    
3988  1320   
3992   2636  
3993 607 703   
3996 2336 1954   
3997    1793 
4000 1927 1872   
4005 5777 4302 651  
4014 1039 884   
4018  1590   
4019 1766 1396   
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4033 945    
4039 710 653 655  
4042 3403 2211 942  
4045 1079 1346   
4049  653   
4054 3123 3359   
4057  1343   
4062 3952 2382   
4064  2611   
4074  1466   
4077 5118 4468   
4078  4133   
4091 1096 733 1348  
4101 12057 13743   
4102  9276   
4104 613    
4110 1217 1119   
4113 1112 761   
4115 1227 888   
4118 611 1849  962 
4121 6550 4560   
4124  693   
4127  897   
4128 780    
4136 2435 1031   
4137  1308   
4155  964   
4157 2919 2265   
4162 4001 4283   
4165 6908 7613 916  
4171   1167  
4173   1907  
4176 1704 1290   
4177  1214   
4179   1718  
4181    2486 
4182  989  1950 
4184 1064 998  1817 
4185    1684 
4186    714 
4187 722 1197   
4188    1621 
4189  3328  761 
4190 2957 3897   
4192  972   
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4193 986    
4198 5493 4361 693  
4203 3478 3926 9604  
4204  922   
4206 630 869   
4207  2213   
4208 3701    
4210 1063 1119   
4211  769 661  
4214   1687  
4215 1404 946   
4218  636   
4223   3095  
4224 607    
4225 1078 2019   
4226   2349  
4229 863 1270   
4231 2832 2021   
4232   2582  
4233 1578 1041   
4235 3378 2183   
4236   2980  
4237 1485 974   
4240 787 655   
4250 1322 1247   
4252  677   
4257 3870    
4258  1890 845  
4260 1610 1623   
4262   1164  
4263 1004 1182   
4265   3066  
4266   683  
4270 5093 6250   
4275  631   
4278 1868 1790   
4280 2518 1601   
4283 2055 1453   
4290 3868 3795   
4293    941 
4294 1571 2424 2289  
4295    933 
4296   1233  
4297    604 
4298  1303 783  
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4300    1721 
4302 680  1562  
4306 1241 1391   
4311  675   
4313   1643  
4318   1943  
4322 1754    
4324   6110  
4330 1609 1676   
4333 2122 1522   
4336 713 656   
4346 884 704   
4349 1108 1326   
4353 804    
4364 4236 2703 1363  
4372 1283 1199 977  
4375 3636 2489   
4384 697 1005   
4386 1201 1423 891  
4387   1446  
4394   1027  
4395 881 968   
4398  657   
4402 666 675   
4408 1346 840   
4411  773   
4412 1210    
4413  876   
4415  1516   
4417   1767 639 
4418  1530   
4419    818 
4420  2464 999  
4422    868 
4424 616    
4429 1926 2839   
4432  727   
4435 2232 2044   
4443 974 955   
4444   785  
4456   17333  
4457 1365 684   
4459 612    
4462 5123 4612   
4464 711 760   
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4467 1409 1455 745  
4469   1256  
4470 806 1119   
4471   727  
4473   671  
4474    2971 
4475   1114  
4476   1072  
4477   844 1157 
4479   2047  
4480 721    
4481   770  
4482   1488 1073 
4484 2030 2078 979 697 
4486    1290 
4487    809 
4488 4271 4372   
4492 1411    
4494 1176    
4495 1587 1237   
4499 1116 1233 5450  
4501 756    
4502  629   
4505 646 1980   
4506 1928 1416   
4509 4612 4359 13536  
4510 1563 1598   
4513 3390 3038   
4521 11167 10224 3540  
4522   2594  
4523  7470   
4524 9317 8398 2059  
4526 657 853   
4529  735   
4530  5334   
4531  5818   
4532 7016 7563 15070  
4537 1382 900   
4540 1869 2186   
4543 2500 3279   
4544  2102   
4546 2169 2291   
4552  842   
4554 1157 681   
4561  1007   
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4563 1578 2133   
4566 3266 2858   
4569 15853 17164   
4572 1744 2216   
4575 692 723   
4578 3459 2582   
4580 2510 2618   
4583  703   
4587    1436 
4588 2595 1783   
4590    1081 
4591    885 
4592 1384 1865   
4598 6234 5713 7539  
4604 1105 1410   
4608 677    
4609   1211  
4610 2078 1828   
4614 4268 3190   
4615  5604   
4620 2629 2132   
4623 4316 4444   
4626 4331 3651   
4631 798    
4637 701    
4642 1137 1398   
4645  625   
4650 1168 1270   
4652 2826 3115   
4662 783    
4671 628    
4682 1164 846   
4683 1038    
4693 851    
4706    787 
4708  1387   
4710  1622   
4713 699 674   
4714  1181   
4722 1212    
4727 735    
4734 730 911   
4744  638   
4746 2116 1955   
4749    725 
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4750 2075 2221   
4755 3716 3622   
4758 5650 3937   
4761    1198 
4762    668 
4764 674    
4767 2309 2155  1535 
4772 3363 4891  1573 
4774  1001  1126 
4776 822    
4779   1460  
4781  1128   
4782 1621 990   
4784  640   
4785 761   1403 
4788    662 
4791 1513 685   
4794 1887 680   
4797 2346    
4802 676    
4804 674    
4805 783    
4807 672    
4810 1018    
4812 821    
4814 5169 872 701  
4815 4995 3622   
4822 7627    
4826 1091    
4827 858 981   
4834 1068    
4836 6892 936   
4837  1269   
4839 17642 2651   
4848 11905 1107   
4850 2967    
4856 1429    
4858 1019    
4861 4244 602   
4869 1808    
4870 846    
4873  628 654  
4879 1936    
4882 4761    
4887 673    
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4897 5342    
4909 2155    
4912 2993    
4918 2937    
4920 1156    
4928 8607 1076   
4936 2793    
4969 906    
4974 3687    
4976 1398    
4979 910    
4982 1935    
4993 1886    
4998 1672    
5004 1018    
5009 1534    
5010   696  
5014 1684    
5017 1409    
5023 1289    
5025 1389    
5030 6628    
5031  612   
5043 2583    
5044   1212 3378 
5045  768 3763  
5047 1261    
5049    758 
5050   1400  
5051   872 719 
5053 1493    
5054  956   
5056 3466   2331 
5062 2974    
5063  990 1302 1708 
5069   1143  
5070 2022 903 974 704 
5072 1553 32266 32337  
5073   817 31606 
5074    766 
5075  1115  1035 
5076   1055  
5077  1097   
5079  929 1084  
5082 2053    
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5083   1038  
5086 780    
5090 630    
5096 1180    
5099 1422  891  
5141    1051 
5148 683    
5208 638    
5213 2067 1133   
5215 17837 7809   
5234 1820 1302   
5240 2731 1332   
5243 3170 974   
5246 5665 2981   
5249 5251 2755   
5257 3991 2889   
5260 1154 1214   
5262 3969 2943   
5265 1104 1618   
5267 2566    
5268  1512   
5276 4419 4303   
5278 4688 2619   
5291   706  
5294  1319 607  
5306 2261 1041   
5309 789    
5322  1500   
5324 4726 3533   
5333 5335 3005   
5340 2833 1286   
5344 2847 1215   
5353 1812 864   
5356    1051 
5358 1142    
5361    2394 
5362    696 
5363 2035    
5364    1210 
5365    1544 
5366 864    
5368 908   602 
5371 13864 5008   
5372 9412 1606   
5374 1318 712 637  
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5375  717   
5378 980    
5379 747    
5382 5735 5583   
5383 3141 3025   
5384  6201 2756  
5389 1490    
5390 730 1011 1210  
5391 3600    
5392  1202   
5393 2163    
5404 1910 918   
5405 848    
5407 1074    
5408 689    
5410 8067 3561   
5411 4772 716   
5418 678    
5421 1290    
5426  847   
5427 784  1239  
5431 1093  794  
5433 7169 1196   
5438 10215 1295   
5442 1292    
5451 1614    
5454 8506 1554 1886 1785 
5456 891    
5459 755   633 
5460  1157 1816 2165 
5461  1116   
5463 1603 30422 31375 32246 
5465    637 
5466 788    
5469 4534 1535   
5474 8723 1504   
5476 1431    
5481 650    
5489 5439 1136   
5492 10279 1787   
5495 757    
5497 3790 744   
5500 2646 652   
5502 1149    
5504 1372    
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5507 3355 900   
5509 877    
5518 8734 623   
5524 1663 613   
5528 813    
5531 819    
5536 1931    
5537 2732    
5544 2221    
5546 820    
5549 810    
5553 1805    
5557 660    
5561 1304    
5562 958    
5564 816    
5570 881 1911   
5575 3872 964   
5581  1242 1905 1161 
5582  1998  1405 
5584 1536 31267 31694 31516 
5586  672   
5594 799    
5597 3107    
5598 3836    
5604 910    
5605 987    
5609 4509    
5611 3598    
5616 4276 671   
5619 4805    
5624 5456 693   
5635   874  
5638    767 
5639 1814    
5641    1078 
5642 1763  670  
5643  606   
5645    1627 
5646  908 855 1719 
5647   1069  
5649   1808 1635 
5651    1997 
5652   679  
5656 5266 1208   
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5658   778  
5661 608    
5663 1257    
5679 708    
5687    805 
5701  4313   
5702 17868 2870   
5705 934    
5707 1757 624   
5711 6849 1579   
5713 12018 7217   
5714   2646  
5717 23474 8871 3638  
5721 3989 1614   
5723 1745 617   
5729 1841 1156   
5732  1330   
5733 3614    
5736  4540   
5737 10734    
5739 4108 1393   
5741  1196   
5742 3005    
5744  2509   
5745 6149 2386   
5749 620    
5753  21218   
5754 32076 12171 2027  
5756  1384 1299  
5757 2469 1288   
5762 698    
5765 1177    
5796 226    
5799 1150    
5802 287  323  
5804    456 
5806 588    
5807   262  
5809    270 
5811 336    
5814 6267 1894  904 
5817 2974    
5822 1090    
5825 939    
5827 1177    
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5829 1062    
5833 694    
5841 555    
5842 776  429 387 
5844 688    
5847 2479    
5855 853    
5859 793    
5863 2310    
5866 237    
5870 1161    
5873 1820    
5875 473    
5879 600    
5881 558    
5885 7783 1321   
5890 1990    
5893 1027    
5894  558   
5895 1581    
5903 1761    
5907 428    
5910 1974    
5917 2403    
5919 1877    
5920  392 281 319 
5924 314    
5929 366    
5953 654 395   
5960 799 861   
5962  1235   
5963 937    
5965 372    
5968 890 373   
5971 348    
5973 337    
5977 1022    
5981 3017    
5983 3020 2099   
5987 686    
5990 320    
5992  212   
5993 285    
5996 9744 484   
6000 318    
Appendices 307 
 
6004 1262    
6007 1143 482   
6011 677    
6013  210   
6014 5704    
6015 630    
6017 911    
6018 445    
6019 754    
6022 675    
6025 282    
6026 293   373 
6028 1732 1297   
6030 2335 686   
6033 459    
6035 602    
6036 240    
6038 251    
6041 2429 203   
6043 3318    
6050  772   
6051 2942    
6052  350   
6053 3653 1186   
6054  212   
6055  1263   
6059 662    
6066 345   228 
6073 1972 259   
6075 898 452   
6078 1246 5290   
6084 1826    
6085  986  207 
6088 1429    
6092    238 
6095 2297 291  334 
6098 319    
6100   292  
6101    818 
6103    438 
6106 2688   204 
6107  3842   
6112 698 234   
6115 1161    
6122 444    
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6128 350    
6133   265  
6134 2114 1073   
6139 1753    
6143 594 542   
6146 412    
6149 240    
6152 545    
6156 298    
6164 457    
6168 898    
6175 797    
6182 310    
6184  6802 476  
6185   307  
6186  810   
6187 5620 6062 201  
6195 552 867 832 829 
6198  435   
6215 761    
6218 286    
6224 374    
6226 471    
6231 282    
6234 310    
6236 948 610   
6241 836    
6248 272    
6252 462    
6255 992 491   
6261 2631 337   
6263 766    
6264  324   
6269 538 458   
6272  312   
6274 2670    
6276 2146    
6277  561   
6282 210    
6283  645   
6286 808 1768   
6288 1256    
6294 696 419   
6296  303   
6297 1503    
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6300 257    
6303 1257 733   
6306 269    
6308  520   
6309 1601    
6310 611    
6311 1023    
6313    441 
6314 954 229   
6315 204    
6319 282 205   
6322  615  486 
6327 365    
6329 1734 330   
6333 1616 478   
6337 308    
6343 1214    
6344 372    
6347 2150    
6352  218   
6353 829    
6357 295    
6364 493    
6368 1627    
6369  1001   
6374 832 3742 562  
6376  2065   
6379 1479 4741 1349  
6383 359 2641   
6386  647   
6387    530 
6388  210   
6389   525  
6390 295  727  
6391    222 
6392   663  
6393 328 720  567 
6394   569  
6395   534  
6400  224   
6406 221    
6415 232    
6417 638    
6419 1740    
6421 220    
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6433 1019 292   
6435 1298    
6440 459    
6449 246    
6457 6781 763   
6458  901   
6460 244    
6465  460   
6467 1303    
6479 598    
6482 671    
6483  574   
6488 2284    
6489  441   
6497 1796    
6499 2673 264   
6501  1022   
6502  232   
6503 2226    
6507 238    
6513 738    
6518 583    
6522 583    
6530 868    
6532  498   
6533 3593    
6536 3058    
6539 355    
6542 353    
6547 4156 208   
6550 352 322   
6553 702    
6557 228    
6561  220   
6562 1633    
6563  421   
6567 2462    
6570 215    
6577 1251    
6585  201   
6586 2209    
6591 1865    
6602 1360 731   
6604 249    
6605 224    
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6607 854    
6608 260    
6610 889    
6612 457    
6614   304  
6615 537    
6621 8190    
6622   265  
6623 7018    
6627 649    
6629 583    
6630 3947 423   
6632 4329 487   
6635 409    
6637 353    
6638 281    
6640 399    
6642 1444    
6644 3561 4992   
6653 2877    
6657 666    
6661 406    
6665 594    
6672 262    
6677 297  7152 4917 
6678  487 2956  
6679  221  387 
6680  1017 1687  
6681    336 
6683 1034 2524 1990 574 
6686  26689 32038 17900 
6687 9181    
6688  274  618 
6692    371 
6699 1361 770   
6701  1236   
6704 288    
6708 1744 265   
6709  614   
6711 509    
6714 1852 239   
6719 7709 510   
6722 4736    
6725 232    
6732 3766 3777   
Appendices 312 
 
6736 560    
6741 5429 225   
6744 2174    
6746 1094 2552   
6751 655 2055   
6760 300    
6763 9150 2736   
6780 1342 509   
6782 740 1360   
6787 453    
6796 2088 554   
6799 1193    
6809   1330  
6810  1696 296  
6811 5675 337   
6813 6393    
6816 977 970   
6819 486    
6821 127    
6834  1005   
6835 8868 747   
6838 1874    
6847 663    
6851 1931    
6853 2144    
6856 4486 226   
6857 495 344   
6861 2816    
6872 4219 594   
6875 408    
6881 1154 252   
6886 611    
6892 1443    
6893   224  
6895 767    
6896   676  
6897 211    
6898   320  
6899   463  
6900 1402    
6901    544 
6902 1390 224   
6903 420    
6905 3609 217  1036 
6907 3961 371   
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6915 1869  326 675 
6916  237 697  
6917 2137 554   
6923 1660    
6925 1757    
6928 506    
6931 631    
6934 719    
6936 946    
6946 1465  238 431 
6951  210 308  
6956   249  
6957 2765    
6961 692    
6967 1147 200   
6969   345  
6972 340    
6975    270 
6983 1224    
7006 543    
7008    229 
7026 308    
7027  399 797 622 
7039  3261 3848  
7042   443  
7048 231    
7060 774    
7062   270  
7064   981  
7068 747    
7070   249  
7073 550 1738 4276 5523 
7075   469  
7078 1839 3849 4789 689 
7080    501 
7081  478 989  
7082 204    
7084  2675 4767 249 
7085 626 243 280 395 
7089 366 969 841  
7093 359 709 3520 4196 
7095 825    
7096  1180 997  
7097   218 534 
7098   438  
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7105 1748 1780 1034  
7109 317 460   
7114 1713 236   
7118  293   
7119 4596 632   
7120  382   
7123 427 534 332  
7126 972    
7131 1356    
7136 1442    
7141 217    
7146 403    
7151 3463    
7155 329    
7157 801  209  
7159 1599    
7161    948 
7162  221 303  
7163   5942  
7164 331    
7165  314 395 732 
7166   536 868 
7167  200 3896  
7168 2859    
7170 1445    
7172 1204    
7173  227   
7174   625  
7175 1457    
7176 1956  3518 12419 
7177  593 1928 9426 
7179 257    
7181    2732 
7182 2417 14618 31046 31670 
7183 2160 17757 31600 12140 
7184 438  5659 5869 
7185  10303   
7186 293    
7187 464 247   
7189  1345 423 250 
7190 381 894 290  
7192  524 289 395 
7194   297 267 
7195   1702  
7197 938 424 1674 459 
Appendices 315 
 
7198 2581 1557 1658 317 
7199 749  3649  
7200 843 1254 703  
7203  281 668  
7204 1400    
7205 1896 1824 342  
7207 4072 3359 1023 434 
7208 6060 1146  231 
7209  223 676 478 
7211  1089 824 988 
7212  373   
7213  3494 4953 4793 
7214 257 366   
7215  918 8953 11930 
7216 476   8255 
7217 3186 7974 10988  
7218 6780 8544 10668 2165 
7222  1662 17750 7635 
7223 2347 12133 7167  
7228 308 1985 4817 3399 
7231 238 382 294  
7232   256  
7235 200 2304 3080 2821 
7236   342 235 
7239 283 3119 6038 4262 
7242  2352 3873 5779 
7244  2341 4693 2195 
7247 520 271   
7248  608   
7251  2001 1375 991 
7253   331  
7254   273 286 
7255 550    
7256    392 
7258 1678 2934 3164 1248 
7261 588  1321 1078 
7264    279 
7265 1181 6788 4569 1458 
7269 499    
7273  1183 307  
7276   728 605 
7282 3555    
7283   5003 5109 
7284 1749 6476 1103  
7286 1061 1329 2304 1145 
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7289   280 258 
7291  9033 6909 3726 
7292 5187 1063 5743 897 
7295 359    
7298 486    
7300 839    
7302 2210    
7307   213  
7309 767    
7310    225 
7312    407 
7313 2627    
7317 491    
7318    269 
7329 823    
7331 3336 1865 4224 2176 
7342 1576    
7344 684    
7345    228 
7346   282  
7347 1203    
7350   822  
7351 1790    
7353 262    
7361 278    
7363 308  6904  
7364  6541 12236 6279 
7365 758    
7366   959 777 
7367  1033   
7378   291 280 
 
 
  
 
 
